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1 
INTRODUCTION 
The brain is a highly interconnected organ, communicating both with itself as well as 
with other parts of the body. It is involved in many of our daily activities, from holding 
this thesis (motor function), seeing the individual words (processing sensory 
information), to understanding their meaning (cognitive function). As Michio Kaku put it: 
“Sitting on your shoulders is the most complicated object in the known universe.”1 While 
the complexity of the brain is a beautiful product of millions of years of evolution, at the 
same time it has left us with an organ that is highly vulnerable to damaging processes, 
with large clinical consequences. Among the most common and debilitating 
neurological diseases are those that are of a neurodegenerative or cerebrovascular 
nature, which are the primary focus of this thesis.  
Research into the pathophysiology of neurological diseases seeks to determine what 
goes wrong in the brains of patients. Instrumental in this have been two fields of study: 
neuroimaging and genetics. On the one hand, neuroimaging technologies such as 
magnetic resonance imaging (MRI) have allowed researchers to non-invasively examine 
the brain of living individuals and visualize various structural and functional 
abnormalities. This has led to the identification of brain structures that are important for 
diseases, which in turn helped to better understand clinical symptoms. Furthermore, 
neuroimaging sometimes even shows signs of damage before a person has noticeable 
problems. Indeed, for many neurodegenerative and cerebrovascular diseases, evidence 
of an ongoing pathophysiological process can precede the moment of clinical 
presentation by years to even decades.2-4 Even so, the exact neural substrate of these 
brain diseases remains unclear. Novel imaging markers have emerged from technical 
advances in the acquirement and processing of images and provide an opportunity to 
shed light on the pathophysiology of neurological disorders; for the majority of these 
markers, however, the clinical relevance has yet to be explored. 
On the other hand, genetics has played an essential role in research on neurological 
diseases, which have varying degrees of heritability.5-8 Early genetic discoveries in the 
field of neurodegenerative and cerebrovascular diseases stem mostly from monogenic 
forms of disease that aggregate in families. Examples of these include APP in Alzheimer’s 
Chapter 1 
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disease,9 NOTCH3 in stroke,10 SNCA in Parkinson’s disease.11 However, sporadic cases 
tend to have a more complex genetic architecture, with many genetic variants 
increasing risk only marginally. Genome-wide association studies (GWAS) in tens of 
thousands of individuals has resulted in the identification of hundreds of genetic 
variants.12-19 While these findings have provided insight into the affected biological 
pathways, they have generally explained only a small amount of the variance in disease 
susceptibility. To uncover the so-called 'missing heritability',20 studies are ongoing with 
even larger sample sizes and implementing next-generation sequencing technologies to 
capture more of the genetic variation. 
Neuroimaging and genetics have, as individual fields, undeniably increased our 
understanding of neurological diseases. Nevertheless, recent advancements within each 
of these fields pave the way for further insights into disease by studying  novel imaging 
markers and newly discovered genetic risk variants. Furthermore, the combination of 
both fields, also called 'imaging genetics', has even more potential. The effects of 
neurological disease genes are likely to be reflected in the brain and, conversely, 
observations on neuroimaging can have a substantial genetics basis. Imaging genetics 
tries to leverage these interrelations in order to gain knowledge about neurological 
diseases that would have been untapped by studying imaging or genetics separately.  
METHODOLOGY 
The innovative nature of both imaging and genetics, and more so of their combination, 
has resulted in analytical demands beyond our current capabilities. Chapter 2 of this 
thesis is dedicated to the development of methodology to enable such studies. First, I 
describe a method for assessing a novel neuroimaging marker, enlarged perivascular 
spaces on MRI – an emerging marker of cerebrovascular disease – (chapter 2.1) and the 
initiation of a global consortium to systematically investigate the clinical relevance of 
this marker (chapter 2.2).  In chapter 2.3, I present a novel meta-analytical method that 
increases power and flexibility when individual participant data cannot be shared 
between sites, which is a common issue in genetic studies that require multi-site efforts. 
Chapter 2.4 covers a method to perform genome-wide and brain-wide association 
studies, a theoretical possibility in imaging genetics that is currently not feasible due to 
General introduction 
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computational and logistic limitations. Finally, chapter 2.5 highlights potential biases in 
a recent study on the transmissibility of amyloid-β , which can impact causal inference. 
This methodological chapter is followed by three applied chapters.   
GENETIC DISCOVERIES 
Chapter 3 describes genetic discoveries of imaging markers. Those markers previously 
linked to neurodegeneration, mostly measures of the structure of the brain, are the 
focus of chapter 3.1. I describe GWAS of intracranial volume (chapter 3.1.1) , 
hippocampal volume (chapter 3.1.2), and the volumes of other subcortical brain 
structures (chapter 3.1.3) in the largest discovery samples to date, identifying 33 novel 
genetic variants in 25,000-34,000 individuals.  Neuroimaging can also assess the burden 
of cerebrovascular disease, which is covered by chapter 3.2. Chapter 3.2.1 reviews our 
current knowledge of the genetics of cerebrovascular disease. Next, I describe the first 
heritability estimates and GWAS of intracranial carotid artery calcification in chapter 
3.2.2.  
In chapter 3.3 I study emerging imaging markers, which are not as established as those 
described earlier in this chapter. The anterior commissure is a recently proposed 
imaging marker for neurodegeneration, and I describe the first heritability and GWAS 
analyses in chapter 3.3.1. Similarly, the results in chapter 3.3.2 are the first 
comprehensive description of the genetic determinants of human gait, as imaged by an 
electronic walkway. Furthermore, emerging neuroimaging phenotypes can describe 
brain structure with great detail on a vertex- or voxel-wise level using thousands to 
millions of measures. For two of such phenotypes, we found them to be promising 
targets for genetic studies: the shape of subcortical brain structures (chapter 3.3.3) and 
the grey matter density using voxel-based morphometry (chapter 3.3.4).  
UNDERSTANDING PATHOPHYSIOLOGY 
Chapter 4 explores the effects of known disease genes on the brain. Chapter 4.1 
considers disease variants in relation to candidate imaging markers: Alzheimer’s disease 
variants and several key vascular and degenerative markers (chapter 4.1.1), intracranial 
Chapter 1 
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aneurysm variants and the presence and size of aneurysms (chapter 4.1.2), and the 
dystrophin gene and cognitive function (chapter 4.1.3). Contrary to the candidate 
markers of chapter 4.1, those in chapter 4.2 have been selected in an unbiased 
approach. This which includes brain-wide studies of genetics variants that increase the 
risk of Alzheimer’s disease  (chapter 4.2.1), frontotemporal lobar degeneration (chapter 
4.2.2 and chapter 4.2.3), and multiple sclerosis (chapter 4.2.4). 
EXPLORING CLINICAL RELEVANCE 
Chapter 5 examines the clinical relevance of neuroimaging and genetics beyond making 
genetic discoveries and understanding pathophysiology. Given that many imaging 
markers are novel, their clinical relevance is yet unclear. In chapter 5.1, I determine 
clinical correlates of a variety of enlarged perivascular spaces, a novel imaging marker: I 
study various demographic and cardiovascular determinants of these enlarged 
perivascular spaces  (chapter 5.1.1) and also their relation to the retinal microvasculature 
(chapter 5.1.2). Similarly, the clinical relevance of recently identified genetic variants that 
increase the risk for neurological diseases is largely unknown. This is explored in chapter 
5.2, with a specific focus on the ability to improve prediction of symptoms and disease at 
an individual level. This was done for genetic risk factors of four neurodegenerative 
diseases in relation to mild cognitive impairment and incident dementia (chapter 5.2.1), 
and also for genetic risk of Parkinson’s disease in relation to basic activities of daily living 
and incident Parkinson’s disease (chapter 5.1.2). 
GENERAL DISCUSSION 
Both neuroimaging and genetics have expanded our knowledge of brain diseases. While 
these advances were largely driven by discoveries in each of these fields separately, joint 
analyses of imaging and genetics can yield even more insight into the pathophysiology 
of diseases and perhaps translate into useful tools for clinicians. In chapter 6, the 
findings described in this thesis are reflected upon from the broader perspective of 
complex diseases. I conclude with a discussion of the implications for future research. 
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ABSTRACT 
Background and Purpose: Dilated Virchow-Robin spaces (dVRS) are an emerging 
neuroimaging biomarker, but their assessment on MRI needs standardization.  
Methods: We developed a rating method for dVRS in four brain regions (centrum semi-
ovale, basal ganglia, hippocampus and mesencephalon) and tested its reliability in a 
total of 125 MRI scans from two population based studies. Six investigators with varying 
levels of experience performed the ratings. Intraclass correlation coefficients (ICC) were 
calculated to determine intra- and inter-rater reliability. 
Results: Intra-rater reliability was excellent for all four regions (ICC>0.8). Inter-rater 
reliability was excellent for the centrum semi-ovale and hippocampus (ICC>0.8) and 
good for the basal ganglia and mesencephalon (0.6–0.8). This did not differ between the 
cohorts or experience levels.  
Conclusions: We describe a reliable rating method that can facilitate etiologic and 
prognostic research on dVRS using MRI. 
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INTRODUCTION 
The study of imaging biomarkers plays an essential role in understanding brain aging as 
well as pathology, such as cognitive impairment, dementia, and cerebrovascular 
disease.21 Structural imaging studies have already shown the importance of white matter 
lesions, infarcts and more recently cerebral microbleeds.21 An emerging potential marker 
are Virchow-Robin spaces (VRS), spaces filled with interstitial fluid that surround the 
blood vessels in the brain.22 VRS can increase in size and such dilated VRS (dVRS) can 
subsequently be found on brain imaging,23 particularly in the mesencephalon, 
hippocampus, basal ganglia and centrum semi-ovale.24, 25 Determinants of dVRS severity 
include age,26 blood pressure26 and inflammation.27 The associated brain pathology is 
diverse, covering small vessel disease,26 28,29 Alzheimer’s disease24,29,30 and CADASIL.31 
Despite increasing literature on dVRS, a major limitation of current research is the lack of 
a robust and generalizable rating method on MRI. Current methods are restricted to 
studies that only use a single MRI protocol and focus on one or two brain regions.23, 24, 26, 
28, 29, 31 A method that can be applied to MRI protocols from different centers and 
scanners and evaluates the whole brain would strongly facilitate etiologic and 
prognostic research on dVRS. Here we propose a novel rating method for dVRS, which 
we apply in two population-based studies, encompassing three different scanning 
protocols.  
METHODS 
We aimed to develop a rating protocol meeting three preconditions. First, the method 
should be standardized and generalizable across various MRI protocols. Second, intra- 
and inter-rater agreement should be high, irrespective of rater experience. Third, the 
method should be easily applicable for other researchers without requiring complex 
image processing. 
Setting 
We used MRI-scans from two population-based cohort studies: the Austrian Stroke 
Prevention Study (ASPS)32 and Rotterdam Scan Study (RSS).33  The ASPS is a prospective 
community-based study investigating the effects of vascular risk factors on brain 
Chapter 2.1 
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structure and function in residents of Graz, Austria (aged ≥45 years). Between 1999-2003, 
a diagnostic work-up including MRI was done. Scans were obtained on a 1.5T Philips 
scanner. The MRI-protocol included axial T1-, T2-, proton-density-weighted and fluid 
attenuated inversion recovery (FLAIR) sequences. The study protocol was described 
previously.32 The RSS investigates causes and determinants of chronic neurological 
diseases in the elderly (aged ≥45 years). Participants are residents of Ommoord, a suburb 
of Rotterdam, the Netherlands. Brain MRI was incorporated into the core study-protocol 
from 2005 onwards using a 1.5T GE MR unit. The protocol has been extensively 
described and includes axial T1-, T2-weighted and FLAIR sequences.33 Earlier in 1995, a 
smaller MRI study was performed using a 1.5T Siemens system with the protocol 
including T1- and T2-weighted sequences.33 
Rating Protocol 
We developed and applied our rating method on scans from the ASPS and 2005 RSS, 
since these were acquired with the most up-to-date protocols available. The primary 
rating sequence was T2-weighted (ASPS: slice thickness 4.5mm, RSS: 1.6mm), which 
shows VRS as hyperintensities (Figure S1). VRS were identified by their linear, ovoid or 
round shape depending on the slice direction and considered dilated when their 
diameter was ≥1mm.34 Also, since dVRS >3mm in shortest diameter may have a distinct 
etiology,23 these large lesions were rated separately and not evaluated in the reliability 
analyses. For differential diagnosis with lacunar infarcts, symmetry of the lesions, sharp 
demarcation, and absence of a hyperintense rim on the FLAIR sequence supported 
rating them as dVRS.34 White matter lesions (WML) are mostly confluent and were 
differentiated from dVRS by signal intensity not equivalent to cerebrospinal fluid on T2. 
dVRS were scored in four brain regions: the centrum semi-ovale (CSO), basal ganglia 
(BG), hippocampus and mesencephalon. This choice was based on the pronounced 
presence of dVRS in these regions that was reported earlier and is known from own 
experience.24, 25 Raters determined dVRS count for each region with a maximum of 
twenty per region. Because CSO and BG are visible on multiple slices, the rating was 
done on a single, predefined slice to decrease inter- and intra-rater variability. For CSO, 
this was the slice 1 cm above the lateral ventricles. For BG, this was the slice showing the 
anterior commissure or, when not visible, the first slice superior to it. In the 
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hippocampus and mesencephalon, all unique dVRS were counted (Figure 1). A blank 
rating form is provided as a supplement (File S1). 
Reliability Assessment 
To assess the intra-rater reliability, one rater (H.H.H.A.) scored 85 scans twice, blinded to 
his initial rating, separated by more than one month. Inter-rater reliability was assessed 
on 100 randomly selected scans and 5 additional scans in case of motion artifacts on the 
initial 100 (40 ASPS, 65 RSS). Every scan was rated independently by three to six 
investigators with varying degrees of experience (1-2 years: H.H.H.A., M.C., B.F.J.V., D.B., 
>10 years: C.E. and R.S.) who were blinded to all clinical data. The order of scans was 
randomized and different for each rater. Afterwards, we also assessed the reliability on 
20 scans from the 1995 RSS MRI-protocol rated by three investigators (H.H.H.A., B.F.J.V., 
D.B.).  
Intra-rater and inter-rater reliability was determined using intraclass correlation 
coefficients (ICC) for all raters combined. Secondary analyses were performed after 
stratifying by MRI-protocol (ASPS vs. RSS), experience level (1-2 years vs. 10 years) or co-
existing brain pathology (WML, atrophy, lacunar infarcts). WML and brain volume were 
measured with automated software within each cohort and dichotomized at the median 
value to provide equally-sized groups. For lacunar infarcts, we restricted to participants 
without lacunar infarcts (n=8).  
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Table 1 | Study population characteristics.
 Total RSS ASPS 
Demographics  
Number of participants, n (%) 105 (100) 65 (62) 40 (38) 
Age in years, mean (SD) 65.8 (5.8) 66.9 (5.7) 64.0 (5.6) 
Women, n (%) 54 (51) 34 (52) 20 (50) 
MRI characteristics  
dVRS, mean (SD)  
Centrum semi-ovale 9.6 (6.8) 9.8 (6.5) 9.3 (7.3) 
Basal Ganglia 5.3 (3.4) 5.7 (3.6) 4.7 (2.9) 
Hippocampus 3.4 (3.1) 4.3 (3.3) 1.8 (2.1) 
Mesencephalon 1.8 (1.7) 2.2 (1.9) 1.1 (1.2) 
Participants with lacunar infarcts, n (%) 8 (8) 5 (8) 3 (8) 
Brain volume as % of intracranial 
volume (SD) 
-* 82.3 (3.5) 79.8 (2.7) 
WML volume in mL, mean (SD) -* 8.2 (1.0) 2.9 (4.7) 
*WML and brain volume measures were not pooled because of differences in quantification 
between the two cohorts.  
 
Table 2 | Intraclass Correlation Coefficient values for inter-rater and intra-rater 
reliability. 
 CSO BG HIP MES 
Intra-rater Total 0.88 0.80 0.85 0.82 
  
Inter-rater  Total 0.80 0.62 0.82 0.75 
By protocol Rotterdam Scan Study 0.78 0.65 0.81 0.78 
 Austrian Stroke 
Prevention Study 
0.85 0.68 0.74 0.74 
By experience 1-2 years 0.76 0.64 0.79 0.82 
 >10 years 0.74 0.58 0.70 0.83 
 Between groups 0.67 0.64 0.77 0.78 
By pathology Small WML volume 0.76 0.65 0.82 0.68 
 Large WML volume 0.81 0.57 0.83 0.80 
 Small brain volume 0.82 0.67 0.86 0.75 
 Large brain volume 0.74 0.59 0.73 0.76 
 No lacunar infarct* 0.78 0.61 0.82 0.76 
Values based on 105 MRI scans for inter-rater and 85 scans for intra-rater reliability. 
*Eight persons with lacunar infarcts were excluded from this analysis. 
BG basal ganglia, CSO = centrum semi-vale, HIP = hippocampaus, MES = mesencephalon 
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Figure 1 | Examples of the four regions used for rating dilated Virchow-Robin spaces. 
A) The mesencephalon with four dVRS, B) hippocampus with two dVRS and one large lesion 
on the right side, C) basal ganglia with eleven dVRS and D) centrum semi-ovale with more 
than twenty dVRS. 
Chapter 2.1 
30  
RESULTS 
Study population characteristics are shown in Table 1 (mean age 65.8 (SD 5.8) years, 54 
(51%) women). The distribution of the average dVRS count showed most dVRS in the 
CSO (9.63 (SD 6.79), followed by the BG (5.30 (3.41)), hippocampus (3.35 (3.14)) and 
mesencephalon (1.78 (1.75)).  
Intra-rater reliability for the 85 scans showed nearly perfect agreement (ICC>0.8) for all 
regions (Table 2). The ICC values for the 105 scans indicate good agreement between 
raters (ICC between 0.6-0.8) for the BG and mesencephalon and nearly perfect 
agreement for the CSO and hippocampus (Table 2). Calculating the ICC for RSS and ASPS 
scans separately gave similar values (Table 2). Furthermore, inter-rater reliability was 
independent of rater experience, WML burden and brain volume (Table 2). Excluding 
participants with lacunar infarcts (n = 8) also did not alter the results (Table 2). In the 20 
additional scans from the 1995 RSS protocol, ICC values were >0.8 for each region (not 
shown). 
DISCUSSION 
We propose a newly developed rating method for dVRS in four brain regions, which 
shows good to nearly perfect inter-rater and intra-rater agreement, independent of rater 
experience and concomitant brain pathology. We applied this method to a total of 125 
MRI scans acquired from three different scanners and protocols across two cohorts, and 
found comparable reliabilities.  
The proposed rating has several strengths which can facilitate future dVRS research. We 
developed the protocol on a large dataset of images from different MRI scanners, with 
multiple raters of differing experience level, and performed secondary analyses for 
factors potentially affecting observer agreement. Also, we included the four brain 
regions with most prevalent dVRS, while rater instructions remained simple and time 
investment was minimal (~3min/scan). Moreover, regular transverse slices were used for 
scoring, thereby eliminating the need for complex planar reformatting of scans. 
Whereas previous studies have only used upper limits in size for defining dVRS,26, 29, 31 we 
also implemented a minimum diameter criterion to consider VRS dilated. This is because 
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the increasing resolution of new MRI scanners will enable detection of many VRS smaller 
than 1mm, which could inflate the dVRS rating and reduce comparability between 
studies if not excluded. Morphological criteria were used for differentiation between 
dVRS, lacunar infarcts and WML.34 Although reliability of our method was not affected by 
concomitant brain pathology visible on MRI, the distinction between dVRS and lacunar 
infarcts in particular remains controversial.34  
As an alternative to counting dVRS, we considered assigning a severity score to each 
region after comparison with a consensus-based template. Although preliminary 
analyses revealed good intra-rater agreement on 30 scans (average of regions: 0.70), 
inter-rater agreement was weak to moderate (0.48). We therefore did not pursue this 
approach further. Existing rating protocols were not evaluated, since there currently is 
no gold standard for quantifying dVRS burden. A future direction would be to compare 
the reliability across different rating protocols.  
In conclusion, this study presents a generalizable rating method for dVRS in the 
mesencephalon, hippocampus, BG and CSO that has been tested in a multi-center 
setting. The protocol allows for better comparability between VRS research and is easy 
to implement by investigators. 
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ABSTRACT 
Background: Virchow-Robin spaces (VRS), or perivascular spaces, are compartments of 
interstitial fluid enclosing cerebral blood vessels and are potential imaging markers of 
various underlying brain pathologies. Despite a growing interest in the study of 
enlarged VRS, the heterogeneity in rating and quantification methods combined with 
small sample sizes have so far hampered advancement in the field.  
Methods: The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement (UNIVRSE) 
consortium was established with primary aims to harmonize rating and analysis (see 
www.uconsortium.org). The UNIVRSE consortium brings together 13 (sub)cohorts from 5 
countries, totaling 16.000 subjects and over 25.000 scans. Eight different MRI protocols 
were used in the consortium. 
Results: VRS rating was harmonized using a validated protocol that was developed by 
the two founding members, with high reliability independent of scanner type, rater 
experience, or concomitant brain pathology. Initial analyses revealed risk factors for 
enlarged VRS including increased age, sex, high blood pressure, brain infarcts, and white 
matter lesions, but this varied by brain region. 
Conclusions: Early collaborative efforts between cohort studies with respect to data 
harmonization and joint analyses can advance the field of population (neuro)imaging. 
The UNIVRSE consortium will focus efforts on other potential correlates of enlarged VRS, 
including genetics, cognition, stroke, and dementia.  
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INTRODUCTION 
Neuroimaging allows for the in vivo assessment of brain structure and function, thereby 
facilitating research on neurodegenerative, psychiatric and cerebrovascular diseases. In 
the past decades, magnetic resonance imaging (MRI) has identified both early and late 
markers of brain pathology that have greatly contributed to our understanding of the 
pathophysiology of neurological diseases. White matter lesions, for example, are now a 
well-established marker of cerebral small vessel disease, and hippocampal atrophy has 
even been translated into a diagnostic marker of Alzheimer’s disease. For several 
neuroimaging markers, standardized definitions were recently proposed, but this was 
already after decades of research using considerably heterogeneous criteria.1 Research 
on emerging neuroimaging markers would benefit from harmonization early on. This 
paper focuses on enlarged Virchow-Robin spaces (VRS), which hold great potential as an 
MRI marker for various pathologies in the brain but remain poorly studied. VRS are fluid-
filled spaces enveloping the brain vasculature only to become visible on MRI after a 
substantial increase in volume. Enlargement of these VRS was traditionally thought to be 
an inconsequential finding on MRI, but this view has repeatedly been questioned in 
recent years through established links with cerebral small vessel disease, Alzheimer’s 
disease and multiple sclerosis, among others. Several theories have been proposed for 
this enlargement, including brain atrophy, inflammation, hypertension, and 
microvascular obstruction (Figure 1).2-9 Consequently, this resulted in the study of 
enlarged VRS in relation to a diverse range of diseases. However, the number of VRS 
studies almost equals the number of methods used for their assessment on MRI.2-4, 10-13 
This has led to the current inability to compare or pool results from different studies, 
which are already limited in number and size. Now, cohorts worldwide have joined 
efforts in trying to harmonize VRS research early on, in order to overcome these 
problems; an initiative which may be exemplary for future population neuroimaging 
research. 
METHODS 
In 2010, the Rotterdam Scan Study (RSS) and Austrian Stroke Prevention Study (ASPS), 
two large population-based studies in aging populations, entered a collaboration with 
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the goal to develop a robust VRS rating method that is reliable, incorporates relevant 
brain regions and can be easily applied by other researchers.14 Briefly, enlarged VRS are 
rated primarily on an axial T2-weighted sequence, which shows VRS as hyperintensities, 
but this has now been extended to allow T1-weighted images, where VRS are 
hypointense, as the primary sequence. VRS are tubular structures that, depending on 
their orientation within the image, can be linear, ovoid, or round in shape. VRS are 
considered enlarged when their diameter is ≥1mm, to be able to distinguish ‘enlarged’ 
VRS from ‘normal’ VRS (Figure 2). The diameter is determined visually by the rater and 
not manually measured for every VRS since the latter would be too time-consuming. VRS 
are rated separately when these are larger than 3mm, since these large lesions 
potentially represent different pathology. The shape of the lesion and its intensity on the 
FLAIR sequence are additionally used to differentiate between enlarged VRS, lacunar 
infarcts, and white matter hyperintensities. 
During the development of our visual rating scale, we focused on its reliability and ease 
of use. The number of enlarged VRS is determined in four relevant brain regions: the 
centrum semi-ovale, basal ganglia, hippocampus and mesencephalon. All unique 
enlarged VRS are counted in the hippocampus and mesencephalon, whereas only a 
single, predefined slice is used for the centrum semi-ovale and basal ganglia, which are 
large brain regions for which counting on all slices would be unfeasible. However, in a 
subset of 40 scans in which all VRS in the brain were counted, there was a high 
correlation (0.79) between the number from our single slice approach and the total 
number in that region, indicating that the VRS burden for the larger regions (centrum 
semi-ovale, basal ganglia) can be captured using only a single slice. We rate the actual 
counts for each region (either the whole region or a single slice), instead of categorizing 
this into a severity score, so that this information is not lost and can be analyzed 
continuously. 
Furthermore, we are exploring the possibilities of an automated segmentation method 
for detecting enlarged VRS, similar to tools for white matter hyperintensities and 
hippocampal size. This would allow for the investigation of count and volume within the 
whole brain, as well as within regions of interest. Even though our visual rating method 
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and those of others have been shown to be reasonably reliable, we expect this objective, 
quantitative approach to greatly reduce noise and increase analytical opportunities. We 
believe automated detection will replace the visual rating as the method of choice for 
determining enlarged VRS load once this is ready to be applied within our consortium. A 
recent study showed that high-resolution images obtained from 7T scanners are better 
suited for automated segmentation,16 although other efforts suggested that this might 
be feasible with weaker field strengths15.  
Since the publication of this method, the founding members have been joined by other 
cohorts that share an interest in VRS research and acknowledge that questions 
regarding their etiology and clinical relevance are best answered through a combined 
effort. The Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement (UNIVRSE) 
consortium was formally established in 2013 and intends to study enlarged VRS using a 
harmonized approach. 
The UNIVRSE consortium currently consists of 13 (sub)cohorts from 5 countries and 
encompasses more than 16,000 persons with over 25,000 MRI scans (Table 1). It includes 
prospective, population-based cohort and family studies from various ethnicities and 
which have all previously been described in detail. A brief overview is provided below. 
Other cohorts that want to join the consortium are referred to the consortium website 
(www.uconsortium.org) for further details.  
Rotterdam Scan Study 
The Rotterdam Study is a Dutch prospective, population-based cohort study that aims to 
investigate causes and determinants of diseases in the elderly.17 A total of 14,926 
subjects aged 45 years or over at baseline were recruited in three subcohorts (1990, 
2000 and 2006) and they are still being followed up. MRI scanning is performed on all 
participants from 2005 onwards as part of the Rotterdam Scan Study, and is repeated 
every 3-4 years.18  
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Austrian Stroke Prevention Study  
The ASPS is a prospective cohort study on the effects of vascular risk factors on brain 
structure and function in cognitively normal middle-aged and elderly inhabitants of 
Graz, Austria.19  In brief, 2007 subjects aged 50 to 75 years without neuropsychiatric 
disease were randomly selected from the official community register, of which a random 
subset of 1,076 participants underwent MRI in two panels (1991-1994 and 1999-2003). 
Between 2006 and 2013, the Austrian Stroke Prevention Family (ASPS-Fam) study was 
recruited as an extension of ASPS using identical inclusion criteria and diagnostic work-
up with updated MRI protocols; ASPS-Fam included 381 members of the original ASPS 
cohort and their relatives. 
Study of Health in Pomerania  
The Study of Health in Pomerania (SHIP) is a longitudinal general population study from 
Greifswald, Germany that enrolled 4,308 middle-aged subjects in SHIP-0 (SHIP-0: 1997-
2001; SHIP-1: 2003-2006; SHIP-2: 2008-2012). In addition to SHIP, a new cohort was 
started in 2008 (SHIP-TREND) with 4,420 subjects.20 In SHIP-2 and SHIP-TREND whole 
body MRI scanning was performed in 3,317 subjects. The next follow-up starts in 
2014/2015 and includes a follow-up MRI scan. 
Framingham Heart Study  
The Framingham Heart Study (FHS) is a single-site, community-based, prospective 
cohort study initiated in 1948 to investigate risk factors for cardiovascular disease and 
comprises three generations of participants.   The original cohort of the Framingham 
Heart Study, Generation 1, consisted of 5,209 participants  from Framingham MA who 
were enrolled into the study in 1948 (mean age 44 years).  Generation 2 included 5,124 
offspring of the original cohort and their spouses who were enrolled into the study in 
1971 (mean age 36 years). Individuals from Generations 1 and 2 received an MRI of the 
brain between 1999-2004 and again between 2005-2011.21, 22 The Generation 3 cohort 
was initiated in 2000 and all subjects were scanned between 2009 and March, 2013.23  
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Epidemiology of Dementia in Singapore Study  
The Epidemiology of Dementia in Singapore (EDIS) Study draws participants from the 
Singapore Epidemiology of Eye Disease (SEED) Study, which is a population-based study 
among Chinese, Malays and Indians.24 EDIS aims to examine the prevalence of and 
investigate risk factors for cognitive impairment and dementia in these three major 
ethnicities of Singapore. A total of 865 subjects aged 60 years and over have been 
recruited between 2010-2013. Cranial MRI is performed in all the individuals.  
Erasmus Rucphen Family study  
The Erasmus Rucphen Family (ERF) study is a family-based cohort study in a genetically 
isolated population from a community in the South-West of the Netherlands (Rucphen 
municipality) including 3,000 deeply phenotyped participants. Participants with brain 
MRI scanning in ERF aged 55–75 years and had hypertension to ensure a high 
prevalence of pathology.25 Persons with a history of stroke or dementia or with MRI 
contraindications were excluded.  Details about subject selection can be found 
elsewhere.26, 27  
Epidemiological Prevention study Zoetermeer  
The Epidemiological Prevention study Zoetermeer (EPOZ) is a population-based follow-
up study that was initiated in 1975.28 It includes 10,361 subjects between 5 and 91 years 
old and originally focused on determinants of various chronic diseases. Participants 
underwent baseline MRI scanning in 1995-1996 and were rescanned in 1999-2000 and 
2008.29, 30 
Statistical analyses 
We will analyze enlarged VRS in a continuous manner when studying their potential 
determinants by employing negative binomial regression models that take into account 
the continuous nature of our visual rating scale. Depending on the specific research 
question, we will use the appropriate statistical tools to analyze the data (e.g., Cox 
regression models for time-to-event data, linear regression for continuous cognitive 
scores). 
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Figure 1 | Hypothesized etiologies for enlargement of Virchow-Robin spaces. 
 
 
Figure 2 | Virchow‐Robin spaces in the centrum semi‐ovale of various sizes. 
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RESULTS 
Study population 
Table 1 summarizes basic demographics and MRI protocols for each study in the 
UNIVRSE consortium. The consortium includes participants from a wide age range (19-
103 years), mainly sampled from a population-based setting. The RSS and ASPS have 
performed multiple rounds of MRI scanning and most of the other cohorts are still 
ongoing or reserve the possibility to perform an additional round of follow-up. 
Furthermore, participants were often part of other rounds of non-MRI data collection, 
since brain MRI was not always part of the core study protocol.  For most cohorts, a wide 
range of measurements are available, of which the most relevant are summarized in 
Table 2. 
Primary outcomes  
We previously developed a rating method that evaluates four regions in the brain where 
enlarged VRS occur frequently: the centrum semi-ovale, the basal ganglia, the 
hippocampus and the mesencephalon. The method was rigorously tested by six raters 
ranging from medical students to experienced specialists using MRI data from three 
different scanners, and showed excellent reliability.14 To promote the use of our VRS 
rating protocol, it has been made freely accessible through our website 
(www.uconsortium.org). Additionally, we have now extended the rating protocol to MRI 
data from the SHIP study: enlarged VRS were rated on the T1-weighted instead of the T2-
weighted sequence, which is the primary sequence for VRS rating but was of too low 
resolution in SHIP for identifying VRS. In order to evaluate how this affects reliability, 25 
scans from the RS with both good quality T1- and T2-weighted sequences were twice 
rated using each sequence separately, with good reliability (mean intraclass correlation 
coefficient = 0.8).  
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The UNIVRSE consortium aims to elucidate the etiology and clinical relevance of 
enlarged VRS. Therefore, it will first investigate potential determinants of enlarged VRS, 
including markers of cerebral small vessel disease, amyloid pathology, and genetic 
factors. Results of a preliminary analysis from only the founding members showed 
region-specific risk factors including sex, APOE genotype, and blood pressure, white 
matter hyperintensities, and lacunar infarcts.31  Additionally, the consortium is 
determining how presence of enlarged VRS affects cognition,3, 32, 33 and whether it is a 
useful marker for predicting diseases such as stroke2, 34, 35 and Alzheimer’s disease6. 
 
Figure 3 | Comparison of statistical power between the UNIVRSE consortium and the 
largest published study on Virchow-Robin spaces. 
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DISCUSSION 
Here we present our initial experiences with data harmonization and joint analyses in a 
large consortium of population neuroimaging studies. We used a robust visual rating 
method for measuring enlarged VRS, which was rigorously tested in three studies prior 
to implementation in the consortium, to decrease heterogeneity and promote inter-
study comparisons and collaboration. Importantly, this collaboration was initiated 
already in a relatively early phase of VRS research, with all the participating studies not 
having published separately using their own methodology, but instead first harmonizing 
ratings across sites and then jointly analyzing the data. For other imaging markers of 
cerebrovascular disease, such collaborative efforts typically follow decades of research 
using heterogeneous methods.1 Initial joint analyses prove the value of this 
collaboration compared to separate, underpowered efforts. 
 While there is an abundance of VRS rating methods, they are usually restricted to 
studies using only a single MRI protocol and only rate the VRS in a limited number of 
regions. Additionally, rating reliability is not always reported and some methods require 
complex transformations of images to perform the actual rating. A crucial step in the 
development process was defining a lower limit for the diameter of VRS to be 
considered enlarged, which has not been done by any rating method before. We 
operationalized enlargement as VRS  ≥ 1mm, while realizing this is an arbitrary 
threshold. However, counting all enlarged VRS, regardless of size, would mean that with 
increasing spatial resolution of the used MRI scanner, persons would have more 
“enlarged” VRS. Every study uses an implicit lower bound because of there is minimum 
size of enlarged VRS that can be detected, which is inherent to the field strength and 
protocol of the MRI scanner. Indeed, studies using a 3T MRI have found a 100% 
prevalence of enlarged VRS, in contrast with much lower prevalences on 1.5T images. 
Additionally, we found that using the T1-weighted images for the primary rating gave 
comparable results to T2-weighted images. This result further establishes our rating 
protocol as a method for reliably quantifying VRS burden, regardless of the sequence 
used for rating. 
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Furthermore, we focused on the ease of use and speed of the method and rated VRS 
only a single slice for the two larger regions (basal ganglia and centrum semi-ovale). 
However, we have counted all VRS in the brain for 40 scans and compared this to the 
single slice that we used in the rating. This showed a high correlation between our single 
slice approach and the total number in that region. Although counting all VRS would be 
ideal, it is extremely time-consuming and given these results also seems unnecessary to 
capture the VRS burden. Still, we could have chosen the most severe slice instead of the 
pre-defined slice that we use now. We made this decision because of two reasons: 1) 
allowing the rater to choose the ‘most severe’ slice adds an additional layer of 
subjectivity to the method, and 2) it is currently unknown whether the spatial 
distribution of VRS is differentially related to pathology. If, for example, parietal VRS are 
related to amyloid depositions, it would introduce bias when only rating certain subjects 
with respect to that part of the brain.  
Main strengths of the UNIVRSE consortium are: (i) the increased statistical power to 
detect associations, achieved by combining datasets; (ii) the harmonized approach of 
enlarged VRS rating, which facilitates the collaboration and allows for better 
comparisons; (iii) the inclusion of demographically diverse studies, with a broad range of 
phenotypic information available. 
Although our rating protocol has several advantages in comparison to other scales, all 
methods still rely on the human assessment of VRS and are therefore subjective in 
nature and labor intensive. However, we are concurrently working on the development 
of an automated segmentation method, which is particularly difficult for VRS. Also, the 
selection of the brain regions is based mostly on prevalence and current knowledge of 
VRS; therefore, new research could for example increase the interest in other regions 
and studying different pathology might also require changes in the protocol.Our future 
research will include other determinants such as markers of cerebral small vessel 
disease, amyloid pathology, and genetic factors. Also, we aim to determine how 
presence of enlarged VRS affects cognition, and whether it is a useful marker for 
predicting diseases such as Alzheimer’s disease and stroke. 
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CONCLUSIONS 
The UNIVRSE consortium is a global initiative that was established in the young field of 
enlarged VRS research. It aims to implement at an early stage the hard-learned lessons 
on the value of data harmonization and joint analyses from decades of population 
imaging. 
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2.3. Meta-analytical approach 
for pooled analysis without 
sharing individual participant 
data 
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2.4. Software for performing 
high-dimensional association 
studies  
 
 
HASE: Framework for efficient high-dimensional association analyses  
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ABSTRACT  
High-throughput technology can now provide rich information on a person's biological 
makeup and environmental surroundings. Important discoveries have been made by 
relating these data to various health outcomes in fields such as genomics, proteomics, 
and medical imaging. However, cross-investigations between several high-throughput 
technologies remain impractical due to demanding computational requirements 
(hundreds of years of computing resources) and unsuitability for collaborative settings 
(terabytes of data to share). Here we introduce the HASE framework that overcomes 
both of these issues. Our approach dramatically reduces computational time from years 
to only hours and also requires several gigabytes to be exchanged between 
collaborators. We implemented a novel meta-analytical method that yields identical 
power as pooled analyses without the need of sharing individual participant data. The 
efficiency of the framework is illustrated by associating 9 million genetic variants with 
1.5 million brain imaging voxels in three cohorts (total N=4,034) followed by meta-
analysis, on a standard computational infrastructure. These experiments indicate that 
HASE facilitates high-dimensional association studies enabling large multicenter 
association studies for future discoveries.  
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INTRODUCTION 
Technological innovations have enabled the large-scale acquisition of biological 
information from human subjects. The emergence of these big datasets has resulted in 
various ‘omics’ fields.  Systematic and large-scale investigations of DNA sequence 
variations (genomics)1, gene expression (transcriptomics)2, proteins (proteomics)3, small 
molecule metabolites (metabolomics)4, and medical images (radiomics)5, among other 
data, lie at the basis of many recent biological insights. These analyses are typically 
unidimensional, i.e. studying only a single disease or trait of interest.  
Although this approach has proven its scientific merit through many discoveries, jointly 
investigating multiple big datasets would allow for their full exploitation, as is 
increasingly recognized throughout the ‘omics’ world5–8. However, the high-dimensional 
nature of these analyses makes them challenging and often unfeasible in current 
research settings. Specifically, the computational requirements for analyzing high-
dimensional data are far beyond the infrastructural capabilities for single sites. 
Furthermore, it is incompatible with the typical collaborative approach of distributed 
multi-site analyses followed by meta-analysis, since the amount of generated data at 
every site is too large to transfer. 
Some studies have attempted to combine multiple big datasets5,8–10, but these methods 
generally rely on reducing the dimensionality or making assumptions to approximate 
the results, which leads to a loss of information. 
Here we present the framework for efficient high-dimensional association analyses 
(HASE), which is capable of analyzing high-dimensional data at full resolution, yielding 
exact association statistics (i.e. no approximations), and requiring only standard 
computational facilities. Additionally, the major computational burden in collaborative 
efforts is shifted from the individual sites to the meta-analytical level while at the same 
time reducing the amount of data needed to be exchanged and preserving participant 
privacy. HASE thus removes the current computational and logistic barriers for single- 
and multi-center analyses of big data. The HASE software is available at our website 
www.imagene.nl/HASE/.  
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RESULTS 
Overview of the methods 
The methods are described in detail in the Methods. Essentially, HASE implements a 
high-throughput multiple linear regression algorithm that is computationally efficient 
when analyzing high-dimensional data of any quantitative trait. Prior to analysis, data 
are converted to an optimized storage format to reduce reading and writing time. 
Redundant calculations are removed and the high-dimensional operations are simplified 
into a set of matrix operations that are computationally inexpensive, thereby reducing 
overall computational overhead. While deriving summary statistics (e.g., beta 
coefficients, p-values) for every combination in the high-dimensional analysis would be 
computationally feasible at individual sites with our fast regression implementation, it 
would be too large to share the intermediate results (>200GB per thousand phenotypes) 
in a multi-center setting. Therefore, extending from a recently proposed method, partial 
derivatives meta-analysis17, we additionally developed a method that generates two 
relatively small datasets (e.g. 5GB for genetics data of 9 million variants and 20MB of 
thousand phenotypes for 4000 individuals) that are easily transferred and can 
subsequently be combined to calculate the full set of summary statistics, without 
making any approximation. This meta-analysis method additionally reduces 
computational overhead at individual sites by shifting the most expensive calculation to 
the central site. The total computational burden thus becomes even more efficient 
relative to conventional methods with additional sites.  
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Comparison of complexity and speed 
We compared the complexity and speed of HASE with a classical workflow, based on 
linear regression analyses with PLINK (version 1.9)11 followed by meta-analysis with 
METAL12; two of the most popular software packages for these tasks.  
Table 1 shows that HASE dramatically reduces the complexity for the single site analysis 
and data transfer stages. For conventional methods, the single site analysis and data 
transfer have a multiplicative complexity (dependent on the number of phenotypes and 
determinants), whereas this is only additive for HASE.  Our approach requires 3.500-fold 
less data to transfer for a high-dimensional association study. Additionally, the time for 
single site analysis does not increase significantly from analyzing a single phenotype to a 
million phenotypes (Table 1). This is due to the fact that speed is determined by the 
highest number of either the determinants or phenotypes. Therefore, in this case with 
nine million genetic variants, the complexity of ࡻ൫࢔࢏࢔࢖൯ is the primary factor 
influencing the speed,whereas 	ࡻሺ࢔࢏࢔࢚	ሻ	plays a secondary role. 
This drastic increase in performance is made possible through the shift of the 
computationally most expensive regression operation to the meta-analytical stage. For 
the meta-analytical stage, the HASE complexity is therefore slightly higher. However, it 
outperforms the classical meta-analysis using METAL (total computation time reduced 
35 times), owing to the efficient implementation of our algorithm.  
Additionally, HASE can be used as a standard tool for high-dimensional association 
studies of a single site, i.e without subsequent meta-analysis or to prepare summary 
statistics for sharing with the central site as in a classical workflow. Although PLINK is a 
very popular tool for association analysis, it is not optimized for high-dimensional data 
sets. Therefore we compared the speed of such analyses to the recently developed tool 
RegScan13, which was developed for doing GWAS on multiple phenotypes and 
outperformed state-of-the-art methods. We conducted several experiments within the 
Rotterdam Study by varying the number of phenotypes and subjects, while keeping the 
number of variants fixed at 2.172.718 since the complexity of both programs is linear 
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with respect to number of variants. HASE outperformed RegScan and the difference 
becomes larger for increasing numbers of subjects and phenotypes (Figure 1).  
Application to real data 
We used HASE to perform a high-dimensional association study in 4,034 individuals from 
the population-based Rotterdam Study. In this proof of principle study, we relate 
8,723,231 million imputed genetic variants to 1,534,602 million brain magnetic 
resonance imaging (MRI) voxel densities (see Supplementary Note). The analysis was 
performed on a small cluster of 100 CPUs and took 17 hours to complete. 
To demonstrate the potential of such high-dimensional analyses, we screened all 
genetic association results for both hippocampi (7,030 voxels) and identified the voxel 
with the lowest p-value.  The most significant association (rs77956314; p = 3 x 10-9) 
corresponded to a locus on chromosome 12q24 (Figure 2), which was recently 
discovered in a genome-wide association study of hippocampal volume encompassing 
30,717 participants14. 
Additionally, we performed the high-dimensional association studies separately in three 
subcohorts of the Rotterdam Study (RSI = 841, RSII = 1003, RSIII = 2190, Supplementary 
Notes) and meta-analyzed the results using the HASE data sharing approach, as a 
simulation of a standard multicenter association study. This experiment required two 
steps. First, for each subcohort we generated intermediate data (matrices A, B and C 
from the Methods section). It took on average 40 minutes on a single CPU for all genetic 
variants and voxels. Second, the meta-analysis, which consist of merging intermediate 
data and running regressions, was performed on the same cluster and took 17 hours to 
complete using 100 cores. We compared the association results of the pooled analysis 
with the meta-analysis. Figure 3 shows that the results are identical as it was predicted 
by theory (see Methods). We would like to point out that for the classical approach with 
inverse-variance meta-analysis such an experiment would be not possible to conduct, as 
it would require generating and sharing hundreds of terabytes of summary statistics.    
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Figure 1 | Analysis time (HASE versus RegScan) with 2.172.718 variants.  
A – for 1 phenotype; B – for 100 phenotypes; C- for 1000 phenotypes.  
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Figure 2 | Manhattan plot of the hippocampus voxel with the most significant 
association after screening all 7030 hippocampal voxels. 
The most significant association (rs77956314; p = 3 x 10-9) corresponded to a previously 
identified locus on chromosome 12q24. Such voxel-wise hippocampus screening would take 
less than 8 hours on standard laptop. 
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DISCUSSION 
We describe a framework that allows for (i) computationally-efficient high-dimensional 
association studies within individual sites using standard computational infrastructure 
and (ii) facilitates the exchange of compact summary statistics for subsequent meta-
analysis for association studies in a collaborative setting. Using HASE, we performed a 
genome-wide and brain-wide search for genetic influences on voxel densities (more 
than 1.5 million GWAS analysis in total), and illustrate both its feasibility and potential for 
driving scientific discoveries. 
A large improvement in efficiency comes from the reduced computational complexity. 
High-dimensional analyses contain many redundant calculations, which were removed 
in the HASE. Also, we were able to further increase efficiency by simplifying the 
calculations to a set of matrix operations, which are computationally inexpensive, 
compared to conventional linear regression algorithms. Furthermore, the 
implementation of partial derivatives meta-analysis allowed us to greatly reduce the size 
of the summary statistics that need to be shared for performing a meta-analysis. Another 
advantage of this approach is that it only needs to calculate the partial derivatives for 
each site instead of the parameter estimates (i.e., beta coefficients and standard errors). 
This enabled us to develop within HASE a reduction approach that encodes data prior to 
exchange between sites, while yielding the exact same results after meta-analysis as if 
the original data were used. The encoding is performed such that tracing back to 
original data is impossible.  This guarantees protection of participant privacy and 
circumvents restrictions on data sharing that are unfortunately common in many 
research institutions.  
When using HASE, it is first necessary to convert the multi-dimensional data to «HDF518» 
format that is optimized for fast reading and writing. This particular format is not 
dependent on the architecture of the file system and can therefore be implemented on a 
wide range of hardware and software infrastructures. To facilitate this initial conversion 
step, we have built-in tools within the HASE framework for processing common file 
format of such big data. HDF5 allows direct access to the data matrix row/column from 
the disk through an index without reading the whole file(s) into memory.  Additionally, it 
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requires much less disk space to store data (Supplementary Notes).This is easily 
generalizable to other large omics datasets in general and we foresee this initial 
conversion step not to form an obstacle for researchers to implement HASE.  
Alternative methods for solving the issues with high-dimensional data take one of two 
approaches. One approach is to reduce the dimensionality of the big datasets by 
summarizing the large amount of data into fewer variables2. Although this increases the 
speed, it comes at the price of losing valuable information, which these big data were 
primarily intended to capture. The second approach is to not perform a full analysis of all 
combinations of the big datasets, but instead make certain assumptions (e.g., a certain 
underlying pattern, or a lack of dependency on potential confounders) that allow for 
using statistical models that require less computing time. Again, this is a tradeoff 
between speed and accuracy, which is not necessary in the HASE framework, where 
computational efficiency is increased without introducing any approximations. 
Unidimensional analyses of big data, such as genome-wide association studies, have 
already elucidated to some extent the genetic architecture of complex diseases and 
other traits of interest1,15–17, but much remains unknown. Cross-investigations between 
multiple big datasets potentially hold the key to fulfill the promise of big data in 
understanding of biology7. Using the HASE framework to perform high-dimensional 
association studies, this hypothesis is now testable. 
METHODS 
HASE 
In high-dimensional associations analyses we test the following simple regression 
model: 
 ܻ ൌ ܺߚ ൅ ߝ (1) 
 
where Y is a ni× np matrix of phenotypes of interest, ni denotes the number of samples in 
the study, np the number of phenotypes of interest, and ε denotes the residual effect.  X 
is a three dimensional matrix ni× nc × nt of independent variables, with nc representing 
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the number of covariates, such as the intercept, age, sex and, for example genotype as 
number of alleles, and nt the number of independent determinants.  
In association analyses we are interested in estimating the p-value to test the null 
hypothesis that β=0. The p-values can be directly derived from the t-statistic of our test 
determinants. We will rewrite the classical equation for calculating t-statistics for our 
multi-dimensional matrices, which will lead to a simple matrix form solution for high-
dimensional association analysis:   
 ܴܵܵሺߚሻ ൌ ሺܻ െ ܺߚሻ்ሺܻ െ ܺߚሻ (2) 
 ߲ܴܵܵ
߲ߚ ൌ െ2ܺ
்ሺܻ െ ܺߚሻ (3) 
 
 ߚመ ൌ ሺ்ܺܺሻିଵ்ܻܺ (4) 
 ܴܵܵሺߚሻ ൌ ்ܻܻ	 െ ்ܻܺሺ்ܺܺሻିଵ்ܻܺ (5) 
 
 ܶ ൌ ߚܵܧ ൌ
ߚ
ට݀݅ܽ݃ሺሺ்ܺܺሻିଵሻ ܴ݂ܵܵ݀
ൌ ሺܺ
்ܺሻିଵ்ܻܺ		
ට݀݅ܽ݃ሺሺ்ܺܺሻିଵሻ ்ܻܻ െ ்ܻܺሺ்ܺܺሻିଵ்ܻ݂ܺ݀
 
(6) 
 
 
Where T is np× nc × nt matrix of t-statistics and df is degree of freedom of our regression 
model. Let’s define  A ൌ X୘X	, B ൌ X୘Y	and	C ൌ Y୘Y, so that we can write our final 
equation for t-statistics:  
 
T ൌ ܣିଵBඨ ݂݀݀݅ܽ݃ሺܣିଵሻሺܥ െ ܤ்ܣିଵܤሻ 
(7) 
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The result of this derivation is that, rather than computing all combinations of covariates 
and independent determinants, we only need to know three matrices: A, B and C, to 
calculate t-statistics and perform the full analysis. These results will be used in the 
section about meta-analysis.  
The most computationally expensive operations here are the two multi-dimensional 
matrix multiplications ሺ࡭ି૚۰ሻ	and	ሺ࡮ࢀ࡭ି૚࡮ሻ, where	࡭ି૚	is a three dimensional 
matrix nc× nc × nt  and ۰	is three dimensional matrix nc× np × nt . Without knowledge of 
the data structure of these matrices, the simplest way to write the results of their 
multiplication would be to use Einstein’s notation for tensor multiplication: 
 ሺܣିଵBሻ௜୨୩ ൌ ሺܣିଵሻ௜௖௞ܤ௖௝௞ (8) 
 
 ሺܤ்ܣିଵܤሻ௝௞ ൌ ሺܤ்ሻ௜௝௞ሺܣିଵBሻ௜୨୩ 
ݓ݄݁ݎ݁ ݅ ൌ 1, ݊௖ሬሬሬሬሬሬሬሬԦ; ݆ ൌ 1, ݊௣ሬሬሬሬሬሬሬሬሬԦ; ݇ ൌ 1, ݊௧ሬሬሬሬሬሬሬሬԦܽ݊݀ ܿ ൌ 1, ݊௖ሬሬሬሬሬሬሬሬԦ 
(9) 
 
As you can see, the result is two matrices of nc× np × nt and np × nt elements respectively. 
Despite the seemingly complex notation, the first matrix just represents the beta 
coefficients for all combinations of covariates (nc by np × nt combinations) and the 
second is fitting values of the dependent variable for every test (np × nt independent 
determinants).  
However, insight into the data structure of A and B can dramatically reduce the 
computational burden and simplify operations. First of all, matrix A depends only on the 
covariates and number of determinants, making it unnecessary to compute it for every 
phenotype of interest, so we just need to calculate it once. Additionally, only the last 
covariate (i.e., the variable of interest) is different between tests, meaning that the (np -
1)×(np -1)×nt  part of matrix A remains constant during high-dimensional analyses. 
Matrix B consists of the dot product of every combination of the covariate and 
phenotype of interest. However, as we mentioned before, there are only (nt + nc 1) 
different covariates, and thus we can split matrix B in two low dimensional matrices: the 
first includes dot products of non-tested covariates - (nc-1)× np elements; the second 
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includes the dot products only of the tested covariates -  np × nt elements. Removing all 
these redundant calculations reduces the complexity of this step from O(nc2·ni·np·nt) to 
O(np· nt). All this allows us to achieve a large gain in computational efficiency and 
memory usage. In Figure 3 we show a 2D schematic representation of these two 
matrices for standard genome association study with the covariates being an intercept, 
age, sex, and genotype. This example could be easily extrapolated to any linear 
regression model.  
Applying the same splitting operation to ࡮ࢀ it is possible to simplify tensor 
multiplication equation (8, 9) to a low-dimensional matrix operation and rewrite the 
equation for t-statistics: 
 ሺܣିଵBሻ௜୨୩ ൌ ሺܣିଵሻ௜ఋ௞ܤఋ௝ ൅ ሺܣିଵሻ௜ఏ௞ܤఏ௝௞ (10) 
 ሺܤ்ܣିଵܤሻ௝௞ ൌ ሺܤ்ሻఋ௝ሺܣିଵBሻఋ୨୩൅ሺܤ்ሻఏ௝௞ሺܣିଵBሻఏ୨୩ (11) 
 
 
T ൌ ሺሺܣିଵሻ௜ఋ௞ܤఋ௝ ൅ ሺܣିଵሻ௜ఏ௞ܤఏ௝௞	ሻඨ
݂݀
݀݅ܽ݃ሺܣିଵሻ ൈ	
ሺܥ െ ቀሺܤ்ሻఋ௝൫ሺܣିଵሻ௜ఋ௞ܤఋ௝ ൅	ሺܣିଵሻ௜ఏ௞ܤఏ௝௞൯௝௞
ఋ
൅			 ሺܤ்ሻఏ௝௞൫ሺܣିଵሻ௜ఋ௞ܤఋ௝
൅ ሺܣିଵሻ௜ఏ௞ܤఏ௝௞൯௝௞
ఏ ቁ ሻିଵଶ 
(12) 
 
Then, to compute t-statistics for high-dimensional association analyses we just need to 
perform several matrix multiplications.  
Meta-analysis 
In classical meta-analysis, summary statistics such as beta coefficients and p-values are 
exchanged between sites. For 1.5 million phenotypes, this would yield around 400TB of 
data at each site, making data transfer to a centralized site impractical. 
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In the previous section we showed that, to compute all statistics for an association study, 
we just need to know the A, B and C matrices. As we demonstrated before17, by 
exchanging these matrices between sites, it is possible to gain the same statistical power 
as with a pooled analysis, without sharing individual participant data, because these 
matrices consist of aggregate data (Figure 4). However, in high-dimensional association 
analyses, matrix B grows very fast, particularly the part that depends on the number of 
determinants and phenotypes (b4 in Figure 3).   
If Y is a ni× np matrix of phenotypes of interest and G is a ni× nt matrix of determinants 
which we want to test (e.g., a genotype matrix in GWAS), then b4 = YT× G. These two 
matrices, Y and G, separately are not so large, but their product matrix has np× nt 
elements, which in a real application could be 106×107 =1013 elements and thus too large 
to share between sites. We propose to create a random ni× ni nonsingular square matrix 
F and calculate its inverse matrix F-1.  Then by definition F× F-1=I, where I is a ni× ni 
elements identity matrix with ones on main diagonal and zeros elsewhere.  Using this 
property, we can rewrite the equation for b4: 
 ܾସ ൌ ்ܻ ൈ ܩ (13) 
 ܾସ ൌ ்ܻ ൈ ሺܨ ൈ ܨିଵሻ ൈ ܩ (14) 
 
 ܾସ ൌ ሺ்ܻ ൈ ܨሻ ൈ ሺܨିଵ ൈ ܩሻ (15) 
 
 ܾସ ൌ ி்ܻ ൈ ܩி  (16) 
where YF  and GF  are  matrices carrying phenotypic and determinant information in 
encoded form respectively.Therefore, instead of transferring TBs of intermediate 
statistics (b4), each side just needs to compute A, C, YF and GF.  Sharing just the encoded 
matrices does not provide information on individual participants and without knowing 
matrix F it is impossible to reconstruct the real data. However, it will be possible to 
calculate b4, perform a high-dimensional meta-analysis, and avoid problems with data 
transfer. Additionally, this method dramatically reduces computation time by shifting all 
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complex computations to central site, where the HASE regression algorithm should be 
used to handle the association analysis in a time efficient way.  
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ABSTRACT 
Jaunmuktane and colleagues reported on eight persons of short stature who had been 
treated with preparations of human-derived growth hormone and subsequently 
developed iatrogenic Creutzfeldt–Jakob disease (CJD)1. On autopsy, the authors found 
marked deposition of parenchymal and vascular amyloid-β (Aβ), which was unexpected 
given the relatively young age (36–51 years) of the patients. The selected comparator 
group included patients with sporadic CJD, who were not of short stature and did not 
receive any growth hormone treatment. These sporadic cases did not show marked Aβ 
pathology. Although the authors make an interesting case for iatrogenic transmission of 
Aβ pathology, their findings could also be explained by two notable differences 
between the eight growth-hormone-treated patients and the comparator group: the 
indication for growth hormone treatment and the treatment itself.  
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MAIN TEXT 
The eight patients at the centre of this study received growth hormone treatment for 
various reasons, including panhypopituitarism (numbers 1, 2, 7), mental retardation 
(number 2), microcephaly (number 2), craniopharyngioma (number 5), and idiopathic 
short stature (numbers 3, 4, 6, 8). The cases with marked Aβ deposition (numbers 4, 5, 6, 
8) were generally of short stature owing to unknown causes. Common to this 
heterogeneous group of patients is the lack of endogenous growth hormone, a 
hormone that plays an important role in learning and memory, synaptic plasticity, 
neurogenesis, and is considered as a treatment for patients with cognitive impairment 
resulting from its deficiency2. Insulin-like growth factor-1 (IGF-1) is one of the main 
downstream targets regulated by growth hormone and supports cell survival and 
growth at multiple levels, with IGF-1 being important in the brain. It plays a well-
documented role in many aspects of neurodegeneration, including Alzheimer’s 
disease3,4, and IGF-1 promotes Aβ production5,6. Lack of IGF-1 has been proposed to 
cause neurodegenerative disorders such as Alzheimer’s disease owing to the disturbed 
trophic support to neurons (for a review, see ref. 7). Absence or reductions in IGF-1 can 
thus promote neurodegeneration and, particularly worrying for the conclusion of 
Jaunmuktane et al. increase Aβ depositions. This mechanism is similar to the lack of 
insulin seen in type 1 diabetes. In other words, the underlying disease state, which was 
the indication to start growth hormone treatment, can act as a shared cause of Aβ 
deposition and — through treatment with human-derived growth hormone — CJD. This 
should therefore be considered a confounder of the effect under study (that is, 
confounding by the indication of growth hormone treatment). The comparator group 
presented by Jaunmuktane et al. does not allow for confounding adjustment, as all 
exposed (that is, growth-hormone-treated) individuals are growth-hormone deficient 
(and of short stature) and all unexposed individuals are not, which means any 
differences between the comparator groups could also be explained by growth 
hormone deficiency. 
Furthermore, growth hormone treatment itself should have been considered as an 
important alternative cause of the Aβ deposition. Although this might seem 
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counterintuitive, as increased IGF-1 levels should increase Aβ clearance, this alternative 
explanation is not without support. Both low and high levels of IGF-1 have been 
observed in neurodegenerative diseases, and this is also the case for Alzheimer’s 
disease8,9. It has been proposed that this is due to an abundance of IGF-1 that reduces 
the sensitivity of the cells7. Given the long-term treatment of patients with growth 
hormone, where the complex circadian and age-dependent rhythm of growth hormone 
secretion is not taken into account, it is plausible that this led to cell resistance to IGF-1. 
This mechanism is similar to the increased levels of insulin (to which patients are 
resistant) seen in type 2 diabetes. Therefore, growth hormone treatment could possibly 
lead to the development of Aβ depositions in individuals at an earlier age than if 
untreated. Similar to the previous point, this would also confound the authors’ 
interpretation, in this case confounding by growth hormone treatment. 
The authors mention prion disease as an improbable cause for their findings, for 
example, through protein cross-seeding or clearance overload, which they attempt to 
rule out by comparing the iatrogenic CJD patients to sporadic cases. On the basis of the 
lack of marked Aβ depositions in the sporadic cases, the authors concluded that prion 
disease does not predispose to Aβ depositions and thus another factor must cause these 
deposits. This conclusion does not appear fully warranted as the excess of Aβ in 
iatrogenic CJD  compared to sporadic CJD does not indicate whether prion disease 
causes Aβ depositions (independently of this other factor). In other words, by restricting 
the study to patients who all have prion disease, the effect of prion disease compared to 
no prion disease cannot be examined. A comparison of persons with CJD to those 
without CJD but who are similar with regard to important confounders (for example, 
age, sex, other medical conditions and treatments) would better inform such an effect, 
as has been done in a previous study10. Although the greater deposition of Aβ in the 
iatrogenic CJD cases compared to the sporadic CJD therefore does not prove or disprove 
prion disease as a cause for this, we agree with the authors that this points to a factor 
other than prion disease causing the additional Aβ deposits. We have already 
mentioned the indication for growth hormone treatment and the growth hormone 
treatment itself as two plausible causes for Aβ deposits; the authors focus on the 
potential human transmissibility. On the basis of the data presented by the authors 
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alone, it is not possible to determine which factor or factors are actually causal; their 
findings are consistent with multiple explanations. 
Given that the results of Jaunmuktane et al. are inconclusive in this respect, what data 
would help to disentangle the hypothesized transmissibility from these competing 
explanations? One study design option would entail comparing persons of short stature 
who received synthetic versus human-derived growth hormone, as the synthetically 
produced treatment could not transmit any infectious agent from another person. We 
understand the difficulty concerning persons treated with synthetic hormone as a 
comparator group, as they have longer expected lifespans than those with (iatrogenic) 
 
Figure 1 | Causal diagram showing the proposed causal pathway, the authors’ 
interpretation, the two confounding biases and the inappropriate conditioning on 
presence of prion disease. 
Horizontal arrows depict the known causal pathway of growth hormone deficiency being the 
indication for growth hormone treatment, which is administered using human-derived 
growth hormone injections, which in turn can cause CJD if contaminated with prions. The 
numbered arrows indicate possible effects on Aβ deposition. From their data, the authors 
conclude (see below) that CJD could not have a direct effect, that is, that the arrow IV is not 
present. The authors then conclude that the shared cause must lie in the human-derived 
growth hormone injections (arrow III), which they infer contained infectious prions as well as 
infectious amyloid. However, there are two alternative shared causes for the co-occurrence of 
prion disease and amyloid, namely the indication of growth hormone treatment (arrow I) and 
the treatment itself (arrow II). In the current study design, these alternative explanations are 
therefore confounders of the proposed arrow III if arrows I and/or II are present. The authors 
sought to rule out arrow IV by comparing iatrogenic CJD patients with sporadic CJD patients. 
However, in this comparison all included patients have prion disease, which thus entails 
conditioning on the exposure (indicated with the square box around prion disease). While this 
comparison may suggest that another factor is causing additional Aβ (e.g, arrows I–III), it does 
not inform about prion disease causing Aβ deposition; that is, arrow IV cannot be proven or 
ruled out. Finally, for simplicity, the causal diagram above does not include additional 
unmeasured shared causes; in particular, if prion disease and Aβ deposition shared other 
causes beyond those described here, then additional confounding and/or selection biases 
invalidating the authors’ interpretation may also be present.
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CJD. Although neuropathology in a comparable age group will therefore be relatively 
difficult to obtain, non-invasive methods to quantify Aβ depositions in the brain, for 
example using positron emission tomography (PET) imaging, might be useful. Four 
possible causes of the marked deposition of Aβ are summarized in Table 1 along with, 
for each of these factors, consistency with the findings of Jaunmuktane et al., and the 
emphasized conclusion of the authors. Figure 1 depicts the suspected confounding 
biases in the current study design11. 
In conclusion, the study presented by Jaunmuktane et al. is consistent with multiple 
explanations for the marked deposition of Aβ. However, the authors emphasize one 
hypothesis indirectly supported by the data over other hypotheses, although a 
considerable body of previous empirical evidence argues in favour of these alternative 
explanations. Furthermore, the improbable explanation of CJD cross-seeding was 
disregarded on the basis of experiments that provide no such evidence, and was 
subsequently discussed at length whereas the plausible alternatives have not been 
mentioned. For these reasons, and in particular given the public health implications 
incited by the publicity of the Jaunmuktane et al. study12, it is imperative to carefully 
consider confounders and study design13,14 when weighing the possibility of human 
transmissibility of Aβ. 
  
Table 1 | Four potential causes of marked Aβ deposition in persons of short stature 
treated with human growth hormone and subsequently developing iatrogenic CJD. 
Potential cause of Aβ deposition* Consistency of the 
purported causal 
effect with findings 
Stated 
conclusions from 
the authors 
Short stature (vs normal stature) Yes Not discussed 
GH treatment (vs no GH treatment) Yes Not discussed 
Human-derived GH (vs synthetic GH) Inconclusive† Causal 
Prion disease (vs no prion disease) Inconclusive‡ Not causal 
The first column shows four potential causes for the observed Aβ deposition in persons of 
short stature who were treated with human-derived growth hormone and developed CJD as a 
result of prion transmission (and their causal contrasts in parentheses). The second column 
indicates whether the causes are consistent with the findings of Jaunmuktane et al., whereas 
the third column contains the conclusions of the authors. 
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ABSTRACT 
Intracranial volume reflects the maximally attained brain size during development, and 
remains stable with loss of tissue in late life. It is highly heritable, but the underlying 
genes remain largely undetermined. In a genome-wide association study of 32,438 
adults, we discovered five novel loci for intracranial volume and confirmed two known 
signals. Four of the loci are also associated with adult human stature, but these 
remained associated with intracranial volume after adjusting for height. We found a high 
genetic correlation with child head circumference (ρgenetic=0.748), which indicated a 
similar genetic background and allowed for the identification of four additional loci 
through meta-analysis (Ncombined = 37,345). Variants for intracranial volume were also 
related to childhood and adult cognitive function, Parkinson’s disease, and enriched 
near genes involved in growth pathways including PI3K-AKT signaling. These findings 
identify the biological underpinnings of intracranial volume and their link to 
physiological and pathological traits.  
Genome-wide association study of intracranial volume 
 97 
3 
INTRODUCTION 
The intricate genetic control of the human brain, complemented by environmental 
factors, leads to the observed variations in brain size in human populations1. Intracranial 
volume is closely related to brain volume in early life as the brain grows.2,3 However, it 
becomes stable after the brain has fully developed and remains unaffected by later age-
related changes such as brain atrophy4,5, thus representing the maximal attained brain 
size. Discovering genetic variants that influence intracranial volume can contribute to 
our understanding of brain development and related diseases, but prior studies have 
only identified two influential genetic loci6-9.  
Here, we performed genome-wide association studies in populations from the Cohorts 
for Heart and Aging Research in Genomic Epidemiology (CHARGE)10 and Enhancing 
NeuroImaging Genetics through Meta-Analysis (ENIGMA)11 consortia on intracranial 
volume measured by magnetic resonance imaging. Genotypes were imputed to the 
1000 Genomes reference panel (phase 1, version 3). Meta-analysis revealed five novel 
loci associated with intracranial volume. We also discovered genome-wide overlap 
between intracranial volume and other key traits including height, cognitive ability, and 
Parkinson’s disease. Furthermore, we found relatively enriched patterns of association 
for certain functional categories of variants and near genes that are involved in specific 
pathways.  
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RESULTS 
Genome-wide association studies 
Detailed information on the population characteristics, image acquisition and 
processing, and genetic quality control can be found in the Online Methods and 
Supplementary Tables S1-3. 
The discovery meta-analysis (N = 26,577) yielded seven genome-wide significant (p < 5 x 
10-8) loci, five of them novel (Figures 1-2; Table 1). The quantile-quantile plot showed 
inflation (λ = 1.092; Figure S1), which we determined to be mainly due to polygenicity 
rather than cryptic relatedness or population stratification using LD score regression12. 
Next we analyzed European samples (N = 2,362; not included in the discovery sample) 
and generalization samples with African (N = 938), Asian (N = 955), and Hispanic (N = 
1,605) ancestries (Table 1). All variants had the same direction of effect in the additional 
European samples (sign test, P = 0.0078), and three variants replicated, at nominal 
significance. Although sample sizes were small for the non-Europeans, here too, the 
direction of effect was generally concordant (sign test, P = 0.039). Five nominally 
significant associations were detected across all three ethnicities.  
Next we were able to map the association to novel variants for two previously identified 
loci at 17q21 (rs199525; P = 3.8 x 10-21) and 6q22 (rs11759026; P = 2.2 x 10-20)6,7. The five 
novel loci were on 6q21 (rs2022464; P = 3.7 x 10-11), 10q24 (rs11191683; P = 1.1 x 10-10), 
3q28 (rs9811910; P = 2.0 x 10-9), 12q14 (rs138074335/ rs7312464; P = 6.2 x 10-9), and 
12q23 (rs2195243; P = 1.5 x 10-8). Functional annotation of the variants and those in LD 
(r2 >0.8) can be found in Table S4.  
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Figure 2 | Regional association and functional annotation of novel genome-wide 
significant loci. 
Regional association plots for the five novel genome-wide significant loci of intracranial 
volume with gene models below (GENCODE version 19). Annotation tracks below from the 
Roadmap Epigenomics Consortium57 highlight the genomic region that likely harbors the 
causal variant(s) (r2 > 0.8 from the top SNP). See Methods for detailed track information. 
Generated using LocusTrack (http://gump.qimr.edu.au/general/gabrieC/LocusTrack/). 
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Height-adjusted analyses 
Four of the seven loci for intracranial volume were previously discovered for height 
(17q21, 6q22, 6q21, and 12q14), prompting us to investigate genome-wide overlap 
between the two traits. As height and intracranial volume are correlated (weighted 
average Pearson’s r = 0.556; Supplementary Table S5) and this could drive association 
signals, we performed a GWAS of intracranial volume adjusted for height in the studies 
that had measured height (N = 21,875). Findings were compared to the corresponding 
subset of studies without adjustment (N = 22,378). Using LD score regression (Online 
Methods), we found that there is considerable genetic correlation between intracranial 
volume and height (ρgenetic = 0.241, P = 2.4 x 10-10), which disappears after adjusting for 
height (ρgenetic = 0.049, P = 0.21) (Table 2). The associations of the seven intracranial 
volume loci, however, remained significant after adjusting for height (Supplementary 
Table S6). To investigate whether more height loci were associated with intracranial 
volume independently of height, we analyzed all 697 genome-wide significant height 
variants13. An additional 73 variants (10.7%; 14 variants not available) showed nominally 
significant associations with intracranial volume but were not attenuated after 
adjustment for height, although none survived Bonferroni correction (Supplementary 
Table S7). For some variants, the direction of effect was discordant, i.e. positive for height 
and negative for intracranial volume. Furthermore, a polygenic score of the 697 variants 
predicted intracranial volume, and this was also the case after adjustment for height in a 
subset of the studies (Supplementary Table S8).  
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Genetic correlation 
In addition to height, we examined the genome-wide genetic overlap between 
intracranial volume and other anthropometric traits, cognitive function, and 
neurodegenerative diseases (Table 2). We found a strong genetic correlation with child 
head circumference (ρgenetic = 0.748), which validates intracranial volume as a measure of 
brain growth during early development. Since this high correlation indicates that the 
genetic determinants of intracranial volume and child head circumference are largely 
shared, we aimed to leverage this information by performing a meta-analysis of both 
traits. The meta-analysis (combined N = 37,345) led to the identification of four novel loci 
(Figure 3; Supplementary Table S9). 
Weaker correlations were found with birth length and weight (ρgenetic < 0.3), which 
attenuated after adjusting for height. Additionally, intracranial volume was genetically 
correlated with cognitive function in childhood (ρgenetic = 0.277, P = 2.2x10-3) as well as 
general cognitive function in middle-aged and older adults (ρgenetic = 0.202, P = 6.3x10-4). 
Furthermore, we found a positive genetic correlation with Parkinson’s disease (ρgenetic = 
0.315, P = 6.6 x 10-7), but there was no significant genetic overlap with Alzheimer’s 
disease, white matter lesions, and psychiatric traits. 
Enrichment analyses 
Next, we assessed whether particular subsets of genetic variants were enriched for 
association with intracranial volume using partitioned heritability and pathway analyses 
(Online Methods). Overall, we found that common variants genotyped from across the 
whole genome explained 25.42% (S.E. 2.73%) of the variation in intracranial volume. 
Partitioning heritability by chromosome showed that chromosome 22 contributed 
twofold more to variation in intracranial volume than would be expected by its size 
(Figure 4A), which was not seen for any of the other complex traits from the genetic 
correlation analysis (Supplementary Figure S2). Partitioning by functional elements 
showed an enrichment for introns and several histone codes that are found in actively 
transcribed promoters (Figure 4B). The enrichment for intronic variants was specific to 
intracranial volume, whereas the other functional classes were also enriched in other 
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complex traits (Supplementary Figure S3).  We also found that loci associated with 
intracranial volume cluster around genes involved in specific pathways, with 94 
pathways significantly enriched (Figure 4C; full list in Supplementary Table S10). These 
pathways included all cell cycle components – the M-, G1-, S-, and G2-phases – and 
various growth factor signaling pathways, including PI3K-AKT. 
Head growth trajectories 
Although intracranial volume reflects brain development until maturation, and we 
identified influences of many growth-related processes contributing to its variation, all 
loci were still discovered via cross-sectional associations in adults. Therefore, we tested 
whether a polygenic score of the 7 loci could predict head growth in a longitudinal 
cohort of 2,824 children of European ancestry followed prenatally until 6 years of age 
(Online Methods). We found that a higher polygenic score, representing a genetically 
larger intracranial volume in adults, was also associated with a larger child head 
circumference (β = .031 per SD, P = 0.010). Furthermore, the effect of the polygenic score 
was age-dependent and more prominent in older children (β = 0.0080 per SD polygenic 
score per year age, Pinteraction = 0.0091). When investigating the individual loci separately, 
both 17q21 and 12q14 showed significant associations with child head circumference, 
but they influenced the trajectories of head growth differently (Figure 4A-B). For 17q21, 
the negative impact of the G allele on head circumference becomes apparent 
postnatally and increases towards six years, whereas the 12q14 locus exerts an effect 
from early pregnancy to one year of age, but is less prominent later in life.
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Figure 4 | Enrichment analyses of common variants associated with intracranial volume. 
Enrichment of subsets of variants for association with intracranial volume: A) by chromosomes, B) by 
functional subtype, and C) by pathway. See Online Methods for additional information. 
 
Figure 5 | Temporal trends of intracranial volume loci during pre- and postnatal brain 
development. 
Mean predicted values of standardized head circumference using linear mixed models with age, sex, and 
the rs199525 or rs138074335 variants. The blue line represents children not carrying the risk allele, purple 
only a single risk allele, and red with two risk alleles. See Online Methods for additional information. Total 
sample size is 2,824.
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DISCUSSION 
Genes contributing to variation in the size of the human brain remain challenging to 
discover. In a worldwide project of unprecedented scale, we performed the largest-ever 
meta-analysis of genome-wide association studies of intracranial volume. We discovered 
five novel genetic loci associated with intracranial volume, and replicated two known 
signals. The discovery sample included Europeans only, but the direction of effect was 
similar in other ethnicities. The genes in these loci provide intriguing links between 
maximal brain size and various processes, including neural stem cell proliferation 
(FOXO3), neurodegeneration (MAPT), bone mineralization (CENPW), growth signaling 
(IGF1, HMGA2), DNA replication (GMNC), and rRNA maturation (PDCD). On a genome-
wide scale, we discovered evidence of genetic correlation between intracranial volume 
and other key traits such as height and cognitive function, and also with Parkinson’s 
disease, indicating that the genes underlying brain development have far-reaching 
effects well beyond the initial years of life.  
The 17q21 locus tags a 1Mb inversion that is under positive selection in Caucasians14. It 
contains multiple genes including the MAPT and KANSL1. The MAPT gene is consistently 
implicated in various neurodegenerative disorders including Parkinson’s disease, 
Alzheimer’s disease, and frontotemporal dementia15,16, and microduplications have been 
reported to cause microcephaly17. KANSL1 causes the reciprocal 17q21.31 microdeletion 
syndrome - a multisystem disorder with intellectual disability, hypotonia and distinctive 
facial features18. The signal at 6q22 is intergenic to CENPW and RSPO3, but now lies 
172kb closer to CENPW. Interestingly, multiple variants at this locus independently 
influence bone mineral density19,20, and our signal particularly overlaps with the variant 
showing high specificity for the skull20. 
The significant variants at chr 6q21 span FOXO3, a gene associated with longevity21, 
height13, and serum IGF1 levels22. FOXO3 regulates the proliferation of neural stem cells, 
and knockout mice show larger brains resulting from increased proliferation 
immediately after birth23, followed by a decrease in adult neural stem cell renewal23,24. 
The rs3800229 variant in strong LD with our top variant (r2 = 0.84) contains chromatin 
promoter marks in the fetal brain (Supplementary Table S4), and regulates serum IGF1 
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levels in infants25. This provides a link to the genome-wide significant locus on chr12q23 
near IGF1, pointing to a potential mechanism through which these loci may affect brain 
growth. Chr12q23 lies 20Mb from one of two loci previously detected for head 
circumference in children26, but that region was not associated with intracranial volume 
in our study (rs7980687; P = 0.06). The other reported child head circumference locus, 
however, corresponded to our chr12q14 signal, with the top variant lying 14kb 
downstream of HMGA2, and already showed suggestive association with intracranial 
volume in a previous report7. It has also previously been associated with height13 and is 
essential for growth27. The chr10q24 LD-block covers multiple genes, but an intronic 
variant within PDCD11 is most significant. PDCD11 encodes an NF-kappa-B-binding 
protein required for rRNA maturation and generation of 18S rRNA28. A variant in LD 
(rs7894407) has recently been identified in a GWAS of cerebral white matter 
hyperintensities29. The top chr3q28 variant is located upstream of GMNC, which codes 
for the geminin coiled-coil domain-containing protein essential for DNA replication30. 
Prior efforts to identify variants affecting intracranial volume were much smaller and 
critically did not adjust for height6-9. We found that 4 out of 7 loci were already 
discovered for height13, but also that over 10% of the known ‘height loci’ actually affect 
intracranial volume, even after regressing out height. Interestingly, some variants 
showed discordant associations for height and intracranial volume - in line with the 
recent finding that different height loci disproportionally affect either leg length or 
spine/head length31 and may be a marker for pathological development32.  Also, height 
might thus serve as a proxy phenotype for intracranial volume, with the tenfold larger 
sample of the height GWAS giving greater power to detect associations. Neural genes 
are also enriched in pathway analyses of height13. However, to fully disentangle whether 
these identified genes are ‘height genes’, ‘brain volume genes’, or ‘growth genes’ (i.e., 
pleiotropic), a large collaborative effort is needed that examines the association of these 
variants with both intracranial volume and height under various models. 
When investigating genome-wide overlap with other traits, we found a strong 
correlation with child head circumference, underlining that intracranial volume is valid 
measure for maximal attained brain size. We were able to leverage this genetic link by 
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meta-analyzing both traits, which led to the identification of four additional loci (2q32.1, 
3q23, 7p14.3, 22q13.2). The correlations with birth length and weight were weaker and 
decreased further after adjusting for height, so a similar phenotypic correlation between 
head size and body size at younger age may drive these correlations. Intracranial volume 
was also genetically associated with cognitive function in childhood as well as general 
cognitive function in middle-aged and older individuals. This indicates that variation in 
maximally attained brain size during development shares a genetic basis with cognitive 
ability later in life and supports intracranial volume as a measure of brain reserve5.  
The brain reserve hypothesis states that premorbid brain size can modify resilience to 
age-related brain pathology33, but there was no indication of a genome-wide overlap 
with Alzheimer’s disease. However, we found a positive genetic correlation with 
Parkinson’s disease that rather points to a brain “overgrowth” hypothesis. Interestingly, 
the IGF1 and the PI3K-AKT pathways, key factors in both growth signaling and our 
current study of intracranial volume, are neuroprotective in a model system of 
Parkinson’s disease34. There were no correlations with other neurological or psychiatric 
traits, indicating that this finding might be specific to Parkinson’s disease. However, it is 
important to note that there is a certain extent of variation in the sample size and power 
of these studies, and larger GWAS might reveal genetic correlation with other traits as 
well. 
It is not yet known if variance in intracranial volume, within the normal range, 
contributes to disease risk or brain reserve. There is no doubt that in the pathological 
extremes of the distribution, size can matter, as in disorders such as microcephaly or 
macrocephaly. Here we found evidence for a shared genetic background between 
intracranial volume and cognitive function, and risk of Parkinson’s disease. While not 
definitive, these are novel pieces of empirical evidence in the debate on whether or not 
whole brain size matters. 
The pathway analyses highlight cellular growth and proliferation and included all 
components of the cell cycle (M-, G1-, S-, and G2-phase) and various growth factor 
signaling pathways. PI3K-AKT signaling has a well described role in brain overgrowth 
disorders35,36, and was the only significant pathway using a different pathway analysis 
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method (Supplementary Table S11). Interestingly, AKT3 intronic variants showed 
suggestive evidence for association with intracranial volume (rs7538011; P = 9.2 x 10-7). 
Deletions of AKT3 cause microcephaly syndromes37, whereas duplications give rise to 
macrocephaly38. Similar to FOXO3, it is part of the IGF1 signaling pathway, which is 
important for human longevity39. The PI3K-AKT signaling pathway seems to have an 
important role in brain growth, not only in pathological extremes, but also for normal 
variation at a population level. Other pathways enriched for association with intracranial 
volume highlight neuronal functions such as neurotransmission and axon guidance. 
We identified novel loci all influencing intracranial volume and, at a genome-wide level, 
there seem to be common pathways, but our longitudinal study reveals that their 
developmental effects are complex. The loci influenced trajectories of head growth 
differently; it also would be interesting to investigate whether their spatial profiles of 
effects are distinct, where certain loci promote growth of particular brain regions. 
Here we identified key genetic loci implicated in intracranial volume within a global 
collaborative effort, followed by computational analyses to determine the important 
biological pathways and functional elements. While the majority of the genetic variants 
are yet to be discovered, it is clear that these will provide better insight into brain 
development, but also into related neuropsychiatric traits such as cognitive functioning 
and even for neurodegeneration late in life. Uncovering the remaining heritability will 
advance our understanding of the brain’s complex genetic architecture. 
METHODS 
Study population 
This study reports data on 32,438 subjects from 52 study sites that are part of the 
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)10 consortium 
and Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA)11 consortium. 
Briefly, the CHARGE consortium is a collaboration of predominantly population-based 
cohort studies that investigate the genetic and molecular underpinnings of age-related 
complex diseases, including those of the brain. The ENIGMA consortium brings together 
numerous studies, mainly with a case-control design, which performed neuroimaging in 
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a range of neuropsychiatric or neurodegenerative diseases, as well as healthy normative 
populations. Studies participated in either the discovery cohort of European ancestry, 
the replication in European ancestry, or the generalization to other ethnicities. An 
overview of the demographics and type of contribution for each cohort is provided in 
Supplementary Table S1. Written informed consent was obtained from all participants. 
Each study was approved by the respective Institutional Review Board or Local Ethics 
Committee. 
Genetics 
Genotyping was performed using a variety of commercial arrays across the contributing 
sites. Both samples as well as variants underwent similar quality control procedures 
based on genetic homogeneity, call rate (less than 95%), minor allele frequency (MAF < 
0.01), and Hardy-Weinberg Equilibrium (HWE p-value less than 1 x 10-6). Good quality 
variants were used as input for imputation to the 1000 Genomes reference panel (phase 
1, version 3) using validated software packages (MaCH/minimac, IMPUTE2, BEAGLE, 
GenABLE). Variants that were poorly imputed (R2 < 0.5) or uncommon (MAF < 0.5%) were 
removed prior to meta-analysis. Full details on the site-specific genotyping and quality 
control may be found in Supplementary Table S2.  
Imaging 
Magnetic resonance imaging (MRI) was obtained from scanners with a diversity of 
manufacturers, field strengths, and acquisition protocols. Images were used to estimate 
milliliters of intracranial volume from automated segmentations generated by freely 
available or in-house methods that have been described and validated earlier. Most sites 
measured intracranial volume for each participant by multiplying the inverse of the 
determinant of the transformation matrix required to register the subject’s MRI scan to a 
common template by the template volume (1,948,105 mm3), using the FreeSurfer 
software. Visual inspections were performed to identify and remove poorly segmented 
images. Either all scans were visually inspected, or sites generated histogram plots to 
identify any outliers, which were defined as individuals with a volume more than three 
standard deviations away from the mean. Statistical outliers were only excluded if the 
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segmentations were deemed improper. . More site-specific information related to the 
imaging is available in Supplementary Table S3.  
Genome-wide association studies 
Genome-wide association studies of intracranial volume were performed for each site 
separately, controlling for age, sex, and, when applicable, age2, population stratification 
variables (MDS / principal components), study site (for multi-site studies only), diagnosis 
(for case-control studies only). Studies of unrelated individuals performed a linear 
regression analyses whereas studies of related individuals (ASPSFam, BrainSCALE, ERF, 
GeneSTAR, GOBS, NeuroIMAGE, NTR-Adults, OATS, QTIM, SYS) used linear mixed models 
to account for familial relationships. Summary statistics, including the effect estimates of 
the genetic variant with intracranial volume under an additive model, were exchanged 
to perform a fixed-effects meta-analysis weighting for sample size in METAL40. After the 
final meta-analysis, variants were excluded if they were only available for fewer than 
5,000 individuals.  Meta-analyses were stratified by race and done separately for 
discovery, replication, and generalization samples. Beta coefficients were recalculated 
from Z-scores, allele frequencies, and the sample, as described earlier41  Site-specific 
quantile-quantile plots were generated to inspect the presence of genomic inflation. 
The variance explained by all variants in the GWAS was estimated using LD score 
regression12,42. Sensitivity analyses were performed by excluding patients. 
Functional annotation 
All tracks of the regional association plots were taken from the UCSC Genome Browser 
Human hg19 assembly. SNPs (top 5%) shows the top 5% associated variants within the 
locus and are colored by their correlation to the top variant. Genes shows the gene 
models from GENCODE version 19. The tracks give the predicted chromatin states based 
on computational integration of ChIP-seq data for 12 chromatin marks in various human 
tissues derived from the Roadmap Epigenomics Consortium43. Additionally, we used 
HaploReg version 3 for annotation of the top variants and all variants in LD (> 0.80) 
(http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php).  
Genetic correlation 
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The genetic correlation analyses were also performed using LD score regression. The 
GWAS meta-analysis of intracranial volume, as well as the height adjusted and height 
subset meta-analyses, were correlated with published GWAS  of the following traits: 
Child head circumference26, birth weight44, birth length45, adult height13, childhood 
cognitive function46, adult cognitive function47, Alzheimer’s disease48, Parkinson’s 
disease49, white matter lesions50, psychiatric disorders51,  neuroticism52, and 
extraversion53. 
Enrichment analyses 
To determine whether the intracranial volume association results were enriched for 
certain types of genetic variants, we employed two strategies: partitioned heritability 
and pathway analyses.  
Partitioned heritability was calculated using a previously described method42. This was 
done by partitioning variants by chromosome and by 28 functional classes: coding, UTR, 
promoter, intron, histone marks H3K4me1, H3K4me3, H3K9ac5 and two versions of 
H3K27ac, open chromatin DNase I hypersensitivity Site (DHS) regions, combined 
chromHMM/Segway predictions, regions that are conserved in mammals, super-
enhancers and active enhancers from the FANTOM5 panel of samples (Finucane et al. 
page 4)42. Multiple testing thresholds were calculated accordingly: Pthresh = 0.05/(22 
chromosomes) = 2.27 x 10-3  for the chromosomes and Pthresh = 0.05/(28 classes) = 1.79 x 
10-3 for the functional classes. 
Pathway analyses were performed using the KGG2.554 and MAGENTA55 software 
packages. LD was calculated based with the 1000 Genomes Project European samples as 
a reference (see URLs). Variants were considered to be within a gene if they were within 
5 kb of the 3’/5’ UTR based on chromosome positions (hg19) coordinates. Gene-based 
tests were done with the GATES test54 without weighting P-values by predicted 
functional relevance. Pathway analysis was performed using the HYST test of 
association56. A multiple testing threshold accounting for the number of pathways 
tested resulting in a significance threshold of Pthresh = 0.05/(671 pathways) = 7.45 x 10-5.   
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Head growth trajectories 
Head growth trajectory analyses were done within the Generation R study, a 
longitudinal cohort study situated in Rotterdam, the Netherlands. For this analysis we 
included 2,824 children of European ancestry followed prenatally until 6 years of age. 
Head size was measured at the following points: prenatally (using echo) during the first, 
second, and third trimester, and postnatally (measuring head circumference) at 0-2 
months, 2 months, 3 months, 4 months, 5-10 months, 10-13 months, 13-17 months, and 
5 years of age. We tested whether a polygenic score of the 7 loci, as well as the 7 loci 
themselves separately, were related to head growth  using linear mixed models and 
included an interaction term between time and the genetic score/variant (SAS software). 
Next, the predicted values were calculated for each person and plotted over time, 
stratified by genotype (0/1/2 risk alleles) using the R software package.   
URLs 
ftp://pricelab:pricelab@ftp.broadinstitute.org/LDSCORE/ 
http://enigma.ini.usc.edu/protocols/genetics-protocols/ 
http://genenetwork.nl/bloodeqtlbrowser/ 
http://gump.qimr.edu.au/general/gabrieC/LocusTrack/). 
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ABSTRACT  
The hippocampal formation is a brain structure integrally involved in episodic memory, 
spatial navigation, cognition, and stress responsiveness. Structural abnormalities in 
hippocampal volume and shape are found in several common neuropsychiatric 
disorders. To identify the genetic underpinnings of hippocampal structure here we 
perform a genome-wide association study (GWAS) of 33,536 individuals and discover six 
independent loci significantly associated with hippocampal volume, four of them novel. 
Of the novel loci, three lie within genes (ASTN2, DPP4, MAST4) and one is found 200kb 
upstream of SHH. A hippocampal subfield analysis shows that a locus within the MSRB3 
gene shows evidence of a localized effect along the dentate gyrus, subiculum, CA1, and 
fissure. Further, we show that genetic variants associated with decreased hippocampal 
volume are also associated with increased risk for Alzheimer’s disease (rg=-0.155). Our 
findings suggest novel biological pathways through which human genetic variation 
influences hippocampal volume and risk for neuropsychiatric illness.  
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INTRODUCTION 
Brain structural abnormalities in the hippocampal formation are found in many complex 
neurological and psychiatric disorders including temporal lobe epilepsy1, vascular 
dementia2, Alzheimer’s disease3, major depression4, bipolar disorder5, schizophrenia6, 
and post-traumatic stress disorder7, among others. The diverse functions of the 
hippocampus, including episodic memory8, spatial navigation9, cognition10, and stress 
responsiveness11 are commonly impaired in a broad range of diseases and disorders of 
the brain that are associated with insults to the hippocampal structure. Further, the 
cytoarchitectural subdivisions (or ‘subfields’) of the hippocampus are associated with 
distinct functions. For example, the dentate gyrus (DG) and sectors 3 and 4 of the cornu 
ammonis (CA) are involved in declarative memory acquisition12, the subiculum and CA1 
play a role in disambiguation during working memory processes13, and the CA2 is 
implicated in animal models of episodic time encoding14 and social memory15. The 
anterior hippocampus, which includes the fimbria, CA subregions, and HATA, may be 
involved in the mediation of cognitive processes including imagination, recall, and visual 
perception16 and anxiety-related behaviors17. 
Environmental factors, such as stress, affect the hippocampus18, but genetic differences 
across individuals account for most of the population variation in its size; the heritability 
of hippocampal volume is high at around 70%19-21. High heritability and a crucial role in 
healthy and diseased brain function make the hippocampus an ideal target for genetic 
analysis. We formed a large global partnership to empower the quest for mechanistic 
insights into neuropsychiatric disorders associated with hippocampal abnormalities and 
to chart, in depth, the genetic underpinnings of the hippocampal structure. 
Here we perform a GWAS meta-analysis of mean bilateral hippocampal volume in 33,536 
individuals scanned at 65 sites around the world as a joint effort between the Enhancing 
Neuroimaging Genetics through Meta-analysis (ENIGMA) and the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE) consortia. Our primary goal is to 
find common genetic determinants of hippocampal volume with previously 
unobtainable power. We make considerable efforts to coordinate data analysis across all 
sites from both consortia in order to maximize the comparability of both genetic and 
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imaging data. Standardized protocols for image analysis and genetic imputation are 
freely available online. In the most powerful imaging study of the hippocampus to date, 
we shed light on the common genetic determinants of hippocampal structure and allow 
for a deepened understanding of the biological workings of the brain’s memory center. 
We confirm previously identified loci influencing hippocampal volume, identify four 
novel loci, and determine gross genetic overlap with Alzheimer’s disease. 
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RESULTS 
Novel genome-wide markers forippocampal volume 
Our combined meta-analysis (n = 26,814 individuals of European ancestry) revealed six 
independent, genome-wide significant loci associated with hippocampal volume (Figure 
1; Table 1). Four are novel: with index SNPs rs11979341 (7q36.3; P=1.42x10-11), rs7020341 
(9q33.1; P=3.04x10-11), rs2268894 (2q24.2; P=5.89x10-11), and rs2289881 (5q12.3; 
P=2.73x10-8). The other two loci have been previously characterized in detail: with index 
SNPs rs77956314 (12q24.22, P=2.06x10-25), in linkage disequilibrium (LD) (r2=0.901 in 
European samples from the 1000  Genomes Project, Phase 1v3) with our previously 
identified variant at this locus (rs7294919) and rs61921502 (12q14.3, P=1.94x10-19), in LD 
(r2=0.459) with previous top locus rs1717800622-24 (Figure 2a-f). In addition to these SNPs, 
we identified nine independent loci with a statistically suggestive influence on 
hippocampal volume (P < 1x10-6; Supplementary Data 4). All pathway results and gene-
based p-values are summarized in Supplementary Data 6 and 7.   
Table 1 | Genetic variants at six loci were significantly associated with hippocampal 
volume. 
RSID Chr Pos 
Nearest 
Gene 
A1 A2 Freq Z-score N P-value 
rs77956314 12 117323367 4 kb 5’ to 
HRK 
T C 0.92 -10.48 26814 2.06x10-25 
rs61921502 12 65832468 intron of 
MSRB3 
T G 0.85 9.017 26814 1.94x10-19 
rs11979341 7 155797978 200 kb 5’ 
to SHH 
C G 0.68 -6.755 24484 1.42x10-11 
rs7020341 9 119247974 intron of 
ASTN2 
C G 0.36 6.645 26700 3.04x10-11 
rs2268894 2 162856148 intron of 
DPP4 
T C 0.54 -6.546 26814 5.89x10-11 
rs2289881 5 66084260 intron of 
MAST4 
T G 0.35 -5.558 26814 2.73x10-8 
The allele frequency (Freq) and effect size (Z-score) are given with reference to Allele 1. Effect 
sizes are additive effects for each copy of Allele 1 given as a Z-score. Additional validation was 
attempted in non-European ancestry generalization samples (shown in Supplementary Data 
5). 
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Variance explained by common variants  
Common variants genotyped from across the whole genome explained as much as 
18.76% (S.E. 1.56%) of the observed variance in human hippocampal volume, based on 
LDSCORE regression25 (Supplementary Fig. 3). Common genetic variants account for 
around a quarter of the overall heritability, estimated in twin studies to be around 70%19-
21. Further partitioning the genome into functional categories using LDSCORE26 revealed 
significant over-representation of regions evolutionarily conserved in mammals 
(P=0.0026): 2.6% of the variants accounted for 43.3% of the 18.76% variance explained 
(Figure 3).  
Effects of top variants on hippocampal subfield volume 
To test for differential effects on individual subfields of the hippocampal formation, we 
examined the six significant variants influencing whole hippocampal volume in a large 
cohort (n = 5,368). We found that the top SNP from our primary analysis, rs77956314, has 
a broad, nonspecific effect on hippocampal subfield volumes with the greatest effect in 
the right hippocampal tail (P = 1.27x10-8). rs61921502 showed strong lateral effects 
across right hippocampal subfields with the largest effect in the right hippocampal 
fissure (P = 6.45x10-9). rs7020341 showed greatest effects bilaterally in the subiculum 
(left: P = 1.59x10-8; right: P = 1.42x10-8). rs2268894 show left-lateralized effects across 
hippocampal subfields with the strongest effect in the left hippocampal tail (P = 1.76x10-
5). The remaining two variants (rs11979341 and rs2289881) did not show significant 
evidence of association across any of the hippocampal subfields. See Supplementary 
Data 8 for the full results. 
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Genetic overlap with hippocampal volume 
We used LDSCORE27 regression to quantify the degree of common genetic overlap 
between variants influencing the hippocampus and those influencing Alzheimer’s 
disease. We found significant evidence of a moderate, negative relationship whereby 
variants associated with a decrease in hippocampal volume are associated with an 
increased risk for Alzheimer’s disease (rg=-0.155 (S.E. 0.0529), P=0.0034; see Methods). 
 
Figure 3 | Analysis of variance explained by functional annotations.  
LDSCORE regression analysis for different functional annotation categories. Plotted values are 
the proportion of h2g explained divided by the proportion of SNPs in a given functional 
category. Values are over- or under-represented if they differ significantly from 1. Values are 
plotted with a standard error calculated with a jackknife in LDSCORE. Evolutionarily conserved 
regions across mammals significantly contributed to the heritability of hippocampal volume 
(indicated by **).  
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DISCUSSION 
We identified six genome-wide significant, independent loci associated with 
hippocampal volume in 26,814 subjects of European ancestry. Of the six loci, four were 
novel: rs11979341 (7q36.3; P=1.42x10-11), rs7020341 (9q33.1; P=3.04x10-11), rs2268894 
(2q24.2; P=5.89x10-11), and rs2289881 (5q12.3; P=2.73x10-8). We previously discovered 
two of the novel loci, rs7020341 and rs226889424, but in this higher-powered analysis 
they now surpassed the genome-wide significance. In addition to the four novel loci, we 
replicated two loci associated with hippocampal volume: rs7492919 and rs1717800623, 24. 
Hibar et al. (2015) previously reported additional support for the rs17178006 association 
with hippocampal volume22.  
Each novel locus identified has unique functions and has previously been linked to 
diseases of the brain. Variant rs7020341 lies within an intron of the astrotactin 2 (ASTN2) 
gene (Figure 2d) which encodes for a protein involved in glial-mediated neuronal 
migration in the developing brain28. Rare deletions overlapping this locus near the 3’ end 
of ASTN2 have been observed in patients with autism spectrum disorder and attention-
deficit/hyperactivity disorder29.  Common variants near this site are associated with 
autism spectrum disorders29 and migraine30. Variant rs2268894 is located in an intron of 
DPP4 (Figure 2e) that encodes dipeptidyl peptidase IV; an enzyme regulating response 
to the ingestion of food31, and an established target of a treatment for type 2 diabetes 
mellitus (vildagliptin)32. In addition, rs2268894 is in strong LD (r2 = 0.83) with a genome-
wide significant locus associated with a decreased risk for schizophrenia (rs2909457)33; 
however, the allele that increases risk for schizophrenia also increases hippocampal 
volume even though patients with schizophrenia show decreased hippocampal volume 
relative to controls6. Variant rs11979341 lies in an intergenic region (Figure 2c) around 
200 kb upstream of the sonic hedgehog (SHH) gene, crucial for neural tube formation34. 
Adult brain expression data provide some evidence that rs11979341-C increases the 
expression of SHH in adult human hippocampus35 (P=0.0089). Finally, variant rs2289881 
lies within an intron of the microtubule-associated serine/threonine kinase family 
member 4 (MAST4) gene (Figure 2f). The protein product of MAST4 modulates the 
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microtubule scaffolding; the gene has been linked to susceptibility for atherosclerosis in 
HIV-infected men36, and atypical frontotemporal dementia37.  
Effect sizes from the full sample were almost identical to those obtained from a subset 
meta-analysis (Pearson’s r2 > 0.99; n = 22,761) that removed all patients diagnosed with a 
neuropsychiatric disorder. Observed effects are therefore not likely to be driven by 
inclusion of patients with brain disorders. All significant loci are tabulated in Table 1. We 
found little evidence that these effects could be generalized to populations of African, 
Japanese, and Mexican-American ancestry, which could be due to the limited power 
from smaller non-European sample sizes available (see Supplementary Data 5). 
We estimated that 18.76% (S.E. 1.56%) of the variance in hippocampal volume could be 
explained by genotyped common genetic variation. This effect was only tested within 
populations of European ancestry and does not necessarily reflect the level of explained 
variance in other populations worldwide. This is a substantial fraction of the overall 
genetic component of variance determined by twin heritability studies, and the 
heritability of hippocampal volume is relatively high at around 70%19-21. With the same 
LDSCORE method, we estimated the amount of variance explained by common gene 
variants belonging to known functional cell categories.26 We discovered enrichment of 
genomic regions conserved across mammals, which may have a strong evolutionary role 
in the hippocampal formation, a structure much more extensively developed in 
mammals than in other vertebrates38. Given that hippocampal atrophy is a hallmark of 
Alzheimer's disease pathology39, we were motivated to examine common genetic 
overlap between hippocampal volume and Alzheimer's disease risk. We found a 
significant negative relationship (rg=-0.155 (S.E. 0.0529), P=0.0034), through which loci 
associated with decreased hippocampal volume also increase risk for AD. This confirms a 
shared etiological component between AD and hippocampal volume whereby genetic 
variants influencing hippocampal volume also modify the risk for developing AD. 
As the hippocampal formation is a complex structure comprised of diverse functional 
units, we sought to examine the genetic variants identified in our analysis for focal 
effects on hippocampal subfield volumes. When assessing 13 subfields of the 
hippocampus (26 total, left and right) we found that two of the top variants from our 
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analysis (rs77956314 and rs7020341) had largely non-specific effects: most of the 
subfield volumes showed significant evidence of association (Supplementary Data 8). 
The variant rs61921502 showed a lateralized effect across the body of the right 
hippocampal formation, which includes the DG, subiculum, CA1, and fissure. Volume 
losses are frequently observed across the hippocampal body in AD40, major depression41, 
bipolar disorder42, and temporal lobe epilepsy43. Prior pathway analyses have implicated 
the rs61921502 with MSR3B, a gene related to oxidative stress24.  Genetic variation at 
MSR3B may influence neurogenesis specifically within the dentate regions of the 
hippocampal body, where cell proliferation is known to continue into adulthood in 
healthy humans44. However, further functional validation is required to test this 
hypothesis. Finally, the variant rs2268894 was associated with volume differences in the 
left hippocampal tail, a subfield that has previously shown shape abnormalities45 and 
volume differences46 in schizophrenia. 
Here we identified four novel loci associated with hippocampal volume and examined 
each variant for localized effects in hippocampal subfields. When partitioning the full 
genome-wide association results into functionally annotated categories, we discovered 
that SNPs in evolutionarily conserved regions were significantly over-represented in 
their contribution to hippocampal volume. Further, we found significant evidence of 
shared genetic overlap between hippocampal volume and Alzheimer’s disease. This 
large international effort shows that by mapping out the genetic influences on brain 
structure, we may begin to derive mechanistic hypotheses for brain regions causally 
implicated in the risk for neuropsychiatric disorders.
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METHODS 
Subjects and sites 
High-resolution MRI brain scans and genome-wide genotyping data were available for 
33,536 individuals from 65 sites in two large consortia: the ENIGMA Consortium and the 
CHARGE Consortium. Full details and demographics for each participating cohort are 
given in Supplementary Data 1. All participants (or their legal representatives) provided 
written informed consent. The institutional review board of the University of Southern 
California and the local ethics board of Erasmus MC University Medical Center approved 
this study.  
Imaging analysis and quality control 
Hippocampal volumes were estimated using the automated and previously 
validated segmentation algorithms, FSL FIRST47 from the FMRIB Software Library 
(FSL) and FreeSurfer48. Hippocampal segmentations were visually examined at 
each site, and poorly segmented scans were excluded. Sites also generated histogram 
plots to identify any volume outliers. Individuals with a volume more than three 
standard deviations away from the mean were visually inspected t o  v e r i f y  p r o p e r  
s e g m entation. Statistical outliers were included in analysis if they were properly 
segmented; otherwise, they were removed. Average bilateral hippocampal 
volume was highly correlated across automated procedures used to measure it 
(Pearson’s r = 0.74)22. A measure of head size - intracranial volume (ICV) - was used as 
a covariate in these analyses to adjust for volumetric differences due to differences 
in head size alone. Most sites measured ICV for each participant using the inverse of 
the determinant of the transformation matrix required to register the subject’s MRI 
scan to a common template and then multiplied by the template volume 
(1,948,105 mm3). Full details of image acquisition and processing performed at 
each site are given in Supplementary Data 2.   
Genetic imputation and quality control 
Genetic data were obtained at each site using commercially available genotyping 
platforms. Prior to imputation, genetic homogeneity was assessed in each sample using 
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multi-dimensional scaling (MDS). Ancestry outliers were excluded by visual inspection of 
the first two components. The primary analysis and all data presented in this main text 
were derived from subjects with European ancestry. Replication attempts in subjects of 
additional ancestries are presented in Supplementary Data 5. Data were further cleaned 
and filtered to remove single nucleotide polymorphisms (SNPs) with low minor allele 
frequency (MAF < 0.01), deviations from Hardy-Weinberg Equilibrium (HWE P < 1x10-6), 
and poor genotyping call rate (<95%). Cleaned and filtered datasets were imputed to 
the 1000 Genomes Project reference panel (phase 1, version 3) using freely available and 
validated imputation software (MaCH/minimac, IMPUTE2, BEAGLE, GenABLE). After 
imputation, genetic data were further quality checked to remove poorly imputed SNPs 
(estimated R2 < 0.5) or low MAF (<0.5%). Details on filtering criteria, quality control, and 
imputation at each site may be found in Supplementary Data 3.  
Genome-wide association analysis 
Genome-wide association scans (GWAS) were performed at each site, as follows. Mean 
bilateral hippocampal volume ((left + right)/2) was the trait of interest, and the additive 
dosage value of a SNP was the predictor of interest, while controlling for 4 MDS 
components, age, age2, sex, intracranial volume, and diagnosis (when applicable). For 
studies with data collected from multiple centers or scanners, additional covariates were 
also included in the model to adjust for any scanning site effects. Sites with family data 
(NTR-Adults, BrainSCALE, QTIM, SYS, GOBS, ASPSFam, ERF, GeneSTAR, NeuroIMAGE, 
OATS, RSIx) used mixed-effects models to account for familial relationships, in addition 
to covariates stated previously. The primary analyses for this paper focused on the full 
set of individuals, including datasets with patients, to maximize power. We re-analyzed 
the data excluding patients to verify that detected effects were not due to disease alone. 
The regression coefficients for SNPs with P < 1x10-5 in the model including all patients 
were almost perfectly correlated with the regression coefficients from the model 
including only healthy individuals (Pearson’s r = 0.996). Full details for the software used 
at each site are given in Supplementary Data 3. 
The GWAS of mean hippocampal volume was performed at each site, and the resulting 
summary statistics uploaded to a centralized site for meta-analysis. Prior to meta-
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analysis, GWAS results from each site were checked for genomic inflation and errors 
using Quantile-Quantile (QQ) plots (Supplementary Fig. 1-2). GWAS results from each 
site were combined using a fixed-effects sample size-weighted meta-analysis framework 
as implemented in METAL49. Data were meta-analyzed first in the ENIGMA and CHARGE 
Consortia separately and then combined into a final meta-analyzed result file. After the 
final meta-analysis, SNPs were excluded if the SNP was available for fewer than 5,000 
individuals.  
Variance explained and genetic overlap in hippocampal 
volume 
The common genetic overlap, total variance explained by the GWAS, and the partitioned 
heritability analyses were estimated using LDSCORE25, 26. Following from the polygenic 
model, an association test statistic at a given locus includes signal from all linked loci. 
Given a heritable polygenic trait, a SNP in high linkage disequilibrium (LD) with, or 
tagging, a large number of SNPs is on average likely to show stronger association than a 
SNP that is not. The magnitude of information conveyed by each variant (a function of 
the number of SNPs tagged taking into account the strength of the tagging) is 
summarized as an LD score. By regressing the LD scores on the test statistics, we 
estimated the proportion of variance in the trait explained by the variants included in 
the analysis. As an extension, two LD score models for two separate traits can be used to 
estimate the covariance (and correlation) structure to yield an estimate of the common 
genetic overlap (rg) between any two trait pairs. Here we estimated the common genetic 
overlap between hippocampal volume and Alzheimer’s disease50. Standard errors were 
estimated using a block jackknife. 
Genomic partitioning into functional categories 
As well as estimating the total variance explained, the genomic heritability (h2g) can be 
partitioned into specific subsets of variants. The functional annotation partitioning used 
the pre-prepared LDSCORE and annotation (.annot) files available online (see URLs) 
following the method of Finucane et al.26. These analyses use the following 24 functional 
classes not specifically unique to any cell type: coding, UTR, promoter, intron, histone 
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marks H3K4me1, H3K4me3, H3K9ac5 and two versions of H3K27ac, open chromatin 
DNase I hypersensitivity Site (DHS) regions, combined chromHMM/Segway predictions, 
regions conserved in mammals, super-enhancers and active enhancers from the 
FANTOM5 panel of samples (Finucane et al., page 4)26. Annotated coordinates are 
determined by a combination of all cell types from ENCODE. As in Finucane et al26, to 
avoid bias, we included the 500bp windows surrounding the variants included in the 
functional classes. The chromosome-partitioned analyses were conducted using 
LDSCOREs calculated for each chromosome. Following the method of Bulik-Sullivan et 
al.25, these analyses focus on the variants within HapMap3 as these SNPs are typically 
well imputed across cohorts. Enrichment of a given partition is calculated as the 
proportion of h2g explained by that partition divided by the proportion of variants in the 
GWAS that fall into that partition. All LDSCORE analyses used non-genomic controlled 
meta-analyses. 
Gene annotation and pathway analysis 
Gene annotation, gene-based test statistics, and pathway analysis were performed using 
the KGG2.5 software package51 (Supplementary Data 6 and 7). LD was calculated based 
on RSID numbers using the 1000 Genomes Project European samples as a reference (see 
URLs). For annotation, SNPs were considered “within” a gene, if they fell within 5 kb of 
the 3’/5’ UTR based on human genome (hg19) coordinates. Gene-based tests were 
performed using the GATES test51 without weighting P-values by predicted functional 
relevance. Pathway analysis was performed using the HYST test of association52. For all 
gene-based tests and pathway analyses, results were considered significant if they 
exceeded a Bonferroni correction threshold accounting for the number of pathways 
tested such that Pthresh = 0.05/(671 pathways) = 7.45 x 10-5.   
Annotation of SNPs with epigenetic factors 
In Figure 2, all tracks were taken from the UCSC Genome Browser Human hg19 
assembly. SNPs (top 5%) shows the top 5% associated SNPs within the locus and are 
colored by their correlation to the top SNP. Genes shows the gene models from 
GENCODE version 19. Hippocampus gives the predicted chromatin states based on 
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computational integration of ChIP-seq data for 18 chromatin marks in human 
hippocampal tissue derived from the Roadmap Epigenomics Consortium53. The 18 
chromatin states from the hippocampus track are as follows: TssA (Active TSS), TssFlnk 
(Flanking Active TSS), TssFlnkU (Flanking TSS Upstream), TssFlnkD (Flanking TSS 
Downstream), Tx (Strong transcription), TxWk (Weak transcription), EnhG1 (Genic 
Enhancers 1), EnhG2 (Genic Enhancers 2), EnhA1 (Active Enhancers 1), EnhA2 (Active 
Enhancers 2), EnhWk (Weak Enhancers), ZNF/Rpts (ZNF genes & repeats), Het 
(Heterochromatin), TssBiv (Bivalent/Poised TSS), EnhBiv (Bivalent Enhancer), ReprPC 
(Repressed PolyComb), ReprPCWk (Weak Repressed PolyComb), Quies (Quiescent/Low). 
Additional information about the 18 state chromatin model is detailed elsewhere53. 
Conservation is the basewise conservation score over 100 vertebrates estimated by 
PhyloP from the UCSC Genome Browser Human hg19 assembly. 
Analysis of hippocampal subfields 
We segmented the hippocampal formation into 13 subfield regions: CA1, CA3, CA4, 
fimbria, Granule Layer + Molecular Layer + Dentate Gyrus Boundary (GC_ML_DG), 
hippocampal-amygdaloid transition area (HATA), hippocampal tail, hippocampal fissure, 
molecular layer (HP), parasubiculum, presubiculum, and subiculum using a freely 
available, validated algorithm distributed with the FreeSurfer image analysis package54. 
We measured the hippocampal subfield volumes within the Rotterdam (n = 4,491) and 
HUNT (n = 877) cohorts. Volumes from the 26 subfield regions (13 in each hemisphere) 
were the phenotypes of interest and individually assessed for significance with the top 
variants from our primary analysis while correcting for the following nuisance variables: 
4 MDS components, age, age2, sex, intracranial volume. Association statistics from each 
of the tests in the Rotterdam and HUNT cohorts were meta-analyzed using a fixed-
effects inverse variance-weighted model yielding the final results. We declare an 
individual test significant if the P-value is less than a Bonferroni-corrected P-value 
threshold accounting for the total number of tests: Pthresh = 0.05/(26 subfields * 6 SNPs) = 
3.21x10-4. 
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Data availability 
The genome-wide summary statistics that support the findings of this study are 
available upon request from the corresponding authors MAI and PMT. The data are not 
publicly available due to them containing information that could compromise research 
participant privacy/consent. 
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ABSTRACT 
Background: Intracranial carotid artery calcification (ICAC) is one of the most important 
risk factors for stroke. Although several environmental risk factors for ICAC have been 
identified, its genetic background remains unclear. 
Methods: Between 2003 and 2006, 2403 participants from the prospective population-
based Rotterdam Study (mean age: 69.6 ± 6.8 years; 51.7% female) underwent 
computed tomography to quantify vascular calcification in the intracranial internal 
carotid artery. Blood samples were drawn for genotyping. Genotypes of the participants 
were imputed to the 1000-Genomes reference panel to generate genetic relationship 
matrices for the estimation of the heritability of ICAC volume. Adjustments were made 
for age and sex. Subsequently, genome-wide association analyses were performed to 
identify specific variants. 
Results: The age- and sex-adjusted heritability (h2) of ICAC was 47% (standard error (SE): 
19%, P=0.009). Genome-wide association analyses identified a variant on chromosome 
9p21.3 (rs1537372; N=2034; P=4.75x10-9) and one variant on chromosome 11p11.2 
(rs11038042, N=2034; P=3.27x10-8), that were significantly associated with ICAC volume. 
Rs1537372 replicated in an independent sample of 716 stroke patients (Pcombined 
=1.38x10-10).  
Conclusions:ICAC volume is a heritable trait which is partly explained by common 
genetic variation. We identified specific genetic variants associated with ICAC, which 
given the importance of ICAC in stroke risk, needs replication in larger-scale studies to 
further elucidate its genetic basis.  
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INTRODUCTION 
Intracranial carotid artery calcification (ICAC) is a leading risk factor for stroke.1-3 Various 
established environmental and lifestyle factors such as smoking and diabetes mellitus 
are known to contribute substantially to the formation of ICAC.1,2,4 Yet, it remains 
unknown to what extent genetics play a role in the development of ICAC. 
For the last decade, genetic research of atherosclerotic calcification has mainly focused 
on the coronary arteries given strong relations with coronary morbidity and mortality. 
Recently, this has led to the identification of three common genetic variants strongly 
related to the presence and amount of coronary artery calcification.5 Yet, preliminary 
evidence suggests that these variants are not associated with calcification in other 
vessels.6 This suggests that although arterial calcification is a systemic process, there are 
important vessel-specific differences in its etiology.7,8 Given that other risk factors such 
as diabetes and smoking are generally thought to exert a systemic effect on the 
formation of arterial calcification, genetic information may be crucial for explaining 
location-specific differences.  
Against this background, it is vital to elucidate the genetic susceptibility underlying the 
development of ICAC. This information may ultimately aid in the development of 
therapeutic or preventive interventions for stroke. 
Therefore, in the current study, we quantified ICAC,3 determined its heritable 
component, and performed a genome-wide association analysis including independent 
replication of top hits.   
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METHODS 
Discovery cohort 
This study was embedded in the Rotterdam Study,9 a prospective population-based 
study investigating the determinants and consequences of age-related diseases in older 
adults. The original cohort consisted of 7,983 participants 55 years or older and was 
extended in 2000-2001 by 3,011 persons. At study entry and every 3 to 4 years, all 
participants are re-examined in a dedicated research center. The Rotterdam Study 
represents a relatively stable, homogeneous middle-class population, largely of 
European descent. The Rotterdam Study has been approved by the medical ethics 
committee according to the Population Screening Act: Rotterdam Study, executed by 
the Ministry of Health, Welfare and Sports of the Netherlands. All participants provided 
written informed consent. 
Between September 2003 and February 2006, we invited all participant who visited the 
research center to undergo non-enhanced computed tomography (CT) scanning to 
quantify calcification in the intracranial carotid arteries (as part of a large project on 
quantification of vascular calcification in multiple vessel beds).10,11Due to errors in image 
acquisition or image artefacts, 29 CT examinations from the 2,524 were not gradable, 
leaving a total of 2,495 persons with a gradable CT examination for ICAC. Of these 2,495 
persons, 2,034 were successfully genotyped. 
Assessment of ICAC 
Non-contrast CT images were obtained using a 16-slice (n=724) or 64-slice (n=1,689) 
multidetector CT (MDCT) scanner (Somatom Sensation 16 or 64, Siemens, Forchheim, 
Germany). We performed two scans: a cardiac scan and a scan that reached from the 
aortic arch to the circle of Willis. Using these scans, we imaged the coronary arteries, the  
aortic arch, the extracranial part of the internal carotid arteries, and intracranial part of 
the internal carotid arteries. Detailed information on the imaging parameters of the 
scans is described elsewhere.8,11  
As marker of intracranial atherosclerosis, we measured ICAC in both internal carotid 
arteries from the horizontal petrous bone segment up to its top.3,4 To quantify ICAC, we 
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used a semi-automated scoring method which is described in detail elsewhere.4,12 In 
short, all calcifications in the trajectory of the intracranial internal carotid artery were 
manually delineated in consecutive MDCT-slices while making sure that bony structures 
were not included. Next, the number of pixels above 130 Hounsfield units was 
determined and the calcification volume (mm3) was calculated by multiplying the 
number of pixels, pixel-size and the increment. Calcification volumes in the coronary 
arteries, aortic arch, and extracranial carotid arteries, were quantified using dedicated 
commercially available software (Syngo CalciumScoring, Siemens, Germany).8 All 
calcification volumes are expressed in mm3. 
Genotyping 
All study participants were genotyped with the 550K, 550K duo, or 610 quad Illumina 
arrays. We removed samples with a call rate below 97.5%, gender mismatch, excess 
autosomal heterozygosity (>0.336), duplicates or family-relations and ethnic outliers. 
Moreover, we removed those variants with call rates below 98.0%, failing missingness 
tests, Hardy-Weinberg equilibrium p-values < 10-6, and minor allele frequencies (MAF) of 
less than 0.1%. Genotypes were imputed using MACH/minimac software to the 1000 
Genomes phase I version 3 reference panel (entire population). 
Heritability analysis 
We used Genome-wide Complex Trait Analysis (GCTA) to estimate heritability in our 
sample of unrelated individuals.13 This method is based on comparing the genetic 
similarity between individuals to their phenotypic similarity, and the heritability 
estimates refer to the proportion of variance explain by the variants on the genome-
wide chip. As previously described,14 the 1000 Genomes imputed genotypes were 
filtered on imputation quality (R2 < 0.5) and allele frequency (MAF < 0.01). We calculated 
pairwise genetic relatedness between all individuals and removed one person for pairs 
with more than 0.02 genotype similarity. 
We performed heritability analyses for calcification volume in the four vessel beds 
separately. Moreover, we assessed the proportion of shared heritability between 
intracranial carotid artery calcification and calcification in the other three vessel beds 
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using the bivariate REML function of GCTA. Because calcification volume had a skewed 
distribution, we used natural log-transformed values and added 1.0 mm3 to the non-
transformed values in order to deal with calcium volumes of zero [Ln(calcification 
volume + 1.0 mm3)]. We adjusted the analyses for age and sex.  
Genome-wide association analyses 
We conducted genome-wide association analyses (GWAS) on calcification in the four 
vessel beds using the R-package ProbABEL (version 0.4.4).15 Given that measures of 
subclinical atherosclerosis in the coronary arteries, aortic arch, and carotid artery 
bifurcation have already been studied in larger GWAS (in some instances also including 
this sample),5,16,17 the main focus was on ICAC.   Calcification measures were analyzed 
under an additive model with linear regression, while adjusting for age and sex. The 
results were adjusted for genomic control and meta-analyzed using the METAL 
software.18 Variants with an R2 < 0.5 and a MAF < 0.05 were removed. Genome-wide 
significance was established at p < 5x10-8. Manhattan-plots and regional association 
plots were generated in R. For the top variants (p < 10-7) and those in linkage 
disequilibrium (r2 > 0.2) we checked HaploReg (v4.1, 
www.broadinstitute.org/mammals/haploreg/) for indications of functionality (eQTLs, 
promotor and enhancer histone marks, and conservation).Next, we investigated the 
association of the top variants from the GWAS on ICAC with calcification volume in the 
other vessel beds. 
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Replication 
Replication of genome-wide significant variants was attempted in the Erasmus Stroke 
Study (ESS), a clinical TIA and stroke registry, in which stroke-patients were enrolled 
between December 2005 and September 2010, in the Erasmus MC, Rotterdam, the 
Netherlands and which is described in detail elsewhere.19 For the current study, we used 
all patients with complete information on ICAC (as assessed by contrast-enhanced 
MDCTA) and in whom blood samples were taken (n = 776). Of these 776, 716 were 
successfully genotyped for rs1537372, and 743 for rs1103842. The stroke subtypes 
according to the TOAST-criteria of these participants were as follows: 1) large vessel 
disease: 17%, 2) cardio-embolism: 12%, 3) small vessel disease: 24%, 4) other: 6%, 5) 
undetermined: 42%. Participants were genotyped using Taqman Allelic Discrimination 
(Thermo Fisher Scientific Inc.). Reactions were performed according to manufacturer’s 
protocol with minor adjustments.  
Table 1. Characteristics of the study population. 
Characteristic Value
Sample size 2034
Female sex, % 50.7
Age, mean (SD), years 69.8 (6.8) 
ICAC prevalence, % 83.0
CAC prevalence, % 81.6
AAC prevalence, % 92.3
ECAC prevalence, % 74.0
ICAC volume, median (IQR), mm3 46.0 (8.0 – 148.0) 
CAC volume, median (IQR), mm3 53.8 (2.0 – 283.6) 
AAC volume, median (IQR), mm3 267.8 (46.8 – 924.5) 
ECAC volume, median (IQR), mm3 26.2 (0.0 – 126.4) 
SD: standard deviation, ICAC: intracranial carotid artery calcification, IQR: interquartile range, 
CAC: coronary artery calcification, AAC: aortic arch calcification, ECAC: extracranial carotid 
artery calcification 
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RESULTS 
Study population 
The characteristics of the study population are shown in Table 1. The mean age of the 
study population was 69.6 ± 6.8 years, and 51.7% were females. 
Heritability of ICAC 
We found an age- and sex-adjusted heritability for ICAC volume of 47% [heritability 
estimate (h2): 0.47 (standard error (SE): 0.19, p = 0.009)]. In comparison, the age- and sex-
adjusted heritability estimates for coronary artery calcification, aortic arch calcification, 
and extracranial carotid artery calcification were 0.52 (SE: 0.20, p = 0.004), 0.36 (SE: 0.19, 
p = 0.024), and 0.17 (SE: 0.19, p = 0.186), respectively. We found a shared heritability of 
intracranial carotid artery calcification with coronary artery calcification of 77% (h2: 0.47, 
p = 0.006). For aortic arch calcification and extracranial carotid artery calcification this 
was 9% and 78% (h2: 0.09, p = 0.400, and h2: 0.78, p = 0.077), respectively. 
GWAS of ICAC 
We performed a GWAS for ICAC volume. Figure 1 plots the p-values for this trait. For 
ICAC volume, 28 variants from a single locus at 9p21.3 (top variant rs1537372; MAF = 
0.41; p = 4.75x10-9) and one variant from a locus at 11p11.2 (rs11038042; MAF = 0.78; p = 
3.27x10-8) reached genome wide significance. We also found one variant at 2q14.1 
(rs34008603; MAF = 0.97, p = 1.91x10-7) that showed a suggestive association with ICAC. 
Figure 2 shows the regional plots for 9p21.3 and 11p11.2. Table 2 shows the top genetic 
variants at three loci associated with ICAC volume of with p < 1 x 10-7. For the 9p21 locus, 
there is a considerable body of literature on potential functional mechanisms. The top 
variant of 11p11.2 shows enhancer histone marks in muscle and stomach cell lines. For 
2q14.1, several variants in LD overlap with promotor or enhancer marks, or affect gene 
expression (Supplementary Table S1). 
Given the known association of the 9p21 locus with ischemic stroke,20 we performed a 
sensitivity analysis in which we excluded participants with prevalent clinical stroke from 
the sample (n = 85). This did not attenuate the association of rs1537372 with ICAC 
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volume (beta = 0.18, p = 9.50x10-9). We also repeated the analyses after excluding 
persons without any calcifications, but this did not materially affect the results 
(Supplementary Table 2). Furthermore, we did not identify any interaction with sex. 
When investigating associations the three top variants for ICAC with calcification volume 
in three other vessel beds, namely the coronary, aortic and extracranial carotid artery. 
We found that rs1537372 and rs11038042 were related to calcification in at least two of 
the other vessel beds, whereas rs34008603 showed only a single nominally significant 
association with the extracranial carotid artery (Table 3).  
Replication of top variants for ICAC 
We were able to replicate our top variant rs1537372 from the locus at 9p21.3 (n = 716; 
beta = 0.13, p = 5.19x10-3).  Rs11038042 at 11p11.2 did not replicate in the independent 
sample (n = 731; beta =       -0.06, p = 0.304). Yet, the direction of the effect was similar to 
that in the discovery cohort. After meta-analyzing both samples we found a more 
significant p-value for rs1537372 (n = 2750; p = 1.38x10-10) and a less significant p-value 
for rs11038042 (n = 2765;  p = 2.99x10-7). 
DISCUSSION 
In this population-based study, we examined the contribution of common genetic 
variants to ICAC, for which the genetic basis is currently unknown. We found a high 
heritability of ICAC volume and identified two loci that influence ICAC, one of which 
replicated in an independent cohort of stroke-patients.  
Strengths of our study are the quantitative assessment of ICAC volume, and the fact that 
the results remained unchanged after excluding participants with a previous clinical 
stroke. There are also methodological considerations to take into account. First, it is 
important to keep in mind that calcification is thought to represent atherosclerosis, but 
represents only a part of the total atherosclerotic plaque. With non-enhanced CT, it is 
not possible to visualize the non-calcified plaque components. Yet, extensive evidence 
demonstrates that calcification volume is an adequate indicator of the total underlying 
atherosclerotic burden.21,22 Second, our analyses were performed on relatively small 
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Figure 2 | Regional plots of loci 9p21 and 11p11 associated with intracranial carotid 
artery calcification 
Upper panel: plot of the genetic variants on locus 9p21.3 which are associated with 
intracranial carotid artery calcification volume. Lower panel: plot of the genetic variants on 
locus 11p11.2 associated with intracranial carotid artery calcification volume. Figures were 
created using the Locuszoom software (http://locuszoom.sph.umich.edu/locuszoom/) 
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samples, both the discovery and replication sample. Yet, this is a direct consequence of 
the lack of other studies that have quantitatively assessed ICAC as well as performed 
genome-wide genotyping and that could have been used to increase the study 
population and hence the statistical power of the association. Nonetheless, we were 
able to obtain genome-wide significant variants and heritability estimates for 
intracranial atherosclerosis. A final consideration is that we used the GCTA to determine 
the heritability estimates, which are measures of the additive heritability, representing 
narrow-sense heritability.13 This directly means that only the additive effects of the 
genes are taken into account, leaving non-additive effects unstudied.   
We found a heritability of over 47% for ICAC, which is comparable to the heritability of 
coronary artery calcification which we found to be 52%. One previous report on the 
heritability of coronary artery calcification quantity showed a heritability of 44%.23 In 
contrast, we found that for calcification in the carotid artery bifurcation only 17% was 
attributable to genetic factors, and aortic arch calcification was heritable for 36%. These 
differences in genetic contribution to the development of calcification in different vessel 
beds provide more insight into the etiology of the previously reported considerable 
variation in atherosclerotic burden across various vessel beds.7,8,24  
In addition to its high heritability, we also identified multiple genome-wide significant 
variants for ICAC at two loci. The first locus, on which we found 28 variants that were 
associated with ICAC, was located on chromosome 9, near the CKDN2a/CKDN2b genes. 
In the METASTROKE Collaboration,20 the 9p21.3 locus has previously been implicated in 
ischemic strokes which were classified as strokes due to large-vessel disease on the basis 
of the TOAST-criteria. Although even using tens of thousands of samples, this did not 
reach genome-wide significance even. Remarkably, we robustly identify a very strong 
signal in only 2000 individuals and show that this locus likely increases risk of stroke 
through calcifications in the intracranial carotid artery. Future large-collaborative 
research is needed to clarify this further. Besides its associations with stroke, variants at 
9p21 have been related to coronary artery calcification volume and myocardial 
infarction.5  In fact, the top variant found in the GWAS on these traits, rs1333049, was in 
our study also strongly associated (p = 1.70x10-8) with ICAC volume. Earlier, we found 
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that this variant was also associated with aortic arch calcification and calcification in the 
carotid artery bifurcation.6 Also, associations with the 9p21 locus have been  found for 
vascular stiffness,25 and aneurysms of the abdominal aorta,26 suggesting a broad 
influence on arterial disease. Of particular note is a recent publication on how 9p21.3 risk 
variants disrupt specific transcription factor-dependent TGF-β regulation of p16 
expression in human aortic smooth muscle cells.27 An interesting hypothesis would be 
that this same mechanism is responsible for vascular disease in other vessel beds by 
affecting smooth muscle cells locally, such as in the carotid arteries, providing a 
potential mechanism on how the risk variants influence vascular disease. 
We identified another variant in the 11p11.2 region on chromosome 11 that associated 
with ICAC volume. Although we were unable to replicate this finding, this was an 
interesting association, especially because this 11p11.2 locus is not known for 
associations with subclinical vascular disease or cardiovascular events. However, this 
region has been linked to fasting glucose homeostasis and a higher risk of type 2 
diabetes.28 Interestingly, diabetes is one of the strongest known risk factors for ICAC.4,29   
Finally, we identified a variant on 2q14.1 which showed a suggestive association with 
ICAC. The DPP10 gene, which is closely located to the variant that we identified, is 
primarily known for its influence on asthma.30 The exact mechanisms underlying the 
associations of these loci with ICAC need further elucidation from future studies. 
In summary, ICAC volume is a heritable trait, which is explained by common genetic 
variation. Moreover, we identified and replicated one variant at locus 9p21.3 which is 
known for its contribution to ischemic stroke. Given the importance of ICAC in the 
development of stroke, larger-scale studies to further elucidate the genetic basis of 
intracranial atherosclerosis are needed. 
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ABSTRACT 
Human gait is a complex neurological and musculoskeletal function, of which the 
genetic basis remains largely unknown. To determine the influence of common genetic 
variants on gait parameters, we studied 2946 participants of the Rotterdam Study, a 
population-based cohort of unrelated elderly individuals. We assessed 30 gait 
parameters using an electronic walkway, which yielded 7 independent gait domains 
after principal component analysis. Genotypes of participants were imputed to the 1000 
Genomes reference panel for generating genetic relationship matrices to estimate 
heritability of gait parameters, and for subsequent genome-wide association scans to 
identify specific variants. Gait domains with the highest age- and sex-adjusted 
heritability were Variability (h2 = 61%), Rhythm (37%), and Tandem (32%). For other gait 
domains, heritability estimates attenuated after adjustment for height and weight. 
Genome-wide association scans identified a variant on 1p22.3 that was significantly 
associated with single support time, a variable from the Rhythm domain (rs72953990; N 
= 2946;  β (SE) = .0069 (.0012), p = 2.30x10-8). This variant did not replicate in an 
independent sample (N = 362; p = 0.78). In conclusion, human gait has highly heritable 
components that are explained by common genetic variation, which are partly 
attributed to height and weight. Collaborative efforts are needed to identify robust 
single variant associations for the heritable parameters.  
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INTRODUCTION 
The planning and execution of gait requires a delicate integration of sensory information 
and motor commands [1]. Consequently, gait in humans is affected by a wide range of 
diseases, including disorders of the brain, muscles, and joints [1-5]. Problems in gait 
strongly increase the risk of adverse health outcomes, including morbidities (e.g. falls) 
and death [3]. Although it is known that various environmental factors contribute to 
variation in gait, it remains unclear to what extent genetics plays a role.  
Variation in gait is associated with age and sex, but also with several complex traits such 
as height, weight and cognitive function, which are all highly polygenic and heritable [6-
8]. Walking speed was found to be heritable in two twin studies, suggesting that gait 
follows a similar genetic pattern [9-11]. However, walking speed alone does not capture 
the complexity of human gait, which consist of many more measurable components 
[12]. Additionally, to our knowledge, no genome-wide association scan (GWAS) has been 
performed to identify genetic variants that are associated with gait. 
Here, we comprehensively assessed gait using an electronic walkway and determined 
the heritabilty of the various parameters comprising gait, followed by genome-wide 
association scans for the heritable parameters. 
MATERIAL AND METHODS 
Setting  
The Rotterdam Study is a prospective, population-based study that investigates 14 926 
inhabitants of Rotterdam aged 45 years or over [13]. Subjects were enrolled during three 
recruitment phases (1990, 2000, and 2006) and visit the research center every 3-4 years 
for various medical examinations. Genotyping was successfully performed on 11 496 
subjects. In March 2009, gait assessment was introduced in the study protocol. The 
Rotterdam Study has been approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study, executed by the Ministry of Health, Welfare and 
Sports of the Netherlands. A written informed consent was obtained from all 
participants. 
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Gait assessment 
A 5.79-m long pressure-activated walkway (GAITRite Platinum; CIR systems, Sparta, NJ: 
4.88-m active area; 120-Hz sampling rate) was used to accurately measure gait 
parameters, as described previously [14,15]. Participants performed standardized 
walking protocols over the walkway. First, participants walked eight times across the 
walkway at their own pace (normal walk). Second, participants walked at their usual 
pace, turned halfway, and returned to the starting position (turning). Third, participants 
walked tandem (i.e., heel-to-toe) over a line on the walkway (tandem walk). The first 
normal walk was considered a practice walk and not included in the analysis. All other 
recordings were visually inspected and individual footsteps were identified and marked 
for further processing by the walkway software, from which 30 spatiotemporal (gait) 
parameters were derived. Principal component analysis identified 7 independent 
components with eigenvalues of 1 or higher, representing the following gait domains: 
Rhythm, Phases, Variability, Pace, Tandem, Turning and Base of Support [14,15]. Varimax 
rotation was used to provide domains that are uncorrelated to each other. 
Study population 
Between March 2009 and March 2012, 3651 people were invited for gait assessment. Of 
these, 129 did not complete gait assessment for the following reasons: 69 for physical 
problems, 45 for technical reasons, 13 for refusal, and 2 for other reasons. Additionally, 
we excluded 34 participants for performing less than 16 steps in normal walking, 
lowering validity of the gait parameters; 3 for using walking aids on the walkway; and 1 
for not following instructions. Of 3484 remaining participants, 2946 were genotyped. 
Since not all participants completed all walking conditions, the numbers of participants 
included vary for the individual variables (where we included the maximal sample size to 
increase power), but are identical for all the domains since these are derived from 
principal component analysis, which does not allow for any missing values in the 30 
variables. 
Genotyping 
The three subcohorts of the Rotterdam Study were genotyped with the 550K (cohort 1), 
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550K duo (cohort 2) and 610K (cohort 3) Illumina arrays. We removed samples with a call 
rate below 97.5%, gender mismatch, excess autosomal heterozygosity, duplicates or 
family relations and ethnic outliers, and variants with call rates below 95.0%, failing 
missingness tests, Hardy–Weinberg equilibrium p-values<10-6, and minor allele 
frequencies<1%. Genotypes were imputed using MACH/minimac software to the 1000 
Genomes phase I version 3 reference panel (all populations).  
Heritability analysis 
To estimate heritability in our sample of unrelated individuals, we used Genome-wide 
Complex Trait Analysis (GCTA) [16]. This method compares genotypic similarity between 
individuals to their phenotypic similarity. The 1000 Genomes imputed genotypes were 
filtered on imputation quality (R2 < 0.5) and allele frequency (MAF < 0.01). Pairwise 
genetic relatedness between all individuals was calculated, and for pairs with more than 
0.02 genotype similarity one person was removed.  
Heritability analyses were performed for the 7 gait domains and (secondarily) for all 30 
variables separately. Adjustments were made for age, sex, and the first 10 principal 
components of population stratification (model 1), and additionally for height (model 2) 
and weight (model 3). For the Tandem domain, step count and step length during the 
tandem walk were also included as covariates.   
Polygenic scores 
Polygenic scores were created from variants associated with height (N=180) and BMI 
(N=32) at genome-wide significance [6,17]. Variants were weighted by multiplying the 
beta coefficient for the corresponding trait with the number of alleles. For each 
individual, the weighted allele scores were added together to generate the polygenic 
score.  
Genome-wide association scan 
Genome-wide association analyses were conducted in the three subcohorts separately 
using the R package ProbABEL (version 0.42). Gait parameters were analyzed under an 
additive model with linear regression, covarying for age and sex, height, weight, and first 
two principal components. The results were adjusted for genomic control and meta-
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analyzed using the METAL software [18]. Variants with an R2 < 0.5 and a minor allele 
frequency (MAF) < 0.01 were removed. Subsequently, a more stringent filter for MAF < 
0.05 was added to remove remaining false-positive signals, resulting in 6.2 million 
variants included in the analyses. Genome-wide significance was established at p < 5x10-
8. Manhattan and quantile-quantile plots were generated in R (version 3.1.0). 
Functional annotation of genetic variants 
Genetic variants showing evidence of association with gait parameters were further 
examined for potential biological function using publicly available databases: 
Regulomedb, GWASdb, rSNPBase, HaploReg, and SNVrap. 
Replication 
For genome-wide significant variants replication was attempted in the Tasmanian Study 
of Cognition and Gait (TASCOG), which investigates cerebrovascular mechanisms 
underlying gait, balance and cognition. TASCOG comprises a population-based sample 
of 395 people aged 60–86 years living  in Southern Tasmania, Australia [19]. They were 
randomly selected from the electoral roll between 2006 and 2008, but excluded if they 
lived in a nursing home, had a contraindication for magnetic resonance scanning or 
were unable to walk without a gait aid.  Participants were genotyped using Illumina 
Hap370CNV chips and completed 6 walks at their preferred walking speed over a 4.6 
meter computerized GaitRite walkway.  Participants started 2 meters before and finished 
2 meters after the walkway. 
Statistical analysis 
Cohort-specific results were meta-analyzed using inverse variance meta-analysis. 
Polygenic scores were transformed into z-scores so that effects are expressed per 
standard deviation increase for each score. A Bonferroni correction for 14 tests (2 
polygenic scores and 7 gait domains) was applied, resulting in a significance threshold of 
p < 0.0036. For the candidate gene analyses, a Bonferroni correction for 1484 tests (212 
variants and 7 gait domains) was applied where p < 3.37 x 10-5 was considered 
significant. Association analyses of the polygenic scores with gait domains were 
performed in SPSS version 22, IBM. 
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RESULTS 
Study population 
Mean (SD) age in the Rotterdam Study was 68.2 (9.5) years, ranging from 50 to 97 years, 
and 1604 (54.4%) were women. Table 1 shows basic demographic and anthropometric 
characteristics of the total study population as well as the population with all gait 
measurements available, which were similar. 
Heritability of gait parameters 
The Variability, Rhythm and Tandem domains showed the highest age- and sex-adjusted 
heritability, which remained after correction for height and weight, but decreased 
slightly for Rhythm after including height. The Variability domain was more heritable 
than any of its constituting parameters. For Rhythm, most parameters had higher 
estimates than the domain score, which was most pronounced for single support time 
and swing time (ρ = .99). The other gait domains had a smaller heritable component 
(<.25) and were strongly attenuated after adjustment for height (Pace) and weight (Base 
of Support, Phases). 
To explore whether these decreases in heritability after adjustment for height and 
weight were due to specific genetic variants related to these traits, polygenic scores of 
height and body mass index (BMI) were studied in relation to gait (Table 3). Indeed, the 
polygenic height score was associated with Rhythm and Pace, but not after adjustment 
for height itself. The BMI score did not associate with any gait domain after multiple 
testing correction, but showed a nominally significant effect on Turning that became 
stronger after adjustment for weight.  
GWAS of gait traits 
GWASs were performed for the three gait domains showing moderate to high 
heritability (Variability, Rhythm, and Tandem) and their highest heritable parameter 
(stride length SD, single support time, and sum of the sidestep distance, respectively). 
Figure 1 shows the Manhattan plots for these traits, with all loci having variants with a p-
value < 1x10-6 summarized in Table 4. Eight variants from a single locus at 1p22.3 
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reached genome-wide significance for single support time (top variant rs72953990; 
minor allele frequency (MAF) = 0.14; p = 2.30x10-8), and were also associated with the 
Rhythm domain (p = 2.43x10-7). No variants reached genome-wide significance for the 
other gait traits. 
Intronic variants in PTPRD (rs71321217; 9p23; p = 7.65x10-7) and PRKG1 (rs10823991; 
10q21; p = 9.72x10-7) showed suggestive association with Rhythm. For Variability a 
variant in DGCR5 (rs11914070; 22q11.21; p = 1.64x10-7), and for stride length SD two 
variants at 9q22.1 and 11p14.3 were found, of which 11p14.3 showed significant 
heterogeneity across the three cohorts. The most reliable signal for Tandem and sum of 
the sidestep distance was located on 1p32.1 in KIF14, with top variant rs10800713 
showing evidence of transcription factor binding affinity. 
Replication of 1p22.3 with single support time 
For the genome-wide significant variant for single support time (rs72953990) replication 
was attempted in the TASCOG study (N = 362), where a similar Rhythm domain was 
constructed (Table 5). The variant associated with the parameters in the opposite 
direction, reaching nominal significance with the Rhythm domain (p = 0.039). 
Table 1 | Study population characteristics. 
 Characteristic 
Rotterdam Study 
– total 
population 
(N=2946) 
Rotterdam Study 
– sub-
population 
(N=2588) 
Tasmanian 
Study of 
Cognition and 
Gait (N=362) 
    
Age in years, mean (SD) 68.2 (9.5) 67.3 (9.1) 72.1 (7.1) 
Women, n (%) 1604 (54.4%) 1396 (53.9%) 148 (40.9%) 
Height in cm, mean (SD) 169.2 (9.3) 169.5 (9.2) 167.5 (9.1) 
Weight in kg, mean (SD) 78.6 (14.3) 78.8 (14.2) 78.2 (15.0) 
MMSE score, mean (SD) 28.0 (2.0) 28.1 (1.8) – 
Abbreviations: MMSE = Mini-Mental State Examination, SD = standard deviation. 
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Table 2 | Heritability estimates of gait domains and parameters, adjusted for age, sex, 
height and weight. 
Gait domain (PVE) / parameter Mean (SD) Correlation 
with factor
Heritability estimate (SE) 
 Model 1 Model 2 Model 3 
      
Variability (20%)   .61 (.23) .63 (.23) .58 (.23) 
Stride length SD (cm) 4.58 (1.67) -0.88 .42 (.21) .43 (.21) .42 (.21) 
Step length SD (cm) 2.86 (0.94) -0.86 .39 (.21) .38 (.21) .37 (.21) 
Stride velocity SD (cm/s) 5.91 (1.97) -0.87 .33 (.21) .34 (.21) .28 (.21) 
Stride time SD (s) 0.03 (0.02) -0.77 .22 (.21) .24 (.21) .26 (.21) 
Step time SD (s) 0.02 (0.01) -0.75 .24 (.21) .24 (.21) .28 (.21) 
Stance time SD (s) 0.03 (0.01) -0.76 .32 (.21) .34 (.21) .37 (.21) 
Swing time SD (s) 0.02 (0.01) -0.65 .01 (.21) .01 (.21) .01 (.21) 
Single support time SD (s) 0.02 (0.01) -0.65 .01 (.21) .01 (.21) .01 (.21) 
Double support time SD (s) 0.02 (0.01) -0.52 .35 (.22) .36 (.22) .36 (.22) 
      
Rhythm (21.5%)   .37 (.24) .28 (.24) .27 (.24) 
Single support time (s) 0.42 (0.04) -0.96 .56 (.21) .45 (.21) .44 (.22) 
Swing time (s) 0.42 (0.04) -0.96 .56 (.21) .45 (.21) .44 (.22) 
Step time (s) 0.55 (0.05) -0.94 .38 (.21) .30 (.21) .34 (.21) 
Stride time (s) 1.10 (0.10) -0.94 .41 (.21) .33 (.21) .37 (.21) 
Cadence (steps/min) 109.8 (9.5) 0.94 .42 (.21) .32 (.21) .35 (.21) 
Stance time (s) 0.67 (0.07) -0.83 .20 (.21) .15 (.21) .23 (.21) 
      
Tandem (7.2%)   .32 (.23) .32 (.23) .34 (.23) 
Sum of sidestep distance (cm) 9.56 (17.0) -0.90 .35 (.22) .35 (.22) .36 (.22) 
Sum of sidestep surface 
(fraction) 0.32 (0.64) -0.91 .28 (.22) .28 (.22) .32 (.23) 
Double step (n) 0.07 (0.28) -0.54 .07 (.23) .07 (.23) .06 (.23) 
      
Pace (9.8%)   .22 (.23) .02 (.23) .03 (.23) 
Stride length (cm) 130.9 (18.2) 0.85 .26 (.21) .15 (.21) .18 (.21) 
Step length (cm) 65.2 (9.13) 0.85 .26 (.21) .15 (.21) .18 (.21) 
Velocity (cm/s) 119.5 (20.1) 0.72 .26 (.21) .27 (.21) .31 (.21) 
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DISCUSSION 
Here we determined the contribution of common genetic variants to an extensive range 
of gait parameters, for which the genetic basis is largely unknown. Subsequently, we 
performed a genome-wide association scan to identify specific loci influencing gait. We 
found that the heritability of gait varies across domains and we identified a variant 
influencing single support time that did not replicate in a small, independent sample. 
      
Table 2 continued. 
Base of Support (3.7%)   .20 (.23) .21 (.23) .11 (.23) 
Stride width SD (cm) 2.40 (0.84) -0.73 .15 (.21) .16 (.21) .15 (.21) 
Stride width (cm) 10.3 (4.02) 0.67 .24 (.20) .23 (.20) .21 (.20) 
      
Phases (19%)   .13 (.23) .13 (.23) .01 (.23) 
Single support (%GC) 38.6 (1.87) 0.97 .18 (.21) .21 (.21) .06 (.21) 
Swing (%GC) 38.6 (1.87) 0.97 .18 (.21) .21 (.21) .07 (.21) 
Stance (%GC) 61.4 (1.87) -0.97 .18 (.21) .22 (.21) .07 (.21) 
Double support (%GC) 23.0 (3.75) -0.97 .19 (.21) .23 (.21) .07 (.21) 
Double support time (s) 0.25 (0.06) -0.85 .14 (.21) .18 (.21) .05 (.21) 
      
Turning (6.1%)   .10 (.24) .10 (.24) .07 (.24) 
Turning step count (n) 4.94 (0.91) -0.92 .03 (.23) .03 (.23) .03 (.23) 
Turning time (s) 2.83 (0.63) -0.85 .25 (.22) .27 (.23) .26 (.23) 
Adjustments were made for age, sex, and the first 10 principal components of population 
stratification (model 1), and additionally for height (model 2) and weight (model 3).  
Abbreviations: GC = gait cycle time, PVE = percentage of variance explained, SD = standard 
deviation, SE = standard error. 
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Gait is an important indicator of health [3]. Identifying factors that contribute to variation 
in gait could aid our understanding of gait dysfunction and its associated diseases. Given 
the highly complex cooperation of multiple organ systems that is required for gait, it is 
not surprising that we found a genetic architecture that is similar to other complex traits 
(i.e., height, cognition), which are partly determined by multiple common genetic 
variants, each with a small effect. Others have studied the heritability of walking speed, 
which mainly forms the Pace domain, [9-11] and found estimates between 16% and 
60%. Similar to Pajala et al., we found walking speed to be only moderately heritable 
(17%). However, the comprehensive and quantitative gait assessment in our study 
enabled us to investigate the genetic influence on the gait pattern in more detail than 
walking speed alone. Interestingly, we found the genetic influence to be much larger on 
several other gait domains, particularly Variability, Rhythm and Tandem. 
Variability in gait was found to be the most heritable (58%). It captures the irregularity in 
walking and is believed to be particularly related to cognitive functioning [15]. 
Interestingly, none of the individual parameters comprising Variability had a heritability 
>42%, suggesting that the principal component analysis extracted a true genetic (and 
Table 5 | Associations between rs72953990 and the Rhythm domain and parameters 
in the TASCOG replication sample (N=362). 
Gait domain (PVE) / parameter Mean (SD) 
Correlation 
with factor 
β (SE) P-value 
     
Rhythm (28.3%)   .107 (.052) .039 
Single support time (s) 0.42 (0.04) -0.69 -.001 (.004) .775 
Swing time (s) 0.42 (0.04) -0.69 -.001 (.004) .775 
Step time (s) 0.55 (0.06) -0.88 -.008 (.007) .213 
Stride time (s) 1.11 (0.12) -0.87 -.016 (.013) .213 
Cadence (steps/min) 109.6 (10.6) 0.91 1.37 (1.15) .235 
Stance time (s) 0.68 (0.09) -0.83 -.015 (.01) .135 
Betas are expressed per minor allele (A) increase of rs72953990 in relation to the respective 
dependent variable (i.e., gait domain or parameter). 
Abbreviations: PVE = percentage of variance explained, SD = standard deviation, SE = 
standard error. 
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biological) construct. Although Variability had the highest heritability, no genome-wide 
significant variants were identified. Importantly, we did not have enough power to 
detect small effects. However, this does not preclude the possibility of a different genetic 
architecture. For example, Variability could be influenced by numerous variants with 
only a small effect that jointly have a large influence but make identification of specific 
variants difficult. Furthermore, it is possible that the gait parameters comprising this 
domain each have distinct genetic determinants with larger effects, but that these 
signals become diluted when analyzing the domain as a whole. However, no genome-
wide significant variants were detected for the highest heritable parameter, stride 
length variability. 
We did identify a variant that reached significance in the GWAS of single support time, 
the highest heritable gait parameter of Rhythm. Replication of the variant was 
attempted in an independent sample (N = 362), but this failed to show an association 
with single support time. Whether this represents a false-positive finding or a 
combination of the winner’s curse and a small replication sample can only be clarified by 
additional studies. This underlines that, in order to detect robust genetic associations for 
gait, more researchers in the field of human gait need to obtain DNA samples and large 
genetic collaborations should introduce phenotyping of gait. 
This increase in sample size seems particularly promising for Variability, Rhythm, or 
Tandem. Other gait domains initially showed small to moderate heritability, but the 
estimates strongly attenuated after adjusting for height and weight. To investigate 
whether the reduction in heritability was due to genetic variants that primarily associate 
with these traits, but not with gait, we explored the effect of established variants for 
height and BMI in relation to gait. Indeed, the polygenic score of height was associated 
with the same gait domains that showed attenuation after adjustment for height. The 
BMI score did not show significant associations with the gait domains. Given the lower 
number of variants for BMI (32) compared to height (180), it is likely that the polygenic 
score of BMI is less powerful to detect effects. This is underlined by the fact that the BMI 
score was not convincingly associated with BMI in our sample (p = 0.056), contrary to the 
height score with height (p = 6.5 x 10-47). As a whole, our analyses thus seem to suggest 
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that Pace, Base of support, and Phases are potentially not very heritable beyond their 
correlation with height and weight, and the polygenic score of height adds an additional 
line of evidence to this finding. 
Important to note is that the heritability estimates calculated using GCTA represent 
narrow-sense heritability, and thus only take into account the additive genetic portion of 
the phenotypic variance while leaving out non-additive effects. Furthermore, GCTA only 
uses the variants provided as input for determining the genetic similarity. However, 
causal variants that are not in included (e.g., rare variants) but are in linkage 
disequilibrium with those that are in the analysis will also be indirectly used. Another 
limitation that is inherent to GCTA analyses is the dependence on unrelated individuals, 
which produces relatively large standard errors for the heritability estimates in our 
sample of less than 3000 persons. This emphasizes the main limitation of our study, 
namely its low power. Although it is well known that the largest effect sizes typically 
explain less than 1% of the phenotypic variance of similar quantitative traits [20], we 
performed this study for several reasons: First, we provide estimates of genetic influence 
on a comprehensive set of gait parameters, which could serve to direct future genetic 
studies of gait and as an incentive for larger initiatives. Second, we excluded to a 
reasonable degree the possibility of genetic variants having large effects on gait. Third, 
we are not aware of additional studies that have both quantitatively assessed gait and 
genome-wide genotyping, making this in fact the largest available sample for genetic 
studies on gait. 
In conclusion, we found that human gait is comprised of various heritable domains. A 
large number of variants remain to be identified for gait, but this will require large-scale 
collaborative efforts.  
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ABSTRACT 
The volumes of subcortical brain structures are highly heritable, but genetic 
underpinnings of their shape remain relatively obscure. Here we determine the relative 
contribution of genetic factors to individual variation in the shape of 7 bilateral 
subcortical structures: the nucleus accumbens, amygdala, caudate, hippocampus, 
pallidum, putamen and thalamus. In 3,686 unrelated individuals aged between 45 and 
98 years, brain magnetic resonance imaging and genotyping was performed. The 
maximal heritability of shape varied from 32.7% to 53.3% across the subcortical 
structures. Genetic contributions to shape extend beyond influences on intracranial 
volume and the gross volume of the respective structure. The regional variance in 
heritability was related to the reliability of the measurements, but could not be 
accounted for by technical factors only. These findings could be replicated in an 
independent sample of 1040 twins. Differences in genetic contributions within a single 
region reveal the value of refined brain maps to appreciate the genetic complexity of 
brain structures..
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INTRODUCTION  
Subcortical brain regions are important for a multitude of biological processes, including 
cognitive and motor functions.1,2 There is substantial structural variation in these 
regions, both within the normal range3 and in the context of various neuropsychiatric 
diseases.4,5 Factors driving individual variation could provide insight into brain 
development, healthy aging, and pathological states, but these remain largely unknown. 
Variation in subcortical brain structures is affected by environmental factors, such as 
education, diet and stress, but a considerable proportion of the variation is determined 
by genes.6,7 A recent twin study of gross subcortical volumes found heritability estimates 
ranging between 0.44 and 0.88,8 which were especially high for the caudate and 
thalamus. 
Even so, aggregate measures such as volume do not capture the complexity of 
subcortical structures. The hippocampus, for example, is made up of several subfields, 
each with partially independent functional roles. More recently, image processing 
methods have been developed to characterize brain structure beyond purely volumetric 
measures, and yielding a range of shape descriptors.9-13 The high-dimensionality allows 
the detection of more localized differences in brain structure, and shape can provide 
relevant biological information in addition to aggregate measures.14-17 Several genetic 
variants that influence the volume of subcortical structures have been identified,18-20 but 
their effect could be localized to certain sub-regions using shape analyses.19,20 However, 
the extent to which genes contribute to the variability in shape of subcortical structures 
has yet to be determined. 
Here, we quantify genetic influences on shape variability of 14 subcortical brain 
structures in 3,686 unrelated individuals from the population-based Rotterdam Study. 
We compare the heritability of vertex-wise shape measures to gross volumes as well as 
other aggregate measures of shape obtained through dimension-reduction techniques. 
We show that the shape of subcortical structures is under genetic control, and 
investigate the relation of the resulting profiles with the gross volume and measures of 
reproducibility. 
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METHODS  
Study population 
This work was performed in the Rotterdam Study,21 a population-based cohort study in 
the Netherlands including a total of 14,926 participants (aged 45 years or over at 
enrollment). The overall aim of the study is to investigate causes and determinants of 
chronic diseases in elderly people, the participants were not selected for the presence of 
diseases or risk factors. Since 2005, all participants underwent brain magnetic resonance 
imaging (MRI) to examine the causes and consequences of age-related brain changes.22 
Between 2005 and 2013, a total of 5,691 unique persons were scanned. The Rotterdam 
Study has been approved by the Medical Ethics Committee of the Erasmus MC and by 
the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet 
Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants 
provided written informed consent to participate in the study and to obtain information 
from their treating physicians. 
Replication was performed in 1040 healthy young adult twins from the Queensland Twin 
IMaging (QTIM) project [de Zubicaray et al. 2008]. All participants of the imaging sample 
were Caucasian and right-handed for throwing and writing (Annett's Handedness 
Questionnaire). The genetic analyses were conducted in the 350 complete twin pairs 
(n = 700): 148 monozygotic (100 male), 120 dizygotic (39 male), and 82 opposite-sex 
pairs. Self-reported data was used to screen participants for contraindications for 
imaging as well as any significant medical, psychiatric or neurological conditions, history 
of substance abuse and current use of psychoactive medication. The study was 
approved by the Human Research Ethics Committees of the Queensland Institute of 
Medical Research, the University of Queensland, and Uniting Health Care, Wesley 
Hospital. Informed consent was obtained from each participant and parent or guardian 
for participants under 18 years of age.  
Genotyping and imputation 
Genotyping in the Rotterdam Study was performed using the Illumina 550K and 550K 
duo arrays.21 Subsequently, we removed samples with call rate below 97.5%, gender 
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mismatch, excess autosomal heterozygosity, duplicates or family relations and ancestry 
outliers, and variants with call rate below 95.0%, failing missingness test, Hardy–
Weinberg equilibrium p-value < 10-6, and minor allele frequency < 1%. Genotypes were 
imputed using MACH/minimac software23 to the 1000 Genomes phase I version 3 
reference panel (all population).  
For QTIM, genotyping of nine markers was used to determine the zygosity of same-sex 
twins, which was later confirmed for >92% of the sample with the Illumina 610K SNP 
array. 
Image acquisition 
For the Rotterdam Study, MRI scanning was done on a 1.5-T MRI unit with a dedicated 
eight-channel head coil (GE Healthcare). The MRI protocol consisted of several high-
resolution axial sequences, including a T1-weighted sequence (slice thickness 0.8 mm), 
which was used for further image processing. In addition, 85 persons were rescanned 
within days to weeks after the first scan to estimate the reproducibility of imaging-
derived measures. A detailed description of the MRI protocol was presented by Ikram et 
al.22 
The twin pairs of QTIM were scanned on a 4T Bruker Medspec (Bruker, Germany) whole 
body MRI system paired with a transverse electromagnetic (TEM) head coil. Structural 
T1-weighted 3D images were acquired (TR=1500ms, TE=3.35ms, TI=700ms, 240mm FOV, 
0.9mm slice thickness, 256 or 240 slices depending on acquisition orientation (86% 
coronal (256 slices), 14% sagittal (240 slices)). 
Image processing 
The T1-weighted MRI scans were processed using FreeSurfer24 (v5.1) to obtain 
segmentations and volumetric summaries of 7 subcortical structures for each 
hemisphere: nucleus accumbens, amygdala, caudate, hippocampus, pallidum, putamen, 
and thalamus (Figure 1A). Next, segmentations were processed using a previously 
described shape analysis pipeline.9,10 Briefly, a mesh model was created for the boundary 
of each structure. Subcortical shapes were registered using the “Medial Demons” 
framework, which matches shape curvatures and medial features to a pre-computed 
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template.25,26 To do this, a medial model of each individual surface model is fit following 
Gutman et al.27, and medial as well as intrinsic features of the shape drive registration to 
a template parametrically on the sphere. To minimize metric distortion, the registration 
was performed in the fast spherical demons framework.10 The templates and mean 
medial curves were previously constructed and are distributed as part of the ENIGMA-
Shape package (http://enigma.ini.usc.edu/ongoing/enigma-shape-analysis/). 
The resulting meshes for the 14 structures consist of a total of 27,120 vertices (Figure 
1A). For these vertices, two measures were used to quantify shape: the radial distance 
and the natural logarithm of the Jacobian determinant. The radial distance represents 
the distance of the vertex from the medial curve of the structure (Figure 1B). The 
Jacobian determinant captures the deformation required to map the subject-specific 
vertex to a template and indicates surface dilation due to sub-regional volume change 
(Figure 1C). 
Finally, we performed 28 principal component analyses: for each of the 14 subcortical 
structures and for both types of shape measures (radial distance and Jacobian 
determinant), we computed the full set of components. This yielded the same number of 
principal components as the original number of vertices that were describd shape 
(Figure 1A). The components were sorted in descending order of the eigenvalues, which 
corresponds to the amount of explained variance of shape. 
Heritability estimation 
We used Massively Expedited Genome-wide Heritability Analysis (MEGHA)28 to estimate 
heritability in our sample of unrelated individuals. This method allows fast and accurate 
estimates of heritability across thousands of phenotypes based on genome-wide 
genotype data of common genetic variants from unrelated individuals. As previously 
described,28 a genetic relationship matrix was constructed using the 1000 Genomes 
imputed genotypes, filtered on imputation quality (R2 < 0.5) and allele frequency (MAF < 
0.01). We calculated pairwise genetic relatedness between all individuals. We removed 
one person for pairs with more than 0.025 genotype similarity, resulting in a final study 
population of 3,686 subjects.  
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Twin-based heritability was estimated using maximum-likelihood variance components 
methods implemented in the SOLAR software (version 6.6.2). 29 To test the hypothesis 
that no variance can be explained genetically, log likelihoods of models with no genetic 
components were compared to those with genetic and environmental components. As 
twice the log likelihood is distributed as a mixture of chi-squared distributions, the 
hypothesis test and p-value can be derived parametrically.29 
To correct for multiple comparisons across all vertices and all structures, we used the 
standard False Discovery Rate (FDR) threshold at q=0.05 to localize regions of significant 
heritability within each of the subcortical structures.30  
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Table 1 | Characteristics of the study population.
Characteristic Rotterdam Study 
(N = 3,686) 
QTIM 
(N = 1,040 ) 
Age, mean (SD), years 65.9 (10.9) 22.9 (2.8) 
Female sex, n (%) 2,029 (55.0%) 641 (61.6%) 
Intracranial volume, mean (SD), cm3 1478.6 (161.3) 1484 (157.1) 
Left hemisphere, mean (SD), cm3
Accumbens 0.56 (0.10) 0.83 (0.15) 
Amygdala 1.31 (0.21) 1.84 (0.25) 
Caudate 3.40 (0.56) 3.76 (0.50) 
Hippocampus 3.84 (0.62) 4.32 (0.46) 
Pallidum 1.47 (0.24) 1.61 (0.25) 
Putamen 4.62 (0.68) 6.60 (0.72) 
Thalamus 6.25 (0.79) 7.82 (0.89) 
Right hemisphere, mean (SD), cm3 
Accumbens 0.49 (0.09) 0.79 (0.11) 
Amygdala 1.39 (0.22) 1.88 (0.25) 
Caudate 3.51 (0.58) 3.92 (0.53) 
Hippocampus 3.85 (0.59) 4.32 (0.46) 
Pallidum 1.41 (0.25) 1.53 (0.18) 
Putamen 4.45 (0.65) 6.00 (0.65) 
Thalamus 6.25 (0.79) 7.43 (0.88) 
Abbreviation: SD = standard deviation. 
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RESULTS 
Study population 
The characteristics of the study population are shown in Table 1. The mean age of the 
Rotterdam study population was 65.9 ± 10.9 years, and 55.0% were women. For the 14 
subcortical structures, the mean volumes were between 0.49 and 6.25 mL. For the QTIM 
study, mean age was 22.9 ± 2.8 years, and 61.6% were women. Mean subcortical 
volumes were higher than in the Rotterdam study across the board, ranging from 0.79 
and 7.82 mL.  
Heritability of subcortical structures: volume and shape 
The structure of subcortical brain regions was quantified by calculating their gross 
volume as well as two measures of their shape. Age- and sex-adjusted heritability 
estimates for the gross volume of each of the subcortical structures were between 1.6% 
and 43.4% (Table 2). For the two vertex-wise shape measures, the maximal heritability 
estimates per structure ranged from 32.7% to 53.3% (Table 2). Both the radial distance 
(Figure 2A-C) and the Jacobian determinant (Figure 2D-F) showed clusters of high 
heritability under various models. Further adjustment for intracranial volume did not 
influence results (Figure 2), and estimates were highly correlated between both models 
(Supplementary Figure 1). The addition of the structure-specific gross volume to the 
model, however, did affect the heritability distribution across the structures (Figure 2), 
particularly for the shape measures that are highly correlated with the gross volume 
(Supplementary Figure 2). 
Heritability of the shape of subcortical structures 
 237 
3 
  
Ta
bl
e 
2 
| H
er
ita
bi
lit
y 
es
tim
at
es
 o
f v
ar
io
us
 s
tr
uc
tu
ra
l m
ea
su
re
s 
of
 s
ub
co
rt
ic
al
 b
ra
in
 re
gi
on
s. 
Re
gi
on
 
G
ro
ss
 v
ol
um
e 
 
Ra
di
al
 d
is
ta
nc
e 
  
 
Ja
co
bi
an
 
de
te
rm
in
an
t  
 
PC
A
 
ra
di
al
 
di
st
an
ce
  
 
PC
A
 
Ja
co
bi
an
 
de
te
rm
in
an
t  
h2
 
p 
 
h2
*  
p 
 
h2
*  
p 
 
h2
*  
p 
 
h2
*  
p 
Le
ft
 h
em
is
ph
er
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
m
yg
da
la
 
8.
1 
0.
18
 
 
47
.7
 
1.
72
 x
 1
0-
6  
 
35
.4
 
2.
85
 x
 1
0-
4  
 
29
.9
 
4.
40
 x
 1
0-
4  
 
27
.9
 
9.
30
 x
 1
0-
4  
A
cc
um
be
ns
 
11
.6
 
0.
09
9 
 
34
.0
 
4.
71
 x
 1
0-
4  
 
33
.7
 
5.
11
 x
 1
0-
4  
 
28
.7
 
7.
04
 x
 1
0-
4  
 
42
.0
 
1.
45
 x
 1
0-
6  
Ca
ud
at
e 
33
.7
 
8.
6 
x 
10
-5
 
 
49
.9
 
6.
33
 x
 1
0-
7  
 
52
.9
 
1.
40
 x
 1
0-
7  
 
42
.4
 
1.
20
 x
 1
0-
6  
 
35
.1
 
4.
73
 x
 1
0-
5  
H
ip
po
ca
m
pu
s 
10
.8
 
0.
12
 
 
32
.7
 
7.
32
 x
 1
0-
4  
 
29
.2
 
2.
23
 x
 1
0-
3  
 
28
.9
 
6.
59
 x
 1
0-
4  
 
29
.6
 
5.
03
 x
 1
0-
4  
Pa
lli
du
m
 
32
.2
 
1.
7 
x 
10
-4
 
 
39
.6
 
5.
75
 x
 1
0-
5  
 
44
.1
 
8.
65
 x
 1
0-
6  
 
30
.8
 
2.
96
 x
 1
0-
4  
 
27
.0
 
1.
33
 x
 1
0-
3  
Pu
ta
m
en
 
43
.4
 
6.
8 
x 
10
-7
 
 
49
.4
 
7.
43
 x
 1
0-
7  
 
52
.7
 
1.
45
 x
 1
0-
7  
 
34
.1
 
7.
16
 x
 1
0-
5  
 
40
.7
 
2.
92
 x
 1
0-
6  
Th
al
am
us
 
34
.1
 
7.
4 
x 
10
-5
 
 
53
.3
 
1.
05
 x
 1
0-
7  
 
45
.3
 
5.
07
 x
 1
0-
6  
 
30
.2
 
3.
78
 x
 1
0-
4  
 
29
.4
 
5.
26
 x
 1
0-
4  
Ri
gh
t h
em
is
ph
er
e 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
m
yg
da
la
 
20
.4
 
0.
01
2 
 
33
.5
 
5.
45
 x
 1
0-
4  
 
31
.5
 
1.
08
 x
 1
0-
3  
 
30
.5
 
3.
45
 x
 1
0-
4  
 
27
.7
 
1.
03
 x
 1
0-
3  
A
cc
um
be
ns
 
1.
6 
0.
43
 
 
33
.1
 
6.
30
 x
 1
0-
4  
 
35
.1
 
3.
13
 x
 1
0-
4  
 
34
.5
 
5.
99
 x
 1
0-
5  
 
31
.7
 
2.
10
 x
 1
0-
4  
Ca
ud
at
e 
34
.7
 
5.
4 
x 
10
-5
 
 
46
.7
 
2.
86
 x
 1
0-
6  
 
47
.5
 
1.
95
 x
 1
0-
6  
 
29
.9
 
4.
45
 x
 1
0-
4  
 
33
.8
 
8.
75
 x
 1
0-
5  
H
ip
po
ca
m
pu
s 
8.
0 
0.
19
 
 
33
.7
 
5.
26
 x
 1
0-
4  
 
17
.7
 
4.
23
 x
 1
0-
2  
 
30
.8
 
3.
00
 x
 1
0-
4  
 
28
.9
 
6.
44
 x
 1
0-
4  
Pa
lli
du
m
 
36
.6
 
2.
3 
x 
10
-5
 
 
46
.4
 
3.
12
 x
 1
0-
6  
 
44
.5
 
7.
22
 x
 1
0-
6  
 
41
.4
 
1.
97
 x
 1
0-
6  
 
29
.2
 
5.
77
 x
 1
0-
4  
Pu
ta
m
en
 
37
.1
 
1.
8 
x 
10
-5
 
 
42
.6
 
1.
70
 x
 1
0-
5  
 
37
.5
 
1.
32
 x
 1
0-
4  
 
32
.7
 
1.
36
 x
 1
0-
4  
 
33
.4
 
1.
01
 x
 1
0-
4  
Th
al
am
us
 
30
.8
 
3.
0 
x 
10
-4
 
 
46
.2
 
3.
50
 x
 1
0-
6  
 
50
.4
 
4.
50
 x
 1
0-
7  
 
37
.1
 
1.
78
 x
 1
0-
5  
 
31
.8
 
2.
02
 x
 1
0-
4  
*E
st
im
at
e 
in
di
ca
te
s h
ig
he
st
 h
er
ita
bi
lit
y 
am
on
g 
al
l v
er
tic
es
 o
r p
rin
ci
pa
l c
om
po
ne
nt
s. 
Ab
br
ev
ia
tio
ns
: h
2  =
 h
er
ita
bi
lit
y 
es
tim
at
e 
in
 %
, P
CA
 =
 p
rin
ci
pa
l c
om
po
ne
nt
 a
na
ly
sis
.  
Chapter 3.3.3 
238    
 
Fi
gu
re
 2
 | 
H
er
ita
bi
lit
y 
m
ap
s 
of
 s
ha
pe
 m
ea
su
re
s 
of
 s
ub
co
rt
ic
al
 b
ra
in
 re
gi
on
s 
un
de
r v
ar
io
us
 m
od
el
s. 
M
ap
s s
ho
w
 th
e 
he
rit
ab
ili
ty
 o
f 7
 b
ila
te
ra
l s
ub
co
rt
ic
al
 st
ru
ct
ur
es
 fo
r t
he
 sh
ap
e 
m
ea
su
re
s o
f r
ad
ia
l d
ist
an
ce
 (P
an
el
s A
-C
) a
nd
 th
e 
Ja
co
bi
an
 d
et
er
m
in
an
t 
(P
an
el
s D
-F
). 
H
er
ita
bi
lit
y 
es
tim
at
es
 w
er
e 
ob
ta
in
ed
 u
sin
g 
th
re
e 
di
ffe
re
nt
 st
at
ist
ic
al
 m
od
el
s: 
a 
ba
sic
 m
od
el
 w
ith
 a
ge
 a
nd
 se
x 
(P
an
el
s A
 a
nd
 D
), 
an
d 
ad
di
tio
na
ly
 a
dj
us
tin
g 
fo
r e
ith
er
 in
tr
ac
ra
ni
al
 v
ol
um
e 
(P
an
el
s B
 a
nd
 E
) o
r t
he
 v
ol
um
e 
of
 th
e 
sp
ec
ifi
c 
st
ru
ct
ur
e 
(P
an
el
s C
 a
nd
 F
). 
Heritability of the shape of subcortical structures 
 239 
3 
Reproducibility of subcortical shape 
Next, we investigated the relation between our heritability estimates and the 
reproducibility of subcortical shape. In a subset of 83 persons who were scanned twice 
within 1-9 weeks, we quantified the reproducibility by calculating intraclass correlation 
coefficients for the vertex-wise shape measures (Supplementary Figure 3). There was 
considerable overlap between heritability and reproducibility (Figure 3A-B), and both 
were correlated within hemisphere (Figure 3C-D). Poorly reproducible shape measures 
were generally not heritable, whereas high reproducibility included the full range of 
heritability estimates (Figure 3C-D). 
Heritability of shape measures through data reduction  
Finally, we explored whether high-dimensional shape data could be reduced to a 
smaller set of variables with a larger genetic contribution. We performed principal 
component analyses on the two vertex-wise shape measures for each structure and 
computed the heritability of the resulting components. Except for the Jacobian 
determinant of both hippocampi, the maximal heritability was lower than for the vertex-
wise measures (Table 2). Similarly, the components were in general less heritable than 
the vertex-wise measures (Figure 4). Furthermore, the order of the components based 
on the eigenvalues did not correlate well with the order based on the heritability (ρ 
ranges from -0.038 to 0.096; Supplementary Table 1). 
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Figure 3 | Concordance between the heritability of subcortical shape and reproducibility of the 
measures. 
Figure showing the concordance between the heritability of the shape (radial distance)  ofsubcortical 
structures and the reproducibililty of these measures. Maps illustrate heritability (high is red) and 
reproducibility (high is blue) and their overlap (purple) from the anterior (Panel A) and posterior (Panel B) 
direction. Scatter plots between heritability and reprodcubility of the left (Panel C) and right (Panel D) 
hemisphere for the 7 subcortical structures. Colors indicate the different structures (see figure legends). 
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Replication of heritability in twins 
The maximum heritability estimates for the two vertex-wise shape measures per 
structure ranged from 48.9% to 78.3%. Both the radial distance (Supplementary Figure 
4A-C) and the Jacobian determinant (Supplementary Figure 4D-F) showed clusters of 
high heritability under various models. Further adjustment for intracranial volume did 
not influence the results (Supplementary Figure 4C, E). The addition of the structure-
specific gross volume to the model, however, did affect the heritability distribution 
across the structures (Supplementary Figure 4C, F). Comparing the results of the twin-
based and population study, we found a considerable overlap and significant correlation 
(p-value = 3.03x10-306) in estimated heritability (Supplementary Figure 5). 
DISCUSSION 
Here we show that, in a general population of middle-aged and elderly individuals, the 
shapes of subcortical structures are under genetic control. The vertex-wise heritability is 
higher than for aggregate measures such as volume and principal components. 
Moreover, the heritability pattern underlines the importance of reproducibility in 
deriving shape measures, but also reveals that the extent of genetic influences is not 
uniformly distributed across subcortical structures. We confirmed our findings in an 
independent cohort of twins, suggesting that the genetic architecture of subcortical 
shapes is similar across populations, despite differences in the sample, the study design, 
scanner types, and methods to compute the heritability.  
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The higher vertex-wise heritability could reflect true biological differences in the degree 
of genetic contribution to the variability in shape. For the cerebral cortex, it has already 
been shown that different genes influence distinct parts of the brain and that the 
heritability also differs between regions.31-33 Subcortical structures are also 
heterogeneous and consist of functionally diverging sub-regions, such as the nuclei of 
the pallidum or the head and tail of the caudate. Our results are in line with a recent 
study by Whelan et al. showing that hippocampal subfields differ in their heritability.34 
However, methodological reasons for this difference in heritability should also be 
considered. Particularly, a lower signal-to-noise ratio in some of the measures might 
have influenced the results, leading to low heritability estimates. Issues in the 
segmentation or registration steps will thus obscure true biological differences if these 
systematically affect certain sub-regions of a structure. We investigated whether this 
plays a role by overlapping our heritability maps with maps of the technical 
reproducibility. Indeed, shape measures that could be poorly reproduced were not 
heritable. However, while high reproducibility was required for detecting a substantial 
genetic component, it did not necessarily translate into a high heritability. For example, 
for the shape measures with a high reproducibility (intraclass correlation coefficients > 
0.75), a wide range of heritability estimates was observed (0% to 53%). Thus, even when 
the signal-to-noise ratio was comparable, we still observed regional differences in the 
degree of genetic contribution. The highly heritable measures are interesting targets for 
more in-depth genetic studies. 
Heritability estimates calculated in our analysis represent both upper and low bounds of 
narrow-sense heritability. Our results are consistent with the theory that twin-based 
heritability tends to be higher than population-based estimates. However, we did not 
find a high correlation between the results, which could be due to several factors. Our 
population study consisted of relatively older individuals, which may impact the 
heritability: the effects of non-genetic factors on subcortical structures (e.g., lifestyle 
factors) accumulate over an individual’s lifetime and the overall contribution of genes 
might be reduced compared to younger individuals. Causal variants not captured on the 
genotyping array or through subsequent imputation also could lead to a different 
distribution of the heritability. Additionally, apart from array limitations, non-additive 
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genetic factors are not taken into account when computing population based 
heritability. These factors should be taken into account when interpreting our results. 
An important question for future research on shape is which variables need to be 
controlled for in a regression analysis. Here, we aimed to provide an answer by studying 
two controversial adjustment variables: the total intracranial volume and the gross 
volume of the structure under study. For the heritability estimates of shape, adjustment 
for intracranial volume did not affect the results, suggesting that the genes regulating 
shape are not general brain growth genes, but rather more specific for a structure or its 
sub-regions. The volume adjustments did change some of the results, but more so for 
vertices whose shape measures correlate most with the gross volume of the structure. 
Likely, the genes underlying a structure’s gross volume are largely driven by these 
vertices as they typically represent the widest parts of a structure (highest mean radial 
distance), where radial measures tend to be highly correlated with its volume. Our 
results are in agreement with previous work,35 where the heritability of region-specific 
measures was reduced after adjustments for the total cortical surface area and thickness.  
The detailed information provided by shape measures being their most attractive 
feature, the increase in dimensionality is potentially counterproductive, especially in the 
case of genetic homogeneity across a structure. We therefore also performed principal 
component analyses to demonstrate that the amount of variability explained by the 
components did not seem related to the heritability: near-zero correlations were found 
between the order of the components based on the eigenvalues and the heritability 
estimates. Although the principal component analysis captures most of the variation 
using fewer variables, methods, which are based on the genetic correlation, may lead to 
biologically more meaningful results. 
While heritability provides an estimate of how much of the variance is determined by 
genetics, it does not point to specific genetic loci. The most commonly accepted 
method for gene discovery is to perform an unbiased screen of all genetic variants, i.e. 
genome-wide association study (GWAS) in order to identify specific genetic factors. 
However, such efforts require large-scale collaborations in the order of tens of thousands 
of individuals in order to identify a robust association18-20,39. Furthermore, additional 
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multiple testing correction should be considered when performing GWAS of 54,000 
shape measures. This could lead to a loss of power if the effects are homogeneous across 
a structure. However, if the effects are localized and mostly affect specific vertices, then a 
GWAS of shape measures may actually increase power since the effect sized will be 
larger compared to a GWAS of an aggregate volume. 
Data reduction methods always rely on assumptions and are often aimed at resolving 
computational issues. However, with the advent of big data collection, methods have 
been developed to analyze such large datasets efficiently. Software packages designed 
for high-dimensional data include MEGHA,36 for heritability analyses, BOLT-LMM,37 for 
genetic correlation analyses, and HASE,38 for genome-wide association studies. These 
improvements in software, and also hardware, now pave the way for full-scale analyses 
without reliance on data reduction methods. 
In conclusion, our work demonstrates that the shape of subcortical brain structures is a 
relevant phenotype for genetic studies, complementary to aggregated measures. Fine-
scale maps of genetic influences on the brain are likely to reveal a complex mosaic of 
genetic modules, with partially divergent sets of genes that drive them. 
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ABSTRACT 
Whether novel risk variants of Alzheimer’s disease (AD) identified through genome-
wide association studies (GWAS) also influence MRI-based intermediate 
phenotypes of AD in the general population is unclear. We studied association of 
24 AD risk loci with intra-cranial volume (ICV), total brain volume (TBV), 
hippocampal volume (HV), white matter hyperintensity (WMH) burden, and brain 
infarcts in a meta-analysis of genetic association studies from large population-
based samples (N=8,175-11,550). In single-SNP based tests, AD risk alleles of APOE 
(rs2075650) was associated with smaller HV (p=0.0054) and CD33 (rs3865444) with 
smaller ICV (p=0.0058)  In gene-based tests, there were associations of HLA-DRB1 
with TBV (p=0.0006) and BIN1 with HV (p=0.00089). A weighted AD genetic risk 
score was associated with smaller HV (beta±SE=-0.047±0.013, p=0.00041), even 
after excluding the APOE locus (p=0.029).However, only association of AD genetic 
risk score with HV, including APOE, was significant after multiple testing correction 
(including number of independent phenotypes tested). These results suggest that 
novel AD genetic risk variants may contribute to structural brain aging in non-
demented older community persons.  
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INTRODUCTION 
Alzheimer’s disease (AD) is the leading cause of dementia and represents a major 
public health burden 1. Converging evidence suggests that pathological processes 
leading to this progressive neurodegenerative disorder start many years before 
clinical diagnosis of dementia 2. MRI-markers of brain aging, including total brain 
volume (TBV) and hippocampal volume (HV), and markers of vascular brain injury, 
including white matter hyperintensities (WMH) and brain infarcts, are powerful 
predictors of dementia and may, at least in part, represent intermediate markers 
reflecting pathological processes leading to AD 2-7. Intracranial volume (ICV), an 
imaging marker reflecting brain growth during development and maturation, was 
suggested to be correlated with resilience to brain damage 8. 
Recently, large scale genome-wide association studies (GWAS) and candidate gene 
based studies have identified novel susceptibility loci for late-onset AD 9-18. These 
AD risk variants have recently been used to examine the genotypic overlap 
between AD and other types of dementia 19. Some of these variants have been 
studied with respect to various MRI measures in a mixed study sample of AD 
patients, mildly cognitive impaired and healthy controls 20, 21. They could also be 
implemented to explore the impact of genetic determinants of AD on MRI-markers 
of structural brain changes in non-demented community persons. Indeed, this 
could provide important information on the disease mechanisms through which 
these genes affect the risk of AD, and could be of interested for the design of 
preventative interventions. Whether all previously and newly discovered AD risk 
loci influence brain structure in advance of clinically detectable dementia has never 
been systematically investigated in large community samples to our knowledge. 
Our aim was to study association of known AD GWAS loci with ICV, TBV, HV, WMH 
burden and brain infarcts in non-demented participants from 10 population-based 
studies. 
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MATERIALS AND METHODS 
Population 
Analyses were performed on 8,175 to 11,550 dementia free participants of 
European ancestry with quantitative brain MRI and genome-wide genotypes 
(N=8,175 for ICV, N=8,673 for TBV, N=11,550 for HV, N=9,361 for WMH burden and 
N=9,401 for brain infarcts), from up to 10 population-based cohort studies 
participating in the Cohorts of Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium: Aging Gene-Environment Susceptibility (AGES)–Reykjavik 
Study, Atherosclerosis Risk in Communities Study (ARIC), Austrian Stroke 
Prevention Study (ASPS), Cardiovascular Health Study (CHS), Framingham Heart 
Study (FHS), Rotterdam Study (RS), Erasmus Rucphen Family (ERF) study, Religious 
Order Study (ROS) & Rush Memory and Aging Project (MAP), Tasmanian Study of 
Cognition and Gait (TASCOG) and the 3C-Dijon study. Each study secured approval 
from institutional review boards, and all participants provided written informed 
consent for study participation, brain MRI, and use of DNA for genetic research. 
Individual studies are described in the Supplementary Appendix. 
MRI scans 
In each study, MRI scans were performed and interpreted in a standardized fashion, 
without reference to clinical or genetic information. Details on MRI parameters and 
phenotype definition are provided in the Supplementary Appendix. Briefly, automated 
or semi-quantitative post-processing software was used to measure ICV and TBV. TBV 
was expressed as percentage of ICV to correct for differences in head size 22. HV was 
evaluated using operator-defined boundaries drawn on serial coronal sections or 
automated methods 23. WMH burden was estimated on a quantitative scale using 
custom-written computer programs in AGES-Reykjavik, ASPS, FHS, and RS; in ARIC and 
CHS, WMH burden was estimated on a semi-quantitative scale 24. Brain infarcts were 
defined as areas of abnormal signal intensity in a vascular distribution that lacked mass 
effect, > 3-4 mm, distinct from dilated perivascular spaces 25. 
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AD GWAS loci 
We manually scanned the GWAS catalog (www.genome.gov/gwastudies) and Alzgene 
(www.alzgene.org/) for GWAS on AD. We only chose studies performed on European 
subjects, including a replication stage, examining single marker based associations and 
having loci reaching genome wide significance (P<5.0×10-8). This led to the identification 
of 24 independent loci. Effect estimates for SNPs with the lowest p-value in each locus 
(defined as the index SNP of the locus)  are presented in Supplementary Table 1. We 
included the CD33 locus (rs3865444) despite absence of replication in the latest AD 
GWAS meta-analysis;15 this locus was previously replicated in several AD GWAS,13, 14 and 
recent functional studies provide strong evidence for involvement of rs3865444 and 
CD33 in AD pathology 26. For the APOE-ε polymorphism we used rs2075650 as a proxy 
(r2=0.48 with rs429358, the APOE-ε SNP), because APOE-ε genotypes cannot be reliably 
imputed on commercial genome-wide chips. The AD risk variants near HLA-DRB115, 
ATP5H/KCTD2 16, in TREM2,18, and APP17 were not included for single-SNP based 
association and genetic risk score based association as no index SNP or proxy (r2>0.3) 
was available among the genome-wide genotypes for MRI-markers of brain aging. 
Power calculation 
Quanto software 27, 28  was used to compute power of of the five MRI marker studies 
assuming additive model of inheritance at α=0.0025 (Supplementary Figure 1). Power 
for the quantitative traits (ICV, TBV, HV, WMH burden) was computed for different 
percentage variance explained while for brain infarcts, a dichotomous trait, it was 
computed for different odds ratios at different allele frequencies. 
Correlation between phenotypes 
Correlation between the five MRI phenotypes in 3C-Dijon and FHS was calculated based 
on Pearson’s correlation using the “rcorr” function in R. These correlations were used to 
compute the equivalent number of independent phenotypes using the online tool 
matSpDlite (neurogenetics.qimrberghofer.edu.au/matSpDlite/). MatSpDlite which is 
based on the same principles used to identify number of independent SNPs in a locus, 
gives the equivalent number of independent variables in a correlation (r) matrix, 
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depending upon the ratio of observed eigenvalue variance (after spectral 
decomposiiton) to its theoretical maximum 29.  
Association Analyses 
Three analytical approaches were taken to examine the associations of interest. 
Single-SNP based association analysis 
We tested for association of AD GWAS loci with MRI-markers of brain aging using 
association estimates obtained from meta-analyses of GWAS for ICV22, TBV22, HV23, WMH 
burden 24 and brain infarcts 25 using genotypes imputed on the HapMap2 CEU reference 
panel. AD risk alleles, as described in the latest AD GWAS meta-analysis,15 were modeled 
as the effect alleles for associations with MRI-markers of brain aging. Logistic (brain 
infarcts) or linear (ICV, TBV, HV and WMH burden) regression was performed within each 
study, adjusting for age, gender, and principal components of population stratification, 
and for familial relationships or study center if relevant. For WMH burden, data was log 
transformed to achieve normal distribution and associations were additionally adjusted 
for ICV (except for studies measuring WMH burden on a semi-quantitative visual scale, 
visual grades being inherently normalized for brain size)24. For most phenotypes (ICV, 
TBV, HV, and brain infarcts) meta-analyses were performed using fixed effects inverse 
variance weighted meta-analysis. For WMH burden, meta-analysis was performed using 
effective sample size weighted meta-analysis, because WMH burden was measured on 
different scales across studies. If the lead SNP at a specific AD GWAS locus was not 
available, a proxy SNP (r2>0.70 in 1000G CEU) of the lead SNP was used to check single-
SNP based association results (Supplementary Table 1).After Bonferroni correction for 
testing 20 independent loci, p<0.0025 was considered significant for single-SNP based 
associations. However, application of a more stringent threshold additionally accounting 
for the number of independent phenotypes tested led to a Bonferroni correction of 
p<0.000625. 
Gene-based association analysis  
Gene-based association tests can be more powerful in comparison to single-SNP based 
association tests when there are many causal variants in a gene with small effects 30. 
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Single-SNP based association results from the respective MRI-marker GWAS meta-
analysis were used to compute gene-based association results using the Versatile Gene-
Based Association Study2 (VEGAS2) software (https://vegas2.qimrberghofer.edu.au/) 30. 
The gene annotations and LD calculation in VEGAS2 are based on 1000 genomes (phase 
1 version 3). This tool annotated all but one gene (MS4A4E) within 50KB of the index 
SNPs. The test incorporates information from all markers within a gene and accounts for 
linkage disequilibrium (LD) between markers by using simulations from the multivariate 
normal distribution. Gene-based association analyses were performed for all protein 
coding genes (N=65 genes) which lie within a 50kb distance of index SNP of the AD risk 
loci. Gene boundaries were defined as 50kb upstream and downstream of the start and 
end of gene 30. The choice of 50 KB boundary to cover a gene was chosen as a trade-off 
between a longer boundary which would have caused excess overlap between nearby 
genes and a shorter boundary which would have ignored potential regulatory regions 30. 
Maximum permutation limits were set to 1000,000.  After correcting for the number of 
genes (N=65) tested the multiple testing threshold was p<0.00077. A more stringent 
correction additionally accounting for number of independent phenotypes (N=4) tested, 
lead to a multiple testing threshold of p< 0.00019 for gene based association. 
Construction of genetic risk score 
We constructed a genetic risk score comprising all selected AD risk variants from 20 
independent AD risk loci to estimate joint effect of these SNPs on MRI-markers of brain 
aging. Methods have been recently developed to apply a genetic risk score to meta-
analysis summary estimates without requiring access to raw data from individual studies 
31. For each MRI-marker of interest, the beta-coefficient for a given SNP, as obtained from 
the GWAS meta-analysis for this MRI-marker, was weighted with the published AD beta-
coefficient for the given SNP. The weighted sum of beta-coefficients for all 20 SNPs 
(Formula-i(a)) was used as the beta-coefficient of the genetic risk score. Similarly, for 
each MRI-marker of interest, the inverse of the variance for a given SNP (from the GWAS 
meta-analysis for this MRI-marker) was weighted by the square of the published AD 
beta-coefficient for the given SNP. These weighted inverse of variances were then 
summed and the inverse of this sum was used as the variance of the genetic risk score 
(Formula-i(b)). The Wald statistic was used to test for significance of associations 
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between the genetic risk score and each MRI-marker 31. For WMH burden, betas and 
standard errors were estimated from Z-statistics provided by the effective sample size 
weighted meta-analysis using Formula-ii. AD beta-coefficients used as weights for the 
score were all drawn from the discovery stage of the recent largest AD GWAS meta-
analysis (17,008 AD cases and 37,154 controls, Supplementary Table 1) 15. Associations 
with p<0.05 were considered significant for genetic risk score based associations. 
βgrs ൌ ∑ ࢝ࢼࡿࡱ
െ૛࢓૚
∑ ࢝૛࢓૚ ࡿࡱെ૛
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βgrs=beta of genetic risk score; SEgrs=SE of genetic risk score; w=weight applied 
(=SNP-specific beta of AD GWAS); β=SNP specific beta of association with MRI-
phenotype; SE= SNP-specific SE of association with MRI-phenotype 
ࡿࡱ~ ൌ ඥࢂࡼ/ሺࡱࡿ ൈ ૛࢖ࢗሻ																																															ࡲ࢕࢘࢓࢛࢒ࢇ െ ࢏࢏ሺࢇሻ 
࡮ࢋ࢚ࢇ ൌ ࡿࡱ ൈ ࢆ																																																																	ࡲ࢕࢘࢓࢛࢒ࢇ െ ࢏࢏ሺ࢈ሻ 
VP=phenotypic variance (approximated to 1); ES=Effective sample size; p=Minor 
allele frequency; q=Major allele frequency.  
After correcting for four independent phenotypes tested, the multiple testing 
threshold for genetic risk score association was P<0.0125.  
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RESULTS 
Correlation and heritability of the five MRI traits 
Based on data from two studies which were part of the original meta-analysis the 
two MRI markers of structural brain aging, ICV and TBV showed high correlation 
with each other but were only moderately correlated with HV (Supplementary 
Table 2). The two MRI markers of vascular brain aging WMH burden and brain 
infarcts showed low correlation with each other and very little or no correlation 
with the three markers of structural brain aging. Depending upon this correlation 
the equivalent number of independent phenotypes calculated using matSpDlite 
was four for both studies. Published literature showed that the five MRI markers 
had moderate to high heritability (Supplementary Table 3). 
Single-SNP based associations 
In total 9 out of 20 AD risk variants that could be analyzed showed association with 
at least one MRI-marker at p<0.05 (Table 1). With only 2 exceptions (CD33 locus 
with brain infarcts (p=0.048) and PTK2B locus with ICV (p=0.028)), betas were in the 
expected direction i.e. the AD risk allele was associated with increased risk for brain 
infarcts and with lower ICV, TBV and HV. The most significant associations were for 
APOE-rs2075650 with HV (beta±SE=-0.042±0.015, p=0.0054) and CD33-rs3865444 
with ICV (beta±SE=-5.209±1.886, p=0.0058) (Table 1). However, none of the single-
SNP based associations were significant after correcting for multiple testing. None 
of the AD risk variants showed associations with WMH burden. 
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Gene-based associations 
Out of the 24 loci investigated, 23 had at least one protein coding gene within 50kb 
distance. Only rs3851179 (11q14) had no protein coding gene within 50kb and was 
not represented in the gene-based association analysis (nearest genes: PICALM 
87.72kb downstream and EED 86.95kb upstream). In total, 65 protein coding genes 
from 23 independent loci were assessed for gene-based association analyses 
(Supplementary Table 4). 
A total of 27 protein coding genes within 50kb of 15 index SNPs were associated 
with ICV, TBV, HV or brain infarcts at p<0.05 (Table 2). For ICV we observed 
association with 13 genes within 50kb of five index SNPs (MEF2C, NME8, PILRB, 
PILRA, ZCWPW1, MEPCE, PPP1R35, C7orf61, MS4A6A, PVRL2, TOMM40, APOE, 
APOC1; p-range: 0.04-0.0078). Eight genes within 50kB of six index SNPs were 
associated with TBV (CR1, HLA-DRB1, HLA-DQA1, HLA-DQB1, TAS2R60, SCARA3, 
ICT1, CD33; p-range: 0.047-0.0006). BIN1, TREML1 and MS4A6A were associated 
with HV (p=0.00089, 0.03 and 0.048, respectively) while MEF2C, AURKA, CSTF1 and 
TAS2R60showed association with brain infarcts (p-range: 0.049-0.033). For WMH 
burden we observed association with three genes from two loci (HLA-DQB1, 
HMHA1 and ABCA7; p=0.01, 0.046 and 0.049 respectively).   If we correct for the 
number of genes tested the association of HLA-DRB1 with TBV remains significant 
but if we additionally correct for the number of phenotypes tested this association 
is not significant. 
Genetic risk score based associations 
The AD genetic risk score was associated with smaller HV (beta±SE=-0.047±0.013, 
p=0.00041) (Table 3). This association was also observed after removing the APOE 
locus from the AD genetic score (beta±SE=-0.050±0.023, p=0.029). There was also 
nominal association of the AD genetic risk score with smaller TBV (beta±SE =-
0.127±0.064, P=0.046) but this association was not significant after excluding the 
APOE locus from the genetic risk score (P=0.13).  Only association of the AD genetic 
risk score with HV including APOE locus was significant after correcting for the 
number of independent phenotypes tested.   
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Table 3 | Genetic risk score based association of the AD loci with MRI-markers of brain 
aging 
 With APOE Without APOE
 Beta SE p Beta SE p 
Intra-cranial volume
(in cm3) 
1.179 2.174 0.59  -6.224 3.945 0.11 
Total brain volume
(in % ICV) 
-0.120 0.061 0.048  -0.166 0.111 0.13 
Hippocampal 
volume 
(in cm3) 
-0.044 0.013 0.00042  -0.050 0.023 0.029 
WMH burdena 0.013 0.020 0.52 -0.019 0.038 0.61 
Brain infarcts
(yes/no) 
-0.039 0.052 0.45  0.055 0.094 0.56 
Key:  Beta, effect estimate, per allele increase of the risk allele; SE, standard error; WMH, white 
matter hyperintensities 
a for WMH burden betas and SEs were estimated from the Z-statistics obtained in the WMH 
burden meta-analysis and do not reflect an interpretable effect size (as the WMH burden was 
estimated using different scales in participating studies) 24. 
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DISCUSSION 
We investigated associations of 24 genome-wide significant AD risk loci with five 
MRI-markers of brain structure and aging (ICV, TBV, HV, WMH burden and brain 
infarcts), in over 8,000 dementia free older community participants from the 
CHARGE consortium. Although no single SNP-based association met the 
significance threshold after correction for multiple testing, index AD risk variants 
mapping to eight of the 21 AD risk loci showed nominal association with at least 
one MRI-marker, the most interesting being association for APOE (rs2075650) with 
smaller HV and for CD33 (rs3865444) with smaller ICV. In gene-based association 
analyses HLA-DRB1 was significantly associated with TBV after correction for 
number of genes tested. A weighted AD genetic risk score was significantly 
associated with smaller HV.  
In Single-SNP based associations none of the associations were significant after 
correcting for multiple testing. Nominally significant associations of an APOE risk 
variant with HV (P=0.0054) and a CD33 variant with ICV (P=0.0058) were observed. 
Since the mid 1990’s (Supplementary Table 5) some studies have described 
significant associations between the APOE-ε4 allele and smaller HV 32-41, however 
other studies did not find such an association 42-45. Using the largest sample size to 
date (N=11,550), as previously reported by our group, our findings are supportive 
of an association of the APOE-ε4 locus with smaller HV 23. The rs3865444 (CD33) AD 
risk allele association with smaller ICV could perhaps be suggestive of an 
involvement of this locus in brain maturation and brain reserve. Recent reports 
suggest that rs3865444 influences CD33 expression, including in young adults in 
their twenties 26, and is associated with diminished internalization of amyloid β42 
peptide, and accumulation of neuritic amyloid pathology and fibrillar amyloid in 
vivo 26. 
Gene-based analyses revealed significant associations of HLA-DRB1 (index SNP 
rs9271192) with TBV. The HLA-DRB1 locus was recently identified to be associated 
with AD in the largest meta-analysis of AD 15. This locus is part of the major 
histocompatibility complex, class II, and our findings add support to the role of 
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autoimmunity in AD. The findings also suggest that the locus may be playing a role 
in pre-symptomatic stages of the disease, as we observe association with smaller 
brain volumes in non-demented older community persons.  
When combined in a weighted genetic risk score, AD risk variants were associated 
cumulatively with decreased HV. Interestingly the association was maintained with 
a similar effect size, although less significant, after removing the APOE locus from 
the analysis, suggesting that, in aggregate, novel AD risk loci are associated with 
smaller HV in non-demented older community persons. The AD genetic risk score 
also showed nominal association with smaller TBV. Although this association was 
no longer significant after removing the APOE locus, other loci were contributing to 
this association, as the APOE risk variant alone was not significantly associated with 
TBV.  
There were fewer associations with WMH burden and brain infarcts. Most 
associations with AD risk variants were observed for ICV, TBV, and HV. This may 
indicate that, even though they are strong predictors of dementia risk,5, 6 MRI-
markers of vascular brain injury could have less shared genetic determinants with 
AD than MRI-markers of brain growth and brain atrophy, as suggested by others 20. 
Noteworthy, our study only tested for overlap of genome-wide significant AD risk 
variants, did not explore shared heritability and may have been underpowered for 
less common variants with smaller effect size (Supplementary Figure 1).  
Our study has limitations. The 24 AD risk loci do not reflect the full spectrum of 
genetic susceptibility to AD and the index SNPs used may not be causal variants. 
The five GWAS of MRI-markers, although the largest of their kind, have fewer 
samples compared to the AD GWAS from which the loci have been obtained 15, 22-25.  
These five GWAS of MRI-markers were performed using imputed genotypes based 
on the HapMap2 panel, which does not cover rare variants and has lower 
imputation accuracy, especially for lower allele frequencies, compared to the more 
recent 1000 genomes reference panels. We therefore couldn’t analyze rare AD risk 
variants in the present study. In addition, despite major efforts to harmonize 
phenotype definitions across studies, there may be some residual heterogeneity in 
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methods for quantifying MRI-markers of brain aging. These elements could have 
reduced our power to detect associations of AD GWAS loci with MRI-markers of 
brain aging. The choice of 50 KB window for a gene based test does not account for 
potential regulatory effects on more distant genes. Our findings cannot be 
generalized to populations of non-European ancestry. Ongoing, larger multi-ethnic 
GWAS of MRI-markers of brain aging, as well as sequencing projects searching for 
rare variants associated with AD risk and MRI phenotypes may enable us to expand 
our findings in the future.  
CONCLUSION 
In conclusion, we have shown that novel AD genetic risk variants are associated 
with MRI-markers of structural brain aging in older, non-demented community 
persons. In aggregate, novel AD genetic risk variants were associated with smaller 
brain volumes, especially HV. Significant gene-based associations and suggestive 
single SNP-based associations with ICV, TBV and HV also provide interesting 
hypotheses for mechanisms underlying genetic associations with AD  
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4.1.2. Genetic determinants of 
unruptured intracranial 
aneurysms 
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ABSTRACT 
Background and Purpose: Genome-wide association studies have identified single 
nucleotide polymorphisms (SNPs) for intracranial aneurysms in clinical samples. 
Additionally, SNPs have been discovered for blood pressure, one of the strongest risk 
factors for intracranial aneurysms. We studied the role of these genetic variants on 
occurrence and size of unruptured intracranial aneurysms, discovered incidentally in a 
general community-dwelling population. 
Methods: In 4,890 asymptomatic participants from the Rotterdam Study, 120 intracranial 
aneurysms were identified on brain imaging and segmented for maximum diameter and 
volume. Genetic risk scores (GRS) were calculated for intracranial aneurysms (10 SNPs), 
systolic blood pressure (33 SNPs) and diastolic blood pressure (41 SNPs). 
Results: The GRS for intracranial aneurysms was not statistically significantly associated 
with presence of aneurysms in this population (OR: 1.16; 95%CI, 0.96-1.40; P=0.119), but 
showed a significant association with both maximum diameter (difference in log-
transformed mm per SD increase of GRS: 0.10; 95%CI, 0.02-0.19; P=0.018) and volume 
(difference in log-transformed μl per SD increase of GRS: 0.21; 95%CI, 0.01-0.41; P=0.040) 
of aneurysms. GRSs for blood pressures were associated with neither presence nor size 
of aneurysms. 
Conclusions: Genetic variants previously identified for intracranial aneurysms in clinical 
studies relate to the size rather than the presence of incidentally discovered, unruptured 
intracranial aneurysms in the general population.  
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INTRODUCTION 
Unruptured intracranial aneurysms are incidentally discovered in imaging studies in 
approximately 2% of the general population.1 Rupture of an intracranial aneurysm can 
result in a non-traumatic subarachnoid hemorrhage (SAH), an acute condition with high 
morbidity and mortality rates. For early risk stratification and potential treatment, it is 
therefore important to better understand the pathophysiology of aneurysm 
development. 
Several risk factors for ruptured intracranial aneurysms have been identified, including 
age, gender, smoking, aneurysm size and location.2-4 In addition, an important 
modifiable risk factor for ruptured intracranial aneurysms is hypertension.5 Less is known 
about risk factors for development of intracranial aneurysms, although there is some 
overlap with risk factors for rupture, including gender, smoking and hypertension.6, 7 
Genetic factors also play an important role in intracranial aneurysms, which is evidenced 
by the fact that persons with a positive family history have a higher risk of developing 
intracranial aneurysms compared to the general population.8 More recently, genome-
wide association studies have identified multiple single nucleotide polymorphisms 
(SNPs) associated with intracranial aneurysms.9 Importantly, most studies investigating 
genetics of intracranial aneurysms have done so in a clinical setting, thereby typically 
including patients presenting with ruptured aneurysms or persons screened for high 
familial risk. In such settings, it cannot be discerned whether these SNPs affect the 
development of intracranial aneurysms or lead to growth and rupture of already present 
aneurysms. A population-based setting provides a unique opportunity to study the 
effect of these SNPs on unselected unruptured aneurysms. 
We investigated in a community-dwelling population the association of SNPs for 
intracranial aneurysms with the occurrence and size of unruptured aneurysms, 
incidentally detected on research imaging. Furthermore, we also studied SNPs for high 
blood pressure and their association with presence and size of unruptured intracranial 
aneurysms. 
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METHODS 
The online-only Data Supplement provides further details on the methods. 
Setting and study population 
This study was embedded in the prospective Rotterdam Study10, a population-based 
cohort study in the Netherlands. Between 2005 and 2014, 5,832 unique persons have 
undergone magnetic resonance imaging (MRI) of the brain.11 The study cohort was 
genotyped across the whole genome, with genotype data available for 4,890 out of 
5,832 subjects. 
Assessment intracranial aneurysms on MRI 
Reported incidental findings by research physicians were reassessed by a 
neuroradiologist and categorized accordingly. None of the participants had a history of 
SAH. Detected intracranial aneurysms were manually segmented. A 3D-model of the 
aneurysm was reconstructed, enabling us to calculate maximum diameter and volume 
of saccular intracranial aneurysms.  
Construction of the Genetic Risk Score 
Due to the small effects of individual SNPs and the relatively small number of aneurysms 
in our population-based setting, we constructed a genetic risk score to leverage the 
cumulative effect of all SNPs, allowing us to achieve higher power. For primary analyses 
we restricted to SNPs reaching a genome-wide significance (P < 5 × 10-8) in Caucasian 
populations, but in secondary analyses we included SNPs from non-Caucasian 
populations. The extracted SNP data is described in Supplementary Table 1. 
Statistical analysis 
We used logistic regression to associate genetic risk scores with presence of intracranial 
aneurysms (yes/no). Among persons with aneurysms we used linear regression to 
associate genetic risk scores with size of saccular intracranial aneurysms. Size was 
defined in both maximum diameter (mm) and volume (μl). For subjects with multiple 
saccular aneurysms, we calculated total aneurysm size by summing up the size of all the 
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saccular aneurysms. In all analyses we adjusted for age, sex and additionally for smoking 
status, systolic blood pressure, diastolic blood pressure and use of blood pressure-
lowering medication (antihypertensives, diuretics, beta blocking agents, calcium 
channel blockers, and ACE-inhibitors). Because persons could have multiple saccular 
aneurysms, hence greatly determining total aneurysm size, we also adjusted for number 
of aneurysms when performing analyses for size. 
 
RESULTS 
In 4,890 MRI-scans we found 120 aneurysms in 109 unique persons (2%), with 10 persons 
having multiple aneurysms (max 3 per person). The persons with intracranial aneurysms 
had a mean age of 65.4 ± 11.9 years and 73 (67.0%) were women. Of the 120 aneurysms, 
Table 1 | Study Characteristics
Variables Persons with
intracranial 
aneurysms (n=109) 
Persons without 
intracranial aneurysms 
(n=4781) 
Women 73(67.0%) 2610(54.6%)
Age, years 65.4±11.9 65.2±10.9
Smoking  
    Never 17(15.6%) 1380(28.8%)
    Past 50(45.9%) 2427(50.8%)
    Current 42(38.5%) 974(20.4%)
Systolic blood pressure, mmHg 140.3±23.1 140.0±21.4
Diastolic blood pressure, mmHg 82.9±11.6 82.4±10.9
Blood pressure-lowering
medication 
50(45.9%) 1712(35.8%)
Hypertension* 64(58.7%) 2427(50.8%)
Number of aneurysms 120 —
    Fusiform aneurysms 7(5.8%) —
    Saccular aneurysms 113(94.2%) —
        Maximum diameter, mm† 5.5(4.3-7.4) —
        Volume, μL† 52.8(27.6-125.6) —
*Defined as systolic blood pressure >= 140 or diastolic blood pressure >= 90. 
†Median with interquartile range. 
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114 (95%) were located in the anterior circulation and 113 (94.2%) were saccular with a 
median (interquartile range) maximum diameter of 5.5 mm (range 4.3-7.4) and volume 
of 52.8 μL (range 27.6-125.6). The 4,781 persons without aneurysms had a mean age of 
65.2 ± 10.9 years and 2610 (54.6%) were women. Study characteristics are described in 
Table 1. We did not find any significant associations between genetic risk scores and 
presence of intracranial aneurysms (Table 2).In contrast, the genetic risk score for 
intracranial aneurysms showed a significant age-sex-adjusted association with 
maximum diameter (difference in log-transformed mm per SD increase of GRS: 0.10; 
Table 2 | Association of Genetic Risk Score and presence of Intracranial Aneurysms 
Genetic Risk Score (per SD increase) OR (95%CI) P 
Model 1* 
    Intracranial Aneurysm (10 SNPs) 1.16(0.96;1.40) 0.119 
    Systolic Blood Pressure (33 SNPs) 1.15(0.95;1.39) 0.166 
    Diastolic Blood Pressure (41 SNPs) 1.09(0.90;1.32) 0.386 
Model 2† 
    Intracranial Aneurysm (10 SNPs) 1.17(0.96;1.41) 0.112 
    Systolic Blood Pressure (33 SNPs) 1.14(0.94;1.38) 0.190 
    Diastolic Blood Pressure (41 SNPs) 1.06(0.88;1.29) 0.525 
*Adjusted for: age, sex.  
†Adjusted for: age, sex, smoking, systolic blood pressure, diastolic blood pressure, 
blood pressure-lowering medication. 
Table 3 | Association of Genetic Risk Score and Saccular Aneurysm Size 
Genetic Risk Score (per SD increase) Max. Diameter (95%CI) P Volume (95%CI) 
Model 1* 
    Intracranial Aneurysm (10 SNPs) 0.10(0.02;0.18) 0.018 0.21(0.01;0.41) 
    Systolic Blood Pressure (33 SNPs) 0.02(-0.07;0.10) 0.728 0.01(-0.20;0.22) 
    Diastolic Blood Pressure (41 SNPs) -0.02(-0.11;0.07) 0.662 -0.06(-0.27;0.15) 
Model 2† 
    Intracranial Aneurysm (10 SNPs) 0.12(0.04;0.20) 0.006 0.26(0.06;0.46) 
    Systolic Blood Pressure (33 SNPs) 0.03(-0.06;0.13) 0.496 0.05(-0.18;0.27) 
    Diastolic Blood Pressure (41 SNPs) -0.02(-0.11;0.08) 0.707 -0.06(-0.28;0.16) 
*Adjusted for: age, sex, number of aneurysms. 
†Adjusted for: age, sex, number of aneurysms, smoking, systolic blood pressure, 
diastolic blood pressure, blood pressure-lowering medication. 
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95%CI, 0.02-0.18; P=0.018) and volume (difference in log-transformed μl per SD increase 
of GRS: 0.21; 95%CI, 0.01-0.41; P=0.040) of saccular aneurysms. The association remained 
statistically significant after additional adjustment (Table 3). Creating a genetic risk score 
by including SNPs identified in non-Caucasian populations yielded slightly attenuated, 
but still statistically significant results (Supplementary Table 2 and 3). Individual analyses 
for each SNP of the risk score are shown in Supplementary Table 4. Two SNPs (rs1333040 
and rs6475606) showed nominal significance with intracranial aneurysm size, but did 
not survive Bonferroni correction. Results for alternative methods of calculating 
aneurysm size are shown in Supplementary Table 5. No significant associations were 
found for the genetic risk scores of systolic blood pressure and diastolic blood pressure. 
DISCUSSION 
In this study of community-dwelling persons, genetic risk variants for intracranial 
aneurysms were not associated with presence of unruptured, incidentally discovered 
intracranial aneurysms. However, these genetic variants in combination were found to 
relate to larger size of incidental saccular aneurysms. Genetic risk variants for blood 
pressure were associated with neither presence nor size of intracranial aneurysms.  
A major strength of our study is, that we obtained unruptured intracranial aneurysms in 
a population-based setting, allowing us to investigate the association between genetic 
risk factors and intracranial aneurysm presence in truly asymptomatic individuals. 
Another strength is the manual segmentation of the entire aneurysm, enabling us to 
calculate saccular aneurysm volume instead of only the diameter, thus representing 
actual aneurysm size more accurately. A limitation of our study is the relatively old age of 
participants. Although aneurysmal SAH incidence increases with age12, a substantial 
portion of patients presenting with SAH are young adults. Due to the high morbidity and 
mortality associated with rupture of aneurysms, these patients were probably not 
included in our cohort of elderly persons. Combined with the limited statistical power 
considering a total of 109 cases, this could also explain why we did not find a statistically 
significant association for presence of aneurysms. Furthermore, the incidental 
aneurysms in the current study were typically small (median volume = 52.8 μL), which 
could make measurements inaccurate. However, inter-rater agreement was excellent for 
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both the maximum diameter and volume, indicating that the estimated aneurysm size 
was reliable. Also, intracranial aneurysms are more prevalent in persons with rare 
genetic diseases such as Loeys-Dietz Syndrome and Polycystic Kidney Disease. Even 
though information about the occurrence of these diseases was not available in our 
population, we expect the influence to be minimal in our cohort of healthy persons. 
Most genetic variants for aneurysms have been identified using cases from a clinical 
setting, i.e., patients with rupture of intracranial aneurysms. In such a setting, it cannot 
be discerned whether these genetic variants affect the development of intracranial 
aneurysms or lead to growth and rupture of already present aneurysms. In our 
community-dwelling population, we did not find a statistically significant association 
between these genetic variants and the presence of incidental intracranial aneurysms, 
although the confidence interval for the odds ratio included values that would indicate a 
potentially important association (OR as large as 1.40). The absence of a statistically 
significant association may thus reflect low statistical power. Interestingly, despite the 
small numbers of persons with aneurysms, we did find an association between these 
genetic variants combined and the size of intracranial aneurysms, which is one of the 
strongest risk factors for rupture.13 In addition, large aneurysms also have an increased 
risk of further enlargement.14 Taken together, our findings suggest that SNPs previously 
associated with intracranial aneurysms in a clinical setting are likely associated with the 
aneurysm size in the general population and thus, potentially with their subsequent 
rupture. 
A previous study in patients presenting with SAH did not find any association between 
similar genetic variants and diameter of aneurysms at the time of rupture15, using 7 of 
the 10 SNPs we used. Possible explanations for the difference in results between studies 
are the difference in study population, and the fact that aneurysm rupture may 
potentially affect the observed aneurysm size.  
Further research could explore the predictive ability of genetic risk scores, identifying 
additional SNPs to enhance discrimination and rupture risk classification in persons with 
intracranial aneurysms. We specifically created genetic risk scores for blood pressure 
genes because hypertension is one of the strongest modifiable risk factors associated 
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with aneurysm rupture. However smoking and heavy alcohol consumption, among 
other risk factors, are also strongly associated with aneurysm formation and rupture,5 
and future research should focus on these as well. 
CONCLUSION 
We demonstrated that genetic risk variants identified for intracranial aneurysms from a 
clinical setting were not associated with aneurysm presence in the general population. 
However we did show that these genetic risk variants affect aneurysm size, known to be 
one of the strongest risk factors for rupture. This possibly suggests that the clinically 
identified SNPs are mainly associated with aneurysm rupture, rather than with the 
presence of aneurysms in a general population.  
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ABSTRACT 
The aim of our study is to investigate whether single nucleotide dystrophin gene 
(DMD) variants associate with variability in cognitive functions in healthy 
populations. The study included 1,240 participants from the Erasmus Rucphen 
family (ERF) study and 1,464 individuals from the Rotterdam Study (RS). The 
participants whose exomes were sequenced and who were assessed for various 
cognitive traits were included in the analysis. To determine the association between 
DMD variants and cognitive ability linear (mixed) modeling with adjustment for age, 
sex and education was used. Moreover Sequence Kernel Association  Test  (SKAT)  was  
used  to  test  the  overall  association  of  the  rare  genetic variants present in the DMD 
with cognitive traits. Although no DMD variant surpassed the pre specified 
significance threshold (p < 1*10-4), rs147546024:A>G showed strong association (β 
= 1.786, p-value = 2.56*10-4) with block design test in the ERF study, while another  
variant  rs1800273:G>A showed suggestive association  (β  =  -0.465,  p-value  = 
0.002) with Mini-mental state examination test in the RS. Both variants are highly 
conserved, although rs147546024:A>G is an intronic variant, whereas, rs1800273:G>A 
is a missense variant in the DMD which has a predicted damaging effect on the 
protein. Further gene based analysis of DMD revealed suggestive association (p-
values = 0.087 and 0.074) with general cognitive ability in both cohorts. In 
conclusion, both single variant and gene based analyses suggest the existence of 
variants in the DMD which may effect cognitive functioning in the general 
populations.  
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INTRODUCTION 
The dystrophin gene (DMD) is localized on the X chromosome. Variants in DMD have 
been recognized as a cause of the most common form of muscular dystrophy during 
childhood, Duchenne muscular dystrophy (DMD).1 This disorder leads to progressive 
muscle weakness and less well described non-progressive central nervous system 
manifestations.2 
A consistent finding among patients with DMD is the reduction in Full-Scale 
intelligence quotient. Although most individuals are not intellectually disabled, 
risk for cognitive impairment is increased among affected males and up to 30 % of 
patients have intellectual disability.3-5 Apart from intellectual abilities, frequently 
reported neurocognitive function  impairment  has  been  published.6   Deficits  in  
short-term  memory,  executive functions, visuospatial ability, as well as deficits in 
some aspect of attention, problems with narrative, linguistic and reading skills have 
been described, irrespective of general intelligence.7-12 Moreover, a higher incidence 
of different neuropsychiatric disorders, such as autism spectrum, attention deficit 
hyperactivity disorder, obsessive-compulsive disorders and social behavior problems 
has been revealed among affected males.13-17 
The impact of DMD on cognitive ability in cognitively healthy populations has not 
been studied to the best of our knowledge, therefore in the current study we aim to 
investigate whether single nucleotide DMD variants associate with variability in 
cognitive functions in general populations, suggesting loci in the DMD 
contributing to cognition, besides genuine DMD variants. 
METHODS 
Study populations 
Our study population consisted of subjects from Erasmus Rucphen Family (ERF) and 
Rotterdam Study (RS). Erasmus Rucphen Family is a family based study that includes 
inhabitants of a genetically isolated community in the South-West of the 
Netherlands, studied as part of the Genetic Research in Isolated Population (GRIP) 
program.18 Study population includes approximately 3,000 individuals who are 
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living descendants of 22 couples who had at least six children baptized in the 
community church. All data were collected between 2002 and 2005. The population 
shows minimal immigration and high inbreeding, therefore frequency of rare alleles 
is increased in this population. All participants gave informed consent, and the 
Medical Ethics Committee of the Erasmus University Medical Centre approved the 
study. 
The Rotterdam study (RS) is a prospective, population-study from a well-defined 
Ommoord district in the Rotterdam city that investigates the occurrence and 
determinants of diseases in the elderly.19 The cohort was initially defined in 1990 
among approximately 7,900 persons who underwent a home interview and extensive 
physical examination at the baseline and during follow-up rounds every 3-4 years. 
Cohort was extended in 2000 and 2005.19 RS is an outbred population, 
predominantly of Dutch origin. The Medical Ethics Committee of the Erasmus 
Medical Center, Rotterdam, approved the study. Written informed consent was 
obtained from all participants. 
Data collection procedure 
Participants from both cohorts underwent extensive neuropsychological examination. 
In ERF study different cognitive domains were assessed using Dutch validated 
battery of neuropsychological tests.20,21  We focused on neurocognitive domains which 
are known to be affected in patients with DMD.8-12  General cognitive ability was 
assessed with the Dutch Adult Reading Test (DART). Memory function was measured 
with a word learning test from which immediate recall and learning scores were 
derived while executive function was assessed with the Trail Making Test parts A 
and B (TMT)22 and verbal fluency tests.22 Visuospatial ability was assessed with the 
WAIS-III block-design subtest. 
In the RS global cognitive function was assessed with the Mini-mental state 
examination test (MMSE), while executive function and information processing speed 
were assessed  with  the  Letter-Digit  Substitution  Task  (LDST)23,  the  Word  
Fluency  Test (WFT)24,  and  the  abbreviated  Stroop  test.25   Examination  was  
performed  at  baseline (MMSE) and during follow up rounds (MMSE, LDST, 
The dystrophin gene and cognitive function in the general population 
 309 
4 
WTF).Participants from the both cohorts who had dementia or clinical stroke were 
excluded from the analysis as these conditions can influence  neuropsychological 
assessment. 
Genotyping/Sequencing 
The exomes of 1,336 individual from the ERF population were sequenced “in- 
house” at the Center for Biomics of the Cell Biology department of the Erasmus MC, 
The Netherlands, using the Agilent version V4 capture kit on an Illumina Hiseq2000 
sequencer using the TruSeq Version 3 protocol. The sequence reads were aligned 
to the human genome build 19 (hg19) using BWA and the NARWHAL pipeline.26,27 
The aligned reads were processed further using the IndelRealigner, MarkDuplicates 
and TableRecalibration tools from the Genome Analysis Toolkit (GATK) and Picard 
(http://picard.sourceforge.net). Genetic variants were called using the Unified 
Genotyper tool of the GATK. About 1.4 million Single Nucleotide Variants (SNVs) were 
called and after removing the low quality variants (QUAL < 150) we retrieved 577,703 
SNVs in 1,309 individuals. Further, for prediction of the functionality of the variants, 
annotations were performed using the SeattleSeq database 
(http://snp.gs.washington.edu/SeattleSeq Annotation131). 
In the Rotterdam study exomes of 1,764 individuals from the RS-I population were 
sequenced using the Nimblegen SeqCap EZ V2 capture kit on an Illumina 
Hiseq2000 sequencer and the TrueSeq Version 3 protocol. The sequences reads 
were aligned to the human genome build 19 (hg19) using Burrows-Wheeler 
Aligner.27 Subsequently, the aligned reads were processed further using Picard 
(http://picard.sourceforge.net), SAMtools28 and Genome Analysis Toolkit (GATK).29 
Genetic variants were called using Unified Genotyper Tool from GATK. Samples with 
low concordance to genotyping array (< 95%), low transition/transversion ratio (< 
2.3) and high heterozygote to homozygote ratio (> 2.0) were removed from the 
data. The final dataset consisted of 903,316 SNVs in 1,524 individuals. 
Statistical analysis 
Baseline descriptive analysis was performed with SPSS version 17. Deviation from  
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normality of cognitive functions was assessed by histograms and P-P plots. As the 
ERF study includes related individuals, all single variants in DMD were tested for 
association applying additive linear-mixed modeling with the „mmscore‟ function 
adjusting for age, sex and education in the GenABEL library of the R software.30  The 
„mmscore‟ function uses the relationship matrix estimated from genomic data in the 
linear mixed model to correct for relatedness among the samples. Additionally, for 
the most interesting results gender stratified analysis was also performed. As most of 
these cognitive tests are correlated (the 
Pearson correlation coefficient ranged from 0.219 to 0.670), in order to adjust for 
multiple testing we first calculated the effective number of independent tests using 
the eigenvalues of a correlation matrix using Matrix Spectral Decomposition 
(matSpDlite) software31, finally Bonferroni correction was applied for the effective 
number of independent tests. The same strategy was also adopted for modeling 
linkage disequilibrium between the SNVs of the DMD. Considering the number of 
independent cognitive tests and independent variants, the significance threshold 
was set to 0.05/(4 independent cognitive tests*124 independent variants) = 1.00*10-
04, whereas suggestive threshold was set to 1/(4 independent cognitive tests*124 
independent variants) = 2*10-3. SNVs were coded 0, 1, 2 for genotypes AA, AB, BB in 
females respectively and 0, 2 for genotypes A, B in males. Since sequencing is likely to 
reveal several variants that may be population specific, we also performed the gene-
based Sequence Kernel Association Test (SKAT), a test specifically  designed  to  
analyze  rare  sequence  variation  in  a  specific  gene/region.32 Assessing the joint 
effect of multiple variants within the gene/region, the SKAT is proposed as a more 
powerful approach for rare variants than a classical single variant analysis and 
several burden tests.32 The significance threshold for gene-wise analysis was set to 
0.05/4 independent cognitive tests = 0.0125, while the suggestive threshold was set to 
¼ independent test = 0.25. 
To assess the relationship between the SNVs variants outside the protein-coding 
regions with gene expression in the tissue we used the Genotype-Tissue Expression 
(GTEx) project database.33 The data were deposited in GWAS Central (HGVST1824). 
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RESULTS 
General characteristics of the studied populations are shown in Table 1. The mean 
age in ERF was 48 years and 39 % of the participants were males while mean age in 
RS was around 68 years and 44 % of the participants were males. Around 30 % of 
participants in the ERF study had only primary education compared to around 36 % 
subjects in the RS. 
Number of SNVs in the DMD discovered by exome sequencing was 165 in the ERF and 
482 in the RS (Supplementary Table 1). Around 70 % of variants in the DMD had 
minor allele frequency (MAF) lower than 0.05 in ERF compared to around 98 % of 
variants in the RS. The results of the association analysis between SNVs in the DMD 
and cognitive functions with nominal level of significance in ERF study are presented 
in Table 2. Although none of the findings surpassed multiple testing correction 
using a Bonferroni threshold of 1.00*10-04, strong association was observed between 
rs147546024:A>G (β = 1.786, p-value = 2.56*10-04) and the block design test. Gender  
Table 1 | Descriptive statistics of the study populations. 
 ERF RS baseline RS follow up 
N 1241 1464 902 
Age 47.9 (14.4) 68.1 (9.4) 72.0 (7.1) 
Gender (% of males) 39.3% 44.3% 44.8% 
Education (% of only primary education) 29.8% 35.6% 29.3% 
Cognitive tests 
Dutch Adult Reading Test, mean (sd) 58.56 (20.31)
AVLT - Immediate recall, mean (sd) 4.37 (1.69)
AVLT - Learning, mean (sd) 33.55 (9.01)
Ratio TMT-B / TMT-A, mean (sd) 2.68 (1.02)
Verbal fluency, mean (sd) 61.66 (18.21)
Block design test, mean (sd)
Mini-mental state examination, mean (sd)
8.24 (2.77)  
27.7 (1.8)
 
27.7 (2.0) 
Letter-Digit Substitution Task, mean (sd) 27.0 (7.2) 
Word Fluency Test, mean (sd) 21.3 (5.5) 
ERF – Erasmus Rucphen family study; RS - Rotterdam study; N -  number of participants; AVLT - 
Auditory Verbal Learning Test; TMT- A, TMT- B - Trail Making Test parts A and B; 
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Figure 1. Carriers of the SNV that achieved the strongest association in the ERF  study 
Carriers are indicated in gray. 
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Figure 2. Carriers of the overlapping SNV in the ERF study. 
Carriers are indicated in gray. 
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stratified analysis showed nominally significant association in both genders (β = 1.796, 
p-value = 0.009 in males and β = 1.623, p-value = 0.018 in females). This rare (A G) 
variant with MAF of 0.011 was localized in the intron 1 of the DMD 
(chrX.hg19:g.33146086A>G) and although being highly conserved over species 
(Conservation score GERP = 4.08) has an unknown effect on the protein. Based on 
localization, we studied the relationship of this variant with gene expression in 
human tissues GTEx database but no significant eQTLs were found for this variant.  
The family-based design of the ERF study allowed us to check if all the carriers (n = 24) 
of this variant were closely related. All carriers were connected to each other in 10 
generations (Figure 1). 
Next, we explored the association of rs147546024:A>G in the population based 
study (RS). Even though rs147546024:A>G is a previously identified genetic variation 
in dbSNP database (present in six copies in 1000 Genomes with a MAF of 0.004) it 
was not present in RS and was not in linkage disequilibrium with any of the other 
SNVs of DMD. This prompted us to look for overlapping variants between the two 
studies. Among 34 overlapping variants we identified the most interesting 
overlapping finding that is shown in Table 3. Among these variants rs1800273 
(chrX.hg19:g.31986607G>A), had similar MAF in both studies (0.038 in the ERF 
and 0.033 in the RS), similar effect size and same direction of the effect in both 
cohorts and was suggestively associated with Block design test in the ERF study (β = 
-0.424, p-value = 0.066) and with MMSE in RS (β = -0.465, p- value = 0.002) (Table 3). 
This G>A variant is localized in exon 45 of the DMD and is classified as a missense 
variant with a predicted damaging effect on the protein (POLYPHEN score = 0.99, 
conservation score GERP = 2.52). This variant is present in 23 copies in 1000 Genomes 
with a MAF of 0.014. All carriers of the variant in the ERF were connected to each 
other (Figure2). 
In the gene based analysis using SKAT suggestive associations (p-values 0.087 and 
0.074) were also observed both in ERF and RS for DART and MMSE respectively. 
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DISCUSSION 
The aim of this study was to investigate possible impact of genetic variants in the 
DMD on cognitive ability in the general population. Even though none of the DMD 
variants surpassed the pre specified significance threshold, rs147546024:A>G was 
suggestively associated with block design test in ERF, whereas rs1800273:G>A was 
nominally associated with Mini-mental state examination test in the RS and 
marginally associated with block design test in ERF. 
rs147546024:A>G is localized in the intron 1, 196 bp far from the promoter of full- 
length protein isoform (Dp427p) which is expressed predominantly in the Purkinje 
cells of the hippocampus. The frequency of this variant in 1000 Genomes was 
observed to be 0.005 in individuals of European origin compared to ERF where the 
frequency was 0.011. This enrichment is expected due to genetic drift and isolation 
of the ERF population.18 Functional prediction of this variant showed high 
conservation score and unknown effect on the protein while gene expression 
analysis found no significant eQTLs in various human tissues. Interestingly, the rare 
allele of rs147546024:A>G was associated with better cognitive performance on block 
design test which is designed to assess visuospatial ability. Similar to some studies 
which have described a sex differences in cognitive ability with a male advantage 
on the spatial domains34, our study confirmed slight, but not significant, higher 
scoring of males on block design test. It is known that better performance on block 
design test is associated with autistic spectrum disorder35-37 and DMD is recognized as 
one of susceptibility genes for autism disorder.38,39  Suppression of the global 
configuration in order to process the information in a detailed fashion, essential for 
this test, is described as a main characteristic of autistic patients.40-43 
Another biologically interesting finding while searching for overlapping variants in 
both studies was the missense G A variant, rs1800273:G>A, which we found 
associated with block design test in ERF and the test of global cognitive ability 
(MMSE) in RS. This variant was observed at a frequency of 0.033 in the individuals 
of European origin and absent in those of African and Asian origin. Localized in exon 
45 of the DMD, this variant was classified as a missense variant with a predicted 
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damaging effect on the protein. Since the DMD has three upstream and four 
intragenic promoters which control expression of full-length (Dp427c, Dp427m, 
Dp427p) and short protein isoforms (Dp260, Dp140, Dp116, Dp71), exon 45 is 
present in the four different isoforms (Dp427c, Dp427m, Dp427p, Dp260) among 
which Dp427c and Dp427p are expressed in the brain.44  The Dp427c is expressed 
predominantly in neurons of the cortex and the CA regions of the hippocampus. It 
has been shown that this form of protein dystrophin colocalizes with inhibitory 
GABA receptor clusters at the postsynaptic membranes of hippocampal and 
neocortical pyramidal neurons where modulate synapse function.45-48 According to 
various studies this dystrophin isoform has a stabilizing effect on the GABA 
receptors by limiting their lateral diffusion outside the synapse.49,50  Importance of 
GABA receptors for the regulation of cognition, emotion and memory is increasingly 
being recognized.51,52 The Dp427p is expressed in the cerebellar and hippocampal 
Purkinje cells and in the cortical brain.53,54 However, exon 45 does not affect three 
shorter DMD isoforms (Dp140, Dp116 and Dp71) which are known to be associated 
with cognitive function in DMD.55,56 rs1800273:G>A was detected earlier in DMD 
patients and is present in the Leiden Muscular dystrophy database.57 Since majority 
of DMD patients have cognitive impairment, the association of rs1800273:G>A with 
DMD may represent association with cognitive impairment. However presence of this 
variant and lack of the dystrophin protein - which can by itself lead to cognitive 
impairment - would make it difficult to study the separate effect of this variant in DMD 
patients. 
One of the difficulties that our study had to deal with is heterogeneity in 
classification of phenotypes. Even though various cognitive tests are used in the 
studied populations, different cognitive domains can be compared since they are 
correlated. Therefore, moderate correlation (the Pearson correlation coefficient 0.429, 
p-value < 0.0001) between visuospatial ability and global cognition ability in the 
ERF, as well as correlation (the Pearson correlation coefficient 0.460, p-value < 
0.0001) between visuospatial ability and executive function which is recognized 
as a central domain of cognitive  functioning58,59    allow  us  to  compare  
association  of  the  most  interesting overlapping variant with block design test in 
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the ERF and MMSE test in the RS. 
The majority of variants called in our study were rare variants. Even though there is 
growing evidence that rare variants contribute to etiology of different complex 
traits, the search for rare variants is very difficult and challenging. Standard methods 
used to test for association with single common genetic variants are not powerful 
enough for the analysis of rare variants.60-62 Therefore with the available sample size, 
our study had limited power to detect association. This we attempted to 
overcome using the recently proposed gene based analysis (SKAT) design for rare 
variant analysis.32 Assessing the cumulative effect of multiple variants in DMD implied 
only suggestive p-value for both cohorts. Still like other approaches that deal with 
rare variants this approach also has limitations in terms of power but suggestive p-
values generated by SKAT pointed out that variants in the DMD may effect 
cognitive functioning in healthy populations. 
In conclusion, analyzing the sequence variants in the exon of DMD in two 
cognitively healthy cohorts we find evidence of association of DMD with cognitive 
functioning in healthy individuals. Larger studies are required for confirmation. 
SUPPLEMENTARY MATERIAL 
Supplementary Information is available at European Journal of Human Genetics website 
(http://www.nature.com/ejhg) 
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4.2.1. Alzheimer’s disease 
genes and the brain 
 
Fine-mapping the effects of Alzheimer’s disease risk loci on brain morphology.  
G.V. Roshchupkin*1,4, H.H.H. Adams*1,2, S.J. van der Lee*2 , M.W. Vernooij1,2, C.M. van 
Duijn2, A.G. Uitterlinden2,6, A. van der Lugt1, A. Hofman2, W.J. Niessen1,3,4, M.A. Ikram1,2,5 
*Authors contributed equally 
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ABSTRACT 
Background: The neural substrate of genetic risk variants for Alzheimer’s disease (AD) 
remains unknown. We studied their effect on healthy brain morphology to provide 
insight into disease etiology in the pre-clinical phase.  
Methods: We included 4071 non-demented, elderly participants of the population-
based Rotterdam Study who underwent brain MRI and genotyping. We performed 
voxel-based morphometry (VBM) on all gray matter voxels for 19 previously identified, 
common AD risk variants. Whole-brain expression data from the Allen Human Brain Atlas 
was used to examine spatial overlap between VBM association results and expression of 
genes in AD risk loci regions. 
Results: Brain regions most significantly associated with AD risk variants were the left 
postcentral gyrus with ABCA7 (rs4147929, p = 4.45 × 10-6), right superior frontal gyrus by 
ZCWPW1 (rs1476679, p = 5.12 × 10-6), and right postcentral gyrus by APOE (p = 6.91 × 10-
6). Though no individual voxel passed multiple testing correction, we found significant 
spatial overlap between the effects of AD risk loci on VBM and the expression of genes 
(MEF2C, CLU, SLC24A4) in the Allen Brain Atlas. Results are available online on 
www.imagene.nl/ADSNPs/. 
Conclusion: In this single largest imaging genetics dataset worldwide, we found that AD 
risk loci affect cortical gray matter in several brain regions known to be involved in AD, 
as well as regions that have not been implicated before.  
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INTRODUCTION  
Alzheimer's disease (AD) is a complex neurodegenerative disease and the most common 
cause of dementia. It has a long preclinical phase, during which there are no symptoms 
but structural brain changes can already be detected, such cortical atrophy and localized 
atrophy of the hippocampus 1,2. 
In recent years, common genetic risk factors for AD have been discovered through large 
meta-analyses of genome-wide association studies (GWAS) 3. However, the underlying 
neurobiological substrate leading to AD for the genes assigned to these risk loci remains 
to be uncovered. Identifying the brain structures affected by these genes can increase 
our understanding of AD and aid future functional studies. Previous studies have 
investigated some of the AD risk loci in relation to neuroimaging measures 4–7. However, 
they were generally focused on candidate regions that are known to play a role in AD, 
such as the hippocampus 6,7 or did not investigate all known risk loci 4,5. Unbiased 
approaches for analyzing brain images have great potential to give novel insights that 
would not have been considered a priori. Voxel-based morphometry (VBM) is a 
hypothesis-free technique for analyzing brain imaging data that characterizes regional 
tissue concentration differences across the whole brain, without the need to predefine 
regions of interest 8. Using VBM, we studied the association of 19 AD genetic risk loci 
with gray matter morphology at the voxel level in 4071 non-demented elderly from the 
Rotterdam study. This study provides insight into non-diseased brain morphology. Such 
knowledge is complementary and intertwined with better understanding disease 
etiology in the pre-clinical phase. Subsequently, we co-localized our results with publicly 
available genetic expression data. We thus identified genetic associations with known as 
well as novel regions affected in AD. 
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Table 1 |The most significant voxel-wise association signals with p-values<10-5. Brain 
region labeling based on the Hammer Atlas segmentation.  
Risk variant  
 
Gene* 
Minimum 
p-value 
Effect 
direction 
Brain Region 
rs4147929 ABCA7 4.46x10-6 - 
postcentral 
gyrus left 
rs1476679 ZCWPW1 5.12x10-6 + 
superior 
frontal gyrus 
right 
rs429358/rs7412 APOEε4 6.91x10-6 + 
postcentral 
gyrus right 
rs11771145 EPHA1 8.91x10-6 - 
precentral 
gyrus right 
rs190982 MEF2C 9.55x10-6 + 
lateral 
remainder of 
occipital lobe 
right 
Genetic Risk Score All 8.02x10-6 + 
postcentral 
gyrus right 
Genetic Risk Score 
Without 
APOE 
1.47x10-5** + 
lateral 
remainder of 
occipital lobe 
right 
Effect direction indicates beta sign, and demonstrates risk loci associated with increasing gray 
matter tissue (+) or decreasing gray matter tissue (-).     
* Assigned risk gene according to Lambert et al [1] 
** P-value is not less than 10-5, shown to compare with GRS without exclusion APOE. 
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METHODS 
Study Population 
The Rotterdam Study is an ongoing population-based cohort study in the Netherlands 
investigating diseases in the elderly and currently consists of 14,926 residents of 
Rotterdam who were aged 45 years or more at baseline 9,10. The initial cohort was started 
in 1990 and expanded in 2000 and 2005. The whole population is subject to a set of 
multidisciplinary examinations every four years. MRI was implemented in 2005 and 5430 
persons scanned until 2011 were eligible for this study. We excluded individuals with 
incomplete acquisitions, scans with artifacts hampering automated processing, 
participants with MRI-defined cortical infarcts, and subjects with dementia or stroke at 
the time of scanning. This resulted in a final study population of 4071 non-demented 
persons with information available on both genome-wide genotyping and MRI data. The 
Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC and by the Ministry of Health, Welfare and Sport of the Netherlands , implementing 
the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All 
participants provided written informed consent to participate in the study and to obtain 
information from their treating physicians. 
Imputation of genotypes 
The Illumina 550K and 550K duo arrays were used for genotyping. Samples with low call 
rate (<97.5%), with excess autosomal heterozygosity (>0.336) or with sex-mismatch were 
excluded, as were outliers identified by the identity-by-state clustering analysis (outliers 
were defined as being >3 standard deviation (SD) from population mean or having 
identity-by-state probabilities >97%). A set of genotyped input SNPs with call rate >98%, 
MAF >0.001 and Hardy–Weinberg equilibrium (HWE) P-value > 10−6 was used for 
imputation. The Markov Chain Haplotyping (MACH) package version 1.0 software 
(Imputed to plus strand of NCBI build 37, 1000 Genomes phase I version 3) and minimac 
version 2012.8.6 were used for imputation. APOE status was genotyped separately, using 
a polymerase chain reaction, as described in 11. APOEɛ4 was coded as the number of 
ApoEɛ4 alleles. 
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MRI acquisition and processing 
From August 2005 onwards, a dedicated 1.5 Tesla MRI scanner (GE Healthcare, 
Milwaukee, Wisconsin, USA) is operational in the Rotterdam Study research center in 
Ommoord. This scanner is operated by trained research technicians and all imaging data 
are collected according to standardized image acquisition protocols 10. Brain MRI scans 
included a high-resolution 3D T1-weighted fast RF spoiled gradient recalled acquisition 
in steady state with an inversion recovery pre-pulse (FASTSPGR-IR) sequence with thin 
slices (voxel size<1mm3) 10. 
Voxel based morphometry (VBM) was performed according to an optimized VBM 
protocol 12. First, all T1-weighted images were segmented into supratentorial gray 
matter (GM), white matter (WM) and cerebrospinal fluid (CSF) using a previously 
described k-nearest neighbor (kNN) algorithm, which was trained on six manually 
labeled atlases 13. FSL software 14 was used for VBM data processing. Then, all GM density 
maps were non-linearly registered to the standard GM probability template. For this 
study we chose the ICBM MNI152 GM template (Montreal Neurological Institute) with a 
1x1x1 mm3 voxel resolution. The MNI152 standard-space T1-weighted average structural 
template is derived from 152 structural images, which have been warped and averaged 
into the common MNI152 co-ordinate system after high-dimensional nonlinear 
registration.  A spatial modulation procedure was used to avoid differences in absolute 
GM volume due to the registration. This involved multiplying voxel density values by the 
Jacobian determinants estimated during spatial normalization. All images were 
smoothed using a 3mm (FWHM 8mm) isotropic Gaussian kernel.  
Statistical analysis 
Linear regression models were fitted with voxel values of GM modulation density as the 
dependent variable and age, sex, and the number of reference alleles (risk alleles for 
Alzheimer’s  disease, Supplementary Table 5) as independent variables. In total 
1,534,602 voxels were processed. To perform a nonparametric permutation test, we 
randomly shuffled the genotype data between persons and performed the VBM 
association analysis with all 1,534,602 voxels in gray matter. This was repeated 10,000 
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times and for every permutation we saved the minimum p-value. Subsequently, we took 
the 5th percentile of this minimum p-value distribution to compute FWE p-value 
threshold, which was 3.0 x 10-7 15. This was then divided by 19 to account for the number 
of independent SNPs, resulting in the final threshold of 1.66 x 10-8. 
Genetic Risk Score 
Genetic risk scores (GRS) were constructed by multiplying the number of risk alleles by 
their reported odds ratio (after natural logarithm transformation) for the disease, and 
summing this weighted allele score of each variant up into a disease risk score for AD16. 
We tested a GRS based on all 19 AD SNPs and second GRS excluding APOEɛ4. 
APOEɛ4 stratified analysis 
To investigate whether it is possible to enrich association signal of AD variants on brain 
morphology we split our sample into groups with increased chance for AD pathology by 
stratifying it for APOEɛ4 status. In total there were 1168 carrier and 2903 non-carrier in 
our data set.  
The Allen Human Brain gene expression analysis 
The Allen Human Brain Atlas (http://human.brain-map.org) includes RNA microarray 
data collected from the postmortem brains of six donors, with no known 
neuropsychiatric or neuropathological history. Around 500 samples per subject, per 
hemisphere were tested for expression profiles of 29,191 genes represented by 58,692 
pro bes. The expression profiles were normalized across samples and across different 
brains as described previously 17.In our analysis we used the three Caucasian donors. For 
each of these donors we extracted expression profiles of 216 genes, which are located 
within ± 500kb from AD risk loci and used the MNI coordinates to map the location of 
the samples. For each probe we derived z-score statistics, which represent deviation of 
gene expression in that sample relative to background expression. Next, using the VBM 
association results from all 19 tested AD SNPs, we formed clusters at the significance 
threshold of p-value<0.05 and identified all tissue samples localized inside these clusters 
or within 10 voxels from them.  
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We performed 10.000 random VBM analyses to generate p-value maps of null 
associations. We formed clusters, based on a p-value threshold of < 0.05, and linked 
these to probes as described above.  For three donors and all probes in the 216 genes (in 
total 667) we calculated the t-test statistic with a null hypothesis that expression of the 
gene within clusters is not significantly different from background expression. We saved 
the minimum p-values for every random VBM map. Subsequently, we took the 5th 
percentile of this minimum p-value distribution to compute the FWE p-value threshold. 
The obtained threshold was 1.7x10-5 . Then we performed the same t-test with the AD 
VBM maps. Thus, we compared expression of genes around AD risk loci in regions 
identified in the VBM analysis with their background expression in the brain. 
Regional analysis 
We used the Hammer atlas 18 to segment the gray matter into 36 regions for both 
hemispheres and compare effects on specific brain regions. We summed all voxels 
values inside segmented region to estimate gray matter volume. For every risk locus and 
brain region we run the same regression model as for the VBM analysis. 
Visualization 
To provide easy access to the study results, we developed an online interactive 
visualization tool (www.imagene.nl/ADSNPs/).  
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RESULTS 
Voxel-based morphometry of AD risk loci to  
The study population for VBM analysis consisted of 4071 non-demented persons with 
information available on both genome-wide genotyping and MRI data from the 
population-based Rotterdam Study. The mean age was 64.7 (± 10.7) years and 2251 
(55%) subjects were women. 
We studied the association of 19 AD risk loci with 1,534,602 voxels of gray matter. None 
of the associations reached the multiple-testing correction threshold 1.66x10-8. Table 1 
shows all associations between AD risk loci and gray matter voxel density with 
suggestive evidence for association p-values < 1 x 10-5. The strongest associations of 
gray matter voxel with AD risk loci were found in the left postcentral gyrus, right 
superior frontal gyrus, and right postcentral gyrus. In Figure 1 we show the three-
dimensional maps of the nominally significant (p-value<0.05) associations for the APOE 
risk loci. The negative clusters of APOE are located close to the medial temporal lobe, in 
particular around the hippocampus, whereas positive clusters are mainly in the occipital 
lobe. The GRSs association also did not reach the correction threshold. The strongest 
signal for risk score with APOE was found in the postcentral gyrus right (p-
value=8.02x10-6) and for the risk score without APOE in the lateral remainder of the 
occipital lobe right (p-value=1.47x10-5). On Supplementary Figure 1 are shown maps for 
all risk loci from Table 1. Supplementary Table 2 provides the full list of the top three 
associated clusters of voxels for each risk locus and more detailed statistical information. 
All study results are available and can interactively be explored on the ImaGene website: 
www.imagene.nl/ADSNPs/. 
In APOEɛ4 stratified analysis none of the signals passed the threshold, however variant 
in MEF2C loci showed much more significant association compare to full sample size 
analysis (Supplementary Table 5). Additionally, the association signal for non-carrier was 
in general less significant (Supplementary Table 6). 
Spatial overlap with gene expression 
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To investigate whether the effect of AD risk loci on VBM overlaps with gene expression 
in the brain, we used the Allen Human Brain Atlas data. We overlapped brain regions 
identified through our VBM analysis with the maps of samples from three Allen Human 
Brain Atlas donors (Figure 3). We compared expression within the identified voxel 
clusters with background expression. In total we tested the expression profiles of 216 
protein-coding genes, located ± 500kb from the AD variants (Supplementary Table 1). 
We found that MEF2C, CLU, SLC24A4 were significantly expressed (p-value<1.7x10-5) in 
the identified voxel clusters compared to other genes at that particular locus. 
Interestingly, these were the genes that were previously assigned as the risk genes at 
each respective locus based on a review of the available literature 3 (Table 2). 
Additionally, we found genes showing significantly different expression, which are 
located in the risk loci but were previously not proposed as the causal gene for AD. 
These are: NGEF (p-value=7.57x10-16) for the region around rs35349669 and GSTK1 (p-
value=1.01x10-5) for the region around rs11771145. Supplementary Table 2 provides the 
full list of genes and more detailed statistical information.  
Regional analysis  
Figure 2 provides a heat map showing all AD risk loci and their effect on different brain 
regions sorted by lobe. None of the association signals passed Bonferroni correction, 
however several loci showed nominal significant association (p-value <0.05; cells with 
stars on Figure 2), among them variant in EPHA1 with less tissue in caudate and in insula, 
CELF1 with more tissue in accumbens and APOE with very strong positive effect in the 
occipital lobe. Variants in APOE, FERMT2, PTK2B, CASS4 and MS4A6A showed the 
strongest effect on hippocampus and were associated with smaller gray matter volume. 
Risk variants in EPHA1 and SORL1 had the largest negative effect on deep gray matter 
structures: putamen, thalamus, and pallidum.   
Chapter 4.2.1 
336  
Fig
ure
 1 |
 Pr
oje
ctio
n o
f A
PO
E r
isk
 loc
i as
soc
iat
ion
 clu
ste
rs f
rom
 VB
M 
to 
cor
tica
l su
rfa
ce.
  
Co
lo
rs
 re
fle
ct
 re
gr
es
sio
n 
as
so
ci
at
io
n:
 b
lu
e 
fo
r n
eg
at
iv
e 
(A
), 
re
d 
fo
r p
os
iti
ve
 (B
). 
Cl
us
te
rs
 fo
rm
ed
 b
as
ed
 o
n 
no
m
in
al
 si
gn
ifi
ca
nt
 p
-v
al
ue
 th
re
sh
ol
d 
0.
05
. 
Alzheimer’s disease genes and the brain  
 337 
4 
  
 
Fi
gu
re
 2
 | 
H
ea
tm
ap
 o
f A
D
 ri
sk
 lo
ci
1  a
ss
oc
ia
tio
n 
ef
fe
ct
s 
fr
om
 R
O
I a
na
ly
si
s.
  
Th
e 
19
 A
D
 ri
sk
 lo
ci
 a
re
 o
n 
th
e 
y-
ax
is 
an
d 
br
ai
n 
re
gi
on
s, 
gr
ou
pe
d 
by
 lo
be
, o
n 
th
e 
x-
ax
is.
 B
ra
in
 re
gi
on
 la
be
lin
g 
w
as
 b
as
ed
 o
n 
th
e 
H
am
m
er
 A
tla
s. 
Bl
ue
 
in
di
ca
te
s t
ha
t r
isk
 lo
ci
 w
er
e 
as
so
ci
at
ed
 w
ith
 le
ss
 g
ra
y 
m
at
te
r t
iss
ue
; r
ed
 in
di
ca
te
s a
ss
oc
ia
tio
n 
w
ith
 m
or
e 
gr
ay
 m
at
te
r t
iss
ue
. S
up
pl
em
en
ta
ry
 T
ab
le
 3
 
pr
ov
id
es
 a
 c
od
ed
 st
ru
ct
ur
e 
lis
t. 
 R
eg
io
ns
 w
ith
 n
om
in
al
 si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n 
(p
-v
al
ue
 <
 0
.0
5)
 m
ar
ke
d 
w
ith
 *.
 
Chapter 4.2.1 
338  
  
 
Figure 3 | Example of spatial overlap between VBM association map for the MEF2C 
risk variant and MEF2C gene expression probes from Allen Human Brain Atlas.  
(A) –samples (red color) distribution from “donor9861” of Allen Human Brain Atlas; (B) – 
clusters of associated with MEF2C risk loci voxels (blue color) identified through VBM analysis 
formed using p-value threshold 0.05; (C) – Spatial overlap between Allen Brain probes and 
VBM clusters; (D) – example of VBM cluster and assigning sample location to them. 
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DISCUSSION 
This study presents the association of 19 genome-wide significant AD risk loci 3 with VBM 
of the gray matter, among 4071 middle aged and elderly subjects from the population-
based Rotterdam Study. The unprecedented sample size has enabled this unbiased 
whole grey matter investigation of established risk variants and their effect on brain 
morphology. We found nominally significant associations with the left postcentral gyrus, 
the right superior frontal gyrus and the right postcentral gyrus. Furthermore, through 
comparing our VBM results to the Allen Brain atlases of human gene expression, we 
found significant spatial overlap for genes previously assigned to be the causal gene in 
these loci (CLU, SLC24A4 and MEF2C). Additionally, we identified two genes, not 
previously suggested to be the causal gene in AD (GSTK1 and NGEF), of which the 
expression in the brain significantly overlaps with our VBM results. 
There currently exists no consensus for voxel-wise genetics studies regarding the 
significance threshold for avoiding false positive findings while not to being too 
conservative 19,20. A number of data processing and statistical analysis methods have 
been proposed in the literature to address this issue for neuroimaging analysis21–23. 
However, all these methods rely on a set of assumptions about the statistical structure of 
the data. Therefore, in our study we decided to use unbiased, but more conservative, 
non-parametric permutation methods to define the statistical threshold of significance. 
Although this is the largest genetic VBM study conducted to date, none of the voxels 
passed this conservative multiple testing correction. However, we have previously 
shown that AD risk loci are associated with cognitive functioning in the general 
population 11,16,24,25 as well as hippocampal volume in a larger sample (N= 9,232)7. This 
showed that subclinical effects of AD risk loci exist and that effects on gray matter could 
be expected. Additionally, we constructed genetic risk scores, to explore the combined 
effect of all AD SNPs on brain morphology. The association signal of GRSs also did not 
pass correction threshold and the strongest signal for GRS with APOE was driven by 
APOE variant, while for GRS without APOE by MEF2C variant (Supplementary Figure 2). 
Furthermore, it is reasonable to assume that the effects of the risk loci are not restricted 
to a single voxel, but rather to a cluster of voxels spanning a certain brain region. 
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Therefore, we further explored the nominally significant associations we found by using 
the Allen Brain Human Atlas to analyze gene expression, and using Hammer brain atlas 
to estimate average effect on specific brain regions.  
In Hammer regional analysis, we found that risk loci for Alzheimer’s disease affect brain 
morphology in established regions such as the hippocampus (e.g. loci near APOE, 
FERMT2, PTK2B), putamen, thalamus (SORL1, EPHA1), as well as regions not often 
reported on including the insula (EPHA1) and occipital lobe (APOE). The heat map in 
Figure 2 summarizes the association results over the whole brain.  
Alzheimer’s disease is a complex disorder with multiple variants from different pathways 
involved in its etiology26,27. Therefore, as previously shown6, the effect of these variants 
on brain morphology could also differ and have different directions. Figure 2 provides a 
detailed map of such heterogeneous effects. For example, large brain structures, such as 
the temporal lobe and central regions, are affected differently. Also, some risk loci have a 
different direction of effects, e.g. FERMT2 is associated with less tissue and SORL1 with 
more tissue in the temporal lobe. Of particular interest is that we found the positive 
association of APOE with the occipical lobe, which could possibly be explained by 
cerebral amyloid angiopathy (CAA). Indeed, CAA is linked to APOEε4 carriership 28,29 and 
has a predilection for the occipital neocortex 30. Moreover, CAA is involved in Alzheimer’s 
disease 31 and is characterized by ß-amyloid deposition in the media and adventitia of 
small and medium sized arteries. In healthy subjects, this may be observed as an 
increase in gray matter tissue density because of the influx of cells to clear the deposits. 
More research on the effects of AD risk loci on brain morphology is needed to further 
unravel the biological substrates involved in disease etiology.  
Previous case-control studies showed ambiguous differential expression of putative 
causal genes for AD in the brain 32 or reported that the regional expression of each of the 
risk loci did not match the pattern of brain regional distribution in Alzheimer pathology 
33. Most of AD variants are non-coding and for the follow up studies would be very 
important to explore the potential roles of these intronic and intergenic regions in the 
regulation of gene expression. Confirmed functional variants underlying validated 
GWAS hits are still sparse in the literature34,35, when considering all the diseases and traits 
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studied, but each of these is extremely valuable to the respective research and clinical 
environments. In our study, we found significant spatial overlap between VBM results in 
the Allen Human Brain atlas with some of the previously identified genes (CLU, SLC24A4 
and MEF2C). This could mean that genetic variability in these genes could act on gray 
matter density through differences in expression. This is also in line with the fact that 
most trait-specific GWAS signals are non-coding and probably act through modulation 
of gene expression36. Our results also suggest that VBM analysis combined with 
expression data could provide evidence for new candidate genes in genetic loci, where 
the causal gene has not been strongly established by biological experiments37. In AD 
loci, examples are NGEF for rs35349669 and GSTK1 for rs11771145. Although the index 
variant rs35349669 is located within INPP5D, this gene is expressed at low levels in the 
brain 3 and the linkage peak spans multiple genes with suggestive signals, including 
NGEF 3. Neuronal Guanine Nucleotide Exchange Factor (NGEF), among its related 
pathway is signaling by G protein–coupled receptors (GPCRs), which are involved at 
many stages of AD disease progression, and this class of receptors is a potential 
therapeutic target for AD 38. Glutathione S-transferase Kappa 1 (GSTK1) is member of the 
superfamily of enzymes that function in cellular detoxification. Interestingly, a significant 
decrease of glutathione transferase activity in different brain regions in patients with 
Alzheimer disease was previously reported 39, suggesting a possible link to Alzheimer 
through diabetes 40,41. 
Our study also has several limitations. The 19 AD risk loci do not include all genetics 
variants associated with AD and the index variants used may not be the causal variants. 
Another consideration is that the cross-sectional nature of our analyses precludes us 
from inferring causality from the associations. Although reverse causality is unlikely for 
genetic variants, it remains unclear whether our findings represent developmental or 
degenerative effects. The absence of significant association, as we mentioned before, 
could be due to strict permutation threshold or lack of power of our study sample size 
compare to GWAS analysis where these risk loci were discovered. Additionally, in the 
experiment to determine spatial overlap between gene expression and regions 
identified through VBM, a number of considerations need to be taken into account. First, 
the threshold to form the clusters is a manual parameter and could be set to a different 
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threshold. However, with decreasing p-value threshold the number and size of the 
clusters goes down lnot enough clusters linked to samples to perform such analysis. 
Second, gene expression depends on the time of measurement and could be different 
over the lifespan and even during the day 42. Second, the association between a risk 
locus and tissue density does not necessarily require the causative gene to be expressed 
in the same brain region, but could also be through a downstream effect of a functional 
pathway. Third, given the difficulties in obtaining brain tissue samples, these analyses 
are all based on relatively small samples. 
CONCLUSION 
Using a voxel-based morphometry study in over 4000 non-demented individuals, we 
provide a list of candidate brain regions that are potentially affected by AD risk loci and 
worthy of further study. Although detecting significant genetic effects on individual 
voxels will require even larger sample sizes, we show that data can be exploited by 
incorporating additional information in the analysis, such as gene expression data. 
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ABSTRACT 
Background: Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease 
characterized by brain atrophy of the frontal and anterior temporal lobes. The associated 
frontotemporal dementia syndromes are clinically heterogeneous and the pattern of 
affected cortical regions varies between subtypes. The TMEM106B rs1990622 
polymorphism is associated with FTLD, but little is known about how it affects the brain.  
Methods: We investigated the rs1990622 polymorphism in relation to regional brain 
volumes to identify potential structures through which TMEM106B confers risk for FTLD. 
In 4413 non-demented and stroke-free participants from the population-based 
Rotterdam Study, 150 cortical brain structures and 6 commissural regions were 
segmented from magnetic resonance imaging (MRI).  
Results: We found a distinct pattern of association between rs1990622 and grey matter 
volume of left-sided temporal brain regions important for language processing, 
including the superior temporal gyrus (β = -88.8 μL per risk allele, p = 7.64 x 10-5), which 
contains Wernicke’s area. The risk allele was also associated with a smaller anterior 
commissure cross-sectional area (β = -.167 mm2, p = 4.90 x 10-5) and posterior part of the 
corpus callosum (β = -15.3, p = 1.23 X 10-5), both of which contain temporal lobe 
commissural tracts.  
Conclusions: The asymmetric, predominantly left-sided involvement suggests an effect 
of TMEM106B on functions lateralized to the dominant hemisphere, such as language. 
These results show that, in non-demented persons, TMEM106B influences the volume of 
temporal brain regions which are important for language processing.  
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INTRODUCTION 
Frontotemporal lobar degeneration (FTLD) is a heterogeneous pathological entity with 
the common feature being prominent frontal and anterior temporal lobe atrophy.1 The 
diverse pathology that can be detected in the brains of patients serves as the basis of 
classification into more homogeneous subgroups.2 These pathological subgroups 
correspond to clinically defined syndromes including behavioral-variant frontotemporal 
dementia, semantic dementia and progressive non-fluent aphasia, with strong 
relationships between certain pathological subgroups and clinical syndromes (e.g., 
between TDP-43 inclusions and semantic dementia).3,4 
A recent genome-wide association study implicated single-nucleotide polymorphisms at 
the TMEM106B-gene in the risk of FTLD.5 Although the initial discovery of TMEM106B 
was in the strictly defined subgroup of FTLD with TDP-43 inclusions,5 it was replicated in 
a more heterogeneous patient group.6 TMEM106B risk variants were subsequently 
associated with cognitive impairment in amyotrophic lateral sclerosis and the 
pathological presentation of Alzheimer’s disease.7,8 TMEM106B encodes a glycoprotein 
that co-localizes with progranulin, another FTLD risk factor, in late endo-lysosomes.9 
FTLD-associated variant rs1990622 is in complete linkage disequilibrium with the 
potential functional coding variant p.T185S, and has been suggested to affect 
progranulin levels and function.10  
The rs1990622 risk allele A is common (~60%) and only increases susceptibility for FTLD 
marginally (odds ratio = 1.3), leaving the majority of carriers free of clinical disease.5,6 It is 
currently unknown if carriers of the risk variant do have subclinical, structural brain 
changes in regions relevant to the pathophysiology of FTLD. Frontal and temporal 
cortical atrophy is a hallmark of FTLD and the patterns of cortical involvement are part of 
the diagnostic criteria used for differentiating between subtypes.1,2,11-14  The regional 
atrophy reflects neuronal loss, mostly of cortical layer III, which contains the commissural 
fibers.15-17  The corpus callosum (CC) and anterior commissure (AC) are reduced in size in 
FTLD patients, with the distribution of atrophy in these commissural tracts 
corresponding to the cortical damage.11,16,18-20  
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Here we investigated the relation of rs1990622 with cortical grey matter and 
interhemispheric white matter within the Rotterdam Study,21 a large population-based 
study of the elderly, to identify potential brain structures through which TMEM106B 
confers risk for FTLD.  
Table 1 | Study population characteristics.
Characteristic Total (n=4413) 
Demographics
Age, years, mean (SD) 64.7 (10.8) 
Women, n (%) 2446 (55.4%) 
Brain volumetry
Intracranial volume, mL, mean (SD) 1487.1 (160.3) 
Grey matter volume, mL, mean (SD) 605.5 (58.3) 
White matter volume, mL, mean (SD) 438.9 (62.4) 
Rs1990622 genotype
AA carriers, n (%) 1546 (35.0%) 
AG carriers, n (%) 2089 (47.3%) 
GG carriers, n (%) 778 (17.6%) 
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MATERIALS AND METHODS 
Subjects 
The Rotterdam Study is an ongoing prospective cohort study that aims to investigate 
causes and determinants of diseases in the elderly.21 Residents of Rotterdam, a city in 
The Netherlands, were recruited from 1990 onwards and the current study population 
consists of 14,926 subjects aged 45 years or over at baseline.21 The Medical Ethics 
Committee of the Erasmus Medical Center and the review board of The Netherlands 
Ministry of Health, Welfare and Sports both approved the study. Informed consent was 
obtained from all subjects.  
Genotyping and quality control 
In 11,496 participants of the Rotterdam Study, genotyping was performed on 550K and 
610K Illumina arrays.21 The genotyped dataset was restricted to persons who reported 
that they were from European descent. Ethnic outliers were further excluded using IBS 
distances > 4SD. Duplicates and/or 1st or 2nd degree relatives were excluded using IBS 
probabilities >97%, as well as samples with gender mismatch and excess autosomal 
heterozygosity. Variants with call rate below 95.0%, those failing missingness test, with a 
Hardy–Weinberg equilibrium p-value<10-6, and minor allele frequency<1% were also 
removed. 
MRI data acquisition and image processing 
To study early structural brain changes of neurodegenerative disease, magnetic 
resonance imaging (MRI) was introduced into the core protocol of the Rotterdam Study 
from 2005 onwards.22 Brain MRI data were acquired with a dedicated 1.5T MR unit (GE, 
Milwaukee, USA) during a 30 minute imaging protocol that was previously described in 
detail.22 This protocol included high resolution axial fluid-attenuated inversion recovery 
(FLAIR), T1- and T2-weighted sequences. Of the 5637 participants with MRI scans 
available, genotyping was performed in a random subset of 4735 persons. Volumetric 
measures of the cortical grey matter and CC were successfully acquired in 4699 (99.2%) 
MRI scans (remaining 36 scans failed due to technical issues) with the FreeSurfer 
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software (version 4.5.0): cortical grey matter was automatically segmented and 
parcellated into 75 regions per hemisphere,23 whereas the CC was divided into five parts, 
namely anterior, mid-anterior, central, mid-posterior and posterior.24 The AC cross-
sectional area was manually segmented in 4732 (99.9%) scans in the mid-sagittal plane 
with high intra-rater reliability (intra-class correlation coefficient = 0.91 in 100 scans) 
using an in-house developed MeVisLab extension which has been made available online 
(see Supplementary Material and http://www.mevislab.de). Outliers, which were defined 
as brain structure volumes falling outside of μ ± 2.5σ, were visually inspected and 
removed if necessary. Trained raters viewed all scans to determine presence of brain 
infarcts using FLAIR, T1- and T2-weighted sequences, and these were classified as 
cortical infarcts in case of grey matter involvement.25  
Data analysis 
Excluded from analyses were people with dementia (according to DSM-III-R26, n=55), 
clinical stroke (baseline medical history and continuous monitoring27, n=162) and MRI-
defined cortical infarcts (n=105), leaving 4413 participants with successful segmentation 
of FreeSurfer structures and/or the AC. Multiple linear regression models, with age and 
sex as covariates, were used to examine associations between rs1990622 and the left 
and right volume of the 75 cortical regions and CC and AC commissural tracts. 
Additionally, the effects on the significant structures were investigated for four 
previously reported TMEM106B variants that are in high linkage disequilibrium with 
rs1990622 and potentially functional (p.T185S and rs1042949)28 or have also been 
genome-wide significantly associated with FTLD (rs6966915 and rs1020004)5. The Sidak 
corrected significance level to maintain α=0.05 for testing 156 correlated outcomes 
(mean correlation ρ=0.25) was determined at p<1.14 x 10-3 (see Supplementary 
Methods).29 For the significant structures, we additionally adjusted for the first four 
principal components to control for potential population stratification. The explained 
variance was calculated by squaring the semipartial correlation coefficients between 
rs1990622 and the brain structures. All analyses were performed with SPSS version 21 
(IBM).
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Table 2 | Nominally significant associations of rs1990622 with cortical grey matter 
volumes and commissural tracts. 
Brain structure Beta (95% CI) P-value R2 
Left hemisphere  
Superior temporal sulcus -88.8 (-44.8;-132.8) 7.64 x 10-5 0.29% 
Angular gyrus -66.1 (-27.1;-105.2) 9.14 X 10-4 0.21% 
Middle temporal gyrus -76.9 (-31.1;-122.8) 1.00 X 10-3 0.18% 
Intraparietal sulcus and transverse parietal sulci -36.4 (-9.9;-62.9) 7.15 X 10-3 0.15% 
Precuneus -42.0 (-10.7;-73.4) 8.60 X 10-3 0.14% 
Central sulcus -26.5 (-5.0;-47.9) 1.55 X 10-2 0.11% 
Middle-posterior cingulate gyrus and sulcus -16.1 (-2.5;-29.6) 2.02 X 10-2 0.10% 
Lateral aspect of the superior temporal gyrus -38.7 (-4.8;-72.5) 2.51 X 10-2 0.09% 
Supramarginal gyrus -43.5 (-3.9;-83.2) 3.13 X 10-2 0.09% 
Subparietal sulcus -15.1 (-0.8;-29.5) 3.82 X 10-2 0.09% 
Precentral gyrus -31.8 (-1.2;-62.4) 4.14 X 10-2 0.07% 
Posterior transverse collateral sulcus -5.7 (-0.2;-11.3) 4.29 X 10-2 0.09% 
Right hemisphere  
Supramarginal gyrus -64.3 (-26.9;-101.6) 7.51 X 10-4 0.22% 
Vertical ramus of the lateral sulcus anterior 
segment 
-7.3 (-2.7;-11.8) 1.91 X 10-3 0.21% 
Planum temporale of the superior temporal gyrus -20.1 (-6.7;-33.4) 3.20 X 10-3 0.17% 
Precuneus -42.5 (-13.6;-71.4) 3.96 X 10-3 0.16% 
Superior temporal sulcus -67.1 (-20.2;-114.0) 5.08 X 10-3 0.14% 
Medial occipito-temporal and lingual sulcus -22.7 (-6.3;-39.0) 6.52 X 10-3 0.13% 
Opercular part of the inferior frontal gyrus -28.4 (-7.8;-49.0) 7.00 X 10-3 0.15% 
Subcentral gyrus (central operculum) and sulci -23.3 (-5.4;-41.2) 1.08 X 10-2 0.13% 
Inferior temporal sulcus -21.8 (-4.7;-38.9) 1.25 X 10-2 0.11% 
Transverse temporal sulcus -5.2 (-1.0;-9.3) 1.46 X 10-2 0.13% 
Anterior part of the cingulate gyrus and sulcus -31.0 (-4.7;-57.4) 2.09 X 10-2 0.09% 
Lateral orbital sulcus -8.8 (-1.2;-16.4) 2.38 X 10-2 0.11% 
Table 2 continued.
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Postcentral sulcus -29.6 (-3.9;-55.2) 2.40 X 10-2 0.11% 
Lateral occipito-temporal gyrus -39.1 (-5.1;-73.1) 2.43 X 10-2 0.10% 
Lateral occipito-temporal sulcus -14.6 (-1.7;-27.6) 2.69 X 10-2 0.09% 
Long insular gyrus and central sulcus of the insula -9.8 (-0.8;-18.7) 3.18 X 10-2 0.10% 
Middle-anterior cingulate gyrus and sulcus -18.5 (-1.4;-35.6) 3.40 X 10-2 0.08% 
Inferior temporal gyrus -50.5 (-2.2;-98.8) 4.04 X 10-2 0.08% 
Anterior occipital sulcus and preoccipital notch -13.7 (-0.6;-26.8) 4.05 X 10-2 0.09% 
Commissural tracts  
Anterior commissure -.167 (-.087;-.248)† 4.90 X 10-5 0.34% 
Corpus callosum, posterior -15.3 (-8.4;-22.1) 1.23 X 10-5 0.41% 
Corpus callosum, mid-posterior -7.3 (-3.6;-11.1) 1.21 X 10-4 0.26% 
Corpus callosum, central -6.9 (-3.4;-10.5) 1.20 X 10-4 0.27% 
Corpus callosum, mid-anterior -4.6 (-0.6;-8.5) 2.32 X 10-2 0.09% 
Corpus callosum, anterior -8.5 (-2.0;-15.0) 1.01 X 10-2 0.12% 
Betas are in μl per risk allele of rs1990622. 
Brain structures surviving multiple testing (p<1.14 x 10-3) are indicated in italic. 
†Beta is in mm2 per risk allele of rs1990622 
R2 is the variance of the brain structure that is explained by rs1990622, calculated by squaring 
the semipartial correlation coefficient. 
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RESULTS 
Population characteristics 
In the final sample of 4413 participants, mean (S.D.) age was 64.7 (10.8) 
years with 2446 (55.4%) women. The call rate of rs1990622 was high 
(>99.9%) with the minor allele (G) frequency corresponding to previous 
reports in healthy, non‐demented populations (0.41) (see Table 1).5,6  
Cortical grey matter 
The risk allele A of rs1990622 was strongly associated with lower grey matter volume of 
the left superior temporal gyrus (β = -88.8 μL per allele, 95% confidence interval (CI) = -
44.8 to -132.8, p = 7.64 x 10-5) and the directly neighboring angular gyrus (β = -66.1, 95% 
CI = -27.1 to -105.2, p = 9.14 x 10-4) and middle temporal gyrus (β = -76.9, 95% CI = -31.1 
to -122.8, p = 1.00 x 10-3) (see Figure 1 and Table 2). The effect was less pronounced in 
the right superior temporal gyrus (β = -67.1, 95% CI = -20.2 to -114.0, p = 5.08 x 10-3) (see 
Figure 1 and Table 2). Post-hoc stratification for self-reported handedness revealed an 
opposite pattern in left-handed persons (n = 195), with a larger effect size for the right 
superior temporal gyrus, although this group was small (see Supplementary Table S1). 
After additional adjustments were made for the superior temporal gyrus volume of the 
contralateral side, the association between rs1990622 and left superior temporal gyrus 
volume remained significant (p = 3.58 x 10-3), but not for the right superior temporal 
gyrus (p = 5.72 x 10-1).  
Furthermore, rs1990622 was associated with a lower volume of the right supramarginal 
gyrus (β = -64.3 μL per allele, 95% CI = -26.9 to -101.6, p = 7.51x 10-4) (see Figure 1 and 
Table 2). Other nominally significant associations are reported in Table 1, with the full 
results for all cortical grey matter volumes per hemisphere provided in Supplementary 
Table S2. Adjustment for the first four principal components did not affect the 
associations between rs1990622 and the brain structures. 
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Commissural tracts 
For the commissural tracts, we found rs1990622 to be associated with CC volume in an 
anterior-to-posterior gradient, with risk allele carriers having lower volumes towards the 
posterior pole (see Figure 1 and Table 2). Additionally, the risk allele was associated with 
a smaller AC cross-sectional area (β = -.167 mm2 per allele, 95% CI = -.087 to -.248, p = 
4.90 x 10-5) (see Figure 1 and Table 2). Similarly, adjusting for the first four principal 
components made no difference on the associations. 
Age x SNP interaction 
An interaction term of ‘age x rs1990622’ for all structures that survived multiple testing 
correction showed a larger effect of rs1990622 with increasing age, but was only 
significant for the anterior commissure cross-sectional area (p=0.004). 
Other TMEM106B variants 
Additional variants in TMEM106B that have been reported to be associated with risk of 
FTLD (p.T185S, rs1042949, rs6966915 and rs1020004) were in high linkage 
disequilibrium with rs1990622 and showed a similar pattern of association (see 
Supplementary Table S3).  
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DISCUSSION 
In this study we investigated TMEM106B in relation to structural brain measures in non-
demented individuals and show that rs1990622 affects cortical regions and commissural 
tracts that are known to be important for semantic processing. This suggests that 
TMEM106B may increase the risk of FTLD by acting on this intermediate phenotype, 
which has particular relevance for the language-based dementia subtypes. We found 
that the risk allele of rs1990622 is associated with a smaller volume of the superior 
temporal gyrus, especially in the left hemisphere. This brain region includes structures 
such as Wernicke’s area that are involved in language processing, a function which in the 
majority of right-handed persons is lateralized to the left (dominant) hemisphere.30 
Problems with language processing are an established clinical feature of frontotemporal 
dementia subtypes such as semantic dementia and progressive non-fluent aphasia. 
Brain atrophy is evident across the whole spectrum of FTLD, but the affected regions and 
pattern of progression varies between subtypes.2,4 Semantic dementia patients typically 
have FTLD with type C TDP-43 inclusions, corresponding to asymmetric, predominantly 
left-sided temporal lobe atrophy.2,4 In this light, it is worth noting that the original 
discovery of TMEM106B was in a strictly defined group of FTLD patients with TDP-43 
inclusions.5 Progressive non-fluent aphasia also causes left-sided superior temporal lobe 
atrophy, but regions more severely affected compared to semantic dementia include the 
right supramarginal gyrus.31 Interestingly, this was the only right-sided cortical region 
that was significantly associated with rs1990622.  
Patients with asymmetric temporal lobe atrophy have impairments in different functions 
depending on which side is affected and the hemispheric specialization.32 The left-to-
right hemispheric shift we observed within left-handed persons suggests that 
TMEM106B is not purely influencing anatomical variation of the left superior temporal 
gyrus, but rather plays a more important role in the actual cognitive functions within 
that structure that are also known to shift to the dominant hemispheres. However, 
although this reversed association is intriguing, it should be carefully interpreted since 
handedness itself is not a specific measure of language lateralization (only 30% of left-
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handed persons are right-dominant),30 and our assessment of handedness was based on 
self-reported data from participants.   
We additionally showed that the risk allele of rs1990622 is associated with gradually 
smaller volumes towards the posterior pole of the CC and a smaller cross-sectional area 
of the AC. Commissural tracts facilitate the interhemispheric cross-talk of the brain and 
are known to be affected by neurodegenerative diseases such as Alzheimer’s and 
FTLD.16,20,33,34 TMEM106B might contribute to the interhemispheric disconnection of 
brain regions involved in the pathophysiology of FTLD. Moon et al. showed that the AC 
thickness measurement could be used to distinguish between AD, FTLD and healthy 
controls.20 Interestingly, in their study, the AC was smallest in the semantic dementia 
subtype.20  Northam et al. have shown that reductions in the temporal connections of 
the posterior CC result in language impairment in adolescents if the AC is also reduced 
in size.35 Since our findings point to brain structures that are important for language, 
information on related phenotypes would be of interest. However, in the Rotterdam 
Study no cognitive tests measuring semantic processing are available, underlining the 
need for future studies to explore functional correlates of the neuroanatomical findings. 
Although TMEM106B is a genetic risk factor for FTLD, we now observe anatomical brain 
differences in a population free of clinical neurodegenerative disease.  The same allele 
that increases risk of FTLD was consistently associated with smaller brain volumes, with 
none of the 156 structures reaching even nominal significance in the opposite direction. 
TMEM106B explained less than 0.4% of the observed variance of the investigated brain 
structures, suggesting it does not severely affect (the volume of) structures such as the 
superior temporal gyrus by itself, but rather has a clinically significant impact in 
combination with other risk factors. Others suggested that disease might develop in 
patients who are vulnerable to additional genetic modifying factors such as 
TMEM106B.10 This was compatible with reported roles of TMEM106B in patients with 
amyotrophic lateral sclerosis and Alzheimer’s disease.7,8 It was recently shown that 
TMEM106B might cause disease through interaction with APOE, the major genetic risk 
factor for Alzheimer’s Disease.36 Our study provides additional evidence for this 
‘increased susceptibility’ hypothesis and specifically points to temporal lobe pathology. 
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However, even though we examine the effects of TMEM106 in an aging population, we 
cannot firmly attribute the structural brain differences that we found to degenerative 
processes due to the cross-sectional nature of this study. Risk allele carriers could for 
example have a smaller anterior temporal lobe as a consequence of impaired 
development during brain growth in early life. Although we were not able to study 
association with brain volume longitudinally, we have performed additional analyses to 
evaluate a potential interaction effect between rs1990622 and age for the significant 
structures. We found a significant interaction term for the anterior commissure, which 
showed that the effect of rs1990622 was stronger with increasing age. This suggests that 
the effect could be attributed to a process later in life, e.g. neurodegeneration. However, 
because such age-interaction was not observed for the other brain structures, 
TMEM106B could also affect brain development earlier in life. Although APOE’s  role of in 
neurodegeneration is well-documented, developmental brain changes have now been 
found in infant carriers of the risk allele.37 This adds to the complexity of 
neurodegenerative disorders and further emphasizes the role of our study in generating 
an agenda for future research, rather than making final conclusions based on our results. 
Longitudinal MRI studies are needed to investigate this relationship of TMEM106B with 
brain volumes. 
Also, the smaller volumes of the CC and AC area suggest that interhemispheric 
connections are reduced, but it is possible that the number of neuronal fibers is similar 
but that they are more densely packed. Techniques that can specifically isolate fiber 
tracts within white matter structures, such as diffusion tensor imaging, can provide more 
insight into which specific white matter tracts are more affected and how TMEM106B 
influences the microstructural integrity. 
To obtain valid measurements of brain volumes, with a balanced investment of 
manpower, we excluded persons with stroke and MRI-defined cortical infarcts, since 
these affect the grey matter of the brain and can distort the image post-processing. 
Additionally, we visually inspected scans when brain structure volumes fel out of 2.5σ 
and, if needed, excluded these outliers. Although this leaves the majority of scans 
uninspected, we note that any residual measurement error would only dilute the 
association between rs1990622 and the brain volumes. 
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The volumes of different brain structures are correlated and partly depend on shared 
environmental and genetic factors. The Sidak corrected significance level takes such 
interdependence into account using the correlation matrix across structures, thereby 
providing an adequate and data-driven adjustment. Even though our findings would 
even have survived the stringent Bonferroni correction, we chose to implement the 
appropriate Sidak correction for future reference by other studies, since using Bonferroni 
in similar situations could lead to false-negative findings in studies that are not as well-
powered as ours. 
In conclusion, our findings show that FTLD-associated TMEM106B variant rs1990622 
influences the volume of temporal brain regions – in particular left hemispheric - and 
interconnectivity of the temporal lobes in an elderly population free of dementia. This 
indicates that the importance of TMEM106B extends outside of the realm of FTLD and 
mainly affects structures that are involved in language. Future studies should therefore 
investigate the effect of TMEM106B on the different aspects of semantic processing. 
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ABSTRACT 
We read with interest the article by Hernández et al. on the TMEM106B genetic variant 
rs1990622 that modifies the risk for frontotemporal dementia (FTD) 1. Although the 
authors were underpowered to detect a significant association with FTD risk in their 
case-control study (n/N=146/381), the effect was concordant with the expected 
direction and slightly decreased in p-value under a recessive model. Similarly, meta-
analysis of published data was more significant assuming a recessive effect for the 
rs1990622 CC genotype.  
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MAIN TEXT 
Previously we showed that the additive effect of rs1990622 is not restricted to FTD but 
that this variant also affects brain structure in the general population free of dementia2. 
Given the findings of Hernández et al. we aimed to determine whether this recessive 
model also holds for the association of rs1990622 in the general population. In line with 
our previous publication, we investigated this question in 4413 non-demented and 
stroke-free participants from the population-based Rotterdam Study who underwent 
both genotyping and magnetic resonance imaging (MRI).3,4 The eight brain structures 
that previously survived multiple testing correction were analyzed under three different 
models: additive (as published), recessive, and dominant. 
As shown in Table 1, associations under both the recessive and dominant model were 
either in the same order of magnitude or less significant than the additive model. This 
does not support the notion of a recessive effect, as found by Hernández et al., in our 
population-based sample in which we investigated brain structure. Rather, it seems to 
suggest that each T allele increase confers an additional risk. We agree with the authors 
that larger studies will provide us the definitive answer with regard to the genetic model 
under which rs1990622 predisposes to FTD. 
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ABSTRACT 
Background: Multiple sclerosis (MS) affects brain structure and cognitive function, and 
has a heritable component. Over a hundred common genetic risk variants have been 
identified, but most carriers do not develop MS. For other neurodegenerative diseases, 
risk variants have effects outside patient populations, but this remains uninvestigated 
for MS. 
Objectives: To study the effect of MS-associated genetic variants on brain structure and 
cognitive function in the general population. 
Methods: We studied middle-aged and elderly individuals (mean age=65.7 years) from 
the population-based Rotterdam Study. We determined 107 MS variants and 
additionally created a risk score combining all variants. Magnetic resonance imaging 
(N=4710) was performed to obtain measures of brain macrostructure, white matter 
microstructure, and grey matter voxel-based morphometry. A cognitive test battery 
(N=7556) was used to test a variety of cognitive domains. 
Results: The MS risk score was associated with smaller grey matter volume over the 
whole brain (βstandardized =-0.016;p=0.044), but region-specific analyses did not survive 
multiple testing correction. Similarly, no significant associations with brain structure 
were observed for individual variants. For cognition, rs2283792 was significantly 
associated with poorer memory (β=-0.064;p=3.4x10-5).  
Conclusion: Increased genetic susceptibility to MS may affect brain structure and 
cognition in persons without disease, pointing to a ‘hidden burden’ of MS. 
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INTRODUCTION 
Multiple sclerosis (MS) is a multifactorial disease of the central nervous system, but the 
etiology has not been entirely unraveled. Magnetic resonance imaging (MRI) is an 
important cornerstone in detecting structural brain changes in MS patients, with the 
most striking features being the characteristic white matter lesions, which represent 
demyelination of nerve fibers.1 These lesions are thought to be the end stage of various 
immunological mechanisms that results in the destruction of myelin in MS.1 However, 
there is a long preclinical phase in which less severe white matter damage is already 
present but remains hidden on conventional MRI images. Diffusion tensor imaging (DTI) 
can capture such microstructural changes and it has shown that the normal-appearing 
white matter is in fact diffusively affected in patients.2,3 More recently, the importance of 
grey matter pathology in MS has also been highlighted, possibly as a result of 
demyelination or secondary to axonal damage.4 Grey matter damage is already 
detectable in the early phases of disease and can become quite severe.5 
Not only are these structural brain changes important contributors to the motor and 
sensory deterioration seen in MS patients,6 cognitive dysfunction is also a frequent and 
debilitating functional impairment among MS patients,7,8 Such cognitive deficits are 
most common in verbal memory and processing speed, with over half of the patients 
showing impairment.9 Other cognitive processes that are affected include information 
processing, executive functioning, and attention.7  
The complexity of MS observed on imaging and in clinical presentation is mirrored in its 
genetics background. MS has a substantial genetic basis that is of a polygenic origin, 
with many common variants exerting modest effects on disease susceptibility.10,11 
Currently, over 100 MS risk variants have been discovered with high statistical 
confidence through large-scale association studies.12-16 The major histocompatibility 
complex (MHC) region harbors some risk alleles with a relatively large effect 
(DRB1*15:01, odds ratio 2.92; DLB1*13:03, 2.66),17 whereas the non-MHC variants only 
account for risk increases in the range of 1.03-1.34 times.16 While these genetic variants 
are common (minor allele frequencies between 5% and 50%16), MS has a relatively low 
prevalence and incidence rate.18 Thus, the majority of carriers of these variants do not 
Chapter 4.2.4 
368  
develop clinically diagnosed disease. The question therefore arises whether these risk 
variants might have a subclinical effect on the brains of apparently healthy individuals 
without MS. 
Here, we aimed to investigate the potential effects of a genetically elevated risk of MS on 
the brain in the general population. Specifically, we determined whether MS-associated 
genetic variants are related to differences in brain structure and cognitive function in 
over 7000 middle-aged and elderly participants of the population-based Rotterdam 
Study. 
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METHODS 
Study population 
This work was performed in the Rotterdam Study,19 a population-based cohort study in 
the Netherlands including a total of 14,926 participants (aged >=45 years at enrollment) 
that was initiated in 1990. The overall aim of the study is to investigate causes and 
determinants of chronic diseases in elderly people. Since 2002, an extensive cognitive 
test battery was implemented in the core protocol, and since 2005, all participants 
underwent brain MRI.20 For this study, we excluded 29 participants with either 
definite/probable MS (N=27), or possible MS (N=2) based on records of general 
practitioners. 
Genotyping and imputation 
Of the 14,897 participants free of MS, genotyping was successfully performed in 11,481 
using the Illumina 550K, 550K duo, and 610K quad arrays.19 Samples were removed that 
had a call rate below 97.5%, gender mismatch, excess autosomal heterozygosity, 
duplicates or family relations and ancestry outliers, and variants were removed with call 
rate below 95.0%, failing missingness test, Hardy–Weinberg equilibrium p-value<10-6, 
and minor allele frequency<1%. Genotypes were imputed using MACH/minimac 
software21 to the 1000 Genomes reference panel. 
Genetic risk score 
We studied all variants reported at genome-wide significance in the most recent and 
largest genome-wide association study of the International Multiple Sclerosis Genetics 
Consortium (IMSGC).16 Variants in the MHC region were not analyzed since these are not 
covered by standard genotyping arrays and, given the complexity of imputing classical 
alleles, require a dedicated effort. Of the 110 non-MHC variants, 3 could not be imputed 
in our dataset nor had reliable proxy variants. 
Since the increase in risk of MS is small for individual variants, we calculated a combined 
genetic risk score to enable detection of the collective associations. This risk score was 
constructed by adding up all the risk alleles per individual weighted by their log-
Chapter 4.2.4 
370  
transformed, reported effect size for the association with MS. A higher genetic risk score 
corresponds to more risk variants and thus a higher risk of MS. Furthermore, we 
calculated a second risk score that excluded all 31 variants with pleiotropic effects on 
other autoimmune disease (Table S8 from IMSGC GWAS16), leaving 76 MS-specific 
variants. 
Image acquisition 
Since the introduction of a dedicated MRI machine in the Rotterdam Study in 2005, MRI 
scanning was done in 4,917 on a 1.5-T MRI unit with a dedicated eight-channel head coil 
(Signa HD platform, GE Healthcare, Milwaukee, USA). The MRI protocol consisted of 
several high-resolution axial sequences, including a T1-weighted (slice thickness 
0.8mm), T2-weighted (1.6mm), and fluid attenuated inversion recovery (FLAIR) sequence 
(2.5mm). The DTI sequence was a single shot, diffusion weighted spin echo EPI sequence 
(TR/TE 8000/68.7; ASSET factor 2; acquisition matrix 96×64; FOV 21cm, 38 contiguous 
slices with slice thickness of 3.5mm). A detailed description of the MRI protocol was 
presented previously.20  
Image processing 
Of the 4917 persons who came for MRI, we excluded 70 without a T1-weighted 
sequence. All T1-images were segmented into supratentorial gray matter, white matter 
and cerebrospinal fluid using a k-nearest neighbor (kNN) algorithm.22 White matter 
lesions were segmented based on T1 tissue maps and an automatically detected 
threshold for the intensity of FLAIR scans.23 To distinguish between the temporal, 
parietal, occipital, and frontal lobes, scans were non-rigidly registered to a template.24 
After visual inspection of all segmentations, an additional 137 persons were excluded 
because of poor quality, leaving 4710 for analysis. 
Of these 4710 persons, voxel-based morphometry was performed with an optimized 
protocol using the FSL software.25 Grey matter density maps were non-linearly 
registered to a the ICBM MNI152 template (Montreal Neurological Institute). The MNI152 
standard-space T1-weighted average structural template has a 1x1x1 mm3 voxel 
resolution and was derived from 152 structural images, which were averaged into the 
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common MNI152 co-ordinate system after high-dimensional nonlinear registration. To 
avoid effects of the registration step on the grey matter we implemented a spatial 
modulation procedure by multiplying voxel densities with the Jacobian determinants 
estimated during spatial normalization. Finally, images were smoothed using an 
isotropic Gaussian kernel of 3mm (FWHM 8mm). After quality control, 88 persons with 
insufficient registration quality were excluded, leaving 4622 persons for the voxel-based 
morphometry analyses. 
Of the 4710 persons with successfully segmented tissues, 295 did not have DTI 
sequences. Preprocessing of DTI data was done using a standardized pipeline that 
includes eddy current and head-motion correction.26 This data was combined with the 
tissue classification to obtain global values in the normal-appearing white matter for 
four DTI measures, namely fractional anisotropy, mean diffusivity, radial diffusivity, and 
axial diffusivity. Next, 27 white matter tracts were segmented using diffusion 
tractography to obtain tract-specific diffusion measures.27 For 12 bilateral tracts, the 
mean of the left and right values was used, resulting in 15 tracts for analysis. We 
excluded persons with poor segmentation of a single (N=180) or multiple tracts (N=92), 
leaving 4143. 
Cognitive function 
Since the cognitive testing began in 2002, out of the 11,481 subjects, 7556 had cognitive 
function assessment. Cognitive function was assessed with the multiple 
neuropsychological test: a 15-word verbal learning test (based on the Rey’s recall of 
words), the Stroop Color and Word Test, the Letter-Digit Substitution Task and a word 
fluency test (animal categories). A measure of general cognitive function (‘G-factor’) was 
obtained through principal component analysis.  
Statistical analyses 
We investigated the association of the genetic risk scores (per standard deviation 
increase) and individual variants (per risk allele increase) with neuroimaging and 
cognitive outcomes using linear regression models. All analyses were adjusted for age 
and sex, and additionally for intracranial volume in the macrostructural and DTI analyses. 
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For the 107 individual variants, the multiple testing threshold was set to p<0.00047 
(0.05/107). Since the neuroimaging measures and cognitive tests consist of correlated 
data, the actual number of independent tests was calculated using 10,000 permutations. 
For α=0.05 this yielded the following corrected significance thresholds: 0.0036 for the 
macrostructural measures, 0.0016 for the DTI tracts, 0.0055 for the cognitive tests, and 
3.0 x 10-7 for the VBM analyses. 
RESULTS 
Study population 
The characteristics of the study population are shown in Table 1, separately for 
participants with neuroimaging or cognition data available. The samples largely 
overlapped (N=4684) and were comparable with respect to age and sex.  
Brain macrostructure 
First, we investigated the relation between genetic risk for MS and gross volumetric 
measures of brain structure, across the whole brain and within individual lobes (Figure 
1A). Nominally significant associations with smaller total grey matter volumes were 
detected for the risk score, which became stronger after restricting to MS-specific 
variants. When separated by lobe, the effects were most prominent for grey matter in 
the frontal lobe. For the single variant analyses, the five most significant associations are 
shown in Figure 1A. None of the individual variants survived multiple testing correction 
in the whole brain analyses, corrected for the number of variants (p<4.7x10-4), or the 
lobar analyses, additionally adjusted for the number of independent lobar volumes 
(p<3.4x10-5). There was no enrichment for association compared to the null distribution 
for any of the whole brain tissue volumes (Figure 1B). Table S1 contains all results. 
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Voxel-based morphometry 
For a more in depth investigation of grey matter, we performed voxel-based 
morphometry. Surface-based representations of the results of the genetic risk score are 
shown in Figure 2A, with the strongest association in the left superior parietal gyrus 
(p=2.1x10-5). Of all variants, only rs212405 had voxel associations surviving the brain-
wide significance level of p<3.0x10-7 (Figure 2B), namely with larger grey matter volume 
in the right posterior temporal lobe (p=1.5x10-7). This association was no longer 
significant after adjustment for all tested variants (threshold p<2.8x10-9). The top VBM 
associations results are listed in Table S2.  
White matter microstructure  
Next, we studied measures of microstructural differences of the white matter in 15 white 
matter tracts using 4 diffusion tensor imaging parameters (Figure 3A-D). No significant 
effects were detected for the non-MHC risk score, while three associations were found 
with the MS-specific score. In the single variant analyses, two variants survived multiple 
testing correction for the number of genetic variants (p<4.7x10-4), but not further 
adjustment for the tracts (p<1.5x10-5). The variant rs1813375 showed nominal 
significance with 24 out of 60 tract measures (lowest p=5.4x10-5, superior longitudinal 
fasciculus), and rs759648 was associated with 15 out of 60 tract measures (lowest 
p=1.5x10-4, parahippocampal cingulum). Table S3 contains all DTI results. 
Cognitive function 
Finally, we explored functional differences in the sample with cognitive data (Figure 4). 
The MS-specific risk score was associated with poorer delayed recall (p=0.039). For the 
single variants, rs2283792 also associated with poorer delayed recall (p=3.4x10-5), 
surviving multiple testing correction for both number of variants (p<4.7x10-4) and also  
for the cognitive tests (p<5.1x10-5). Table S4.contains all cognition result. 
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DISCUSSION 
Here we show the relation of genetically elevated risk for MS with brain structure and 
function in middle-aged and elderly individuals from the general population who are 
free of MS. Scores combining all common genetic risk variants were associated with 
smaller grey matter volumes, in particular in the frontal lobe. Single variant analyses 
revealed associations with white matter microstructure (rs1813375) and cognitive 
function (rs2283792), but only the latter survived multiple testing correction. 
MS has traditionally been viewed as a heritable disease primarily affecting women of 
certain ages and geographic regions. However, genes involved in MS could exert more 
widespread detrimental effects in the general population than thus far suspected. We 
have previously shown that for other neurodegenerative diseases genetic risk variants 
can also affect cognitive function and brain structure in the general population,28-30 
which included Alzheimer’s disease, Parkinson’s disease, frontotemporal lobar 
degeneration, and amyotrophic lateral sclerosis. Others have suggested that 
schizophrenia risk variants are also associated with structural brain changes in persons 
without disease,31 but such an effect was disputed in the general population.32 Other 
found genetic overlap between MS and putamen volume on a genome-wide scale.33 
Our study suggests that MS variants may also play a role outside of the MS population, 
but most findings do not reach pre-defined thresholds for statistical significance. Given 
that MS is a demyelinating disease, we put emphasis on white matter changes by 
investigating both its macro- and microstructure. Macrostructural MRI measures 
included both the volume of the white matter and the volume of T2-weighted 
hyperintensities, or ‘white matter lesions’, which are a marker of demyelinated white 
matter.1 Furthermore, we quantified the white matter microstructural integrity using DTI, 
which has been shown to be decreased in MS patients.1,2 Importantly, this loss of 
integrity picked up by DTI is seen earlier than macrostructural damage on conventional 
MRI,1 making it particularly attractive for our research question. The top five variants for 
each of the four diffusion parameters showed consistent results across the white matter 
tracts: the risk alleles were associated with presumably better white matter integrity, i.e. 
higher FA but lower MD, RD, and AD. The strongest and most widespread effect was for 
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rs1813375, an intergenic variant without known function. However, not even this variant 
would survive additional multiple testing correction for the DTI tracts. 
Since the role of grey matter in MS is increasingly apparent, we also examined the grey 
matter using macrostructural measures and voxel-based morphometry. For the global 
and lobar volumes, both risk scores were associated with smaller grey matter volumes 
over the whole brain and particularly in the frontal lobe. Frontal lobe atrophy is present 
in patients with MS and also correlates with the degree of cognitive dysfunction.34 
Contrary to the DTI analyses, the most significant individual variants did not show a 
similar pattern of association. We also attempted to map the effects of MS variants in 
detail using voxel-based morphometry, but no results surpassed multiple testing 
correction. 
Besides structural measures, we also studied the effect of genetic risk of MS on cognitive 
outcomes. The significant risk variants were generally associated with worse cognition, 
but only rs2283792 survived multiple testing for all variants and cognitive tests. Each 
additional risk allele was associated with a 0.064 standard deviation decrease in the 
delayed recall test, which measures memory performance. Interestingly, memory 
impairment is among the most common cognitive deficits in persons suffering from MS.9 
This variant lies within MAPK1, but affects expression of multiple genes across various 
tissues. In the brain, the chromatin of this region contains H3K4me1, H3K27ac, and 
H3K9ac marks. This included tissue samples obtained from the hippocampus, an 
important brain structure for memory. If this finding is validated in other studies it could 
help understand the molecular mechanism underlying this association. 
Overall, the combined impact of all genetic risk variants, as captured by the risk scores, 
was modest and suggests that MS variants do not have a large effect on the brain in the 
general population, but are instead restricted to MS patients. Such risk variants could 
exert their effect only when another environmental factor is present or through gene-
by-gene interaction. Also, it is possible that the findings would have been stronger in a 
different population. Future studies might consider to study younger individuals, as the 
subclinical effects may have been obscured in our elderly population by the presence of 
age-related brain changes. 
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Another explanation is that we did not have enough power to detect any effects. 
However, the 110 MS variants explain almost 20% of the variance in disease 
susceptibility,16 which is comparable to or even higher than many other complex 
diseases. The use of a genetic risk score further reduced the multiple testing burden, but 
this did not reveal any strong associations. The variants themselves might not have 
similar effects on the various neuroimaging measures and cognitive tests, and a 
combined score could thus have decreased power. Furthermore, other traits might need 
to be considered. Enlarged perivascular spaces are an emerging cerebrovascular disease 
marker and potentially related to inflammation.35 Their enlargement is seen in MS and 
may captured other pathology. 
While our focus was on brain structure and cognitive function, any subclinical effect of 
these variants need not be restricted to the brain. Another interesting line of research 
could be to study effects on the immune system. In this light, it should be noted that the 
IMSGC GWAS identifying and/or confirming the 110 MS risk variants employed the 
ImmunoChip for genotyping.16 In its design, this genotyping platform was enriched for 
variants near immune-related genes and known autoimmune disease loci, thus making 
immune-related traits worthwhile for future studies on subclinical effects of MS variants. 
Conversely, this means that the current set of variants may be depleted for those 
primarily affecting the brain. Since many of the MS risk variants are indeed also 
associated with other autoimmune diseases, we constructed a second risk score that 
only included MS-specific variants, and is therefore potentially more related to brain-
related traits. This MS-specific risk score showed a trend for more significant associations 
across the investigated traits, although the findings still did not surpass the multiple 
testing threshold. 
In conclusion, this exploratory study suggests carriers of MS risk variants may at most 
have subtle differences with respect to brain structure and cognitive function, but 
further evidence is needed to confirm this.  
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5.1.1. Determinants of 
enlarged perivascular 
spaces 
Determinants of enlarged perivascular spaces in the general population:  
a pooled analysis of individual participant data in the UNIVRSE consortium 
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ABSTRACT 
Background and Purpose: Perivascular enlargement in the brain is a putative imaging 
marker for microvascular brain damage, but this link has not yet been confirmed using 
direct in vivo visualization of small vessels. We investigated the relation between 
microvascular calibers on retinal imaging, and enlarged perivascular spaces [ePVSs] on 
brain MRI.  
Methods: We included 704 participants from the Rotterdam Study. Retinal arteriolar and 
venular calibers were measured semi-automatically on fundus photographs. ePVSs were 
counted in the centrum semi-ovale, basal ganglia, hippocampus, and mesencephalon, 
using a standardized rating method. We determined the association between retinal 
vascular calibers and ePVS with negative binomial regression models, adjusting for age, 
sex, the other vascular caliber, structural brain MRI-markers, and cardiovascular risk 
factors.  
Results: Both narrower arteriolar and wider venular calibers were associated with more 
ePVSs in the centrum semi-ovale and hippocampal region. Rate ratios (95% confidence 
interval) for arterioles in the centrum semi-ovale and hippocampus were 1.07 (1.01-1.14) 
and 1.13 (1.04-1.22), respectively, and for venules 1.08 (1.01-1.16) and 1.09 (1.00-1.18), 
respectively. These associations were independent from other brain MRI-markers, and 
cardiovascular risk factors. 
Conclusions: Retinal microvascular calibers are related to ePVSs, confirming the putative 
link between microvascular damage and enlarged perivascular spaces. 
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INTRODUCTION 
Enlarged perivascular spaces [ePVSs] in the brain, also known as Virchow-Robin spaces, 
have emerged as a promising imaging biomarker for vascular brain pathology.1 These 
are spaces filled with interstitial fluid that surround the blood vessels as they extend into 
the brain. Increasing evidence suggests that ePVSs are affected by vascular risk factors, 
including high blood pressure and inflammation.2 Additionally, ePVSs are strongly 
associated with other structural imaging markers, such as white matter lesions [WMLs] 
and lacunes, both hallmarks of cerebral small-vessel disease.3 In histopathology, ePVSs 
and characteristics of microvascular diseases are often found concomitantly, further 
indicating that ePVSs might reflect damage to cerebral microvessels.4 However, the link 
between microvascular damage and ePVSs has not yet been shown in vivo. The main 
difficulty is to directly assess the cerebral microvessels (<200 μm) in vivo with current 
brain imaging techniques. A robust alternative is visualization of the retinal 
microvasculature, as the retinal and cerebral microvasculature share anatomy, 
physiology and embryology.5 Indeed, there is convincing evidence showing links 
between retinal microvascular damage and (sub)clinical vascular brain disease.6 Here, we 
investigated the association of retinal microvasculature with ePVSs in the general 
population. 
METHODS 
See Supplemental Methods for detailed methods. 
Setting and Study Population 
This study was embedded within the population-based Rotterdam Study.7 Between 
2004-2006, we randomly invited 1,073 persons for brain MRI, of which 704 non-
demented persons had complete scans and gradable fundus transparencies. The 
Rotterdam Study has been approved by the medical ethics committee according to the 
Population Study Act Rotterdam Study. Written informed consent was obtained from all 
participants. 
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Measurement of retinal vascular calibers 
Fundus photographs centered on the optic disc were analyzed with a semi-automated 
system (Interactive Vessel ANalyzer (IVAN)) following standardized protocols.8 For each 
participant one summary value was calculated for the arteriolar and venular calibers (in 
μm), and adjusted for possible magnification variations to approximate absolute 
measures.  
Enlarged perivascular spaces rating 
Perivascular enlargements were counted according to a previously published protocol9 
in the centrum semi-ovale, basal ganglia, hippocampus, and mesencephalon, areas in 
which ePVSs frequently occur. PVSs were identified by their linear, ovoid, or round 
shape, and considered enlarged when their diameter was ≥1 mm.9  
Statistical analysis 
We used negative binomial regression models to determine the association between 
retinal vascular calibers and count of ePVSs. Rate ratios (interpreted as ratios of ePVSs 
count) with 95% confidence intervals were estimated per SD decrease in arterioles, or 
increase in venules. We adjusted for age, sex, and the other vascular caliber, and 
additionally for structural brain MRI-markers (intracranial volume, WML volume, infarcts, 
and microbleeds), and for cardiovascular risk factors. We explored effect modification by 
stratifying for sex, hypertension, diabetes mellitus, and smoking. Analyses were 
performed using SPSS 21.0 (IBM corp., Armonk, New York). 
RESULTS 
Study population characteristics are reported in Table 1. Average age was 66.0 years, 
and 52% were females. We found that narrower arteriolar calibers and, to a lesser extent, 
wider venular calibers were significantly associated with more ePVSs in the 
hippocampus and centrum semi-ovale. Adjusting for structural brain MRI-markers and 
cardiovascular risk factors slightly attenuated these associations, but these remained 
statistically significant (Table 2). Excluding participants with a history of stroke (n=11) did 
not change the associations. Stratified analyses revealed no interactions (pinteraction >0.05). 
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Table 1 | Characteristics of the study population, N=704
Characteristic
Age, years 66.0 (5.1) 
Female 365 (52%) 
Systolic blood pressure, mmHg 143.1 (17.8) 
Diastolic blood pressure, mmHg 81.0 (10.3) 
Anti-hypertensive medication 249 (35%) 
Body mass index, kg/m2 27.5 (3.9) 
Total cholesterol, mmol/L 5.7 (0.9) 
High-density lipoprotein cholesterol, mmol/L 1.4 (0.4) 
Diabetes mellitus 65 (9%) 
C-reactive protein, mg/L 2.1 (3.7) 
Carotid plaque score≥4 173 (25%) 
Current smoker 89 (13%) 
 
Intracranial volume, ml 1138.4 (115.5) 
WML volume*, ml 3.5 (2.1-7.0) 
Infarcts 58 (8%) 
Cerebral microbleeds 111 (16) 
 
Retinal arteriolar diameter, μm 149.3 (15.3) 
Retinal venular diameter, μm 232.4 (22.1) 
Regions of ePVSs *
 Centrum semi-ovale 6.0 (3.0-11.0) 
 Basal ganglia 3.0 (1.0-5.0) 
 Hippocampus 3.0 (1.0-5.0) 
 Mesencephalon 2.0 (0.0-3.0) 
Values are presented as means (standard deviation) or as numbers. 
*Values are presented as median (interquartile range), because of skewed distribution. 
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DISCUSSION 
Here, we found that narrower arteriolar and wider venular calibers were associated with 
more ePVSs, independently of structural brain MRI-markers, and cardiovascular risk 
factors. 
Previous studies showed that ePVSs are related to subclinical and clinical vascular brain 
disease,1, 2  supporting that perivascular enlargements reflect microvascular damage. 
However, no study has directly investigated in vivo the association of PVSs with 
microvasculature. We provide the first in vivo evidence that microvascular calibers are 
related to ePVSs, but the mechanism remains undetermined. 
First, PVSs drain interstitial and cerebrospinal fluid to the subarachnoid space, and 
eventually into cervical lymph nodes. Hence, a failure in this transmission may result in 
hemodynamic pressure differences that might manifest themselves in changed vascular 
calibers. Future studies are warranted to show how that would specifically lead to 
narrower arterioles. Second, narrower arterioles may lead to a state of cerebral 
hypoperfusion, eventually resulting in atrophy, and thus to perivascular enlargement. 
This ischemic mechanism is further supported by findings showing wider venular 
calibers to be associated with cerebral hypoxia.10 Finally, it is also possible that shared 
risk factors explain the relation between retinal microvascular calibers and PVSs. 
Structural MRI-markers of cerebral small-vessel disease, or cardiovascular risk factors, are 
likely candidates as confounders, but these factors did not fully explain the association in 
our study, indicating that other processes also play a role. These include 
arteriolosclerosis, inflammation, venous collagenosis, and cerebral amyloid angiopathy. 
Interestingly, ePVSs in the brain regions most associated with the retinal vessels, namely 
the centrum semi-ovale and hippocampus, are related to cerebral amyloid angiopathy.11 
The perivascular drainage system in the basal ganglia is thought to process amyloid 
more efficiently and ePVSs there are associated more to vascular pathology. However, 
we did not find a significant association of retinal vascular calibers and ePVSs in the basal 
ganglia. 
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Strengths of our study are the population-based setting, the standardized rating 
protocol, and the extensive available data on brain MRI-markers and cardiovascular risk 
factors. A limitation is the cross-sectional design of our study, which precludes 
inferences on the temporal link between microvascular damage and ePVSs. Also, it is 
difficult to completely rule out misclassification of small infarcts as perivascular 
enlargements. This potential differential misclassification may have led to 
overestimation of our associations. However, since we used count data on PVSs as 
outcome, a single or even a few misclassified infarcts are unlikely to have majorly 
influenced our results. Finally, we used a static measure of the microcirculation instead 
of dynamic functional measures synchronized on the cardiac cycle. This may have 
caused random misclassification, leading to an underestimation of our associations.  
In conclusion, our study shows that microvascular calibers are related to ePVSs, 
independent of structural MRI-markers of cerebral small-vessel disease, and 
cardiovascular risk factors. 
REFERENCES 
1. Groeschel S, et al. 
Neuroradiology. 2006 
2. Zhu YC, et al. Stroke. 2010 
3. Doubal FN, et al. Stroke. 2010 
4. Adachi M, et al. 
Neuroradiology. 1998 
5. Liew G, et al. Circ Cardiovasc 
Imaging. 2008 
6. Heringa SM, et al. J Cereb 
Blood Flow Metab. 2013 
7. Hofman A, et al. Eur J 
Epidemiol. 2015 
8. Hubbard LD, et al. 
Ophthalmology. 1999 
9. Adams HH, et al. Stroke. 2013 
10. de Jong FJ, et al. 
Ophthalmology. 2008 
11. Charidimou A, et al. Neurology. 
2014 
Prediction of clinical outcomes 
 415 
5.2. Prediction of clinical 
outcomes 
Chapter 5.2 
Prediction of clinical 
outcomes 
Chapter 5.2 
416  
  
Genetic risk of neurodegenerative diseases, MCI, and dementia 
 417 
5 
5.2.1. Genetic risk of 
neurodegenerative 
diseases, mild cognitive 
impairment and dementia 
 
Genetic risk of neurodegenerative diseases is associated with mild cognitive 
impairment and conversion to dementia 
Hieab H.H. Adams, MSca,b; Renée F.A.G. de Bruijn, MDa,c; Albert Hofman, MD, PhDa; André 
G. Uitterlinden, PhDd; Cornelia M. van Duijn, PhDe; Meike W. Vernooij, MD, PhDa,b; Peter J. 
Koudstaal, MD, PhDc; M. Arfan Ikram, MD, PhD
Chapter 5.2.1 
Genetic risk of 
neurodegenerative 
diseases, MCI, and dementia 
Chapter 5.2.1 
418  
ABSTRACT 
Background: Neurodegenerative diseases are a major cause of cognitive impairment and 
can ultimately lead to dementia. Genome-wide association studies have uncovered 
many genetic variants conferring risk of neurodegenerative diseases, but their role in 
cognitive impairment remains unexplored. 
Methods: In the prospective, population-based Rotterdam Study, 3605 non-demented 
persons aged ≥55 years were genotyped, screened for MCI in 2002-2005 and underwent 
continuous follow-up for dementia until 2012. Weighted polygenic risk scores of genetic 
variants for Alzheimer’s disease (AD), Parkinson’s disease (PD), and the frontotemporal 
lobar degeneration/amyotrophic lateral sclerosis disease spectrum (FTLD/ALS) were 
constructed and investigated for association with mild cognitive impairment (MCI) and 
subsequent conversion to dementia.  
Results: In total, 360 (10.0%) persons had MCI, of whom 147 (4.1%) amnestic and 213 
(5.9%) non-amnestic. The AD risk score was associated with both MCI subtypes (odds 
ratio for all MCI 1.15 [95% CI, 1.03-1.28]), whereas PD and FTLD/ALS risk scores were 
associated only with non-amnestic MCI (odds ratios 1.15 [1.00-1.32] and 1.19 [1.03-1.37], 
respectively). The AD risk score, but not PD and FTLD/ALS risk scores, was associated 
with an increased risk of dementia (hazard ratio 1.55 [1.37-1.77]).  
Conclusions: Genetic evidence supports the view that multiple neurodegenerative 
pathways lead to MCI and that subsequent conversion to dementia, primarily of the AD 
subtype, is mainly due to the AD pathway(s).  
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INTRODUCTION 
Aging populations worldwide face an increasing burden of neurodegenerative 
diseases.1 Major diseases, in terms of mortality, morbidity and health care costs, include 
Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal lobar degeneration 
(FTLD) and amyotrophic lateral sclerosis (ALS). Cognitive impairment is most prominent 
in AD2,3 and FTLD4, but it is also an important feature of PD5 and ALS.6 Our genetic 
understanding of these neurodegenerative diseases has improved considerably over the 
past years through large-scale genome-wide association studies that have identified a 
large number of novel risk variants.7-12 However, due to the hypothesis-free design of 
genome-wide association studies, it remains largely unknown how these genetic 
variants lead to cognitive decline and ultimately clinical disease. 
The severe deterioration in cognitive function seen in neurodegenerative diseases is 
often preceded by a pre-clinical stage with only subtle cognitive deficits that deteriorate 
over time. Mild cognitive impairment (MCI) describes this intermediate state and is 
variable in both its clinical presentation and conversion to dementia.3 Given that MCI 
provides a window of opportunity for preventive or therapeutic interventions, it is 
important to uncover risk factors for MCI and factors that lead to conversion of MCI to 
dementia. The diagnosis of MCI is made on clinical grounds and, although cognitive 
abilities are highly heritable,13 the genetic basis of MCI remains largely unknown.2 APOE, 
the major risk gene in AD, is known to play a role in MCI,14 but whether other, recently 
identified genetic variants for neurodegenerative diseases are also involved has yet to 
be determined.  
In this study, we investigated the effect of genetic risk variants of AD, PD, FTLD and ALS 
on MCI status and subsequent conversion of MCI to dementia.   
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METHODS 
Setting 
The Rotterdam Study is an ongoing population-based cohort study in the Netherlands 
investigating diseases in the elderly and currently consists of 14 926 residents of 
Rotterdam who were aged 45 years or more at baseline.15 The initial cohort was started 
in 1990 and expanded in 2000 and 2005. The whole population is subject to a set of 
multidisciplinary examinations every four years. Genotyping was performed in 11 496 
participants at study entry. MCI status was assessed only between 2002 and 2005, and 
was available in 4198 participants. This resulted in a final study population of 3605 non-
demented persons with information available on both genome-wide genotyping and 
MCI status, who were subsequently followed up for the development of dementia until 
2012. The Rotterdam Study has been approved by the medical ethics committee 
according to the Population Study Act Rotterdam Study, executed by the Ministry of 
Health, Welfare and Sports of the Netherlands. A written informed consent was obtained 
from all participants. 
Genotyping 
The Illumina 550K and 550K duo arrays were used for genotyping. We removed samples 
with call rate below 97.5%, gender mismatch, excess autosomal heterozygosity, 
duplicates or family relations and ethnic outliers, and variants with call rate below 95.0%, 
failing missingness test, Hardy–Weinberg equilibrium p-value<10-6, and minor allele 
frequency<1%. Genotypes were imputed using MACH/minimac software to the 1000 
Genomes phase I version 3 reference panel (all population). APOE-ε4 genotyping was 
performed separately using polymerase chain reaction and was available in 3524 (97.8%) 
participants.16 
Genetic risk scores 
We searched the literature for genetic variants for AD, PD, FTLD and ALS. Given our 
population-based setting, we focused on sporadic mutations and therefore excluded 
mutations of familial disease (e.g., PS1, PS2 and APP in AD and PGN in FTLD). Since 
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various candidate gene studies have been performed that implicated hundreds of 
variants in these four neurodegenerative diseases, we have tried to minimize false-
positives by including only those variants that were genome-wide significant in the 
largest meta-analysis of that disease. We chose to use this objective threshold and did 
not base decisions on functional work that potentially corroborated the findings. 
Notable loci that did not pass this strict threshold were CD33 and ACE. Other variants 
that were considered but not included were not genotyped nor imputed with sufficient 
quality (R2<.5) in our dataset, and a suitable proxy variant was absent: these were 
typically rare (TREM2, PLD3, GBA) or in the poorly covered HLA-region (AD: rs111418223, 
PD: rs115736749, rs9275326). 
For our analyses we identified 19 variants for AD, 25 variants for PD, 1 variant for FTLD 
and 2 variants for ALS (Table 1).7-12,17-19  Since FTLD and ALS are considered extremes of 
the same disease spectrum, and the FTLD variant is also implicated in ALS, we decided to 
pool the three variants together for increased power. The variant rs3849943 is tagging 
the C9orf72 hexanucleotide expansion, which itself was not assessed in our study.9  
Genetic risk scores were constructed by multiplying the number of risk alleles by their 
reported odds ratio (after natural logarithm transformation) for the disease, and 
summing this weighted allele score of each variant up into a disease risk score for AD, PD 
and FTLD/ALS. Similarly, a combined genetic risk score of all neurodegenerative disease 
variants was created. 
MCI screening 
From 2002-2005 onwards, we implemented extensive cognitive testing to allow for 
screening of MCI. All participants of the three Rotterdam Study sub-cohorts who were 
alive in 2002-2005 were invited to undergo these tests and assessed for MCI. However, 
as the third sub-cohort of the Rotterdam Study is comprised of relatively young 
participants (45 years and over), but still would yield a considerable number of screen-
positives for MCI,  it was not included in the current study population at risk. MCI was 
defined as the presence of both subjectively and objectively measured cognitive 
impairment, in the absence of dementia.3  
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Subjective cognitive impairment was considered present if persons reported complaints 
on any of three questions on memory (difficulty remembering, forgetting what one had 
planned to do, and difficulty finding words) or three questions on everyday functioning 
(difficulty managing finances, problems using a telephone, and difficulty getting 
dressed). Objective measures of cognitive functioning were neuropsychological tests 
(Letter-Digit Substitution Task, Stroop test, Verbal Fluency Test, and the 15-Word verbal 
Learning Test based on Rey’s recall of words) that were incorporated into robust 
compound scores of memory function, information-processing speed, and executive 
function, as described previously.20 Scores below 1.5 SD of the age- and education-
adjusted means were considered indicative of objective cognitive impairment. MCI was 
further classified as ‘amnestic’ in case of an objective memory deficit (irrespective of 
other domains), or as ‘non-amnestic’ if only other cognitive domains were affected. The 
MCI assessment in the Rotterdam Study was previously described in more detail.21 
Assessment of dementia 
Participants were screened for dementia at each of the Rotterdam Study examination 
rounds and additionally by using information obtained from the general practitioners 
and regional outpatient care centers (follow-up completed until January 2012).15 Mini-
Mental State Examination (MMSE)22 and the Geriatric Mental Schedule (GMS)23 were used 
to identify high-risk individuals (MMSE<26 or GMS >0) for an additional interview with 
the Cambridge Examination for Mental Disorders in the Elderly (CAMDEX).24 When 
required, further neuropsychological testing and neuroimaging were used by a 
consensus panel for diagnosis according to established criteria for dementia (Diagnostic 
and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R)) and 
Alzheimer’s Disease (National Institute of Neurological and Communicative Diseases and 
Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA)).25,26 
Statistical analyses 
Genetic risk scores were transformed into z-scores to facilitate comparisons of their 
effect per standard deviation increase across each score. Logistic regression models 
were used to examine associations between the risk scores and MCI status. To evaluate 
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conversion of MCI to dementia and incident dementia in cognitively normal persons 
separately, Cox proportional hazard models stratified for MCI status were used. 
Additionally, the effects of individual variants were explored and considered significant 
after Bonferroni correction for the number of tested variants (p=0.05/47=0.0011). 
Regressions models were adjusted for age and sex, and additionally for vascular risk 
factors. Furthermore, potential interaction between the genetic risk scores and age-at-
onset of MCI and dementia was examined.  
To determine diagnostic and predictive accuracy of the genetic risk scores, the area 
under the receiver operating curve was calculated for a basic model including age and 
sex, and compared with a model additionally incorporating the genetic risk scores.  
All analyses were performed with SPSS version 22, IBM. 
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Table 2 | Study population characteristics. 
Characteristic Total (N=3605) 
Demographics  
Age, years 71.9 (7.2)
Females 2057 (58.2%) 
Educational level
     Primary education 360 (10.1%)
     Lower vocational education 1022 (28.7%) 
     Lower secondary education 585 (16.4%)
     Intermediate vocational education 967 (27.1%)
     General secondary education 145 (4.1%)
     Higher vocational education 438 (12.3%)
     University 49 (1.4%)
Vascular risk factors  
Hypertension 2912 (81.0%) 
Diabetes mellitus 529 (14.7%)
Waist circumference, cm 93.6 (11.8)
Total cholesterol, mmol/L 5.61 (0.99)
HDL-cholesterol, mmol/L 1.45 (0.40)
Smoking 
     Never 1054 (29.2%) 
     Former 1998 (55.4%) 
     Current 553 (15.3%)
Cognition  
Letter-digit substitution task, no. of items/min 27.1 (6.8)
Stroop test (color word interference), s 56.4 (21.0)
Verbal fluency test, no. of animals/min 20.9 (5.1)
15-word verbal learning test, no. of words 6.54 (2.69)
Diagnosis  
MCI 360 (10.0%)
     Amnestic 147 (4.1%)
     Non-amnestic 213 (5.9%)
Dementia 
     Incident cases 191 (5.3%)
     Follow-up time, years 6.04 (1.50)
Values are mean (SD) or number (percentage). Missing values are present in educational level 
(n=39), hypertension (n=9), waist circumference (n=9), and cholesterol levels (n=59). 
Abbreviations: MCI = Mild cognitive impairment, HDL = High-density lipoprotein.   
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RESULTS 
Population characteristics 
Mean (SD) age was 71.9 (7.2) years and 2057 (57.1%) were women. A total of 360 (10.0%) 
participants met the criteria for MCI, of whom 147 (4.1%) with amnestic and 213 (5.9%) 
with non-amnestic MCI. Mean (SD) follow-up was 6.0 (1.5) years, during which 191 
persons were diagnosed with dementia (156 with AD). More characteristics can be found 
in Table 2. 
MCI status 
The association with MCI status was significant for the genetic risk score of AD (OR=1.15 
[1.03 - 1.28]) and suggestive for PD (1.10 [0.99 – 1.23]) and FTLD/ALS (1.09 [0.98 - 1.22]). 
Investigating subtypes of MCI separately, we found an association with amnestic MCI for 
the risk score of AD only (1.16 [0.99 - 1.36]) which attenuated after excluding APOE from 
the risk score (1.11 [0.94 - 1.31]). In contrast, risk scores of AD, PD and FTLD/ALS were all 
associated with the subtype of non-amnestic MCI (see Table 3). The combined risk score 
for all neurodegenerative diseases was significantly associated with MCI, particularly 
non-amnestic MCI. Results were similar after adjustment for education and vascular risk 
factors (see Table S1).  
Investigating the objective and subjective complaints that make up the MCI diagnosis 
revealed that the AD score associated with subjective memory complaints (Table 4). The 
AD score without APOE as well as PD and FTLD/ALS affected objective measures of 
cognitive complaints, particularly information-processing speed and executive function, 
although PD also related to problems getting dressed. No significant interactions were 
detected between the risk scores and age-at-onset of MCI. In single variant analyses, AD 
risk variant rs6733839 near BIN1 was associated with MCI after Bonferroni correction 
(Table S2 for all results). 
Conversion to dementia 
The risk score for AD, but not for PD and FTLD/ALS, was associated with incident 
dementia. This association was particularly strong for conversion from MCI (1.59 [1.23 - 
Chapter 5.2.1 
428  
2.05]). Exclusion of APOE attenuated the association of the AD risk score with incident 
dementia, remaining only borderline significant among persons without MCI (1.21 [1.02-
1.43]). The combined genetic risk score was significantly associated with incident 
dementia. The associations were similar after additional adjustment for vascular risk 
factors (see Table S3). There was a significant interaction between the AD genetic risk 
score and age-at-onset of dementia (p=0.003), which indicated a stronger genetic effect 
when age at onset was lower. 
Among all variants individually, only APOE survived multiple testing. Other AD variants 
that were related to incident dementia were rs983392 (MS4A6A), rs10948363 (CD2AP) 
and rs9331896 (CLU). Interestingly, rs6733839 (BIN1) which was associated with MCI, was 
not associated with incident dementia. The results of the genetic risk scores are in Table 
5 and of single variants in Table S4. Additionally, the AD risk score without APOE was 
examined after stratification for APOE ε4 carrier status ( Table S5).  
Diagnosis and predictive accuracy 
The addition of the genetic risk scores to models of age and sex for diagnosing MCI and 
predicting dementia resulted in small increases of <0.025 of the area under the receiver 
operating curve (see Table 6).  
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DISCUSSION 
We found in a population-based cohort study that a genetic risk score for AD was 
associated with amnestic and non-amnestic MCI, whereas genetic risk scores for PD and 
FTLD/ALS only associated with non-amnestic MCI. Furthermore, only the genetic risk 
score for AD was associated with incident dementia, which attenuated after exclusion of 
APOE. The diagnostic and predictive accuracy of these risk scores was only modest. 
We found that genetic susceptibility to various neurodegenerative diseases associates 
with MCI. The clinical concept of MCI could therefore reflect an underlying 
heterogeneity of disease pathways leading to deterioration of cognitive functions. 
Amnestic MCI, the subtype which increases risk of AD, was associated with APOE, but the 
novel AD risk variants identified through GWAS were related more to the non-amnestic 
subtype. AD genes might thus influence different cognitive domains, with the common 
feature of (jointly) increasing risk of AD. The role APOE of in Alzheimer’s disease is well-
documented, and is often used as a model for ‘typical’ AD: neurodegeneration starting 
in the medial temporal lobe, giving episodic memory problems, amnestic MCI and then 
leading to dementia. It is therefore interesting to see that the novel genetic loci are 
acting differently from APOE, and the underlying pathophysiological mechanism(s) 
might also be different and thus result in this atypical presentation. Studying the novel 
loci separately and in combination could complement our current knowledge of the 
pathophysiology, and might eventually even warrant more detailed subtyping of the 
heterogeneous entity of AD.  Non-amnestic MCI was associated with various genetic risk 
factors of PD and FTLD/ALS, which indicates that further characterization of MCI 
subgroups might also be appropriate. 
Alternatively, these associations could be explained by persons with incipient disease 
who were classified as having MCI. However, all persons meeting criteria of dementia, 
including causes of AD, PD and FTLD, were excluded from the analyses with MCI, and a 
minimal contribution of ALS is expected due to our community-based setting. 
Unfortunately, family members or caregivers were generally not present during the 
center visits, and could therefore not be asked about subjective cognitive complaints of 
the participant. Also, visuospatial functions were not explicitly assessed. However, given 
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the extensive collection of both interview data and cognitive tests for each participant, it 
seems unlikely that this would results in a substantial number of undiagnosed MCI cases. 
Another consideration is that we were unable to assess incident MCI, since MCI 
screening was only performed at the baseline of our study. However, because genetic 
variants reflect life-long exposure, reverse causality or unmeasured confounding is 
highly unlikely.  
A potential limitation is that we have not completed follow-up of participants until the 
end of their lifetimes, which would correspond to an expected 30 years of additional 
follow-up. Although mean age was already 72 years at baseline, and Cox proportional 
hazard models took the variation in starting age and follow-up time into account, we 
further evaluated whether age-at-onset modifies the association of the risk scores, which 
was true only for the AD risk score including  APOE. Nonetheless, competing risks are a 
potential source of bias, and this bias remains even after following persons until the end 
of their lifetimes. 
MCI is often called an intermediate stage, implicitly suggesting that it is merely an earlier 
form of dementia with more cognitive functions still remaining intact, but this might not 
be an adequate representation of MCI. Although risk factors between 
neurodegenerative diseases and MCI overlap, many people with MCI remain stable or 
can even return to normal.2,3 In our study, the AD genetic risk score indeed associated 
with both MCI and incident dementia, but examining the individual risk variants 
separately suggests that each of these two processes could be driven by different 
factors; e.g., BIN1 contributes more to initiating MCI (OR=1.32, p<.001) than to 
conversion to AD (OR=1.13, p=.31). If validated in other studies, these findings could 
help prioritize certain AD targets for early intervention. Since only part of the MCI 
population develops dementia, the heterogeneity of this group could therefore provide 
an explanation why some genes only predispose to MCI, namely that this factor for 
example mostly causes a stable MCI subtype. Also, the dementia trajectory spans 
decades, and even infant changes have recently been implicated.27 Rather than a single 
process that is responsible for all dementia pathology across its various stages, different 
processes might either predispose to, initiate, or propagate cognitive decline. Which 
process is affected by a gene, and in particular when in the dementia trajectory this 
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process is relevant, might thus be reflected in stronger associations with MCI, that are 
less prominent later (conversion to dementia), such as with BIN1. 
We note that the majority of our dementia cases were due to AD. Therefore, we were 
unable to detect any association of the other genetic risk scores with dementia due to 
PD or FTLD/ALS. It is possible that separate genetic risk scores increase the risk of 
disease-specific dementia subtypes only, but this needs to be studied further. An 
important consideration is that variant rs3849943 is tagging the GGGGCC expansion 
within open reading frame 72 (C9orf72), which was shown to be responsible for this 
GWAS signal on chromosome 9.9 This expansion is present in 4-21% of sporadic ALS 
cases.28,29 Phenotypes of neurodegenerative diseases are uncommon when less than 20 
expansions are present, and it usually requires more than 50 expansions for ALS cases to 
develop dementia. Since we were unable to assess the exact number expansions, and 
given our population-based setting, it is possible that the average number of expansions 
was low in our current study. Future efforts should therefore investigate this locus in 
more detail to understand its role in MCI and subsequent conversion to dementia. 
Our diagnostic and prediction models incorporating the genetic risk scores resulted in 
marginal improvement of diagnosing MCI and predicting dementia. This is in line with 
two previous studies that used a smaller set of variants.30,31 It has been questioned if a 
sufficient level of accuracy will ever be achieved for complex diseases, as unraveling 
their complete causal pathways may be impossible.32 However, further genetic 
discoveries in combination with other risk factors might eventually prove the clinical 
utility of polygenic risk scores, as has been shown for age-related macular degeneration 
and height.33,34 Importantly, the genetic variants that are currently known explain only 
little of the variance in disease risk of AD, PD, FTLD and ALS. Uncovering the “missing 
heritability” through larger GWAS and the novel focus on rare variants could improve 
the clinical utility of genetic risk scores. Additionally, the current genetic variants could 
have a larger effect through gene-gene and gene-environment interaction. Stratification 
for APOE ε4 carrier status showed differences in associations of the various risk scores, 
but this needs to be explored further. Moreover, non-genetic factors could aid in more 
accurately diagnosing MCI and predicting dementia by themselves.  
Chapter 5.2.1 
436  
In conclusion, MCI is genetically heterogeneous, whereas dementia develops through 
disease-specific mechanisms. Future research should focus on disentangling different 
genetic causes of MCI and subsequent conversion to dementia.  
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ABSTRACT 
Introduction: We investigated whether a risk score based on genetic risk variants for 
Parkinson's disease (PD) is associated with the risk and improves prediction of incident 
PD, and whether the risk score is associated with basic activities of daily living (BADL) in 
healthy individuals. 
Methods: Within the population-based Rotterdam Study, we genotyped 26 independent 
risk variants for PD and constructed a genetic risk score in 7167 participants who were 
free of parkinsonism and dementia at baseline (1990 or 2000). Participants were 
followed for a maximum of twenty years for the onset of parkinsonism, dementia or 
death until January 1, 2011 (median follow-up 12.1 years). We studied the relationship 
between the genetic risk score and incident PD with adjustment for age, sex, smoking 
and parental history. In an independent sample of 2997 persons free of parkinsonism 
and dementia, we studied whether the PD risk score was associated with BADL. 
Results: During follow-up (median 12.1 years), 99 persons were diagnosed with incident 
PD. The genetic risk score was associated with incident PD (hazard ratio per standard 
deviation risk 1.25 [95% confidence interval=1.02;1.55]), but did not substantially 
improve prediction (change in C-statistic 0.687 [0.628; 0.745] to 0.698 [0.635; 0.760], 
ΔC=0.011 [-0.011;0.033]). The genetic risk score was associated with a higher probability 
of any impairment in BADL (odds ratio=1.11 [1.00;1.23]). 
Conclusion: Genetic variants for PD are associated with the risk of incident PD in the 
general population and with impairment in daily functioning in individuals without 
clinical parkinsonism, but do not improve the clinical prediction of PD. 
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INTRODUCTION 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
among the elderly.1 Clinically, the disease is characterized by parkinsonism, an absence 
of markers suggestive of other causes, and supportive prospective criteria.2 Clinical PD is 
preceded by a prodromal phase during which neurodegeneration has already started, 
but the signs defining parkinsonism are not present.3 During this period, individuals 
often experience a combination of early motor and non-motor signs and symptoms that 
could affect their daily activities, ranging from subtle movement deficits under 
challenging conditions to autonomic dysfunction, rapid eye movement sleep behavior 
disorder, and depression.4 
Several factors are associated with an altered risk of incident PD, such as environmental 
risk factors (e.g., smoking, exposure to pesticides) and early clinical features (e.g., 
anosmia, rapid eye movement behavior disorder).1, 5 However, there is a lack of empirical 
data on whether these factors can identify a large group of persons at high risk for the 
disease from the general population. During the last decade, several studies have 
suggested a substantial genetic contribution to PD, including the identification of risk-
increasing mutations in GBA and LRRK2 that are common in PD patient populations,6, 7 
with a large proportion of contributing genes still to be identified.8 In addition, genome-
wide association studies have yielded a total of 28 independent risk variants that are 
common at a population level, 22 of which are genome-wide significant.9 Recent case-
control studies have shown a risk score based on these variants may contribute to 
discrimination of PD patients and healthy controls,10, 11 and average genetic risk may be 
higher in patients with an early disease age at onset.12  However, the clinical usefulness 
of these variants in prospectively predicting PD remains untested. Also, it is unclear 
whether these risk variants evoke symptoms related to PD in individuals without clinical 
parkinsonism, leading to subtle problems in daily functioning.  
We hypothesized that a genetic risk score based on currently identified risk loci would 
be a risk factor for incident PD in the general population, and that the genetic risk score 
would improve prediction of PD. Furthermore, we hypothesized that PD genes affect 
daily activities in community-dwelling individuals without parkinsonism.  
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METHODS 
Study design and setting 
The study was embedded in the Rotterdam Study, a large, prospective, population-
based study in the Netherlands.13, 14 The original study cohort (RS-I) started in 1990 and 
consisted of 7983 community-dwelling people aged 55 years and older, residing in the 
suburb Ommoord, Rotterdam. They were re-examined every 4 years, with the last re-
examination between 2009 and 2011. In 2000, the cohort was expanded with 3011 
people aged 55 years and older (RS-II). The last follow-up examination for this subcohort 
took place between 2011 and 2012. The study was approved by the Medical Ethics 
Committee of Erasmus MC University Medical Center Rotterdam, the Netherlands. All 
participants provided written informed consent to participate in the study. 
For PD prediction analyses, all participants in RS-I and RS-II free of parkinsonism and 
dementia at baseline with available genotype information on 26 risk loci for PD were 
eligible (n=7705). Of these persons, 7224 were interviewed at baseline on their smoking 
habits (never, past, current) and parental history of PD. Finally, 51 persons refused to 
provide informed consent, leaving 7167 participants (93.1%) for PD prediction analyses. 
We followed participants for a maximum of twenty years for onset of PD from baseline 
until the first of: onset of parkinsonism, onset of dementia, death or 1 January 2011.  
For basic activities of daily living (BADL) analyses, we invited all participants (n=3855) 
who were still alive, free of parkinsonism as well as free of dementia at the time of the 
last center visit round of both cohorts (RS-I in 2009-2011 and RS-II in 2011-2012). Of 
these persons, 3046 (79.0%) agreed to participate and were able to participate. Twenty-
five persons were excluded because of unknown smoking status at time of the BADL 
assessment and another twenty-four persons did not complete their BADL assessment, 
leaving 2997 persons for BADL analyses. 
Genotyping  
The Illumina 550K (RSI), 550K duo, and 610 quad (RSII) arrays were used for genotyping. 
We removed samples with call rate below 97.5%, gender mismatch, excess autosomal 
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heterozygosity, duplicates or family relations and ethnic outliers, and variants with call 
rate below 95.0%, failing missingness test, Hardy–Weinberg equilibrium p-value<10-6, 
and minor allele frequency<1%. Genotypes were imputed using MACH/minimac 
software to the 1000 Genomes phase I version 3 reference panel (all population).  
In the largest genome-wide association study of PD to date, 22 genome-wide significant 
primary variants, four secondary signals that remained significant in conditional analyses 
as well as two sub-genome-wide significant, potential risk variants were associated with 
the risk of disease at genome-wide significance in persons without known mutations in 
genes associated with mendelian forms of PD.15 An overview of the of risk alleles as well 
as their reported effect size for the association with PD is presented in Supplementary 
file 1. Two of these variants were not genotyped in our dataset, nor reliably imputed 
(R2<.3), and also lacked a proxy variant (rs113579895, MAPT; rs115462410, HLA-DQB1), 
leaving 26 variants for analysis.  
Ascertainment of parkinsonism and PD 
At baseline, all participants were screened at the research center for signs of 
parkinsonism.16 Individuals who screened positive received a structured clinical workup 
by a research physician specialized in neurologic disorders to establish parkinsonism. 
Persons who were suspected of having PD were further evaluated by an experienced 
neurologist. 
During follow-up, we used four overlapping modalities to screen for potential 
parkinsonism: in-person screening (every 4 years), in-person interviews, use of 
antiparkinson medication, and clinical monitoring alerts.17 Of all persons who screened 
positive in any of these methods, complete medical records were studied and case 
reports were drawn up covering all potentially relevant information to establish 
presence and subtype of parkinsonism. These case reports were evaluated by a panel led 
by an experienced neurologist. PD was only diagnosed after exclusion of parkinsonism 
associated with preexistent dementia, use of anti-dopaminergic drugs and 
cerebrovascular disease, multiple system atrophy, progressive supranuclear palsy and in 
the absence of evidence for other rare causes (e.g., corticobasal degeneration).16 Persons 
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who first developed PD and then dementia within 1 year of the diagnosis of PD were 
also considered PD cases. After initial diagnosis, medical records of all incident 
parkinsonism cases (both PD and secondary) continued to be scrutinized until the end of 
the study period for new information that could lead to a revision of the diagnosis. 
Ascertainment of dementia 
Participants were screened for dementia at baseline and follow-up examinations using a 
three-step protocol,18 comprising two brief tests of cognition to screen all subjects and 
the Cambridge Examination for Mental Disorders of the Elderly in individuals with 
positive screen results.19 Additional information was obtained from in-person 
examination by a neuropsychologist, clinical monitoring and neuro-imaging . A 
consensus panel, led by a neurologist, decided on the final diagnosis in accordance with 
standard criteria using the DSM-III-R criteria for dementia.  
Basic activities of daily living 
Basic activities of daily living (BADL) was assessed based on the disability index from the 
Stanford Health Assessment Questionnaire, which consisted of 20 items constituting 
eight components: dressing and grooming, arising, eating, walking, hygiene, grip, reach, 
and activities.20 In our study, two out of three items of eating (ability to lift a glass of milk 
and ability to cut meat) were combined into one. Items were scored from 0 to 3, as 
follows: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 
3=unable to. Component scores were calculated as the highest scored item per 
component.20 The BADL score was calculated by summing all components, obtaining a 
score between 0 and 24. We considered scores from 0 to 8 as no to mild disability and 
from 8 to 24 as moderate to severe disability.21 
Statistical analysis 
We constructed a genetic risk score for each individual, by adding up their number of 
risk alleles weighted by the log-transformed, reported risk-increasing or risk-decreasing 
effect size for the association with PD.9 Risk scores were transformed into z-scores to 
facilitate evaluation of their effect per standard deviation increase. A higher genetic risk 
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score corresponds to a larger weighted number of risk alleles and thus a higher risk of 
PD. We constructed two models: model I comprised age and sex for overall analyses, and 
only age for sex-stratified analyses. Model II comprised model I plus parental history of 
PD and smoking (never, past, current), and model III comprised model II plus the genetic 
risk score.  
We investigated the association between the genetic risk score and incident PD by 
comparing each model using the method proposed by Fine and Gray, which takes into 
account the risk of competitive events (i.e., incident dementia or death).22 In 
subanalyses, we separately added interaction terms between the genetic risk score and 
age, sex, smoking, and parental history to model III. The discriminative value of both 
models was expressed with Uno’s C-statistic, which takes into account right-censoring.15 
Separately, we repeated the prediction analysis after addition of the GBA p.E326K variant 
to the risk score (its weight was calculated using the previously meta-analysed odds 
ratio of 1.71).23 In other sensitivity analyses, we assessed the cross-sectional 
discriminative value of the risk score by combining prevalent PD cases with complete 
covariate data (n=68) and incident PD cases and performing logistic regression analyses.  
To study the association between the genetic risk score and activities of daily living, we 
dichotomized BADL scores for having any difficulty in daily functioning or none. Because 
of the highly skewed distribution of BADL scores in our population,(Supplementray file 
2) we used a binary logistic regression model to analyze the association of the genetic 
risk score with any difficulty in BADL, adjusting for age, sex and smoking. We report p-
values based on 1000 permutations. In separate subanalyses, we added interaction 
terms between the genetic risk score and age, sex and smoking to the model. 
Furthermore, we used multinomial logistic regression models to examine the association 
of the genetic score with mild and moderate to severe BADL impairment separately. 
Also, we examined associations between the genetic risk score and impairment on each 
BADL domain separately using logistic regression models. Finally, we examined the 
association of each of the 26 single risk variants with any impairment in BADL, adjusting 
for age, sex, and smoking with a Bonferroni correction for 26 comparisons (p=0.05/26). 
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RESULTS 
Characteristics of the study population at risk for PD and the persons examined for daily 
activities are presented in Table 1. In Supplementary file 3, we present population 
characteristics stratified by incident PD case status. During follow-up (median 12.1 
years), 99 (1.4%) individuals suffered from incident PD and 930 (13.0%) from incident 
dementia, while a total of 3286 (45.8%) persons died.  
  
Table 1 | Population characteristics 
Characteristic
At risk for PD* 
BADL 
examination** 
Number of individuals 7167 2,997
Women (%) 4135 (57.7) 1756 (58.6) 
Age at baseline, mean, y (SD) 67.3 (8.4) 76.8 (6.6) 
Smoking (%)  
 Never 2353 (32.8) 1036 (34.6) 
 Past 3,237 (45.1) 1672 (55.8) 
 Current 1,580 (22.0) 289 (9.6) 
Parental history (%)  
  No 6,962 (97.1) -
  1 parent with PD 205 (2.9) -
  2 parents with PD 3 (<0.1) -
PD, Parkinson’s disease; BADL, activities of daily living; y, year; SD, standard deviation.  
Smoking status was assessed at baseline for PD risk prediction analyses and during the last 
center visit for BADL analyses.  
*Included in longitudinal association and prediction analyses for Parkinson’s disease.  
**Included in cross-sectional association analyses for activities of daily living.  
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Table 2 | Prediction of incident Parkinson’s disease in the general population  
 HR (95% CI) C-statistic (95% CI) 
 
Model I  0.659 (0.599; 0.720) 
Age 1.05 (1.03; 1.07)
Female 0.66 (0.44; 0.98)
 
Model II 0.687 (0.628; 0.745) 
Age 1.05 (1.03; 1.07)
Female 0.48 (0.30; 0.76)
Smoking (past) 0.57 (0.35; 0.94)
Smoking (current) 0.36 (0.18; 0.70)
> 1 parent with PD 1.29 (0.40; 4.15)
 
Model III 0.698 (0.635; 0.760) 
Age 1.05 (1.02; 1.07)
Female 0.48 (0.30; 0.76)
Smoking (past) 0.57 (0.35; 0.93)
Smoking (current) 0.36 (0.19; 0.71)
> 1 parent with PD 1.25 (0.39; 4.03)
Genetic risk score 1.25 (1.02; 1.55) 
HR, hazard ratio for incident Parkinson’s disease per standard deviation increase in risk score. 
CI, confidence interval.   For smoking, the reference category was never.   
 
Table 3 | Genetic risk score and basic activities of daily living 
BADL N (%) OR (95%CI) P value 
 
No impairment 
461  
(15.4) 
1.000 
(reference) 
 
Any impairment 
2536 
(84.6) 
1.110
(1.002; 1.230) 
0.016 
  Mild impairment 
2017 
(67.3) 
1.123
(1.013; 1.246) 
0.020 
  Moderate to 
severe impairment 
519  
(17.3) 
1.020
(0.889; 1.171) 
0.768 
BADL, basic activities of daily living. N, number of persons. OR, odds ratio. 95%CI, 95% 
confidence interval. 
Odds ratio per standard deviation increase in genetic risk score. 
Reference category for both mild and moderate to severe impairment is no impairment. 
All analyses were adjusted for age, sex and smoking. 
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In Table 2, we show that the genetic risk score was independently associated with the 
onset of PD. There was no significant interaction between the genetic risk score and any 
of the covariates in the model (p=0.57 for interaction with age; p=0.81 with sex; p=0.59 
with smoking, p=0.88 with family history). Adding smoking and parental history to age 
and sex yielded borderline improvement in the prediction of incident PD (change in 
C=0.027 [-0.002; 0.056]), while addition of the genetic risk score to age and sex also 
produced improvement (change in C=0.038 [0.000; 0.076]). As shown in table 2, the 
genetic risk score did not improve prediction beyond age, sex, smoking and parental 
history (change in C =0.011 [-0.011; 0.033]). The GBA p.E326K variant had a minor allele 
frequency of 0.021 in our population, and incorporation of this variant in the genetic risk 
score did not affect its incremental predictive value (change in C = 0.009 [-0.009;0.026]).  
The univariate C-statistic of the genetic risk score was 0.56 [0.48; 0.64]. In cross-sectional 
sensitivity analyses, the genetic risk score yielded a similarly small improvement of C-
statistics  beyond age, sex, smoking and parental history (C=0.663 to C=0.677). 
The genetic risk score was associated with any impairment in BADL (p=0.016). There was 
no significant interaction of the genetic risk score with age, sex, or smoking (p>0.10 for 
all interaction terms). As shown in Table 3, the genetic risk score was significantly 
associated with mild impairment (p=0.020), but not with moderate to severe 
impairment (p=0.768) in separate analyses. In contrast to the overall BADL-score, the 
genetic risk score was not associated with any of the eight BADL domains separately 
(p>0.20 for each domain).  
None of the 26 single risk variants was associated with impairment in BADL after 
Bonferroni correction. Interestingly, risk alleles in three PD loci were nominally 
borderline associated with any impairment BADL: GCH1 (rs11158026; p=0.055), CCDC62 
(rs11060180; p=0.058) and GBA-SYT11 (rs35749011; p=0.054). None of the remaining 23 
variants was associated with any impairment in BADL (p>0.10 for each variant). 
DISCUSSION 
In this large population-based sample with a median of 12 years of follow-up, we found 
that a genetic risk score for PD based on the most recent set of genome-wide significant 
variants was associated with a modest but significant increase in the risk of PD. However, 
Genetic risk of Parkinson disease in the general population 
 447 
5 
in addition to age, sex, smoking status at baseline and parental history, the genetic risk 
score hardly improved the prediction of incident PD. In cross-sectional analyses, we 
further found that the genetic risk score was associated with any and with mild 
impairment in BADL.  
As far as we know, only case–control studies have previously been employed to examine 
the use of a genetic risk score for PD to discriminate between PD cases and healthy 
controls.10-12, 24 These studies showed that a risk score based on these variants may 
contribute to discrimination of PD patients and healthy controls,10, 11 and average 
genetic risk may be higher in patients with an early disease age at onset.12 In a recent 
diagnostic case-control study of PD, the univariate C-statistic of a genetic risk score that 
comprised 30 genetic variants including the 26 used in our study ranged from 0.62 to 
0.64,11 which was slightly higher than in our predictive study (C-statistic=0.56). This 
relatively small difference may be explained by the difference in study design: in case-
control studies, controls are recruited with strict criteria that ensure maximal distinction 
from PD cases, whereas participants in prospective, population-based studies such as 
the Rotterdam Study are included irrespective of PD risk. The advantage of prospective 
population-based studies is that all participants were included and followed up using 
the same methodology, and following up persons in the general population presumably 
ensured a realistic estimate of the risk of incident PD. Several limitations of our study 
should be noted, however. We lacked histologic confirmation on PD diagnosis, 
suggesting that misclassification of PD cases occurred. The detailed in-person and 
clinical information on the presence and possible causes of parkinsonism throughout 
the study period make it unlikely that the misclassification was differential. Still, non-
differential misclassification may underestimate the predictive ability of the genetic risk 
score for histologically confirmed PD. Also, part of the RS-I cohort used for prediction of 
PD was also among the discovery cohorts of the PD genes: the overlap comprised 44 
incident PD cases (0.3%) and 5609 controls (5.9%).9 We believe that it is unlikely that this 
small proportion of overlap influenced our findings. In addition, current effect estimates 
were based on a GWAS of PD cases across various Caucasian populations. It is possible 
that other variants have larger effects in the Dutch population than the published 
tagging SNPs. Including these population-specific variants in the risk score could 
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improve power. Furthermore, we were probably underpowered to a small improvement 
in PD prediction and, similarly, to detect interaction of the genetic risk score with 
traditional risk factors and parental history. In addition, we could only assess the 
predictive value of the risk score for incident PD in persons aged 55 years and older. 
Since high polygenic risk is associated with a lower age of onset of PD,12 this probably 
led to a slight underestimate of the predictive value of the genetic risk score, 
considering the relatively small proportion of PD patients aged younger than 55 at a 
population level.1 
The main motivation for learning how to predict PD is to identify PD patients as early as 
possible. At this time, although neuroprotective agents with sustainable effects remain 
elusive, PD manifestations can often be treated or delayed effectively, and surveillance 
could allow early symptomatic treatments, perhaps with long-term benefits on quality 
of life.25, 26 As the pathological processes of PD advance, early clinical features become 
increasingly more prevalent in prediagnostic PD patients than in controls,27 and 
discrimination of clinical PD patients and healthy controls can be accurately established 
(as reflected by high C-statistics) using just one early feature (impaired olfaction).11 
However, during the early pathological phase of PD, clinical differences between 
prediagnostic PD patients and controls are generally not yet overt, and discrimination 
between these groups is less accurate, as reflected by lower C-statistics. Early prediction 
is therefore based on basic demographics (e.g., age, sex, family history) and 
environmental risk factors (e.g., smoking, exposure to pesticides). The discriminative 
value of demographics is remarkably similar for long-term prediction (as in our study) 
and clinical diagnosis of PD as in diagnostic studies,10, 11 with integrative demographic C-
statistics typically ranging from 0.60 to 0.70. Smoking was previously included in a 
diagnostic model for PD,10 but contributed insufficient independent information to be 
included in a recent integrative diagnostic algorithm for PD.11 The latter was surprising 
for two reasons. First, smoking is common at a population level, and current smoking in 
particular is strongly inversely associated with PD in case-controls studies.28 Second, PD 
patients who smoke are able to quit smoking more easily than controls,29 making the 
discriminative value of smoking even higher for PD diagnosis than for PD prediction. 
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Over the past few years, genetic risk scores have been shown to be of marginal value in 
prediction of diseases with strong preexistent demographic and clinical factor-based 
predictive models.30, 31 However, they have enabled improvement in prediction of 
diseases without such models,32, 33 and in a recent diagnostic study of Alzheimer’s 
disease, genetic risk scores based on GWAS variants and APOE variants improved 
diagnostic accuracy beyond age and sex.34 In this study of more than 7000 individuals, 
we showed that addition of a genetic risk score for PD did not improve prediction 
beyond age, sex, smoking and parental history. Thus, our findings do not support a role 
for routine PD risk allele genotyping in a clinical setting at this time. This is similar to our 
previous observation of that genetic risk variants had limited predictive value for 
Alzheimer’s disease and all-cause dementia.35, 36 As more PD risk variants become known, 
however, their incorporation into the genetic risk score may explain more of the 
heritability that was first implied by familial aggregation of PD,37 and is now estimated to 
be 0.27.8 A recent meta-analysis showed that mild to severe GBA mutations are more 
common in PD populations than in controls.6 For the carriers of the severe GBA 
mutations, it has been suggested that the high increase in risk of PD (OR 14.6 – 19.3) may 
warrant a closer clinical follow-up,6 similar to carriers of the G2019S mutation in the 
LRRK2 gene.38 However, the predictive value of such rare variants at a population level 
remains undetermined, and we note that the current genetic risk score did not include 
the G2019S mutation in LRKK2 and only focused on the p.E326K variant in GBA. 
To our knowledge, this is the first study to investigate the relationship of a genetic risk 
score for PD with daily activities in the general population. The genetic risk score was 
associated with any impairment in BADL, suggesting that alleles with an established 
association with PD may also affect prodromal phenotypes linked with PD in the general 
PD-free population. Interestingly, we observed a clear association of the genetic risk 
score with mild impairment in BADL, but not with moderate to severe impairment. We 
offer two possible explanations for this observation. First, since we excluded individuals 
with parkinsonism and dementia from our analyses, the majority of persons with 
moderate to severe impairment probably comprised individuals with common, non-
neurodegenerative diseases (e.g., locomotor diseases, COPD 39). We note that we are 
unaware of substantial genetic overlap with PD for these diseases or of empirical 
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evidence for antagonistic pleiotropic effects of PD risk variants on BADL.. Second, we 
studied risk variants that are relatively common in the general population, and these 
variants may affect BADL more subtly than rarer risk variants with larger effect sizes on 
the risk of PD.  
In conclusion, in this study in the general population, a genetic risk score based on 26 
independent risk variants was associated with a higher risk of incident PD and a larger 
probability of impairment in BADL, but did not result in a substantially better prediction 
of PD beyond age, sex, smoking and parental history. Our results suggest that the use of 
this weighted combination of known risk loci is not yet as useful for the prediction of the 
risk of PD as it is for further elucidating the etiology of the disease. However, we were 
probably underpowered to detect a small improvement in PD prediction. 
REFERENCES 
1. de Lau LM, et al. Lancet Neurol. 2006 
2. Lees AJ, et al. Lancet. 2009 
3. Berg D, et al. Mov Disord. 2014 
4. Berg D, et al. Lancet Neurol. 2013 
5. Noyce AJ, et al. J Neurol Neurosurg 
Psychiatry. 2016  
6. Gan-Or Z, et al. Neurology. 2015 
7. Healy DG, et al. Lancet Neurol. 2008 
8. Keller MF, et al. Hum Mol Genet. 2012 
9. Nalls MA, et al. Nat Genet. 2014 
10. Hall TO, et al. Genet Med. 2013 
11. Nalls, et al. Lancet Neurol. 2015 
12. Escott-Price V, et al. Ann Neurol. 
2015 
13. Hofman A, et al. Eur J Epidemiol. 
1991 
14. Hofman A, et al. Eur J Epidemiol. 
2015 
15. Uno H, et al. Statistics in Medicine. 
2011 
16. de Rijk MC, et al. Neurology. 1995 
17. de Lau LM, et al. Neurology. 2004 
18. Schrijvers EM, et al. Neurology. 2012 
19. Roth M, et al. Br J Psychiatry. 1986 
20. Fries JF, et al. J Rheumatol. 1982 
21. Bruce B, et al. Health Qual Life 
Outcomes. 2003 
22. Fine JP, et al. Journal of the 
American Statistical Association. 1999 
23. Pankratz N, et al. Ann Neurol. 2012 
24. Do CB, et al. PLoS Genet. 2011 
25. Connolly BS, et al. JAMA. 2014 
26. Castrioto A, et al. Lancet Neurol. 
2014 
27. Schrag A, et al. Lancet Neurol. 2015 
28. Noyce AJ, et al. Ann Neurol. 2012 
29. Ritz B, et al. Neurology. 2014 
30. Meigs JB, et al. N Engl J Med. 2008 
31. Paynter NP, et al. JAMA. 2010 
32. Chen H, et al. PLoS One. 2011 
33. Hageman GS, et al. Hum Genomics. 
2011 
34. Escott-Price V, et al. Brain. 2015 
35. Verhaaren BF, et al. Biol Psychiatry. 
2013 
36. Adams HH, et al. Alzheimers 
Dement. 2015 
37. Sveinbjornsdottir S, et al. N Engl J 
Med. 2000 
38. Giladi N, et al. J Neurol Sci. 2011 
39. Odding E, et al. Eur J Epidemiol. 
2001 
General discussion 
 451 
6 
Chapter 6 General discussion Chapter 6 
General discussion 
Chapter 6 
452  
ABSTRACT 
In this thesis I used genetics and neuroimaging to study complex neurological diseases. 
This chapter places the main findings into context and also includes a discussion of 
methodological considerations and clinical implications. I conclude by describing 
strategies for future research, also looking beyond neurodegenerative and 
cerebrovascular diseases.  
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GENETIC DISCOVERIES 
Genetics play an important role in many neurological diseases.1-4 Understanding which 
genetic factors are relevant for a particular disease can yield insight into the 
pathophysiology and potentially lead to novel therapies. Furthermore, it can improve 
diagnosis and prediction by removing part of the uncertainty of who has or will develop 
a disease. Genome-wide association studies (GWAS) in tens of thousands of individuals 
have identified hundreds of genetic risk variants for neurodegenerative and 
cerebrovascular diseases,5-11 but the amount of variance in disease susceptibility that is 
explained by these variants is relatively small. The remaining unexplained variance is 
also called 'missing heritability',12 and we aimed to uncover part of it in chapter 3 using 
an imaging genetics approach. 
We studied the genetic determinants of imaging markers that are important for 
diseases. In contrast to dichotomous clinical diagnoses of healthy versus diseased, 
quantitative biomarkers obtained from imaging can classify individuals in a continuous 
and biologically more plausible manner (see Figure 1). These biomarkers take into 
account residual variation within groups of persons that are classified as healthy or 
diseased, thereby also capturing differences in severity of disease. Such information is 
lost by dichotomization, making continuous phenotypes statistically more powerful for 
detecting (genetic) effects. Furthermore, genetic effects on biomarkers might be larger, 
and thus easier to detect, compared to the effect sizes observed for neurological 
diseases: the multifactorial nature of most brain diseases means that there is 
heterogeneity in the underlying causes. Biomarkers that isolate specific disease 
processes would reduce the noise from other causes, assuming that this component is 
indeed genetically more homogeneous. Naturally, this raises the question: Which 
neuroimaging phenotypes should be used as biomarkers for which diseases? 
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One criterion on which to select neuroimaging phenotypes is that they should capture 
part of the disease process. To this end, studies are necessary to determine their 
associations with diseases, with longitudinal studies being in the unique position to 
investigate disease as it develops. An informative marker has added value beyond the 
clinical diagnosis, and it should be noted that any link need not be causal: as long as the 
biomarker classifies individuals in a more meaningful way than ‘healthy’ versus 
‘diseased’ it does not matter whether it is a causally related risk factor, a consequence of 
disease, or even a confounded association. The only prerequisite for identifying disease 
genes is that the underlying genetic determinants are shared between the biomarker 
and disease of interest (see section 6.4 about genetic correlation). Structural imaging 
markers have been widely investigated in relation to clinical outcomes and are the focus 
of chapter 3.1. Partly motivated by the high heritability, initial GWAS on these structural 
phenotypes have focused on intracranial volume,13,14 a marker of brain reserve,15 and the 
volumes of various subcortical structures,14,16,17 which have been related to 
 
Figure 1 | The value of biomarkers beyond clinical diagnosis. 
Plot illustrating the relation between biomarker values, disease severity, and clinical diagnosis. 
The blue line depicts values of a hypothetical biomarker in relation to disease severity. The red 
line indicates the point at which a sufficient amount of damage due to the disease leads to the 
clinical diagnosis. While labelling persons as 'healthy' or 'diseased' can successfully separate 
the most severe cases from those with less severe disease, the biomarker values provide 
additional information on the actual placement of an individual within the spectrum of 
di
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neurodegenerative and psychiatric diseases.18-20 The paucity of large-scale neuroimaging 
studies, however, has made current efforts underpowered. So far only 9 variants have 
been identified for these structural phenotypes and they fail to explain a substantial 
amount of the phenotypic variance. We found 33 additional loci for these and several 
novel traits, including the first genome-wide variants for the size of the brainstem, 
amygdala, pallidum, accumbens, and the anterior commissure. Furthermore, the 
additional loci identified for some phenotypes begin to highlight certain pathways. For 
intracranial volume, for example, we found that there is an enrichment for variants near 
genes involved in growth pathways. The most prominent was PI3K-AKT signaling: it is 
related to brain overgrowth disorders21,22, with AKT3 deletions causing microcephaly 
syndromes23 and AKT3 duplications cause macrocephaly.24 Our results show that the 
effect of these genes is not restricted to persons who have severe syndromes, but also is 
of importance for determining brain size in the general population. 
Besides genes implicated in human disease our GWAS are also informative for more 
fundamental biological research on brain development. We noted a striking overlap 
between studies of the anterior commissure in model organisms and the first 
investigation of genes influencing the human anterior commissure in chapter 3.3.1. 
Mouse and fruit fly experiments pointed to several gene families that are important for 
the development of commissural tracts and we now find genetic associations either 
within or very close to such genes: the Semaphorin SEMA6A and the Ephrin EPHA3 loci 
are the two most significant loci in our anterior commissure GWAS, and they both 
belong to these major families of commissural genes. It is difficult to do experimental 
studies in humans that capture the complexity of the intricate network of commissural 
neurons, and approaches that capture part of this process (e.g., migration during 
development) are often not feasible for high-throughput. Our in vivo genetic analyses 
have now identified reliable candidate genes for further experimental studies to 
understand their exact function in interhemispheric communication.  
Neuroimaging can also measure the extent of cerebrovascular disease, which is covered 
by chapter 3.2, and includes prominent imaging markers of small vessel disease, 
intracranial atherosclerosis, and cerebral blood flow.25,26 Stroke patients typically have 
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subclinical cerebrovascular disease that can already be detected on MRI before a clinical 
event takes place.27-29 In vascular dementia, imaging markers of cerebrovascular disease 
are part of the diagnostic criteria,30 and their relevance for other types of dementia is 
increasingly being appreciated.31,32 For intracranial carotid artery calcification, we 
reported the first GWAS and identified two significant loci, of which one was replicated 
in a sample of clinical stroke patients. GWAS have already identified 5 variants for white 
matter hyperintensities,33 while efforts have been unsuccessful for brain infarcts,34 and 
not yet undertaken for other markers of cerebrovascular disease. For enlarged 
perivascular spaces, such studies are complicated by the fact that heterogeneous 
methods exist for their assessment. In  chapters 2.1 and 2.2 I described a reliable rating 
protocol for enlarged perivascular spaces to enable collaborative studies on these 
markers. These steps are the groundwork for facilitating multi-site genetic studies of 
such imaging markers, which will hopefully yield more insight into cerebrovascular 
disease in coming years.  
Additionally, gene discovery is contingent on the imaging marker itself being genetically 
determined. Heritability studies can inform on the relative contribution of genes to the 
observed variation between individuals. Traditionally, such studies were done in 
families, but recently developed methods now also make this possible in samples of 
unrelated individuals.35,36 In chapter 3 I report the first heritability studies for both 
established and emerging imaging markers and found that they have a considerable 
genetic component using studies of both related and unrelated individuals. We found 
most investigated imaging markers to be suitable for genetic studies. The volumes of 
subcortical brain structures and in particular the brainstem were highly heritable, and 
this was also the case for some of the vertex-wise and voxel-wise measures of subcortical 
grey matter structures. Other imaging markers also showed substantial heritability: the 
amount of intracranial carotid artery atherosclerosis, size of the anterior commissure, 
and certain gait parameters. How does this further our understanding of these traits? 
Here too it is good not to dichotomize traits into ‘heritable’ versus ‘not heritable’ since 
the degree of heritability varies a lot. The heritability analysis of the shape of subcortical 
structures in chapter 3.3.3 showed regions within the same structure with both high and 
low heritability. Partly this could be explained by the fact that some measures contain 
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more measurement error than others. However, even when focusing on those measures 
that were very reproducible there exists a large variation in heritability. This indicates 
that the influence of genes on brain structure really does vary and some regions of the 
brain are more determined by environmental factors. Depending on which regions are 
the most relevant for neurological diseases, research can refocus on either genetic or 
environmental risk factors. Another conceptual advance is illustrated by chapter 3.3.2: 
while some gait domains initially showed a quite promising heritability, we found that 
this was mainly driven by genes underlying height and weight. So although there are 
clinical correlates of these gait domains beyond height and weight, subsequent genetic 
studies do not seem promising for revealing novel associations besides those identified 
for these two anthropometric traits. Especially given the large sample sizes for height 
and weight GWAS,37,38 it is unlikely that scarcely collected gait data could ever provide a 
meaningful contribution.   
So far, the largest GWAS discovery sample of a neuroimaging marker comprised 13,171 
individuals,17 only 5% of the GWAS of height, another quantitative trait for which 697 
variants were identified in a study of 253,288 individuals.38 To work toward similar 
successes in imaging genetics, we undertook larger studies. In chapter 3, I describe 
GWAS of intracranial volume, hippocampal volume, and other subcortical brain 
structures in the largest discovery samples to date, identifying 33 novel genetic variants 
in 16,000-37,000 individuals. Similarly, for cerebrovascular disease markers we identified 
the first genome-wide significant variants for the amount of intracranial carotid artery 
atherosclerosis. We also studied, for the first time, emerging markers such as the anterior 
commissure and gait parameters. In total, we were able to report 42 significant novel 
associations for the various markers in chapter 3. Some of the identified variants were 
indeed related to clinical outcomes. Perhaps the best illustration of the biomarker 
approach comes from chapter 3.3.1, where I described a GWAS of the anterior 
commissure. Here, we were able to detect a strong association of genetic variants near 
the gene TMEM106B with the size of the anterior commissure. This particular gene was 
previously identified to increase the risk of frontotemporal lobar degeneration in a 
sample of 567 cases and 3,380 controls (p = 2.7 x 10-9). In the GWAS of  the anterior 
commissure, however, we achieved a more significant signal in a smaller sample of the 
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older cohorts (3,015 individuals; p = 3.8 x 10-11). In some way this can be seen as an 
intentional form of sampling bias: the associations in these older individuals are not 
representative of the general population. This approach is helpful when the goal is 
enrich for associations of a disease processes that occur in a certain population, but not 
if the goal is external validity.  
While bigger may be better, another worthwhile approach is further refinement of the 
neuroimaging phenotype. For total brain volume, no genetic variants could be detected 
using sample sizes of almost 10,000 individuals.13 While larger studies might indeed 
uncover some of its genetic determinants, it remains a rather crude phenotype that 
aggregates the entire brain into a single measure. Studying the volume of the 
hippocampus already gives better results, but also this is a crude phenotype. In chapter 
2.4, we illustrated how further refinement of the hippocampal structure at a voxel-wise 
level can yield a stronger association. This chapter was aimed at solving the 
methodological problems that currently obstruct us from performing an actual genome-
wide and brain-wide search for association signals.  
 
Figure 2 | From gene to disease: understanding the pathophysiological mechanism. 
Schematic overview of DNA variation eventually causing clinical disease. The 
pathophysiological mechanism could lead to various subcellular effects such as altered 
methylation, gene expression, or protein function. This can in turn affect measurable 
endophenotypes, including neuroimaging markers. 
Abbreviations: CNV = copy number variation, SNP = single nucleotide polymorphism 
General discussion 
 459 
6 
UNDERSTANDING PATHOPHYSIOLOGY 
Another avenue for combining neuroimaging and genetics is by exploring the effects of 
known disease genes on the changes that occur in the brain. While GWAS have 
identified genetic variants for disease, there is still a long way from genetic association 
to pathophysiological mechanism (see Figure 2). These variants have in common that 
they confer risk for a particular disease, but the pathophysiological mechanism is not 
necessarily the same. For complex diseases in particular, this potentially opens up 
research to several different pathways. Imaging genetics can shed light on which 
specific pathways are actually involved by studying known genetic variants for a disease 
in relation to the relevant imaging markers of that disease. 
Since genetic variants primarily exert subcellular effects, a lot of efforts in recent years 
aimed to systematically map these: expression quantitative trait loci, predicted 
damaging effects on protein structure, and epigenetic modifications are among many 
characteristics that can inform on the potential functionality of genetic variants.39-44 But 
these subcellular effects eventually translate into clinical disease by affecting the brain, 
and determining the type of changes can improve our understanding of the disease 
mechanism. Similar to the previous question on genetic discoveries, here too the 
question arises: which phenotypes to use?  
One approach is to have the selection of phenotypes guided by prior knowledge of the 
presumed pathophysiological mechanism through which the gene leads to disease. 
Chapter 4.1 considered genetic disease variants in relation to such candidate 
phenotypes: Alzheimer’s disease variants and several key vascular and degenerative 
markers (chapter 4.1.1), intracranial aneurysm variants and the presence and size of 
aneurysms (chapter 4.1.2), and the dystrophin gene and cognitive function (chapter 
4.1.3). For example, when investigating the genetic variants for the occurrence 
symptomatic aneurysms in a sample from the general population, we found that these 
variants were associated with the size of the aneurysms rather than their presence per 
se. This was an interesting finding that suggested that these genetic variants for 
clinically relevant aneurysms were perhaps not leading to persons developing an 
aneurysm, but increasing the size of an existing aneurysm and thus risk of rupture. 
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Another approach to understand pathophysiology is to be unbiased towards certain 
hypotheses, to prevent any confirmation bias by only selecting phenotypes supporting 
prior beliefs, as is done in chapter 4.2. These studies can still be in line with patterns that 
would be expected a priori, such as the effects of risk variants for frontotemporal lobar 
degeneration being mainly on frontal and temporal brain regions (chapters 4.2.2 and 
4.2.3), but they could also point to regions not implicated before as with brain-wide 
studies of Alzheimer’s disease variants (chapter 4.2.1).  
Another critical question in study design is which study population to use. The study of 
patients may be obvious, but is the effect of ‘disease genes’ really restricted to patients? 
One finding suggesting otherwise is that most of the risk variants are common in the 
general population, with minor allele frequencies between 1-50%.5-11,13 Although it is 
possible that common risk variants only cause disease in a subset of carriers, e.g. 
because they exert an effect only in combination with other risk factors, there is also an 
alternative explanation: patients with a clinical diagnosis of disease are at the extreme 
end of a continuous spectrum, with non-diseased carriers of the risk variants showing 
less severe phenotypes. Knowledge on which of these explanations applies to risk 
variants can further our understanding of what causes disease. The studies in chapter 4 
were all done in the general population to test this hypothesis. For variants of nearly all 
diseases we indeed found effects outside patient populations: Alzheimer’s disease, 
intracranial aneurysms, frontotemporal lobar degeneration, Parkinson’s disease, and 
amyotrophic lateral sclerosis. Only for multiple sclerosis (chapter 4.2.4) the effect of risk 
variants was not as apparent. In the field of psychiatry, research has been conflicting 
with regard to the effects of schizophrenia risk variants on structural brain changes in 
the general population.45-47 However, while GWAS are generally done in a collaborative 
setting and include a replication stage, this is rarely a requirement for such follow up 
studies on potential pathophysiological mechanisms. For many of these findings, formal 
replication of the results could provide stronger evidence for the suspected role of 
disease variants in the general population.  
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Figure 3 | Shared variance between neuroimaging, genetics, and disease 
susceptibility. 
Venn diagram of the variance in imaging, genetics, and disease, and their interrelations. The 
intersections (formally denoted by ∩) indicate shared variance between imaging and disease 
(A), genetics and disease (B), imaging and genetics (C), and variance that is common across all 
three traits (D). 
EXPLORING CLINICAL RELEVANCE 
Besides genetic discoveries and understanding pathophysiology, imaging genetics 
ideally results in clinical translation. While insight into pathophysiology might reveal 
drug targets, such translations typically take decades before a treatment is actually 
implemented.48 However, clinical utility does not only incorporate treatment, but also 
covers diagnosis and prediction. For this purpose, it is important to consider the 
variance observed in imaging, genetics, and disease (see Figure 3). Each of these three 
traits shows differences between individuals, corresponding to brain differences 
measurable on imaging, carrier status of genetic variants, or whether someone is 
diseased or not. The non-overlapping parts in Figure 3 consist of variance that is 
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restricted to one of these three traits. This includes both variance that is biologically 
unrelated to the other traits as well as measurement error (e.g. noise in image 
acquisition, genotyping errors, or misclassification of disease status). However, part of 
the variance is shared and can be leveraged to derive clinical value, forming the basis of 
chapter 5. 
The intersection of imaging and disease, i.e. the shared variance between the two, is 
denoted by the letter A in Figure 3 (i.e., including D). This is part of the variance captured 
by imaging that is informative for disease. Given that many imaging markers are novel, 
their clinical relevance is yet unclear. In chapter 5.1, I determined clinical correlates of a 
variety of novel imaging markers. For enlarged perivascular spaces, there were 
associations with cardiovascular risk factors and cerebrovascular disease (chapter 5.1.1 
and chapter 5.1.2). The number of enlarged perivascular spaces in the basal ganglia, for 
example, were related to hypertension beyond other risk factors or markers of 
cerebrovascular disease, suggesting that this might be a complementarily imaging 
marker for disease prediction. Similarly, intersection B represents the genetic variants 
that are associated with disease. Their clinical relevance was explored in chapter 5.2, 
specifically to determine whether these variants can improve individual prediction of 
symptoms and diseases. Genetic risk factors of four neurodegenerative diseases were 
related to mild cognitive impairment and incident dementia (chapter 5.2.1), and genetic 
risk of Parkinson’s disease was related to basic activities of daily living and incident 
Parkinson’s disease (chapter 5.1.2). However, the added predictive value of these genetic 
variants was low, in line with findings from recent studies.49,50 This indicates that the 
currently identified variants for these neurodegenerative diseases do not yet have 
enough explanatory power to provide meaningful discrimination between individual 
who will develop disease versus those who will not.  
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FUTURE RESEARCH 
In this section I describe future directions for research that I consider to have potential to 
move the field further forward beyond the work performed in my thesis. 
For genetic discoveries, the most obvious approach is to increase the sample size for 
discovery. This has been successful for other complex traits,11,37,38,51,52 and there is little 
doubt that this will also improve the power in genetic studies of imaging markers. The 
research I have presented in this thesis used data from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE)53 and Enhancing NeuroImaging Genetics 
through Meta-Analysis (ENIGMA)54 consortia. These global collaborations incorporate 
the vast majority of studies with both neuroimaging and genetic data available. The 
research in chapter 3.1 shows that the current maximal sample size that can be attained 
is at most 35,000 individuals, which includes those of non-European descent. Large 
biobanks have been initiated in past years,55,56 and the first batches of data have already 
become available for analysis.57-62 Biobanks are likely to receive a prominent role in 
genetic discoveries within the coming years, and it is therefore imperative that their 
limitations are also acknowledged, such as potential bias in such large-scale data 
collection. For the UK Biobank, for example,  9.2 million persons were invited to 
participate, whereas only slightly over 5% were actually recruited.63 From an 
epidemiological perspective this low participation rate is worrying because it has the 
potential to induce non-response bias and further complicate the generalizability of the 
obtained results. Replication of results across different population can alleviate those 
concerns, but will be increasingly difficult for effects that have been detected by pooling 
all available data together. 
Statistical power can also be improved in ways other than adding more samples. One 
such approach is by reducing the measurement error in both genetics and imaging. 
The haplotype reference consortium has pooled together 65,000 human haplotypes to 
create a reference panel to which genotypes with minor allele frequencies as low as 
0.1% can still be reliably imputed.64 Advances in DNA sequencing and reductions in the 
associated costs also pave the way for obtaining whole genomes sequences.65 This will 
enable the identification of the causal variants instead of tagging variants, where the 
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association signal is diluted. Similarly, imaging markers contain noise that is due to the 
equipment or subsequent image processing. While ultra-high field strength MRI 
scanners can provide more detail of the brain,66-69 it also comes with drawbacks for 
participants in the form of longer scanning times and dizziness.70 Furthermore, a large 
amount of data has already been acquired in the past decades and improved image 
processing can also reduce measurement error. In case persons have been scanned 
more than once, the additional images can be taken along to reduce the noise in the first 
image using longitudinal image processing techniques.71-74 These techniques are 
employed to study changes in the brain in a longitudinal setting,75-79 but they have not 
been applied to generate cross-sectional measures where the noise has been reduced 
and which are subsequently analyzed on their own. In a preliminary analysis within the 
Rotterdam Study of over 2000 individuals who have been scanned twice, I calculated the 
volume of the left hippocampus using two methods (Figure 4): extracting the 
hippocampus from each scan separately (‘cross’) for time point 1 (TP1) and time point 2 
(TP2), or by extracting the hippocampus using a longitudinal image processing pipeline 
(‘long’). Next, I determined which part of the variance in hippocampal volume is 
determined by genetics. For the cross-sectional measures of hippocampal volume the 
heritability was comparable for both time points at slight more than 30%. Intriguingly, 
the heritability was almost 55% when information from the other scan was taken along 
when determining the hippocampal volume. Since this analysis was done in the same 
set of individuals and scans, it suggests that the longitudinal processing helps extract 
true biological variance in hippocampal volume. Studies that have multiple scans 
available could thus boost power for genetic discoveries by using data from another 
time point. However, the advantages and disadvantages of such an approach needs to 
be carefully studied before large-scale application. While it might be reasonably argued 
that measurement error is random, recent research has suggested that, for example, the 
amount of head motion during resting state functional MRI is also heritable.80 If image 
processing algorithms are affected by the presence of motion this will result in a 
differential misclassification, a form of information bias. Such factors resulting in 
measurement error are not specifically considered in imaging genetics studies (and to a 
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certain extent imaging studies in general), and it also remains to be determined how 
these influence longitudinal processing. 
A final approach to maximize statistical power is by using more powerful statistical 
techniques. In chapter 2.3 I describe a novel meta-analytical technique that allows for 
combining results from multiple studies in a way that yields the same results as a pooled 
analysis, which is statistically the most powerful, but does not require the raw data to be 
shared. This is relevant for many collaborative settings where the individual participant 
data  cannot be shared due to various including legal, ethical, and logistic reasons. Such 
collaborations currently resort to less powerful meta-analytical techniques, but 
implementation of our novel method can both adhere to restrictions of not sharing 
individual participant data without compromising on statistical power. It will also be 
possible to include studies with small sample sizes that would otherwise have been 
 
Figure 4 | Noise between two scans for cross-sectional versus longitudinal 
processing. 
Differences in hippocampal volume between the first and second scan using cross-sectional 
processing (red) versus longitudinal processing (green). TP = time point. 
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excluded in a conventional meta-analysis. This not only reduces statistical power, but 
potentially leads to a selection bias. Furthermore, in this thesis I focus on univariate 
linear regression models for analyzing associations between genetic variants and 
imaging markers. Here too there is room for improvement with more sophisticated 
methods including machine learning algorithms, e.g. deep learning or support vector 
machines.81-85 
The selection of imaging markers will have an important impact on future research in a 
more general sense. Even though we might be able to obtain a more accurate 
hippocampal volume, this by itself is a fairly gross measure and simplifies the complexity 
within this brain structure. Genes themselves might affect specific regions of the brain 
and the use of an aggregate measure can make such localized effects difficult to find. An 
illustration of this is a genetic locus that was associated with hippocampal volume in 
chapter 3.1.2, using a sample of over 30,000 individuals, and was also genome-wide 
significant in chapter 2.4 when performing GWAS of all 7,000 voxels in the hippocampus. 
The latter analysis was done in only 4,400 individuals, but the higher resolution provided 
by studying voxels was able to outweigh the smaller sample size. An important part of 
this thesis was to make such genome-wide association studies of many (imaging) traits 
possible, and that has now been successfully done as described in chapter 2.4. Future 
studies should therefore not be restricted by previous computational and logistic issues 
that prohibited the use of novel imaging markers that aim to measure the brain in more 
comprehensive and biologically meaningful ways, usually with thousands to even 
millions of values. Naturally, these refined imaging markers can be of benefit to genetic 
discoveries, but perhaps even more so for understanding the pathophysiology of 
neurological diseases. Emerging imaging markers that can be relevant for 
neurodegenerative diseases include cortical thickness, surface area, and gyrification.86-91 
For cerebrovascular diseases genetic studies are needed on enlarged perivascular spaces 
and brain microbleeds.92-97 Phenotyping of the brain for genetic studies need not be 
restricted to conventional MRI imaging. Future studies can extend the scope of imaging 
genetics to other clinically relevant and heritable imaging markers, including the 
microstructural integrity of white matter as measured by diffusion tensor imaging and 
functional connectivity assessed by functional MRI. 98-112  
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A further consideration is that while a phenotypic correlation may exist between 
imaging markers and neurological diseases, and both may be heritable, this does not 
necessarily mean that the underlying genes are also shared. The presence of a genetic 
correlation is thus also important when determining whether a certain imaging marker 
is relevant for a certain disease. Currently, there has not been a systematic mapping of 
genetic correlations between imaging markers and neurological diseases. Such a study 
would provide valuable information for researchers regarding which imaging markers 
they actually need to investigate, especially as novel imaging markers are constantly 
being developed.113-129 Even when the most relevant markers for a disease of interest 
have been identified, the genetic correlation will never be perfect. A risk of using 
markers of diseases for genetic discoveries will thus be that the identified variants are 
not necessarily related to the disease outcome. However, I would like to describe how a 
genetic correlation is not a requirement per se for variants to have a clinical utility. I now 
return to Figure 3 and focus on the genetic variants influencing imaging markers which 
are in intersection C and can be divided into two groups: those also associated with 
disease, intersection D, or those only influencing the imaging markers, i.e. the remaining 
part of intersection C. The genetic variants in D explain part of the variance in disease 
susceptibility, likely because the effect of these variants is exerted through changes in 
the brain that are captured by these imaging markers. Identification of such variants, as 
described in chapter 3, can thus directly be used to investigate their clinical utility in 
predicting disease onset, severity, or specific symptoms. For the remaining part of 
intersection C, the added value for prediction is less direct. Since only part of the 
variance in imaging markers is related to disease (intersection A), methods to reduce the 
‘non-relevant’ variance could results in neuroimaging phenotypes with a better 
predictive performance. Thus genetic variants that influence clinically relevant imaging 
markers, but are themselves not related to disease, could help accentuate the variance 
in imaging markers that can predict disease. So, even when a genetic correlation 
between an imaging marker and disease is lacking, the identified genetic variants might 
still harbor clinical value. 
Eventually the goal is to map the effects of all genetic variants on the brain so that this 
information can be leveraged for understanding pathophysiology and determining their 
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clinical relevance, as described above. Ideally, as with GWAS summary statistics, we will 
have publicly available repositories with these neuroimaging maps. It will then be 
possible to link genetic profiles of neurological diseases to the accompanying brain 
differences or to see whether a certain radiological presentation has a genetic basis. 
Furthermore, cross-investigations with other sources of biological data (e.g., 
transcriptomics, proteomics, metabolomics, microbiomics) can amplify the synergistic 
value of imaging genetics. These data represent yet another dimension that can be 
added on top of imaging and genetics, and may therefore also require novel methods 
to be developed for facilitating such studies.  
CONCLUSION 
In this thesis, I have used an imaging genetics approach to report novel gene 
discoveries, add to our understanding of the pathophysiology of neurological diseases, 
and explore the clinical relevance of genetics and neuroimaging. Furthermore, I describe 
how future research can build upon this work. Genetic discoveries can be boosted with 
larger samples, particularly biobanks, but also by using more comprehensive 
genotyping, refined imaging markers, and smarter data analysis. With the surge of novel 
imaging markers, it will also be good to determine which are the most relevant for 
specific outcomes. For this, a systematic investigation is needed of the phenotypic and 
genetic correlations between these markers and neurological diseases. Also, there is 
promise in combining imaging genetics with other biological data, but come with their 
own methodological challenges. Novel genetic discoveries can eventually lead to clinical 
translation, but the life cycle of such translational research can span many decades.48 
Similarly, most advancements in this thesis will not have a direct impact on patients or 
their physicians. Rather, this research lays groundwork to enable tangible clinical 
translation in the future. 
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ENGLISH SUMMARY 
In this thesis I studied complex neurological diseases and focused on those of a 
neurodegenerative or cerebrovascular nature, which include very common and 
debilitating diseases. I have used genetics and neuroimaging to further our 
understanding of these diseases and the main findings, described in chapters 2 through 
5, are summarized here. 
Chapter 2 deals with methodological aspects related to genetics and neuroimaging. 
Chapter 2.1 describes a method for assessing a novel neuroimaging marker, enlarged 
perivascular spaces on MRI – an emerging marker of cerebrovascular disease – whereas 
chapter 2.2 presents a newly initiated global consortium to systematically investigate 
the clinical relevance of this marker.  In chapter 2.3 we present a novel meta-analysis 
method for increased power and flexibility when individual participant data cannot be 
shared between sites. This is a common issue in multi-site studies, which are routinely 
performed in the field of genetics and increasingly so in neuroimaging. Building further 
upon this method, we developed a novel software in chapter 2.4 that enables genome-
wide and brain-wide association studies, overcoming the huge computational and 
logistic limitations. Finally, chapter 2.5 highlights potential biases in a recent study on 
the transmissibility of amyloid-β , which illustrates how causal inference can be affected 
in observational studies. 
Chapter 3 reports genetic discoveries of imaging markers, including those linked to 
neurodegeneration (chapter 3.1), cerebrovascular disease (chapter 3.2), and emerging 
imaging markers that are not as well established (chapter 3.3). In the largest discovery 
samples to date, we identified a total of 33 novel genetic variants in studies of 25,000 to 
34,000 individuals. We describe studies of intracranial volume (chapter 3.1.1) , 
hippocampal volume (chapter 3.1.2), and the volumes of other subcortical brain 
structures (chapter 3.1.3). We further found genetic overlap between some of these 
markers and neurodegenerative diseases, which can aid in the discovery of disease 
genes. In chapter 3.2.1 I review our current knowledge of the genetics of cerebrovascular 
disease, which remains limited compared to other fields within neurology. Chapter 3.2.2 
then describes the first estimates of the heritability of intracranial carotid artery 
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calcification and also identifies its first genetic determinants. In chapter 3.3.1, I studied 
the anterior commissure, a recently proposed imaging marker for neurodegeneration, 
and present the first heritability and genetic association analyses. Similarly, chapter 3.3.2 
describes the first comprehensive investigation of the genetic determinants of human 
gait, which was imaged using an electronic walkway. Next, I focus on two emerging 
neuroimaging phenotypes: the shape of subcortical brain structures (chapter 3.3.3) and 
the grey matter density (chapter 3.3.4). These markers describe the structure of the brain 
with greater detail than the established markers by using thousands to millions of 
measures. We found both to be promising for genetic studies with high heritabilities, 
but also with regional variability in the extent of the genetic contribution. 
Chapter 4 covers known disease genes and their effects on the brain, using candidate 
imaging markers (chapter 4.1) and unbiased searches of the brain (chapter 4.2). In 
chapter 4.1.1 we studied Alzheimer’s disease genetic variants in relation to several key 
vascular and neurodegenerative markers and found these variants contribute to 
structural brain aging. In chapter 4.1.2, we report that variants for clinically diagnosed 
intracranial aneurysms relate to the size rather than the presence of aneurysms that 
were discovered incidentally in the general population. Chapter 4.1.3 describes a study 
of dystrophin gene variants and cognitive function, where no significant association was 
found. In the subsequent chapters, we report brain-wide studies of genetics variants that 
increase the risk of Alzheimer’s disease (chapter 4.2.1), frontotemporal lobar 
degeneration (chapter 4.2.2 and chapter 4.2.3), and multiple sclerosis (chapter 4.2.4). We 
found that ‘disease variants’ also have subclinical effects on the brains of non-diseased 
individuals from the general population.    
Chapter 5 focuses on the clinical relevance of neuroimaging and genetics for 
neurological disease, which is yet to be established for novel imaging markers (chapter 
5.1) and recently identified genetic variants (chapter 5.2). In chapter 5.1.1, we study 
demographic and cardiovascular determinants of enlarged perivascular spaces and find 
that their burden is determined by various factors with considerable regional specificity, 
pointing towards a multifactorial origin. In chapter 5.1.2 we further find that enlarged 
perivascular spaces are related to the retinal microvasculature, providing strong 
evidence that these represent small vessel disease. Chapter 5.2.1 covers a study of 
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genetic risk factors for four neurodegenerative diseases in relation to mild cognitive 
impairment and incident dementia, and chapter 5.1.2 investigates the genetic risk of 
Parkinson’s disease in relation to basic activities of daily living and incident Parkinson’s 
disease. While both studies showed associations of the genetic variants with clinical 
endpoints there was little improvement in the ability to predict symptoms and disease 
at an individual level.  
Chapter 7 
478  
DUTCH SUMMARY 
In dit proefschrift heb ik complexe neurologische ziektebeelden bestudeerd met een 
nadruk op neurodegeneratieve en cerebrovasculaire aandoeningen, welke 
veelvoorkomend zijn en slopende gevolgen kunnen hebben. Ik heb gebruik gemaakt 
van genetica en beeldvorming van de hersenen om ons begrip van deze ziektebeelden 
te bevorderen. De voornaamste bevindingen uit hoofdstukken twee tot en met vijf 
worden hier samengevat. 
Hoofdstuk 2 behandelt methodologische aspecten die belangrijk zijn voor genetica en 
hersenbeeldvorming. Hoofdstuk 2.1 beschrijft een methode voor het bepalen van een 
nieuwe marker op hersenbeeldvorming, vergrote perivasculaire ruimtes op MRI – een 
opkomende marker van cerebrovasculaire aandoeningen – terwijl hoofdstuk 2.2 een 
recent geïnitieerd globaal consortium presenteert om systematisch te bestuderen wat 
de klinische relevantie is van deze marker. In hoofdstuk 2.3 presenteren we een nieuwe 
meta-analyse methode: deze methode verbetert de statistische kracht en flexibiliteit 
wanneer data van individuele deelnemers niet gedeeld kan worden tussen verschillende 
onderzoeksgroepen. Dit is een vaak voorkomend probleem in studies met meerder 
groepen, welke routinematig worden uitgevoerd binnen de genetica en ook steeds 
vaker in het veld van hersenbeeldvorming. Voortbouwend op deze methode hebben wij 
een nieuwe software ontwikkeld in hoofdstuk 2.4 die het mogelijk maakt om genoom-
wijde en brein-wijde associatie studies uit te voeren door het wegnemen van 
beperkingen in de rekenkracht en logistiek. Tot slot benadrukt hoofdstuk 2.5 mogelijke 
aanwezigheid van bias in een recente studie over de overdraagbaarheid van het 
amyloid-β eiwit, wat illustreert hoe de causale gevolgtrekking kan worden beïnvloed in 
observationele studies. 
Hoofdstuk 3 rapporteert genetische ontdekkingen van markers uit de beeldvorming, 
met inbegrip van markers die verband houden met neurodegeneratie (hoofdstuk 3.1), 
cerebrovasculaire aandoeningen (hoofdstuk 3.2), en opkomende markers welke nog niet 
gangbaar zijn (hoofdstuk 3.3). In de grootste ontdekkingsstudies tot nu toe hebben wij 
in totaal 33 nieuwe genetische varianten ontdekt door het onderzoeken van 25.000 tot 
34.000 deelnemers. We beschrijven studies van het intracraniële volume (hoofdstuk 
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3.1.1) , het volume van de hippocampus (hoofdstuk 3.1.2), en het volume van andere 
subcorticale hersenstructuren (hoofdstuk 3.1.3). We hebben verder gevonden dat er 
genetische overlap is tussen deze markers en neurodegeneratieve aandoeningen, wat 
kan helpen bij het ontdekken van nieuwe ziektegenen. In hoofdstuk 3.2.1 geef ik een 
overzicht van onze huidige kennis van de genetica van cerebrovasculaire aandoeningen, 
die relatief beperkt blijft in vergelijking met andere gebieden binnen de neurologie. 
Hoofdstuk 3.2.2 beschrijft vervolgens de eerste schattingen van de erfelijkheid van 
calcificaties van de intracraniële halsslagader en identificeert ook de eerste genetische 
determinanten. In hoofdstuk 3.3.1 bestudeerden we de grootte van de commissura 
anterior, een recent voorgestelde marker van neurodegeneratie, en presenteren we de 
eerste erfelijkheid en genetische associatie analyses. Evenzo hoofdstuk 3.3.2, welke het 
eerste uitgebreide onderzoek beschrijft naar de genetische determinanten van het 
menselijke looppatroon, wat werd afgebeeld met behulp van een elektronische 
loopmat. Vervolgens richt ik me op twee opkomende hersenbeeldvorming markers: de 
vorm van de subcorticale hersenstructuren (hoofdstuk 3.3.3) en de grijzestofdichtheid 
(hoofdstuk 3.3.4). Deze markers beschrijven de hersenstructuur in groter detail dan de 
gangbare markers door duizenden tot miljoenen maten te gebruiken. Wij vonden beide 
markers veelbelovend te zijn voor genetische studies vanwege de hoge erfelijkheid, 
maar er was ook regionale variabiliteit in de mate waarin genen bijdragen. 
Hoofdstuk 4 bestudeert bekende ziektegenen en hun effect op de hersenen, 
gebruikmakend van kandidaat beeldvormingsmarkers (hoofdstuk 4.1) en studies vrij van 
bias (hoofdstuk 4.2). In hoofdstuk 4.1.1 onderzochten we genetische varianten voor de 
ziekte van Alzheimer in relatie tot enkele belangrijke vasculaire en neurodegeneratieve 
markers en vonden dat deze varianten bijdragen aan structurele hersenveroudering. In 
hoofdstuk 4.1.2 rapporteren wij dat genetische varianten voor klinisch 
gediagnosticeerde intracraniële aneurysmata meer samenhangen met de grootte dan 
de aanwezigheid van aneursmata die onvoorzien zijn ontdekt in de algemene 
bevolking. Hoofdstuk 4.1.3 beschrijft een studie van genetische variatie in het dystrofine 
gen en cognitieve functie, waarin geen significante associatie was gevonden. In de 
volgende hoofdstukken rapporteren wij breinwijde studies van genetische varianten die 
het risico verhogen op de ziekte van Alzheimer (hoofdstuk 4.2.1), frontotemporale 
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lobaire degeneratie (hoofdstuk 4.2.2 en hoofdstuk 4.2.3), en multiple sclerosis 
(hoofdstuk 4.2.4). We vonden dat ‘ziektegenen’ ook subklinische effecten hebben op de 
hersenen van personen zonder ziekte uit de algemene bevolking.   
Hoofdstuk 5 richt zich op de klinische relevantie van hersenbeeldvorming en genetica 
voor neurologische aandoeningen, wat nog moet worden vastgesteld voor nieuwe 
markers uit de beeldvorming (hoofdstuk 5.1) en recent geïdentificeerde genetische 
varianten (hoofdstuk 5.2). In hoofdstuk 5.1.1 bestuderen we demografische en 
cardiovasculaire determinanten van vergrote perivasculaire ruimten en vinden we dat 
hun ernst bepaald wordt door meerder factoren met een aanzienlijke specificiteit per 
hersengebied, wat wijst op een multifactoriële oorsprong. In hoofdstuk 5.1.2 zien we 
verder dat vergrote perivasculaire ruimten gerelateerd zijn met de retinale 
microvasculatuur, een sterke aanwijzing dat deze een vaatlijden vertegenwoordigen van 
de kleine hersenvaten. Hoofdstuk 5.2.1 heeft betrekking op een studie naar genetische 
risicofactoren voor vier neurodegeneratieve aandoeningen en hun relatie met milde 
cognitieve stoornissen en het ontwikkelen van dementie in de toekomst, en hoofdstuk 
5.1.2 onderzoekt het genetisch risico op de ziekte van Parkinson met betrekking tot het 
uitvoeren van dagelijkse activiteiten en het ontwikkelen van de ziekte van Parkinson in 
de toekomst. Hoewel beide studies associaties tonen tussen genetische varianten en 
klinische eindpunten was er weinig verbetering in het vermogen om de symptomen en 
ziekten op individueel niveau te voorspellen. 
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EPILOGUE 
Epidemiology aims to answer one of the key questions humans currently face: what 
causes disease? 
It is clear that for the numerous diseases that can befall us, the culprits can take various 
forms: they might be genes, what you eat and drink, or your environment. 
Consequently, an epidemiologist must become fluent in the relevant subject matter of a 
particular disease if he or she truly wishes to understand it. This is why epidemiologists 
can be seen asking you to fill out questionnaires, measuring your local water quality, or 
taking blood samples for further analysis in lab. The required skills and knowledge 
cannot be set in stone, making it a truly remarkable discipline. The drive to understand 
disease therefore leads to considerable heterogeneity between epidemiologists, but it is 
also what binds them. 
The work in this thesis, where I investigated complex neurological diseases, underlines 
these characteristics of epidemiology. The chapters describe 'classic epidemiology', but 
also mathematics, bioinformatics, neuroimaging, genetics, and cell biology. Beyond the 
contents of these chapters, this thesis is also built upon friendship, collaboration, 
politics, anger management, business, and a healthy dose of mind games. 
Although genetics is a key part of my thesis, it is important to realize the impact of your 
environment. During the past years, I was able to get a lot done, meaning I am indebted 
to a lot of people.  
Guiding me through this journey, my supervisors have been crucial along the way. 
My promotors Prof.dr. Hofman and Prof.dr. Van der Lugt:  
Bert, thank you for the opportunity to be part of your department. Our first conversation 
was during my interview where I applied for the NIHES research master, and requested 
to do this in parallel to medical school and another research master. From all the people 
I had spoken to about this triple degree idea, you were literally the only person who 
supported me from the beginning. I have tried to repay this faith with my grades and 
master theses, and this doctorate thesis is the first fruit that was grown on this diverse 
education. Also, I would like to thank you for tempering two of my fears of growing old: 
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losing my passion and losing my hair. Although you don't believe in the term yourself, I 
think you are a great example of 'healthy aging'. 
Aad, thank you for your contributions to the various manuscripts. I appreciate your 
attention to detail and also enjoyed our conversations about the ‘big picture’. Your 
passion for radiology has definitely rubbed off on me during the past years.  
My co-promotors (Prof.)Dr. Ikram and Dr. Vernooij:  
You are both principal investigators at the Rotterdam Study, an impressive population-
based study that is very suitable to investigate the central question of my thesis. 
However, larger studies are constantly being initiated, newer MRI scanners are 
becoming available, and the genetic technologies are revolutionized every few years. 
Why then choose to do my doctorate research here? More important than all these 
factors are the people you work with. I can honestly say that without you being my co-
promotores, I would have probably even passed up the beautiful Rotterdam Study. 
Arfan, you would typically be late to meetings, but compensate by immediately having 
great input. I joined the department around your thesis defence and it gives me joy that 
you are now becoming professor when I am defending mine. While you scientific 
achievements have been widely recognized, I also admire your broad interest and in-
depth knowledge of other fields, whether it is physics, religion, or music.  
Meike, your work ethic is unparalled. I often forget that besides running a successful 
research group you are also working in the clinic, and additionally have an active life 
beyond the Erasmus MC. It is amazing that you remain so approachable for your 
students and are always looking out for their best interests. It certainly explains why are 
loved by all who know you, and I feel lucky for having you as a co-promotor. 
They say that the greatest compliment you can give your teachers is to surpass them, so 
I would like to thank you both for setting the bar extremely high for my PhD. I am sure 
your accomplishments will continue to motivate me during the rest of my career. 
I’m also honered to have as part of my reading committee Prof.dr. Kushner, Prof.dr. 
Franke, and Prof.dr. Grabe. Steven, you’re an inspiration for every young researcher and 
for me in particular for combining basic science with population level research. Barbara, 
you do wonderful work and I look forward to seeing Nijmegen and Rotterdam become 
Epilogue 
 485 
8 
closer partners. Hans, it’s inspiring to see you involved in so many endeavors but still 
managing to stay (or appear) relaxed at the same time. 
I would also like to thank the Prof.dr. Tiemeier, Prof.dr. Uitterlinden, and Dr. White for 
being part of my committee: 
Henning, while collaborations are usually initiated with a research question in mind, I 
can say that for me working with you is actually a goal by itself. André, thank you for 
your input on the various papers, especially when there was strict submission deadline! 
Tonya, it’s great to see someone in your position who has retained a thorough 
understanding of all aspects of her field of research. 
Given the impressive committee, I obvisously was left with no choice but to intimidate 
them with my paranymphs Sirwan Darweesh and Gennady Roshchupkin. This does 
not only apply to your physical prowess, but also your academic achievements. 
Sirwan, before everything, you are truly an amazing friend. I cherish the valuable time 
we have spent together during past years, which have had a unique impact on me. I was 
excited that you decided to join our department and not at all surprised to see your rise 
to the top in such a short period. You surely have an amazing future ahead of you, which 
I will be following with the utmost interest. 
Gena, I couldn’t have wished for a better intellectual sparring partner during my PhD 
than you. From day one it felt like you were a longtime friend and this feeling has only 
become stronger after all the papers, ‘short’ stories, and discussions of various scientific 
and non-scientific topics. I look forward to our secret plan to take over Rotterdam. 
Thank you both for having my back and let’s continue the paranymph outings! While our 
marital status allows this, of course. 
Next I would like to thank the participants of the Rotterdam Study, whose selflessness 
made this research possible. I feel connected with the Rotterdam Study, as we both had 
our conception in 1989 and actual birth in 1990. Many people have contributed to make 
this effort as successful as it is, which I couldn’t possibly all name here, but I would like to 
mention at least a few of them. Frank, Yolande, and Nano, your continuous support of 
researchers is much appreciated. Also, I’m very grateful to the MRI personnel, including 
Charlotte, Pauli and Lydia: your dedication lies at the basis of all the data we publish on.  
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Furthermore, the former and current principal investigators of the Rotterdam Study for 
their vision and hard work. In particular, I would like to mention Prof.dr. Breteler, 
Prof.dr. Van Duijn, and Prof.dr. Franco: 
Monique, I couldn’t have wished for a better introduction to science. Your cirtical and 
results-oriented thinking have taught me a lot. I have to admit that as a teenager I was 
surprised that, instead of a textbook on the principles of epidemiology, your first 
suggested piece of literature was ‘The Art of War’ by Machiavelli. However, it makes 
sense now. Good luck with the new RS, I’m sure it will make a big impact on the field!  
Cornelia, thank you for your valuable comments on manuscripts during the past years. 
Oscar, your positive energy is contagious and this effect is noticeable department-wide.  
Making sure that all runs smoothly, there were Hetty, Jacqueline, Erica, and Gabrielle. I 
am very thankful for the secretarial support over the past years! 
Leading up to my PhD, I have been lucky to receive an extraordinary scientific training.  
From NIHES, I would like to thank Astrid, Annet, Koos, Lenie, and Neetlje. From MolMed, 
my gratitude goes out to Prof.dr. Grootegoed, Benno, Dr. Poot, and Dr. Moen: 
Raymond, while your track record initially attracted me to work in your lab, it was your 
mentorship that made me request an exception to stay there for a prolonged period. I 
greatly appreciate your advice on research projects, career choices, and personal 
matters. I hope we can build on the cellular epidemiology concept in the coming years. 
Maaike, I’ve learned a lot from you about labwork, going from holding a pipet wrongly 
to performing elaborate experiments. You perfectly balanced out Raymond with your 
orderliness. Although our years of work is represented by ‘only’ a single paper in my 
publication list, it holds a special place in my heart. 
I would further like to thank Prof.dr. Frens and Prof.dr. Themmen. Maarten, you did an 
amazing job with the Honours Class. The program resulted in the connections that 
ultimately led to this thesis, and it was a great platform to meet and befriend likeminded 
students. I am proud to have been a part of it and hear similar things about the Erasmus 
University College. Good luck on your next steps! 
Over the course of my PhD, I have shared offices with fantastic colleagues: Ben, thanks 
for your warm welcome into the group. I’m glad we could work together and wish you  
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all the best in the clinic and with the family life. 
Vincent, thank you for some of the most unproductive times at the office, which is one 
of the dangers of having a similar (i.e., great) sense of humor.  But I also should thank you 
for some of the most productive times, when discussing ideas for new projects, 
statistical or epidemiological concepts, or splitting the helpdesk work. It was a priviledge 
to be your paranymph and I can’t wait to be there to celebrate your next achievements. 
Saloua, oh Saloua. How I miss you. You inspired one of my candidate 11th propositions: 
“If there was a SPSS gene, it would be located on the Y chromosome.” All kidding aside 
though, your hard work and pragmatic mindset are truly an inspiration.  
Rens, I miss walking into an office filled with pictures of legs. I hope you will be able to 
satisfy your needs as a neurologist. Please come back every now and then for a match! 
And a rematch! 
Liz! What can I say, we really had a        of a time. I wish you all the best at Harvard 
with Carlo. Thanks for staying in touch. You will probably be hearing about the great 
postdoc positions that Rotterdam is offering. 
Daniel, I always had difficulty to determine what I enjoyed more: your presence, or the 
sound of your computer. Even though your stay in Boston made me realize I probably 
got the better half of the deal, I’m still looking forward to having you back. 
Ryan, the most popular person of Erasmus MC. It’s unbelievable how much work you got 
done, given that you were always helping out others, not least of all myself. Thanks for 
feeding me lots of sweets and always being available! 
Tavia, you might be perfect. I’m pretty sure you are. I didn’t think I could ever love 
someone as much as I love food, and you proved me right. Our lunches and dinners 
were amazing, and I can’t wait to finish the ever-growing to-do list. Plus thanks for the 
geese! They look oriental. And yes, you’re perfect. 
Eline and Jory, I enjoyed your short but pleasant company in the office. 
Next, my colleagues from the neuro-epi group: 
Kamran, I’m glad you decided to return to Rotterdam, the city where everything 
happens (except for our lunch meetings). I’m looking forward to continue seeing you do 
great things. 
Hazel, you were an adequate colleague. Other people that I would like to thank are 
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… hihi  Oh Hazel, where to start? One of the first things I found out about you is that 
you also love sushi. It wasn’t long before it became clear that we have much more in 
common: a geeky attraction to scripting, never closing a single web page (since you 
might need it some day), germophobia, other obsessive compulsive behaviours, and our 
favorite hobby – incidental finding ratings. However, there obviously are some 
differences too. For example, you would be much happier than me if the KRTHAP1 gene 
was suddenly reactivated in humans. While this hasn’t changed for me, other things 
have. I want to thank you for loosening me up a bit, or perhaps even too much: I think 
we can agree we were both quite successful in exploring the limits of what can and 
cannot be said (that’s why they invented chocolate, right?). Hazel, thanks forever. 
Saira, I can’t wait to see you the 22nd of November! Thanks so much for booking a last 
minute flight, it wouldn’t be the same without you!  If however this does not make you 
feel guilty enough to fly across the Atlantic, please know that for me you never left – I 
still want to jump in and talk to you when I walk by your old office. 
Abbas and Jasper, I’m very glad to have had such talented students. While you are both 
completing your medical studies now and considering to specialize afterwards, I think it 
is clear you would also have promising careers in research. 
Frank, your research topic made you the centre of our group and I think we’ve learnt a 
lot from your healthy scepticism during the neuro meetings. It’s too bad you will be 
travelling during my defence! Also, given your sense of humour, you might have realised 
there is a reason this is the only part of my thesis written in British English. 
Lotte!! When people say ‘Guess what?’ my standard reply is ‘You’re pregnant?’. I was so 
happy that one day when I guessed correctly! I’m jealous of Vinz because he gets to 
spend more time with such a loving, talented, and energetic person. 
Sanaz, how I enjoyed our shared interests. You are into self-mockery, and I’m also a big 
fan of mocking you. It’s also not a coincidence that we both have a Dr. Phil seat / gossip-
chair in our room. Thanks for the good times and for making me feel normal! 
Sven, as a member of the three STW-musketeers you were essential for the scientific 
output. Besides this, you’re also politically savvy and a very likable person. I can’t wait for 
the moment a mini-Sven appears at our department!  
Vanja, pile moje lepo! I always wondered what was under those bangs and I’m glad I  
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found out it was a dedicated and generous mind. Thanks for all the edible gifts from 
your trips, I’m pretty sure I can still smell one of them. I’m hopeful you will still come by 
quite often when you’re doing your PhD! 
Unal, I’ve rarely seen someone so focused on getting results and I admire how much 
time and effort you spent on self improvement. But enough on foosball. 
I also shared many moments with other colleagues from the neuro-epi: Ana, Ayesha, 
Eline, Elisabeth, Hoyan, Marielle, Marileen, Pauline, Pinar, Renée, Renske, Sander, Silvan, 
Sonja, Thom, Unal, and Vincent K. 
My thanks also go out to others in our department, in particular the genetic 
epidemiology unit with Najaf, Dina, Adriana, Shazad, Ashley, and Ivana. For the cluster 
support, this includes Maarten and Lennart: thank you for the quick responses to my 
queries. Lennart, luckily my thesis is already written in English, so I don't need to 
translate it for you :). 
Furthermore, I thank Natalie for the ups and downs of debugging PLINK, experimenting 
with our favorite function, and the discussions about ALBI and other new software. Your 
unquenchable thirst for improvement is admirable and I foresee a great career ahead of 
you. Maybe in the field of neuro? Abbas, it has been great to see you grow over the 
years at our department and I envy your colleagues in London. Others I would like to 
mention are Carolina, Fernando, Janine, Symen, and Paul. 
Much of the work in this thesis wouldn’t have been possible without our close 
collaboration with BIGR, headed by Prof.dr. Niessen: Wiro, you have set up an amazing 
department and the many honors and prizes are a testimony to this. The team you have 
established is simply amazing. 
Marius, you rock! I was really excited when, after sharing a lot of laughs, we finally also 
got to work together. While you now moved to Cambridge, it’s luckily only a short fly 
away hihi. ;) 
I’m also grateful for all the hard work of others, including: Annereet, Fedde, Florian, 
Hakim, Henri, Marcel, Marleen, Raimon, Wyke, and Yuan. 
I have been privileged to work with many international collaborators as well through the 
CHARGE, UNIVRSE, and ENIGMA consortia. With great sample size comes great statistical 
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power and responsibility. My experiences gave me the fullest confidence that the future 
is in able hands, only a few of which I mention here: Sudha Seshadri, Lenore Launer, 
Myriam Fornage, Will Longstreth, Helena Schmidt, Josha Bis, Paul Nyquist, Stephanie 
Debette, Joanna Wardlaw, Ganesh Chauhan, Vincent Chouraki, Claudia Satizabal, Albert 
Smith, Edith Hofer, Charles DeCarli, Bernard Mazoyer, Reinhold Schmidt, Alexander 
Teumer, Tomáš Paus, Katharina Wittfeld, Mohamad Habes, Michelle Luciano, Christopher 
Chen, Paul Thompson, Derrek Hibar, Neda Jahanshad, and Boris Gutman. 
Sudha, I have met people who were either very smart, friendly, strong, or huggable, but 
is so rare to all these traits in a single person. You continue to inspire me and 
undoubtledly many others. 
Paul, it’s truly amazing to work with the busiest person I know. When I visited your lab 
for half a year, I think there were two weeks where you weren’t traveling. Nonetheless, 
you always make time for everyone and you still pay attention to details when reviewing 
a paper. LONI is very successful and an important reason for this is its excellent team: 
Derrek, I miss you! Neda, I miss you more! Boris, I miss you even… ok, I definitely miss 
Neda the most. I really enjoyed working with you guys and I’m happy that you visited 
Rotterdam a few times. You are always welcome again, and the same goes for Adam, 
Jason, Josh, Madeleine, Priya, and Sarah, as well as the other LONI peeps. 
I am also grateful to Alfred Aho, Peter Weinberger and Brian Kernighan. 
I feel lucky to have such great friends who value the quality of our contact above the 
quantity. I hope that this thesis serves as a good alibi for the past years. 
Spring, the ostrich delivery always was the highlight of my week. Two pistachios fighting 
(in) a nuclear reactor. Thank you so much for never delivering an ostrich. 
Sinan, every now and then when work gets too stressful I think about your helmets. I 
hope you will continue to grow the collection in the future to reach your final goal of 
having approximately three helmets. 
Michael, your charitable work is an inspiration to all of us, but especially to Martinox. 
Evgeny, one of my fondest memories is of the day when someone we don’t know settled 
a lawsuit. I wish you could have been there! 
Rick, I would love to do a genetic study on you about stress resilience. Thanks for the 
great times  and for giving me something to look forward to during my internships!  
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Nevertheless, genetics remain important, so I’d like to end by thanking my family.  
ﺓﺭﺫﺑ ﺓﺭﺟﺷﻟﺍ ﻝﻭﺃ 
At the first place my parents: 
Thank you for planting the seed that would would turn into this thesis. 
Pipi, you taught me to set big goals and work harder than everyone else to achieve 
them. I’m glad I inherited some of your appetite for knowledge and critical thinking, and 
I’m relieved you are not part of my committee. Thank you for raising me to be 
independent, but also for letting me know (very often) that you are there for me if I need 
anything. 
Mimi, you taught me important lessons on dedication, compassion, and respect. 
Furthermore, I learned a lot about cooking, crocheting, and fashion design. Although I 
was often immersed in my laptop, your presence brought me a lot of joy and motivation, 
even though I might not have always shown this. Thank you for making me understand 
the value of family and for keeping us together. 
I also owe a lot to my brothers, who nurtured this seed further: 
Hu, you repeatedly reminded me that relaxing is just as important as work, if not more 
so. Looking back, I regret not taking you up on more offers to do things together 
because of a deadline, but we will compensate this surely! Thank you for being who you 
are, but above all, thank you for expanding our family: Hanin, I couldn’t have wished for 
a sweeter sister.  
Ha, all the pages in this book would not suffice to thank you for what you have done for 
me. You cultivated my creativity (HiHa-ballen), passion to save lives (the 'kussen'-
incident), work ethic (Pokémon), scientific thinking ('leuk' discussiëren), and you taught 
me to live life to the fullest (the legendary CTCT trip). You are incontestably the smartest 
person I know, and your guidance is the foundation of this thesis and all my 
achievements. While it is an unreachable goal, I motivate myself by aiming to catch up to 
you one day. Thank you. 
“Congratulations! Now, you found the most important magic in the world. It is love and 
friendship and mmhvummduokbm!”. 
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